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Chapter 1 
General introduction 
 
 
 
“In the history of mankind few, if any, pandemics will have led to as much suffering 
and premature deaths as is emerging from the global epidemic of chronic disease.” 
Professor Sir John Bell, 2008 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parts of the general introduction have been published as: 
• Elissen AMJ, Duimel-Peeters IGP, Spreeuwenberg C, Vrijhoef HJM. DISMEVAL: Europees onder-
zoek naar ‘best practices’ op het gebied van disease management evaluatie. Tijdschrift voor Ge-
zondheidswetenschappen, 2011;89(3):180-84. 
• Elissen AMJ, Duimel-Peeters IGP, Spreeuwenberg C, Vrijhoef HJM. Naar zorg op maat voor type 2 
diabetes. Tijdschrift voor Gezondheidswetenschappen, 2013 (in press).  
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INTRODUCTION 
Although few things in life can be predicted with certainty, there is little doubt 
that chronic conditions will form the top priority of 21st century health care. 
Medical-technological advances, greater longevity, and increasing unhealthy 
lifestyles have led to unprecedented numbers of people living with one or more 
long-standing health problem(s).[1] In the European Union (EU), 20 to 40 per-
cent of persons aged 15 years or older has a self-reported chronic condition[2]; 
in the United States (US), estimates are that one in every two adults is chroni-
cally ill.[3]  
In coming years, with the baby-boom generation on the verge of retirement, 
these numbers will unavoidably grow further.[4] Although there will be a par-
ticularly large increase in the share of the population living with co-existing 
chronic disorders, a phenomenon most common among the elderly, the preva-
lence of chronic conditions is accelerating across virtually all age groups.[5] The 
implications for individuals, health systems, and society as a whole are consid-
erable. Besides causing significant morbidity and mortality[6], chronic condi-
tions increasingly strain the human and financial capital available to health care, 
and thereby threaten fundamental health system principles, such as universal-
ity, solidarity, and sustainability.  
This dissertation is about advancing the science and, with that, the evidence 
supporting decisions on how best to care for the growing population of chroni-
cally ill. Although multiple strategies for different conditions are studied, under-
lying research focuses on disease management interventions for type 2 diabetes 
mellitus. This first chapter introduces the burden and challenges of chronic 
conditions, explains the nature of type 2 diabetes mellitus, and discusses some 
of the key deficiencies in traditional care for long-standing health problems. 
Subsequently, the main strategies guiding international redesign efforts are 
discussed and the Dutch context for chronic care innovation is introduced. The 
chapter further explores the methodological challenges of disease management 
evaluation and outlines the main research project underlying this dissertation. 
Finally, the aims and structure of the dissertation are specified.  
CHRONIC CONDITIONS 
The World Health Organisation (WHO) defines chronic conditions as ‘conditions 
of long duration and generally slow progression’.[7] Most are caused by accu-
mulated exposure during one’s lifetime to a small number of known and pre-
ventable risk factors, including tobacco use, physical inactivity, and poor nutri-
tion.[8] The occurrence of chronic disease naturally rises with age; thus, it is not 
uncommon for a person reaching pensionable age to have two or three long-
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standing health problems. In the Netherlands, estimates are that around two-
thirds of persons aged 65 years and above suffer from multimorbidity; among 
those 85 years and older, this proportion is even higher.[9]  
Today, the most common somatic chronic conditions are diabetes, cardio-
vascular diseases, chronic respiratory conditions, and cancers.[10] Besides be-
ing a leading cause of morbidity throughout the world, these conditions in par-
ticular were responsible for 36 out of 57 million global deaths in 2008, a num-
ber that is expected to increase by an additional 15 percent before the year 
2020.[6] Depression is the most prevalent mental chronic condition: it is cur-
rently ranked the fourth leading cause of disability worldwide and expected to 
become second only to heart disease in terms of disease burden within the near 
future.[11,12]  
Not surprisingly, chronically ill patients are large-scale consumers of health 
care services. Østbye et al.[13] calculated that guideline-adherent management 
of no more than 10 common chronic conditions requires more time than general 
practice has available for all patient care. Across the US and Europe, including in 
the Netherlands, chronic conditions already account for approximately three-
quarters of available health care budgets.[14] Managing multimorbidity is espe-
cially expensive: about 96 percent of the American Medicare budget is currently 
allocated to older patients with co-occurring conditions.[15] In the Netherlands, 
estimates are that before the end of this decade, 40 percent of health care con-
sumption will be due to people with chronic multimorbidity.[16] 
TYPE 2 DIABETES MELLITUS 
Type 2 diabetes mellitus, formerly known as non-insulin dependent diabetes, is 
a chronic metabolic disorder that develops when the human body does not re-
spond properly to insulin, a hormone made by the pancreas.[17] Insulin is nec-
essary to help glucose, which is a form of sugar that is drawn from food, to enter 
the body’s cells, where it is converted into energy. Insulin resistance leads to 
excessive glucose levels building up in a person’s blood stream, which over time 
may damage the nerves and small blood vessels. This predisposes diabetes pa-
tients to a number of serious complications, including cardiovascular disease, 
which is the leading cause of death among people with diabetes, but also kidney 
failure, diabetic retinopathy, and lower limb amputations, amongst others.[18]  
 Type 2 diabetes mellitus is the most common form of diabetes, accounting 
for approximately 90 percent of cases, whereas the remaining 10 percent is 
attributable to type 1 diabetes mellitus and gestational diabetes.[19] Notwith-
standing the complex, multifactorial nature of the disease – which is caused by 
interactions between various genetic, environmental, and behavioural factors – 
its single most important predictor is excessive body weight.[20] It is therefore 
not surprising that over the past thirty years, parallel to rising rates of over-
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weight and obesity, the global prevalence of diabetes more than doubled to an 
estimated 366 million people in 2011.[17] The metabolic condition is becoming 
especially more common among young adults and adolescents, where it was 
traditionally associated with higher age. Estimates are that by the year 2030, 
there will be 552 million diabetes patients worldwide, representing almost 10 
percent of the world’s adult population aged between 20 and 79 years.[17] In 
the Netherlands, type 2 diabetes mellitus is already the most important physical 
chronic condition, with approximately 1 million known cases and an associated 
2.5 billion euros in direct medical costs.[21] 
Lifestyle interventions, such as increased exercise and dietary modification, 
constitute the cornerstone of treatment for type 2 diabetes mellitus, combined, 
where necessary, with medications such as metformin and/or insulin.[22] With 
the correct management, many people with diabetes are able to prevent or at 
least delay the onset of complications. However, in many countries with differ-
ent health care systems, usual care for type 2 diabetes mellitus – and for chronic 
conditions more in general – is suboptimal both in terms of the quality of ser-
vices offered and the achievement of treatment goals.[23] Given the human and 
economic burden associated with diabetes, it is perhaps not surprising that 
globally, efforts to improve the management of chronic conditions typically start 
in the area of diabetes care.[24] 
WHY TRADITIONAL CARE DOES NOT SUFFICE 
Historically, health care systems were developed to fit the needs of patients 
experiencing acute, episodic conditions, such as infectious and perinatal dis-
eases.[25] Although the impact of these conditions has become relatively limited 
over the past century, the reigning health care paradigm has only more recently 
begun to evolve and remains to be driven, for a considerable part, by urgent 
demands.[8] The growing prevalence of chronic conditions seriously challenges 
the effectiveness and efficiency of the acute care model.[26] Problems have be-
come evident at all levels of the health system and range from a failure to em-
power and collaborate with patients to fragmentation of services, limited fol-
low-up, insufficient evidence-based practice, inadequate information systems, 
and poor integration with community resources.[25,27] To illustrate, research 
from the US has shown that diabetes patients receive less than half of recom-
mended care services.[28] Self-reported patient figures from the Netherlands 
suggest that in 2008, approximately 60 percent of diabetes patients received 
four basic recommended screening tests, whereas no more than 35 percent was 
given a written care plan to manage their care at home.[29] As a result, while 
health care expenditures are escalating, the effectiveness of chronic care deliv-
ery is far from optimal, improvements in population health are not accom-
plished, and patients are largely dissatisfied with their care.  
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INNOVATIVE CHRONIC CARE STRATEGIES 
The health care needs of chronically ill patients are remarkably alike, regardless 
of their ailment. According to Nolte and McKee[4], they require ‘a complex re-
sponse over an extended time period that involves coordinated inputs from a 
wide range of professionals and access to essential medicines and monitoring 
systems, all of which need to be optimally embedded within a system that pro-
motes patient empowerment’. Working from Donabedian’s[30] premise that 
every system is perfectly designed to achieve exactly the results it gets, Wagner 
et al.[25] propose that meeting these needs will require nothing less than a 
transformation of health care, from an essentially reactive system that responds 
to acute episodes of illness to a proactive system focused on maintaining health 
and preventing or at least postponing disease.  
Over the past two decades, various innovative care concepts have been de-
veloped to increase the quality of chronic care delivery, improve health out-
comes, and, ultimately, reduce costs. This study focuses on the concept of dis-
ease management, which is commonly defined as ‘a system of coordinated 
health care interventions and communications for populations with conditions 
in which patient self-care efforts are significant’.[31] Disease management in-
terventions were originally initiated in the 1990s by third parties in the US 
health system, mostly from the pharmaceutical industry, which viewed these 
programmes as an opportunity to extend their activities beyond drug develop-
ment to health care management.[32] The primary aim of the early programmes 
was to reduce the costs of chronic care delivery, by identifying patients more 
quickly, providing educational services, and standardising care using evidence-
based guidelines and protocols.[33] Although American pharmaceutical compa-
nies were soon forced by law to significantly reduce their involvement in dis-
ease management[34], programmes in the US are still offered primarily by inde-
pendent, commercial organisations.[35] Much to the contrary, in Europe and 
elsewhere, where the American disease management interventions quickly 
caught attention and initially received wide support[36], these structured care 
strategies are offered as an integral part of existing health care delivery systems.  
In recent years, disease management interventions have increasingly come 
under pressure, mainly for neglecting the growing problem of multimorbidity 
and offering few possibilities for prevention of chronic conditions.[33,37] To 
overcome these limitations, several countries – amongst which the Netherlands 
– are slowly moving towards more comprehensive and integrated systems of 
chronic care delivery, often based on the Chronic Care Model (CCM).[25] Rather 
than adding on disease-specific interventions to existing health care structures, 
the CCM constitutes an evidence-based framework for health system redesign, 
which identifies the essential elements that encourage high-quality chronic care 
provision (see Figure 1). These are the community, the health system, self-
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management support, delivery system design, clinical information systems, and 
decision support.[25] 
To date, in most countries the implementation of the CCM has progressed as 
far as that contemporary disease management interventions combine two or 
more of the framework’s six components to improve the quality of care for spe-
cific chronic conditions in defined patient groups. More comprehensive popula-
tion health approaches, which address the full spectrum of CCM elements and 
target people with more than one chronic condition, are rare. The specific na-
ture and scope of disease management interventions offered to chronically ill 
patients depends strongly on the health care systems in which the concept is 
applied.[38] 
CHRONIC CARE INNOVATION IN THE DUTCH CONTEXT 
In the Netherlands, share care arrangements formed a precursor for more wide-
ranging disease management strategies for specific chronic conditions, which 
were initially introduced around the millennium by professional groups on a 
regional level.[26,39] The first initiatives focused primarily on type 2 diabetes 
mellitus, which has long been a priority disease in the chronic care policies of 
the Dutch Ministry of Health, Welfare and Sports. Despite considerable variation 
– especially during the early years – in the nature and organisation of initiatives, 
disease management in the Dutch context can broadly be defined as ‘the pro-
grammatic and systematic approach of specific diseases and health problems by 
using management instruments that aim at the advancement of quality and 
efficacy’.[34] 
Due to lack of a structured framework and fragmentary funding, the uptake 
of disease management initially remained limited in the Netherlands.[40] In 
2003, the Netherlands Diabetes Federation, an umbrella organisation of diabe-
tes care providers, scientists, and patients, published the first evidence-based, 
national care standard for a chronic condition. This standard for type 2 diabetes 
care, intended for diagnosed patients without serious complications, was up-
dated in 2007 and describes the essential components of high-quality, generic 
diabetes management.[41] In 2005, the Diabetes Care Programme Task Force 
developed an action plan to further improve the care for type 2 diabetes melli-
tus, which, in 2007, led to the first experiments with a bundled payment scheme 
for integrated diabetes management on the basis of the care standard for this 
condition. Within the pilot programme, which was set up by the Netherlands 
Organisation for Health Research and Development (ZonMw) and evaluated by 
the National Institute for Public Health and the Environment (RIVM), ten so-
called ‘care groups’ were offered financial incentives to start working with bun-
dled payments covering the complete package of standard outpatient care for 
generic type 2 diabetes mellitus.[42-44] Care groups gather providers from 
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multiple disciplines, but are typically managed by general practitioners (GPs); 
they are situated in primary care and freely negotiate with health insurers on 
the price for generic diabetes care bundles.  
 
 
Figure 1: The Chronic Care Model [25] 
 
The experiments in diabetes care laid the foundation for a broad innovative 
approach to disease management in the Netherlands. In 2010, the bundled pay-
ment system, based on recognised care standards, was formally implemented on 
a nationwide scale for type 2 diabetes care, COPD care, and vascular risk man-
agement. Despite considerable debate and uncertainty about the impact of the 
new care financing and delivery strategy, care groups rapidly achieved national 
coverage in the Netherlands. Today, almost 100 groups covering approximately 
80 percent of Dutch GPs have a bundled payment contract with a health insurer 
for the delivery of type 2 diabetes disease management.[45] The Dutch govern-
ment appointed a committee to evaluate the initial experiences with the bun-
dled payment system and recommend whether or not the system should be 
maintained, changed, or expanded after the voluntary transition stage, which 
ends in 2012.[46] Based on a secondary analysis of the (preliminary) results of 
studies conducted by Dutch research institutes, governmental agencies, health 
insurers, health professionals, and patient associations, the committee con-
cluded that the current system is a work in progress and ‘might turn out to be a 
useful step in the direction of risk-adjusted integrated capitation payment for 
multidisciplinary provider groups offering primary and specialist care for a 
defined group of patients’.[47] 
G E N E R A L  I N T R O D U C T I O N  
 17 
MEASURING DISEASE MANAGEMENT PERFORMANCE 
Besides the US and the Netherlands, disease management approaches have been 
implemented on a relatively large scale in countries like Australia, England, 
Sweden, and Germany, which now has some of the largest programmes in the 
world, covering almost five million patients in 2008.[48,49] Yet the evidence on 
the ability of these approaches to actually resolve the problems in chronic care 
remains uncertain.[50] Most of what we know about the effectiveness of disease 
management comes from pilot studies undertaken in academic settings, which 
usually target high-risk patients.[51] Comparatively much less insight exists into 
the impact of the population-wide approaches that have been implemented in 
actual health care settings.  
An important reason for the uncertain evidence-base is the methodological 
complexity of conducting disease management evaluations in routine practice. 
Obvious practical limitations, such as lack of a suitable number of control sub-
jects unexposed to the intervention, hamper the use of the randomised con-
trolled trial (RCT), which is generally considered the gold standard of medical 
research.[52] However, for practice-based disease management evaluations, the 
RCT design is not only unpractical; it arguably also lacks desirability.[53] Dis-
ease management strategies are highly complex interventions, which are im-
plemented in different care settings, comprise multiple, interrelated compo-
nents, and target whole populations of chronically ill patients, who differ in 
terms of disease severity, socio-demographic features, and health behaviour, 
amongst others. Rather than taking into account this vast amount of heterogene-
ity, RCTs tend to correct for variation so as to minimise the potential for con-
founding.[26] This leads to the situation where findings might be scientifically 
robust but at the same time uninformative for everyday clinical practice, where 
heterogeneity cannot be so easily ignored.  
Observational research designs are more operationally feasible for per-
formance assessment in real clinical practice and, as such, widely used for rou-
tine evaluations of disease management effects.[54] However, these designs 
commonly have methodological flaws that limit the validity and reliability of 
findings.[55] Moreover, they tend to produce so-called ‘grand means’ across 
large populations of patients, which provide little guidance regarding what 
works best for whom. More rigorous and detailed observational research meth-
ods are an important precondition for evidence-based decision-making on how 
best to respond to the complex health care needs of different groups of chroni-
cally ill patients within the context of their health care settings.  
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CHRONIC CARE RESEARCH AT MAASTRICHT UNIVERSITY 
This dissertation is part of a long-standing tradition of research into innovative 
care for chronic conditions at Maastricht University Medical Centre (MUMC+), in 
particular within the CAPHRI School for Public Health and Primary Care, the 
Department of Health Services Research, and the Division Patient & Care. Over 
the past ten to twenty years, extensive studies have been – and are being – con-
ducted into concepts such as, for example, joint care consultations[56], shared 
care initiatives[57], integrated care programmes and policies[58-63], regional 
disease management programmes for type 2 diabetes mellitus, asthma, and 
chronic obstructive pulmonary disease[26], new models of chronic care fund-
ing[64,65], theories guiding integrated service delivery[66,67], multidiscipli-
nary cooperation between health care providers[68,69], task substitution from 
physicians to nurses[70], and self-management support interventions[71] such 
as web-based patient education tools[72,73], telemonitoring[74], and motiva-
tional interviewing techniques.[75,76] Researchers from the MUMC+ are fur-
thermore actively involved in national policymaking in the area of chronic care, 
as illustrated by their participation in, amongst others, the platform for devel-
opment of the care standard for vascular risk management, the Netherlands 
Diabetes Federation’s Commission on Care Standards and Guidelines, the Na-
tional Committee for Evaluation of Bundled Payment, and the Dutch Health Care 
Inspectorate’s Visible Care Programme.  
ADVANCING DISEASE MANAGEMENT EVALUATION: DISMEVAL 
The majority of work described in this dissertation was conducted as part of the 
European collaborative DISMEVAL (‘Developing and Validating Disease Man-
agement Evaluation Methods for European Health Care Systems’) project, which 
was funded by the European Commission’s Seventh Framework Programme 
(FP7) for research.[77,78] DISMEVAL was initiated in 2009 in response to the 
need to better understand the effects of large, practice-based chronic disease 
management approaches using evaluation methods that are both scientifically 
robust and practical for routine settings. Gathering researchers from six Euro-
pean countries, that is, Austria, Denmark, France, Germany, the Netherlands, 
and Spain, DISMEVAL aimed to improve current methods for disease manage-
ment evaluation so as to support selection of effective and efficient interven-
tions to address the increasing burden of chronic disease.  
The project comprised a programme of work divided in three phases. The 
first phase sought to review the approaches to managing chronic conditions 
developed and/or implemented in different countries in Europe, as well as to 
provide an overview of the types of evaluation approaches being used in Europe 
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to estimate the impact of structured approaches to disease management on the 
quality and outcomes of chronic care. During the second phase, data from exist-
ing disease management approaches in the six countries participating in DIS-
MEVAL were utilised in order to test and validate the different evaluation op-
tions reviewed in Phase 1. Finally, the third phase sought to summarise findings 
and present best practices and lessons learned concerning the methods for dis-
ease management evaluation.[77,78] 
The Dutch country study included in Phase 2 of DISMEVAL tested and vali-
dated potentially valuable evaluation methods on routine patient data from the 
population-wide disease management approach for type 2 diabetes imple-
mented in the Netherlands. Researchers from the National Institute for Public 
Health and the Environment (RIVM) evaluated the Dutch disease management 
experiments between the years 2009 and 2012[44], and cooperated as an ex-
ternal partner in the Dutch DISMEVAL research team. 
AIM AND OUTLINE OF THE DISSERTATION 
The aim of the research described in this dissertation is to advance the science 
underlying disease management evaluation and, in so doing, to strengthen exist-
ing evidence on the impact of population-wide disease management approaches 
implemented in actual health care settings in the Netherlands and abroad. Be-
cause robust evaluation requires in-depth knowledge of the intervention under 
study, the next three chapters of the thesis provide a detailed exploration of 
disease management approaches for chronic conditions implemented both na-
tionally and internationally. Chapter 2 describes the recent redesign of type 2 
diabetes care in the Netherlands that forms the basis for the evaluation research 
conducted in the Dutch case study of DISMEVAL. The level of patient-
centeredness of this health system reform is assessed by comparing quality 
improvement goals to gaps in health care quality perceived by chronically ill 
patients in the Netherlands. Chapter 3 presents an overview of international 
chronic care management strategies for type 2 diabetes, based on a systematic 
review of the literature. This review is part of a series analysing the effective-
ness of chronic care management for different long-standing health problems – 
besides diabetes, these include COPD[79], heart failure[80], and depression[81] 
– which was conducted by a consortium of researchers from five Dutch research 
institutes (i.e. Erasmus University, the National Institute for Public Health and 
the Environment (RIVM), Twente University, the Trimbos Institute, and Maas-
tricht University). The included disease management interventions are analysed 
descriptively as well as meta-analysed to assess pooled effect estimates on care 
process and outcome measures. Chapter 4 examines the role of the regulatory, 
funding, and organisational context in the development and implementation of 
approaches to chronic care, focusing specifically on policies to achieve better 
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coordination within and across care sectors. For this purpose, examples are 
used from Austria, Germany, and the Netherlands.  
The remaining chapters of the dissertation, that is, chapters 5 through 9, fo-
cus on improving the methodology underlying disease management evaluations 
in clinical practice and providing a detailed assessment of the impact of disease 
management approaches on the quality and outcomes of care for (different 
groups of) chronically ill patients. Chapter 5 presents the main findings from the 
Dutch country study embedded in the DISMEVAL project, which analyses 
changes over time in the clinical parameters of a total of 105,056 patients re-
ceiving disease management for type 2 diabetes, taking into account heteroge-
neity in the care provided and patients covered. Based on an international re-
view, Chapter 6 explores whether and how self-management support – a vital 
yet difficult to implement component of high-quality disease management – is 
integrated into chronic care approaches in 13 European countries. Chapter 7 
investigates the suitability of using routine performance data for assessing the 
‘real-world’ effects of population-wide disease management approaches imple-
mented in actual health care settings. In Chapter 8, multilevel regression meth-
ods are introduced as useful techniques for the analysis of patient data in prac-
tice-based disease management evaluation. By allowing investigations of the 
consistency of findings, these methods can identify differences in outcomes as a 
function of features of the intervention and/or patient population. Finally, in 
Chapter 9, the main findings presented in the dissertation are discussed and 
recommendations are formulated regarding future developments in disease 
management design and evaluation.  
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ABSTRACT 
Objective: The aim of this article is to assess to what extent recent chronic care 
reform in the Netherlands can be considered patient-centered, that is, in line 
with gaps in quality of service provision experienced by chronically ill patients.  
Methods: We gathered literature from various national and international 
sources to gain insight into Dutch chronic care reform since 2008. To compare 
reform goals with patients’ experiences of poor quality, we used the Dutch out-
comes of the 2008 Commonwealth Fund International Health Policy survey of 
chronically ill adults (N=1,000). Four researchers independently linked policies 
with patient experiences, after which a meeting was held to achieve consensus. 
Results: In 2009, the Netherlands formally introduced a bundled payment sys-
tem for chronic care, under which health insurers and multidisciplinary care 
groups – guided by disease-specific care standards – negotiate the price for a 
complete package of outpatient services for a specific condition. In line with 
patients’ experiences of poor quality, the reform focuses on improving coordina-
tion and chronic care management rather than access and safety. Protocol ad-
herence and coordination of care appear to improve as a result of the bundled 
payment system, though considerable boundaries remain between sectors. To 
date, self-management support and clinical information systems remain under-
developed. 
Conclusions: Although from a patient perspective, the Dutch reform of long-
term care targets the right areas for quality improvement, the daily practice of 
service provision is still far from patient-centered. Further improvements are 
necessary to meet the complex care needs of the chronically ill.  
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INTRODUCTION 
Now that chronic conditions are the most common diseases in western society, 
active participation of patients in their treatment – often referred to as ‘self-
management’ – has become both crucial and inevitable. Crucial because the 
outcomes of chronic care are highly contingent on patients’ motivation and abil-
ity to self-care, i.e. to adequately deal with the often substantial medical, behav-
ioural, and emotional consequences of long-term illness.[1,2] Inevitable because 
only patients themselves, as ‘owners of their disease’, can be responsible for 
their day-to-day care over the full course of illness.[3]  
Our traditional, acutely-oriented health systems are ill-equipped to support 
patients in their efforts to adequately manage chronic disease. Care provision is 
often impersonal, fragmented across providers and settings, episodic, reactive, 
and insufficiently evidence-based, resulting in poor disease control and gener-
ally dissatisfied patients.[4,5] Dealing with the problems in chronic care has 
been characterised by some as the greatest challenge facing 21st century health 
care.[6] Although there is general consensus that ‘doing more of the same’ is not 
an option, the question how best to transform health systems to better meet 
patients’ complex care needs remains subject of great debate. International 
diversity makes a universal solution unlikely, as what works in one setting 
might not be feasible in another. Nonetheless, countries can learn from experi-
ences abroad, as illustrated by the use of originally American health service 
innovations, such as disease management and the well-known Chronic Care 
Model (CCM), to guide health system reconfigurations in countries like Austra-
lia, Canada, Germany and the United Kingdom.[6,7]  
As the central actors in high-quality chronic care management[1], patients’ 
experiences with service delivery might be the most important indicators of the 
type and extent of improvement that is necessary in a given health system. In 
2008, the Commonwealth Fund (CWF) conducted an International Health Policy 
Survey of chronically ill patients’ experiences with four aspects of their care: 
access; coordination and transitions; safety; and chronic care management.[5] 
Among the eight participating countries, the Netherlands often ranked first or 
second for positive experiences, especially with regard to (timely) access to 
recommended care and medications, and safety of service provision. Coordina-
tion of care, in particular during transitions from and to hospitals, was evaluated 
somewhat less positive than in most other countries.[5] 
Since the CWF survey of 2008, Dutch government has introduced a compre-
hensive reform package to (further) improve the quality of chronic care deliv-
ery. In this article, we describe the reform of long-term care provision in the 
Netherlands and, more importantly, we use the Dutch CWF survey results to 
assess the level of patient-centeredness of this system redesign, by analysing the 
extent to which improvement goals correspond with gaps in quality experienced 
by patients. In order to contextualise Dutch chronic care management, a concise 
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overview is given of key features of the Dutch health system relevant to caring 
for the chronically ill. First, however, the study methods are explained.  
METHODS 
To gain insight into chronic care reform in the Netherlands since 2008, we used 
data gathered as part of the European DISMEVAL (‘Developing and Validating 
Disease Management Evaluation Methods for European Health Care Systems’) 
project; the data collection template that was used is described in detail else-
where.[8] The DISMEVAL data, drawn primarily from Parliamentary documents 
and policy notes, were complemented by a qualitative review of the published 
and grey literature concerning recent Dutch long-term care redesign. To assess 
to what extent the reform of chronic care in the Netherlands targets the right 
areas for improvement, i.e. those areas where patients experience gaps in qual-
ity, we used the Dutch outcomes of the 2008 Commonwealth Fund (CWF) Inter-
national Health Policy Survey of chronically ill adults in Australia, Canada, 
France, Germany, the Netherlands, New Zealand, the United Kingdom, and the 
United States. In the Netherlands, this survey targeted a sample of 1,000 chroni-
cally ill adults, suffering from at least one of seven conditions: hypertension, 
heart disease (including heart attack), diabetes, arthritis, lung problems (asth-
ma, emphysema, and chronic lung obstruction), cancer or depression.[5]  
To allow for a structured, systematic comparison between the goals of 
Dutch chronic care reform on the one hand and gaps in service quality experi-
enced by patients on the other, we summarised the questionnaire items in-
cluded in the CWF survey (i.e. solely those items that specifically concerned 
health care experiences) into the rows of a table. For each link that could be 
made between a redesign goal on the one hand and an aspect of patients’ health 
care experience (i.e. survey item) on the other, a ‘+’ sign was filled into this ta-
ble. Where no link could be found, a ‘-’ sign was filled in. To prevent bias due to 
subjectivity, the linking exercise was first completed independently by each 
author, after which a meeting was held to discuss individual results and achieve 
consensus where necessary. Table 1 provides an overview of the links agreed 
upon during this meeting.  
RESULTS 
An introduction to health care in the Netherlands 
Similar to some other European countries, the Netherlands has a long tradition 
of non-governmental health care provision, which originated in private and 
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often charitable, voluntary organisations.[9] The majority of Dutch hospitals and 
care institutions is still privately-owned; the regulation of the health system is 
predominantly a task of government, which has relatively weak hierarchical 
power.[10,11]  
Since the Second World War, health care financing in the Netherlands has 
been characterised by a dividing line between statutory sickness fund insurance, 
which covered about 63% of the population, and private health insurance, cov-
ering the remaining 37%.[12] In 2006, after many years of political debate, this 
dual arrangement was replaced by a compulsory social health insurance (SHI) 
scheme with competing private insurance funds.[13] All Dutch citizens contrib-
ute to the SHI scheme, which covers ‘essential curative care’, by paying flat-rate 
premiums to the insurer of their choice as well as an income-dependent em-
ployer contribution.[9]  
With regard to service delivery, a unique attribute of the Dutch health sys-
tem is the pivotal role of the general practitioner (GP), who is positioned at the 
center of a strong primary care sector. GPs form the first point-of-contact for 
care-seeking individuals, are specialised in common, minor and chronic disease, 
and are available to their patients at close proximity both during and outside of 
office hours.[14] As gatekeepers to secondary care, GPs prevent unnecessary 
use of more expensive specialist services.[9] 
Dutch chronic care redesign 
Persons suffering from one or more chronic conditions require coordinated 
services from a wide range of health care providers over an extended period of 
time, embedded in a system that is organised around the patient.[13] Yet in 
most countries, financial, legal, cultural, and positional barriers hamper the 
coordination of inputs that is necessary to optimise chronically ill patients’ 
health and prevent or at least postpone the coming about of serious complica-
tions.[15] In the Netherlands, the existence of fragmentation within and be-
tween care sectors has long been a major source of concern. In the early 1990s, 
shared care initiatives were developed by collaboratives of primary and secon-
dary care professionals to reduce the boundaries between sectors in specific 
areas of service provision.[11] Although some local initiatives evolved into more 
comprehensive disease management programmes for conditions such as diabe-
tes and stroke[16,17], uptake of disease management initially remained limited, 
mainly due to lack of a structured framework and fragmentary funding.[18] 
These two barriers to improving coordination of care were addressed simulta-
neously with the introduction of the so-called ‘bundled payment system’ for 
integrated chronic care based on recognised, disease-specific care standards, 
which started out as a small-scale, experimental pilot in type 2 diabetes care in 
2007.[19,20] In 2008, the Dutch Minister of Health, Welfare and Sports pre-
sented the concept of bundled payments to Dutch Parliament in two let-
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ters[21,22]; in September 2009, nationwide implementation of the reformed 
payment system was formally approved for type 2 diabetes care, chronic ob-
structive pulmonary disease (COPD) care, and vascular risk management.[23] 
Under the bundled payment system, which is currently voluntary, health in-
surers pay a single fee to a regional care group – a legal entity in primary care, 
most commonly owned by GPs, that delivers care itself and/or subcontracts 
(other) care providers – to cover the complete package of outpatient services for 
a specific chronic disease.[23] Care bundle price is freely negotiated between 
care group and insurer; the fees for subcontractors are negotiated between care 
group and relevant professionals, such as physical therapists, dieticians, labora-
tories, and/or specialists. Since 2007, the number of care groups with a bundled 
payment contract for the provision of generic type 2 diabetes care has grown 
exponentially to more than 100 groups gathering about 80% of Dutch GPs in 
March 2010. A survey among 55 of these groups showed that contracts for 
COPD care and vascular risk management are coming about more slowly: in 
2010, no more than 13% of groups had a bundled payment contract for manag-
ing one or both of these conditions.[24] 
The services to be covered by bundled payment contracts are codified by 
disease-specific care standards developed on the national level by patient and 
provider organisations.[25-27] These standards are based on existing guidelines 
for GPs and include general modules (such as information, education and self-
management support, smoking cessation, physical activity, and nutrition and 
diet) as well as disease-specific modules.[28] In the case of, for example, type 2 
diabetes care, the latter comprise a defined frequency of GP visits, regular foot 
and eye examinations, and laboratory testing.[25] All services included in care 
bundles are covered by the basic SHI package that is mandatory for Dutch citi-
zens.[23]  
Comparing redesign goals to patient experience 
Table 1 shows the rankings of the Dutch health care system on the items of the 
2008 Commonwealth Fund (CWF) International Health Policy Survey of chroni-
cally ill adults.[5] In addition, the table links the chronic care reform policies 
introduced in the Netherlands since 2008 with the outcomes of the CWF survey, 
thereby showing the extent to which the right improvement areas are targeted, 
i.e. those areas where chronically ill patients experience poor quality. The links 
between chronic care reform and patients’ experiences will be discussed per 
survey topic.  
Access to care 
Table 1 shows that compared to patients elsewhere, Dutch chronically ill per-
sons are most positive about the accessibility of their care system. Comprehen-
sive health insurance benefits guarantee that people do not experience cost as a 
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major deterrent to seeking (at least essential) medical help.[5] Timely access is 
facilitated by the existence of a well-developed primary care system, in which 
GPs are the central care providers.[9,14] In line with patients’ positive appraisal 
of their access to care, Table 1 shows that the recent reform of Dutch chronic 
care does not target any direct improvements in this area.  
Care coordination and transitions  
The outcomes of the 2008 CWF survey show that Dutch chronically ill patients 
experience insufficient coordination of care across different providers and set-
tings. They report problems with medical records and test coordination, unnec-
essary duplication of tests, a lack of insight into their medical histories, and in-
sufficient control during transitions from ambulatory to inpatient care and vice 
versa.[5] Conform the poor CWF survey scores, improving coordination of care 
is an important goal of the recent Dutch chronic care redesign.[21,22] That be-
ing said, we found surprisingly few links between this redesign and the coordi-
nation-related survey items, most likely because while the latter focus predomi-
nantly on continuity of care during transitions between sectors, Dutch long-term 
care reform is concentrated in primary care.[29] By allowing free negotiations 
on the price of care bundles while at the same time demanding transparency 
regarding performance on various processes and outcomes, the system intends 
to motivate primary care providers to engage in (interdisciplinary) cooperation 
and provide coordinated, high-quality care to chronically ill patients according 
to evidence-based care standards.[23]  
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Safety 
When compared to the other countries included in the 2008 CWF survey, the 
Netherlands scores well on issues related to safety in health care. Relatively few 
patients indicate having experienced mistakes in their treatment during the 
two-year period prior to completing the survey. The results concerning safety of 
medication use appear contradictory: while the management by care providers 
is experienced as particularly poor, Dutch patients are least likely to experience 
medication errors.[5] In concurrence with patients’ perception of this aspect of 
their care, medication control is the only safety-related issue targeted by the 
recent reform of chronic care in the Netherlands. By including pharmacists into 
the group of providers with whom care groups are stimulated to reach struc-
tural working agreements, the goal is to prevent physicians, especially those 
separated by different health care settings, from unknowingly prescribing po-
tentially harmful combinations of medications to patients.[25]  
Chronic care management 
According to the CWF survey, chronically ill patients in the Netherlands are 
relatively dissatisfied with the management of their disease, especially with the 
extent to which they are involved in treatment decisions and the follow-up of 
their condition over time.[5] Table 1 shows that the goals of Dutch chronic care 
reform can be linked to all issues relating to chronic care management, thus 
reflecting the poor experiences of patients. These issues broadly concern three 
topics: (1) active participation/self-management of patients; (2) expanded roles 
for nurses; and (3) evidence-based service provision.[5] As to the first, self-
management support forms an important building block of the Dutch care stan-
dards for chronic conditions, which emphasise that patients must be educated 
and empowered to be able to take on a central role in their treatment.[25-27] 
Moreover, an individual care plan stipulating agreed upon treatment goals and 
activities should be developed by each patient and his/her practice team.[28] 
Task redistribution from doctors to nurses is stimulated by the functional de-
scription of service delivery in the care standards, which stipulate what services 
must be offered rather than by whom or where.[20] To stimulate evidence-
based care delivery, bundled payment contracts oblige care groups to provide 
health insurers with annual performance data on a range of standard-related 
indicators for chronic care processes and outcomes.[23]  
DISCUSSION 
Since the first experiments with bundled payments for generic diabetes care in 
2007, chronic care in the Netherlands has undergone a comprehensive reform 
that fundamentally changed the way services are provided to patients suffering 
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from type 2 diabetes, COPD, and/or vascular risks. Our study shows that the 
goals of this reform can be considered patient-centered, i.e. in line with gaps in 
quality experienced by 1,000 Dutch chronically ill patients participating in the 
2008 Commonwealth Fund (CWF) International Health Policy survey.[5]  
Access to care and safety of service provision are experienced positively by 
patients and, in line with this appraisal, are not areas where direct improve-
ments are sought after in the Netherlands. With regard to access, it is important 
to note that several historical characteristics of Dutch health care – most notably 
the universal coverage of essential care costs and the existence of a strong pri-
mary care sector – minimise the boundaries experienced by patients in gaining 
care and are widely considered as crucial prerequisites for improving chroni-
cally ill persons’ health outcomes.[30,31] The main safety-related goal of the 
chronic care reform is to improve medication control, for which purpose coop-
eration with pharmacists is stimulated by the care standards for specific condi-
tions. However, a survey among 55 diabetes care groups in 2010 showed that in 
practice, few groups (19%) have actually made structural working agreements 
with pharmacists.[24]  
Most links with recent Dutch chronic care reform policies were found in 
those sections of the CWF survey where patients reported experiencing multiple 
gaps in quality, that is, ‘care coordination and transitions’ and ‘chronic care 
management’.[5] Overcoming fragmentation is perhaps the most important aim 
of implementing bundled payments for chronic care in the Netherlands.[20] 
However, contrary to most of the coordination-related items in the CWF survey, 
the Dutch bundled payment system focuses mainly on bridging barriers be-
tween providers working within primary care and not on reducing fragmenta-
tion between sectors. The first-year results of experimenting with bundled 
payments for type 2 diabetes care showed that the coordination of services for 
patients with this condition improved.[19,20] Because of the strong focus of 
reform policies on generic, outpatient care, however, there is no population 
management and – perhaps even more importantly – considerable (financial) 
barriers remain between primary and secondary care. These barriers put pa-
tients, especially those with complex conditions who require regular inputs 
from both generalists and specialists, at risk of unnecessary errors and adverse 
advents during their transitions between ambulatory and inpatient care.[5,17]  
Another potential shortcoming of the redesigned chronic care system in the 
Netherlands with regard to coordination of care is that service delivery follows a 
disease management-like, single condition approach. In recent years, disease 
management has come under increasing international pressure for neglecting 
multimorbidity, a phenomenon most common among the elderly.[28,32,33] It 
remains to be seen whether the Dutch care bundles for individual conditions can 
meet the complex needs of patients suffering from multiple conditions and not 
exacerbate the already existing fragmentation in service provision for this grow-
ing population.[13] Future efforts to improve coordination of care for the 
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chronically ill in the Netherlands should focus, amongst others, on advancing 
clinical information systems, which providers participating in the diabetes care 
experiment reported to be flawed and inadequate.[19,20] Information technol-
ogy can be used to enhance communication between physicians and patients, 
and to enable continuous monitoring of patients’ health status from a distance. 
Systematic reviews of international evidence have shown that telemonitoring 
can positively affect clinical outcomes for chronically ill patients.[34-36] 
 With regard to chronic care management, the Dutch reform policies target 
improvements in self-management support, the role of nurses, and the extent of 
evidence-based care provision. As to the latter two, and especially providers’ 
adherence to evidence-based treatment protocols, the first-year evaluation of 
the diabetes care pilot demonstrated positive results. Across care groups, the 
proportion of patients with registered measurements of glycated haemoglobin, 
blood pressure, kidney function, low-density lipoprotein, and body mass index 
was above 85%. With regard to patient outcomes, the evaluation did not (yet) 
demonstrate considerable changes on any of these clinical measures after one 
year follow-up.[19] Nurses traditionally play an important role in Dutch chronic 
care[16,37] and are now represented in the vast majority of care groups: of 55 
diabetes groups surveyed in 2010, 98% employed general practice nurses and 
76% either employed or structurally collaborated with specialised diabetes 
nurses.[24] Studies in the Netherlands and elsewhere have shown that nurse-
led care can have promising effects on patients’ self-management and, ulti-
mately, on their health outcomes.[16,37-39] However, despite the involvement 
of nurses and the emphasis on the central role of patients in the Dutch care 
standard for diabetes, self-management support remains underdeveloped and is 
generally not purchased by health insurers.[19,20] A recent survey among more 
than 630 Dutch patients receiving vascular risk management showed that less 
than 40% is involved in treatment decisions and that only about 6% has an indi-
vidual care plan.[40,41] Given the impact of patients’ self-management on their 
health outcomes[38], it is important that in coming years, broad dissemination 
of local ‘best practices’ in self-management support is stimulated through clear 
and proactive policymaking. Moreover, health care professionals must be of-
fered the knowledge, skills, resources, and incentives to empower patients to 
take on an active role in their treatment. To date, patient self-management sup-
port is not part of the medical curriculum in the Netherlands, financial incen-
tives appear to motivate standardised rather than personalised chronic care 
provision[42], and valuable technology – such as telemonitoring devices and 
interactive patient education websites – is still in its infancy.  
Limitations 
Our study has several limitations. Most importantly, the fact that our findings 
are based on literature research makes them prone to search bias. We at-
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tempted to minimise this by using a structural data collection template and 
gathering data from multiple sources. Moreover, even though Table 1 was filled 
out after a consensus meeting between four independent researchers, the links 
identified between Dutch chronic care reform and patients’ scores on the items 
of the CWF survey are to some extent subjective. Hence, it is important to note 
here that our findings, based on the linking exercise, corroborate the conclu-
sions drawn in a recent report of the Dutch Court of Audit, which investigates 
whether central government policy is implemented as intended. According to 
the Court, the assumption that coordinated care will arise automatically follow-
ing the introduction of bundled payments is too optimistic.[43]  
CONCLUSIONS 
Although from a patient perspective, the Dutch reform of long-term care targets 
the right areas for improvement, i.e. those areas where patients perceive gaps in 
quality, the daily practice of service provision is still far from patient-centered. 
The available evidence on the effects of bundled payments for diabetes care 
indicates that while improvements have occurred in coordination of care and 
protocol adherence, much work remains to be done in the Netherlands. In com-
ing years, further advances are necessary with regard to self-management sup-
port and clinical information systems; also, attention must be given to the coor-
dination of care across settings and, for the growing population of multimorbid 
older patients, across conditions. As the reform plays out, it will be essential to 
monitor the effects of bundling care services on a wide variety of indicators, 
including not only clinical outcomes but also more patient-centered measures – 
such as quality of life, patient satisfaction, and self-efficacy – and to compare 
these with experiences elsewhere, so as to stimulate evidence-based chronic 
care redesign.  
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ABSTRACT 
Objective: To support decision-making on how best to redesign diabetes care 
by investigating three potential sources of heterogeneity in effectiveness across 
trials of diabetes care management.  
Methods: Medline, CINAHL, and PsycInfo were searched for systematic reviews 
and empirical studies focusing on: (1) diabetes mellitus; (2) adult patients; and 
(3) interventions consisting of at least two components of the Chronic Care 
Model (CCM). Systematic reviews were analysed descriptively; empirical studies 
were meta-analysed. Pooled effect measures were estimated using a meta-
regression model that incorporated study quality, length of follow-up, and num-
ber of intervention components as potential predictors of heterogeneity in ef-
fects.  
Results: Overall, reviews (N=15) of diabetes care programmes report modest 
improvements in glycaemic control. Empirical studies (N=61) show wide-
ranging results on glycated haemoglobin (HbA1c), systolic blood pressure, and 
guideline adherence. Differences between studies in methodological quality 
cannot explain this heterogeneity in effects. Variety in length of follow-up can 
explain (part of) the variability, yet not across all outcomes. Diversity in the 
number of included intervention components can explain 8 to 12% of the het-
erogeneity in effects on HbA1c and systolic blood pressure.  
Conclusions: The outcomes of chronic care management for diabetes are gen-
erally positive, yet differ considerably across trials. The most promising results 
are attained in studies with limited follow-up (<1 year) and by programmes 
including more than two CCM components. These factors can, however, explain 
only part of the heterogeneity in effectiveness between studies. Other potential 
sources of heterogeneity should be investigated to ensure implementation of 
evidence-based improvements in diabetes care.  
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INTRODUCTION 
Traditional models of care, developed to react to acute episodes of illness, are 
not sufficiently equipped to deal with complex chronic diseases, such as diabe-
tes mellitus.[1,2] Widespread quality deficiencies exist, including fragmentation, 
insufficient adherence to evidence-based practice guidelines, and limited follow-
up of patients over time.[3-7] As a result, the outcomes of diabetes care – in 
terms of effectiveness, disease control, and patient satisfaction – are often in-
adequate. In response to these problems, new strategies of providing diabetes 
care are being introduced in many countries around the world. These strategies 
are as diverse as the health care systems in which they are implemented and 
include such concepts as case management, integrated care, and care coordina-
tion.[8-10] Perhaps best known internationally are disease management and the 
Chronic Care Model (CCM), both of which were introduced first in the United 
States (US). The CCM was adopted by the World Health Organisation (WHO) as 
an evidence-based guide for improvement in the four basic elements necessary 
for the provision of high-quality chronic care: self-management support, deliv-
ery system design, clinical information systems, and decision support.[11,12] 
Despite the inherent logic and appeal of chronic care management – i.e. bet-
ter care today will result in better health and less expensive care in the future – 
coming to strong conclusions regarding effectiveness has proven difficult.[13-
16] The existing evidence base is limited and flawed by a high level of statistical 
heterogeneity, that is, variance in measured effects.[17-23] Variation in nomen-
clature contributes considerably to this heterogeneity in outcomes across stud-
ies, as do differences in methodology.[24,25] It is, however, especially the inher-
ently multicomponent nature of chronic care management that presents evalua-
tors and, in particular, systematic reviewers with challenges. Previous research 
has shown that differences between studies in the number and combination of 
included intervention components complicate the pooling of data that is so cru-
cial to evidence-based medicine.[26] 
In recent years, some authors have cautioned against the impulse to widely 
implement innovative but unproven care strategies, which might waste re-
sources and could even have adverse effects on patients’ health.[14,16,27] To 
prevent this, it is crucial that we revisit the current body of literature and eluci-
date the existing heterogeneity in effectiveness. The present review addresses 
this issue by synthesising the international literature on diabetes care manage-
ment and, subsequently, assessing the extent to which differences in outcomes 
between studies of diabetes care management can be explained by differences 
in either of three factors: (1) methodological study quality; (2) length of follow-
up; and (3) number of included intervention components according to the CCM. 
Study quality is investigated because this has been criticised in diabetes re-
search[25] and including good and poor quality trials in a systematic review 
may increase heterogeneity of estimated effects across trials.[28, 29] Length of 
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follow-up is important in investigating complex multicomponent interventions, 
such as chronic care management, because the required behavioural, organisa-
tional and cultural changes need time to come about.[13] Hence, studies with a 
short follow-up period may either over- or underestimate effects.[30] The num-
ber of components included in an intervention is investigated as a potential 
cause of heterogeneity in results because the CCM assumes that more compre-
hensive programmes attain more promising effects.[11,12] Meta-analysis and 
meta-regression will be used to determine the pooled effects of diabetes care 
management programmes on different outcomes as well as to investigate the 
three potential sources of heterogeneity described above. Aim of the review is to 
support the understanding of and decision-making about how best to redesign 
diabetes care.  
METHODS 
Literature search 
We combined Medical Subject Headings (patient care team; patient care plan-
ning; primary nursing care; case management; critical pathways; primary health 
care; continuity of patient care; guidelines; practice guideline; disease manage-
ment; comprehensive health care; and ambulatory care) and text words (disease 
state management; disease management; integrated care; coordinated care; and 
shared care) related to chronic care management with the MeSH term diabetes 
mellitus to search the databases Medline, CINAHL and PsycInfo for English-
language systematic reviews published between 1995 and 2011. The references 
from each of the included reviews were hand-searched for potentially relevant 
empirical studies.  
Study inclusion and data extraction 
We included any systematic review or empirical study that focused on: (1) dia-
betes mellitus as the main condition of interest; (2) adult patients as the main 
receivers of the interventions; and (3) interventions consisting of at least 2 
components of the CCM.[11-13] Case reports and expert opinions were ex-
cluded, as were studies that did not report on any relevant outcome measure. 
Three members of the research team (AE, LS, LL) independently screened cita-
tions and abstracted included reviews and studies using separate structured 
data entry forms. Disagreements were resolved by consensus. 
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Assessing sources of heterogeneity 
Based on the existing literature, we a priori identified three potential sources of 
heterogeneity in effects: methodological quality[25,28,29], length of follow-
up[13,30], and number of included intervention components.[11,12] We used 
the validated HTA-DM instrument to classify studies as demonstrating either 
low (<50 points), moderate (50 to 69 points), or high quality (70 to 100 
points).[31] The use of quality scales in systematic reviews has been criticised, 
particularly as a means to exclude or assign weights to trials[28,29], yet we 
applied a tailor-made, validated instrument and used this solely to categorise 
studies according to their quality. Length of follow-up was measured in months. 
For the purpose of meta-analysis, this variable was dichotomised (<1 year, ≥1 
year); in the meta-regression, length of follow-up was included as a continuous 
variable (number of months). To group diabetes care programmes according to 
the four basic elements of the CCM, we followed the coding method of Zwar et 
al.[32], using the most recent description of the model’s components by Wagner 
et al.[12]  
Statistical analyses 
Data collected from the reviews were analysed descriptively; data from empiri-
cal studies were in addition meta-analysed with the Review Manager (version 
5.0.2; The Cochrane Collaboration). An a priori decision was made to meta-
analyse the two most frequently measured clinical outcome indicators (glycated 
haemoglobin [HbA1c] and systolic blood pressure [SBP]) and the single most 
reported indicator of process (guideline adherence). To account for baseline 
differences between groups in clinical outcomes, the mean changes from base-
line to follow-up were compared. Variances of changes were rarely reported, in 
which case they were assumed to be equal to one half of the sum of the vari-
ances of the baseline and follow-up measures.[33] Missing standard deviations 
were calculated by using reported 95% confidence intervals (CIs) or p-
values[34] or, if such estimations were impossible, requested from the authors. 
In case of no response, the studies were excluded from the meta-analysis.  
Given the heterogeneity between studies’ results, we used the random-
effects meta-analysis model of DerSimonian and Laird[35] to calculate pooled 
mean differences and 95% CIs in HbA1c and SBP. This model was also used to 
determine the pooled relative ratios (RR) and 95% CIs for guideline adherence. 
The I² statistic was calculated to quantify the heterogeneity between studies on 
the basis of the chi-squared (χ²) test and its degrees of freedom.[34] A univari-
able meta-regression model (PROC MIXED, SAS Version 9.2, SAS Institute Inc, 
Cary, North Carolina) was fitted to estimate the extent to which covariates on 
the study level can explain the differences between studies in measured ef-
fects.[36,37] For this purpose, the effects of the empirical studies were weighted 
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by the inverse variance weight formulas. Relative ratios were logarithm trans-
formed.[38] All covariates – i.e. study quality, length of follow-up, and number of 
intervention components – were entered into the regression model as continu-
ous variables. The level of heterogeneity explained was expressed as the per-
centage change in τ2 (between-study variance) following separate inclusion of 
the covariates. 
RESULTS 
Fifteen systematic reviews[17-23,26,33,39-44] (eight of which included a meta-
analysis) and 61 empirical studies[45-105] met all inclusion criteria (Figure 1). 
The number of studies included in the reviews varied from 5 to 58, with a me-
dian of 20. The set of empirical studies included 41 randomised controlled trials 
(RCTs), 6 controlled clinical trials (CCTs), and 4 before-after (BA) studies. The 
remaining 10 trials were observational studies.  
Findings from systematic reviews 
The reviews (Appendix 1) synthesise evidence on a wide variety of strategies for 
diabetes care, ranging from disease management and case management to tele-
monitoring, specialist nurse interventions, and shared care. Common aspect of 
the programmes is their strong focus on improving glycaemic control to prevent 
diabetes-related complications, such as hypoglycaemia. The outcomes reported 
in the reviews vary, but some frequently measured variables are HbA1c (N=13), 
blood pressure (N=9), and quality of life (N=5). Overall, the reviews draw posi-
tive conclusions about effectiveness, although improvements in glycaemic con-
trol are often modest. 
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Potentially relevant reviews identified and  
title/abstract screened for retrieval: N=86 
Reviews retrieved for full text evaluation: N=41 
Empirical studies identified from included reviews 
and title/abstract screened for retrieval: 213 
Systematic reviews included in the analysis: N=15
Reviews excluded: N=45
Reasons (reviews may be excluded for more than one reason): 
1) Focus on single-component interventions: N=20  
2) No systematic review or meta-analysis: N=25  
3) Main focus on other condition than diabetes mellitus: N=4 
4) Main focus on other than adult population: N=1  
Reviews excluded: N=26
Reasons (reviews may be excluded for more than one reason): 
1) Focus on single-component interventions: N=11 
2) No systematic review or meta-analysis: N=18  
3) Main focus on other than adult population: N=3 
Empirical studies excluded: N=129
Reasons (studies may be excluded for more than one reason): 
1) No empirical study: N=23 
2) Single-component intervention: N=109 
3) Main focus on other condition than diabetes mellitus: N=23 
4) Main focus on other than adult population: N=16 
5) Abstract not available: N=4  
Empirical studies excluded: N=23
Reasons (studies may be excluded for more than one reason): 
1) Full-text not available: N=12 
2) Single-component intervention: N=12 
3) No relevant outcome measure reported: N=4 
Empirical studies retrieved for full text evaluation: N=84
Empirical studies included in the analysis: N=61  
Figure 1: Study inclusion/exclusion flowchart  
Findings from empirical studies 
Of the 61 empirical studies (Appendix 2), 39% scored high on methodological 
quality, 56% scored moderate, and 5% scored poor. Length of follow-up varied 
from 3 to 48 months, with a median of 12 months. Forty-two studies (69%) 
reported a follow-up of 12 months or more. Twenty-one studies evaluated 
chronic care management programmes with two CCM components, 19 evalu-
ated programmes with three components, and 21 evaluated programmes with 
four components. The most frequently included components of the CCM were 
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delivery system design (DSD; N=52) and self-management support (SMS; N=49), 
followed by clinical information systems (CIS; N=47) and decision support (DS; 
N=35). The 21 programmes consisting of two CCM components favoured a com-
bination of SMS and DSD (43%), whereas the 19 three component interventions 
most commonly combined SMS, DSD, and CIS (53%).  
Although the operationalisation of CCM components differed between stud-
ies, some general trends can be identified. SMS most frequently took the form of 
patient education and regular follow-up by diabetes nurse educators. DSD often 
consisted of the introduction of multidisciplinary care teams or the involvement 
of pharmacists, case managers, and/or nurse specialists in the care for diabetes 
patients. CIS were mainly telemonitoring systems but also computerised patient 
databases, shared patient records, and reminder systems. DS was offered 
through the implementation of diabetes guidelines as well as medication algo-
rithms. Most interventions aimed to improve glycaemic control by supporting 
self-management, reducing fragmentation, and/or providing evidence-based 
care. In general, control groups continued to receive usual care from their pri-
mary care physicians, although some were also given access to educational ma-
terials (Appendix 2). The two clinical outcomes measured most frequently were 
HbA1c (N=60) and SBP (N=34), whereas guideline adherence was measured 
most regularly as a process indicator (N=19). These three variables were meta-
analysed (Table 1).  
Glycated haemoglobin (HbA1c)  
All but one study[79] assessed HbA1c levels (N=60), although 
some[62,69,82,103] reported the fractions of patients accomplishing a certain 
level of glycated haemoglobin at study end (e.g. <53 mmol/mol [7.0%]) rather 
than the actual values. These studies were excluded from the meta-analysis, as 
were those for which missing data could not be estimated nor re-
trieved.[50,59,63,64,78,89,99,104] 
Overall, the pooled effect estimate (N=48) demonstrates that chronic care 
management for diabetes results in a statistically significant reduction in HbA1c 
of 5 mmol/mol [0.5%], compared to (mostly) usual care (95% CI: -7 to -3.5 
mmol/mol [-0.6 to -0.3%]). Subgroup analyses (Table 1) reveal that, apart from 
low quality studies (N=1), all subgroups of studies show a significant positive 
effect on HbA1c. The most notable improvements are attained by three compo-
nent programmes, studies with a follow-up of less than 12 months, and moder-
ate quality studies. The overall as well as the subgroup analyses show strong 
heterogeneity (I² ranging from 71 to 87%). Meta-regression demonstrates no 
significant effect of study quality, length of follow-up, or number of intervention 
components on the reduction in HbA1c (Table 1), although correcting for the 
latter covariate does result in an 8% reduction in statistical heterogeneity.  
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Table 1: Results of the meta-analysis and meta-regression 
 No. of  
Studies 
No. of  
Participants 
Mean difference 
(95% CI; I²) 
Explained  
heterogeneity (p) 
HbA1c (mmol/mol [%]) 48 11,457 -5 [-0.5] (-7, -3.5 [-0.6, -0.3]; 80%)  
Study quality    1% (p=0.68) 
Low quality 1 56 -2 [-0.2] (-9, 4 [-0.8, 0.4]; NA)  
Moderate quality 26 5,174 -6 [-0.6] (-9, -3.5 [-0.8, -0.3]; 82%)  
High quality 21 6,227 -4 [-0.4] (-6, -2 [-0.6, -0,2]; 77%)  
Length of follow-up    0.5% (p=0.66)  
<1 year 19 2,097 -7 [-0.6] (-9, -4 [-0.9, -0.3]; 71%)  
≥1 year 29 9,360 -4 [-0.4] (-6, -2 [-0.6, -0.2]; 83%)  
Number of components    8% (p=0.22) 
2 19 4,697 -4 [-0.3] (-6, -1 [-0.55, -0.1]; 71%)  
3 13 1,667 -8 [-0.7] (-13, -3 [-1.2, -0.3]; 87%)  
4 16 5,093 -4.5 [-0.4] (-7, -2 [-0.6, -0.2]; 75%)  
 No. of  
Studies 
No. of  
Participants 
Mean difference 
(95% CI; I²) 
Explained  
heterogeneity (p) 
SBP (mmHg) 25 7,719 -2.8 (-4.7, -0.9; 68%)  
Study quality    1.5% (p=0.68) 
Low quality 0 0 Not estimable  
Moderate quality 11 3,099 -2.7 (-5.0, -0.4; 54%)  
High quality 14 4,620 -3.0 (-5.9, -0.1; 76%)  
Length of follow-up    5% (p=0.42) 
<1 year 5 593 -3.4 (-7.0, -0.25; 18%)  
≥1 year 20 7,126 -2.7 (-4.8, -0.6; 72%)  
Number of components    12% (p=0.20) 
2 9 2,860 -0.6 (-4.6, 3.4; 83%)  
3 5 809 -3.3 (-6.1, -0.5; 3%)  
4 11 4,050 -4.4 (-6.8, -2.0; 57%)  
 No. of  
Studies 
No. of  
Participants 
Relative ratio  
(95% CI; I²) 
Explained  
heterogeneity (p) 
Yearly eye examination 10 6,232 1.88 (1.46, 2.42; 95%)  
Study quality    11% (p=0.2758) 
Low quality 1 1,644 1.58 (1.44, 1.74; NA)  
Moderate quality 5 3,387 3.04 (1.67, 5.55;97% )  
High quality 4 1,201 1.20 (1.05, 1.37; 52%)  
Length of follow-up    21% (p=0.1185) 
<1 year 0 0 Not estimable  
≥1 year 10 6,232 1.88 (1.46, 2.42; 95%)  
Number of components    7% (p=0.3727) 
2 0 0 Not estimable  
3 7 4,989 2.13 (1.56, 2.91; 96%)  
4 3 1,243 1.45 (0.87, 2.43; 94%)  
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 No. of  
Studies 
No. of  
participants 
Relative ratio  
(95% CI; I²) 
Explained  
heterogeneity (p) 
Yearly foot examination 10 6,818 2.11 (1.55, 2.86; 98%)  
Study quality    1% (p=0.7341) 
Low quality 1 1,644 7.91 (5.98, 10.46; NA)  
Moderate quality 5 3,387 1.94 (1.30, 2.91; 97%)  
High quality 4 1,787 1.64 (1.14, 2.35; 95%)  
Length of follow-up    49% (p=0.0032) 
<1 year 0 0 Not estimable  
≥1 year 10 6,818 2.11 (1.55, 2.86; 98%)  
Number of components    1% (p=0.7360) 
2 1 769 1.27 (1.09, 1.48; NA)  
3 6 4,806 2.80 (1.72, 4.55; 98%)  
4 3 1,243 1.55 (0.97, 2.49; 94%)  
NOTE: CI indicates confidence interval; I², statistical heterogeneity; NA, not applicable; HbA1c, 
glycated haemoglobin; SBP, systolic blood pressure 
Systolic blood pressure (SBP) 
More than half (N=34) of the studies included in this review assessed 
SBP.[45,48,53-56,58,60,61,64,65,67-70,72,73,75-77,79,84-86,88-90,93,95-
98,100,102] Excluded from the meta-analysis were studies reporting the frac-
tions of patients achieving a certain level of SBP rather than the actual values at 
follow-up and studies for which variances of changes could not be estimated nor 
retrieved.[48,64,65,68,69,89,90,96,102]  
The meta-analysis (N=25) demonstrates a statistically significant overall re-
duction in SBP of 2.8 mmHg (95% CI: -4.7 to -0.95 mmHg) in the intervention 
groups as compared to the control groups. Subgroup analyses show that two-
component interventions and studies with a follow-up of less than one year are 
not associated with a significant reduction in SBP. Moderate heterogeneity ex-
ists between studies in terms of measured effects (I²=68%). Meta-regression 
demonstrates no significant effect of study quality, length of follow-up, or num-
ber of intervention components on the reduction in SBP (Table 1), although 
correcting for the latter covariate does result in a 12% reduction in statistical 
heterogeneity.  
Guideline adherence 
About one third of the included studies (N=19) uses providers’ adherence to 
evidence-based guidelines as an indicator of process and compares the extent to 
which intervention and control patients received recommended medical proce-
dures over specific periods of time (usually 12 months).[47,52-55,60,62, 
64,67,69,79,80,86,89-91,100,103,104] As the content of the diabetes guidelines 
used in the chronic care management programmes differs considerably, the two 
most uniformly and frequently measured recommendations were meta-
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analysed (Table 1). These concern the yearly provision of one eye examination 
(N=10) and one foot examination (N=10).  
The meta-analysis for eye examinations[60,62,69,80,86,89,90,100,103,104] 
provides a pooled RR of 1.88 (95% CI: 1.46 to 2.42), indicating a significantly 
greater probability of yearly eye screenings in the intervention groups. The 
likelihood for patients to receive a yearly foot exam is 111% higher in the inter-
vention groups (N=10; RR=2.11; 95% CI: 1.55 to 2.86).[54,60,62,69,80, 
86,89,90,103,104] Subgroup analyses, which were possible for number of com-
ponents and study quality, demonstrate that only three-component pro-
grammes attain statistically significant improvements in the rates of yearly eye 
and foot examinations. Meta-regression does not, however, show significance 
for either of these covariates, which implies that they cannot explain the hetero-
geneity between studies (I² ranging from 52 to 98%). Variation in length of fol-
low-up, included in the meta-regression as a continuous variable (i.e. number of 
months), explains 49% of the heterogeneity in effects on foot screening 
(p=0.003), yet cannot explain variability with regard to effects on eye examina-
tions (p=0.12). 
DISCUSSION 
In line with previously conducted systematic reviews in this field, our meta-
analysis suggests that chronic care management programmes have positive 
effects on the processes and outcomes of diabetes care. However, the empirical 
studies underlying our analysis differ considerably in both the directions and 
sizes of measured effects. Diversity in study quality does not appear to explain 
this statistical heterogeneity, although few of the trials included in our analysis 
were categorised as having low quality (which might be a consequence of our 
strategy of searching for empirical studies via systematic reviews). Variety in 
length of follow-up explains 49% of the variability across trials in effects on 
providers’ adherence to foot screening guidelines (p=0.003). In terms of effects 
on clinical outcomes, the overall positive impact of chronic care management 
appears to diminish with increased length of follow-up, although the differences 
between subgroups are not statistically significant. Given that the positive ef-
fects of education on patients’ self-management behaviour – and, thus, their 
glycaemic control – are difficult to maintain over time[106-108], short studies 
might overestimate effectiveness.  
Variety in the number of intervention components elucidates 8 to 12% of 
the diversity between studies with regard to measured changes in HbA1c and 
SBP. Three- and four-component interventions attain stronger, though not sig-
nificantly stronger, effect estimates than do two-component strategies. This 
finding is conform the presumption of the CCM that changes must be made in 
multiple areas in order to considerably improve the quality and outcomes of 
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chronic care.[11,12] Relatively few trials evaluated diabetes care programmes 
that integrated all CCM components, even despite the relatively long existence of 
and strong scientific support for this framework.[11-13] This might very well 
limit the effects of chronic care management on patient outcomes.  
As far as we are aware, this study is the first meta-analysis of chronic care 
management for diabetes that attempts to explain statistical heterogeneity by 
assessing differences in methodological quality, length of follow-up, and number 
of intervention components according to the CCM. Shojania et al.[26] conducted 
a meta-analysis of diabetes care strategies with adjustment for effects of study 
size and mean baseline HbA1c values: these factors reduced statistical hetero-
geneity by approximately 50%. More recently, Pimouguet et al.[44] assessed the 
effect of various patient characteristics and disease management features on 
changes in HbA1c concentration. The authors found that disease management 
programmes are more effective for patients with poor glycaemic control (base-
line HbA1c >8.0%). Moreover, treatment adjustment (i.e. the ability of disease 
managers to start or modify medical treatment) and patient education were 
identified as effective features of disease management. In line with our results, 
Pimouguet et al.[44] also found that shorter studies report more promising 
effects on glycaemic control than do longer studies, although this difference did 
not achieve statistical significance. 
Other reviews have also attempted to answer the question ‘what is most ef-
fective’ in diabetes care[16,17,21], but their results are divergent and question-
able, as there is a lack of clear terminology in the area of chronic care manage-
ment. Hence, fundamentally different interventions share the same moniker, 
which may obscure important information concerning their working mecha-
nisms, especially when they differ in effectiveness.[24] The potential causes of 
heterogeneity included in our analyses were selected on the basis of the avail-
able evidence. Nonetheless, the variation in effect sizes across trials is likely to 
be caused by other study-level factors, such as differences in study design, target 
population, and implementation context. The degree of integration of interven-
tion components might also be an important cause of statistical heterogeneity, 
as the CCM assumes that programmes in which elements are strongly interre-
lated result in better outcomes than programmes in which elements are more 
loosely coupled.[11,12]  
Our study used an extensive search strategy following the internationally 
accepted definition of chronic care management[109] and was conducted on the 
basis of combined expertise from five research institutes. Nevertheless, some 
limitations should be noted. First, it can be questioned whether the HTA-DM 
instrument[31] – the only relevant and tested instrument for assessing the qual-
ity of studies evaluating chronic care management – allows for proper scoring of 
items that bias the effect of interventions for diabetes, as it focuses primarily on 
the quality of reporting. Further validation of a quality instrument for studies 
evaluating complex interventions, such as chronic care programmes, is needed. 
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Second, the care received by intervention as well as control patients is often 
poorly described, which makes comparisons between studies difficult and com-
plicates the mapping of intervention components to the CCM. In addition, many 
studies exhibit a paucity of descriptive detail – standard deviations and p-values 
are rarely reported – which necessitates either the use of estimates or exclusion 
from the analyses. Finally, the outcomes of our review are restricted to the effect 
measures used most frequently in the existing evidence on diabetes care man-
agement, whereas others, such as patients’ health-related quality of life, self-
efficacy, and satisfaction with care, might be equally or even more impor-
tant.[110-113]  
More research is needed to understand and support decision-making on 
how best to redesign the care for patients suffering from diabetes. Coming to 
strong and consistent conclusions about the impact of chronic care management 
necessitates a clear framework of the mechanisms underlying various strategies 
and their expected effects. The latter should be measured with adequate length 
of follow-up and linked logically with an intervention’s aims and components as 
well as the underlying theory driving the anticipated behaviour change in both 
patients and care providers. Moreover, evaluation efforts must be based on 
proper understanding of the characteristics of disease management pro-
grammes (i.e. scope, content, dose, context) and the populations that specific 
interventions target (i.e. disease type, severity, case-mix).[114] Elucidating het-
erogeneity in this manner allows for more in-depth and disentangled insights 
into the effects of chronic care management and aids in answering the vital 
question of ‘what works best for whom’ in diabetes care.  
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ria
ls, 
let
ter
s, o
r 
me
eti
ng
 ab
str
act
s; a
bs
tra
cts
 w
ere
 re
jec
ted
 if 
the
y d
id 
no
t re
po
rt a
ny
 ob
jec
tiv
e m
ea
su
re-
me
nts
 of
 di
sea
se 
ma
na
ge
me
nt,
 re
fer
red
 to
 cli
-
nic
al t
ria
ls c
om
pa
rin
g s
ing
le p
ha
rm
aco
log
ica
l 
ag
en
ts 
or 
dia
gn
ost
ic p
roc
ed
ure
s, o
r d
id 
no
t u
se 
a s
yst
em
ati
c a
pp
roa
ch
 to
 ca
re;
 st
ud
ies
 w
ere
 
exc
lud
ed
 if 
the
y l
ack
ed
 su
ffic
ien
t in
for
ma
tio
n 
to 
me
asu
re 
the
 ef
fec
t o
f a
n i
nte
rve
nti
on
 on
 at
 
lea
st 1
 ou
tco
me
 of
 in
ter
est
 an
d i
ts 
va
ria
nc
e. 
Dia
be
tes
 di
sea
se 
ma
na
ge
me
nt 
pr
o-
gra
mm
es 
can
 im
pr
ov
e g
lyc
ae
mi
c 
co
ntr
ol 
to 
a m
od
est
 ex
ten
t a
nd
 ca
n 
inc
rea
se 
scr
ee
nin
g f
or 
ret
ino
pa
thy
 
an
d f
oo
t c
om
pli
cat
ion
s.  
Lo
ve
ma
n e
t a
l., 
20
09
 
De
scr
ipt
ive
 re
vie
w;
 
N=
6 (
5 R
CT
s, 1
 CC
T)
 
Tw
o d
iab
ete
s s
pe
cia
lis
t n
ur
se/
nu
rse
 
cas
e m
an
ag
em
en
t in
ter
ve
nti
on
s in
 
dia
be
tes
 ca
re:
 (1
) s
pe
cia
lis
t n
ur
se 
int
erv
en
tio
n i
n a
dd
itio
n t
o r
ou
tin
e c
are
; 
(2)
 pe
dia
tri
c s
pe
cia
lis
t n
ur
se 
int
erv
en
-
tio
n i
n t
he
 m
an
ag
em
en
t o
f c
hil
dr
en
 
wi
th 
dia
be
tes
. 
Stu
die
s w
ere
 in
clu
de
d i
f th
ey
: w
ere
 RC
Ts
 or
 
CC
Ts
 w
ith
 a m
ini
mu
m 
tri
al 
du
rat
ion
 of
 6 
mo
nth
s; i
nc
lud
ed
 pa
tie
nts
 w
ith
 ty
pe
 1 
or 
2 
dia
be
tes
 m
ell
itu
s; c
om
pa
red
 sp
eci
ali
st 
nu
rse
 
int
erv
en
tio
ns
 w
ith
 no
 sp
eci
ali
st 
nu
rse
 in
ter
-
ve
nti
on
s, o
r p
ed
iat
ric
 nu
rse
 in
ter
ve
nti
on
s t
o 
sta
nd
ard
 sp
eci
ali
st 
nu
rse
 in
ter
ve
nti
on
s, i
n 
wh
ich
 it 
wa
s r
eq
uir
ed
 th
at 
the
 in
ter
ve
nti
on
 
wa
s e
va
lua
tin
g t
he
 nu
rse
 al
on
e (
i.e
. n
ot 
a 
tea
m 
ap
pr
oa
ch
), w
he
re 
ed
uc
ati
on
 w
as 
ind
i-
vid
ua
lly
 ba
sed
, an
d w
he
re 
nu
rse
s h
ad
 re
-
Th
e p
res
en
ce 
of 
a d
iab
ete
s s
pe
cia
lis
t 
nu
rse
/n
ur
se 
cas
e m
an
ag
er 
ma
y 
im
pr
ov
e p
ati
en
ts’
 di
ab
eti
c c
on
tro
l 
ov
er 
sh
ort
 tim
e p
eri
od
s, b
ut 
fro
m 
cu
rre
ntl
y a
va
ila
ble
 tr
ial
s t
he
 ef
fec
ts 
ov
er 
lon
ge
r p
eri
od
s o
f ti
me
 ar
e n
ot 
ev
ide
nt.
 Th
ere
 w
ere
 no
 sig
nif
ica
nt 
dif
fer
en
ces
 ov
era
ll i
n h
yp
og
lyc
ae
mi
c 
ep
iso
de
s, h
yp
erg
lyc
ae
mi
c in
cid
en
ts,
 
or 
ho
sp
ita
l a
dm
iss
ion
s. Q
ua
lity
 of
 lif
e 
wa
s n
ot 
sh
ow
n t
o b
e a
ffe
cte
d b
y i
np
ut 
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Au
th
or
,  
ye
ar
 o
f  
pu
bl
ic
at
io
n 
An
al
ys
is
 ty
pe
, n
o.
  
of
 s
tu
di
es
 in
cl
ud
ed
 
Co
nc
ep
t/
de
fin
it
io
n 
of
 c
hr
on
ic
 c
ar
e 
pr
og
ra
m
m
es
 
In
cl
us
io
n/
ex
cl
us
io
n 
cr
it
er
ia
 
Au
th
or
s’
 c
on
cl
us
io
ns
 
sp
on
sib
ilit
y f
or
 ad
jus
tin
g t
rea
tm
en
t r
eg
i-
me
ns
; a
sse
sse
d o
ne
 or
 m
ore
 of
 th
e d
efi
ne
d 
ou
tco
me
 m
ea
su
res
. 
fro
m 
a d
iab
ete
s s
pe
cia
lis
t 
nu
rse
/n
ur
se 
cas
e m
an
ag
er.
 
No
rri
s e
t a
l., 
20
02
 
Me
ta-
an
aly
sis
; N
=2
7 
(5 
RC
Ts
, 6
 CC
Ts
, 1
3 
pr
e-p
os
t, 3
 co
ho
rt 
stu
die
s w
ith
 co
m-
pa
ris
on
 gr
ou
p).
 
Dis
ea
se 
ma
na
ge
me
nt 
wa
s d
efi
ne
d a
s a
n 
org
an
ise
d, 
pr
oa
cti
ve
, m
ult
ico
mp
on
en
t 
ap
pr
oa
ch
 to
 he
alt
h c
are
 de
liv
ery
 th
at 
inv
olv
es 
all
 m
em
be
rs 
of 
a p
op
ula
tio
n 
wi
th 
a s
pe
cif
ic d
ise
ase
 en
tit
y s
uc
h a
s 
dia
be
tes
. 
To
 be
 in
clu
de
d i
n t
he
 re
vie
w,
 st
ud
ies
 ha
d t
o: 
be
 pr
im
ary
 in
ve
sti
ga
tio
ns
 of
 in
ter
ve
nti
on
s 
sel
ect
ed
 fo
r e
va
lua
tio
n; 
be
 co
nd
uc
ted
 in
 
Es
tab
lis
he
d M
ark
et 
Ec
on
om
ies
; p
ro
vid
e 
inf
orm
ati
on
 on
 on
e o
r m
ore
 ou
tco
me
s o
f 
int
ere
st 
pr
ese
lec
ted
 by
 th
e t
ea
m;
 an
d m
ee
t 
mi
nim
um
 qu
ali
ty 
sta
nd
ard
s. A
ll t
yp
es 
of 
co
mp
ara
tiv
e s
tud
y d
esi
gn
s w
ere
 in
clu
de
d, 
inc
lud
ing
 st
ud
ies
 w
ith
 co
nc
ur
ren
t o
r b
efo
re-
an
d-a
fte
r c
om
pa
ris
on
 gr
ou
ps
. 
Ev
ide
nc
e s
up
po
rts
 th
e e
ffe
cti
ve
ne
ss 
of 
dis
ea
se 
ma
na
ge
me
nt 
on
 gl
yca
em
ic 
co
ntr
ol;
 on
 sc
ree
nin
g f
or
 di
ab
eti
c 
ret
ino
pa
thy
, fo
ot 
les
ion
s a
nd
 pe
rip
h-
era
l n
eu
rop
ath
y, a
nd
 pr
ote
inu
ria
; a
nd
 
on
 th
e m
on
ito
rin
g o
f li
pid
 co
nc
en
tra
-
tio
ns
.  
No
rri
s e
t a
l., 
20
06
 
De
scr
ipt
ive
 re
vie
w;
 
N=
18
 (8
 RC
Ts
, 6
 
be
for
e-a
nd
-af
ter
 
stu
die
s, 3
 st
ud
ies
 
wi
th 
no
n-r
an
do
mi
sed
 
all
oc
ati
on
 of
 tr
ea
t-
me
nt 
an
d c
om
pa
ri-
so
n 
gro
up
s, 1
 st
ud
y w
ith
 
po
st-
int
erv
en
tio
n 
me
asu
res
 
on
ly)
. 
Dia
be
tes
 pr
og
ram
me
s in
clu
din
g c
om
-
mu
nit
y h
ea
lth
 w
or
ke
rs 
(CH
Ws
) a
s t
ea
m 
me
mb
ers
 in
 a v
ari
ety
 of
 ro
les
. C
HW
s a
re 
de
fin
ed
 as
 ‘co
mm
un
ity
 m
em
be
rs 
wh
o 
wo
rk 
alm
os
t e
xcl
us
ive
ly 
in 
co
mm
un
ity
 
set
tin
gs 
an
d w
ho
 se
rve
 as
 co
nn
ect
or
s 
be
tw
ee
n h
ea
lth
 ca
re 
co
ns
um
ers
 an
d 
pr
ov
ide
rs 
to 
pr
om
ote
 he
alt
h a
mo
ng
 
gro
up
s t
ha
t h
av
e t
rad
itio
na
lly
 la
ck
ed
 
acc
ess
 to
 ad
eq
ua
te 
he
alt
h c
are
’. 
Stu
die
s in
clu
de
d r
ep
ort
ed
 th
e e
va
lua
tio
n o
f 
an
 in
ter
ve
nti
on
 in
vo
lvi
ng
 CH
Ws
 de
liv
ere
d t
o 
ad
ult
s w
ith
 di
ab
ete
s. C
HW
s w
ere
 ei
the
r t
he
 
so
le 
foc
us
 of
 th
e i
nte
rve
nti
on
 un
de
r s
tud
y o
r 
on
e c
om
po
ne
nt 
of 
a m
ult
i-c
om
po
ne
nt 
int
er-
ve
nti
on
 or
 te
am
. P
art
ici
pa
nts
 ha
d t
o b
e ≥
18
 
ye
ars
 ol
d a
nd
 ha
ve
 di
ab
ete
s (
typ
e 1
, 2
 or
 
ge
sta
tio
na
l). 
Stu
die
s r
ep
ort
ing
 at
 le
ast
 on
e 
ou
tco
me
 am
on
g t
he
 pa
rti
cip
an
ts 
we
re 
in-
clu
de
d. 
Th
ere
 w
ere
 no
 re
str
ict
ion
s o
n s
tud
y 
de
sig
n. 
Th
e f
oll
ow
-up
 in
ter
va
l w
as 
of 
an
y 
du
rat
ion
. E
xcl
ud
ed
 w
ere
: st
ud
ies
 ex
am
ini
ng
 
on
ly 
ou
tco
me
s a
mo
ng
 th
e C
HW
s (
e.g
. re
po
rts
 
of 
CH
W 
tra
ini
ng
 in
ter
ve
nti
on
s);
 st
ud
ies
 
inv
olv
ing
 pe
er-
led
 pa
tie
nt 
su
pp
ort
 gr
ou
ps
; 
stu
die
s in
vo
lvi
ng
 fa
mi
ly 
me
mb
ers
 as
 pr
ov
id-
ers
 of
 ca
re.
 
Dia
be
tes
 pr
og
ram
me
s in
clu
de
 CH
Ws
 
as 
tea
m 
me
mb
ers
 in
 a v
ari
ety
 of
 ro
les
. 
Th
ere
 ar
e s
om
e p
rel
im
ina
ry 
da
ta 
de
mo
ns
tra
tin
g i
mp
rov
em
en
ts 
in 
pa
rti
cip
an
t k
no
wl
ed
ge
 an
d b
eh
av
iou
r. 
Mu
ch
 ad
dit
ion
al 
res
ea
rch
, h
ow
ev
er,
 is 
ne
ed
ed
 to
 un
de
rst
an
d t
he
 in
cre
-
me
nta
l b
en
efi
t o
f C
HW
s in
 m
ult
i-
co
mp
on
en
t in
ter
ve
nti
on
s a
nd
 to
 
ide
nti
fy 
ap
pr
op
ria
te 
set
tin
gs 
an
d 
op
tim
al 
rol
es 
for
 CH
Ws
 in
 th
e c
are
 of
 
pe
rso
ns
 w
ith
 di
ab
ete
s. 
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Au
th
or
,  
ye
ar
 o
f  
pu
bl
ic
at
io
n 
An
al
ys
is
 ty
pe
, n
o.
  
of
 s
tu
di
es
 in
cl
ud
ed
 
Co
nc
ep
t/
de
fin
it
io
n 
of
 c
hr
on
ic
 c
ar
e 
pr
og
ra
m
m
es
 
In
cl
us
io
n/
ex
cl
us
io
n 
cr
it
er
ia
 
Au
th
or
s’
 c
on
cl
us
io
ns
 
Pim
ou
gu
et 
et 
al.
, 
20
11
 
Me
ta-
an
aly
sis
 an
d 
me
ta-
reg
res
sio
n; 
N=
41
 (a
ll R
CT
s) 
Dis
ea
se 
ma
na
ge
me
nt 
wa
s d
efi
ne
d a
s 
on
go
ing
 an
d p
roa
cti
ve
 fo
llo
w-
up
 of
 
pa
tie
nts
 th
at 
inc
lud
es 
at 
lea
st 
tw
o o
f th
e 
fol
low
ing
 fiv
e c
om
po
ne
nts
: p
ati
en
t 
ed
uc
ati
on
 (d
iet
ary
 an
d e
xe
rci
se 
co
un
-
sel
lin
g, s
elf
-m
on
ito
rin
g, a
nd
 kn
ow
led
ge
 
of 
dis
ea
se 
an
d m
ed
ica
tio
n);
 co
ach
ing
 
(th
e d
ise
ase
 m
an
ag
er 
en
co
ur
ag
es 
the
 
pa
tie
nt 
to 
ov
erc
om
e p
syc
ho
log
ica
l o
r 
so
cia
l b
arr
ier
s t
ha
t im
pe
de
 au
ton
om
y 
or
 im
pr
ov
em
en
t in
 m
ed
ica
tio
n c
om
-
pli
an
ce
); t
rea
tm
en
t a
dju
stm
en
t (
the
 
dis
ea
se 
ma
na
ge
r is
 ab
le 
to 
sta
rt 
or
 
mo
dif
y t
rea
tm
en
t w
ith
 or
 w
ith
ou
t 
pr
ior
 ap
pr
ov
al 
fro
m 
the
 pr
im
ary
 ca
re 
ph
ys
ici
an
); m
on
ito
rin
g (
the
 di
sea
se 
ma
na
ge
r g
ets
 m
ed
ica
l d
ata
 fr
om
 th
e 
pa
tie
nt)
; a
nd
 ca
re 
co
or
din
ati
on
 (t
he
 
dis
ea
se 
ma
na
ge
r r
em
ind
s t
he
 pa
tie
nt 
ab
ou
t u
pc
om
ing
 ap
po
int
me
nts
 or
 
im
po
rta
nt 
asp
ec
ts 
of 
sel
f-c
are
 an
d 
inf
or
ms
 th
e p
rim
ary
 ca
re 
ph
ys
ici
an
 
ab
ou
t c
om
pli
ca
tio
ns
, tr
ea
tm
en
t a
d-
jus
tm
en
t o
r t
he
rap
eu
tic
 re
co
mm
en
da
-
tio
ns
). 
On
ly 
RC
Ts
 w
ere
 in
clu
de
d. 
Th
e s
ea
rch
 w
as 
lim
ite
d t
o E
ng
lis
h l
an
gu
ag
e p
ub
lic
ati
on
s. 
Inc
lus
ion
 w
as 
res
tri
cte
d t
o s
tud
ies
 th
at 
re-
po
rte
d H
bA
1c
. In
 ad
dit
ion
 to
 th
e o
pe
rat
ion
al 
de
fin
itio
n o
f d
ise
ase
 m
an
ag
em
en
t, t
he
 fo
llo
w-
ing
 in
clu
sio
n c
rit
eri
a w
ere
 de
fin
ed
: th
e s
tud
y 
ha
d t
o i
nv
olv
e a
du
lts
 w
ith
 ty
pe
 1 
or
 2 
dia
be
-
tes
; it
 ha
d t
o r
ep
or
t b
oth
 pr
e- 
an
d p
os
tin
ter
-
ve
nti
on
 Hb
A1
c le
ve
ls;
 an
d p
os
tin
ter
ve
nti
on
 
Hb
A1
c le
ve
ls h
ad
 to
 be
 as
ses
sed
 af
ter
 at
 le
ast
 
12
 w
ee
ks
 of
 fo
llo
w-
up
. E
xcl
ud
ed
 w
ere
 tr
ial
s 
in 
wh
ich
 th
e i
nte
rve
nti
on
 di
d n
ot 
inv
olv
e 
dir
ect
 co
nta
ct 
be
tw
ee
n t
he
 di
sea
se 
ma
na
ge
r 
an
d t
he
 pa
tie
nt 
or
 w
as 
un
cle
ar,
 un
sp
eci
fie
d o
r 
ex
clu
siv
ely
 ba
sed
 on
 co
nta
ct 
by
 In
ter
ne
t o
r 
ma
il. 
  
Dis
ea
se 
ma
na
ge
me
nt 
pr
og
ram
me
s 
ha
d a
 cli
nic
all
y m
od
era
te 
bu
t s
ign
ifi-
can
t im
pa
ct 
on
 Hb
A1
c le
ve
ls a
mo
ng
 
ad
ult
s w
ith
 di
ab
ete
s. E
ffe
cti
ve
 co
m-
po
ne
nts
 of
 pr
og
ram
me
s w
ere
 a h
igh
 
fre
qu
en
cy 
of 
pa
tie
nt 
co
nta
ct 
an
d t
he
 
ab
ilit
y f
or
 di
sea
se 
ma
na
ge
rs 
to 
ad
jus
t 
tre
atm
en
t w
ith
 or
 w
ith
ou
t p
rio
r 
ph
ysi
cia
n a
pp
rov
al.
 
Re
nd
ers
 et
 al
., 
20
00
 
De
scr
ipt
ive
 re
vie
w;
 
N=
41
 (2
7 R
CT
s, 1
2 
co
ntr
oll
ed
 be
for
e-
an
d-a
fte
r s
tud
ies
, 2
 
int
err
up
ted
 tim
e 
Dif
fer
en
t in
ter
ve
nti
on
s, t
arg
ete
d a
t 
he
alt
h c
are
 pr
ofe
ssi
on
als
 or
 th
e s
tru
c-
tur
e i
n w
hic
h h
ea
lth
 ca
re 
pr
ofe
ssi
on
als
 
de
liv
er 
the
ir c
are
, ai
me
d a
t im
pr
ov
ing
 
the
 ca
re 
for
 pa
tie
nts
 w
ith
 di
ab
ete
s in
 
Inc
lud
ed
 ty
pe
s o
f s
tud
ies
: R
CT
s, C
CT
s, c
on
-
tro
lle
d b
efo
re-
an
d-a
fte
r s
tud
ies
, in
ter
ru
pte
d 
tim
e s
eri
es.
 In
clu
de
d t
yp
es 
of 
pa
rti
cip
an
ts:
 
he
alt
h c
are
 pr
ofe
ssi
on
als
, ta
kin
g c
are
 of
 no
n-
ho
sp
ita
lis
ed
 pa
tie
nts
 w
ith
 ty
pe
 1 
or 
2 d
iab
e-
Mu
ltif
ace
ted
 pr
ofe
ssi
on
al 
int
erv
en
-
tio
ns
 ca
n e
nh
an
ce 
the
 pe
rfo
rm
an
ce 
of 
he
alt
h p
rof
ess
ion
als
 in
 m
an
ag
ing
 
pa
tie
nts
 w
ith
 di
ab
ete
s. O
rga
nis
ati
on
al 
int
erv
en
tio
ns
 th
at 
im
pr
ov
e r
eg
ula
r 
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Au
th
or
,  
ye
ar
 o
f  
pu
bl
ic
at
io
n 
An
al
ys
is
 ty
pe
, n
o.
  
of
 s
tu
di
es
 in
cl
ud
ed
 
Co
nc
ep
t/
de
fin
it
io
n 
of
 c
hr
on
ic
 c
ar
e 
pr
og
ra
m
m
es
 
In
cl
us
io
n/
ex
cl
us
io
n 
cr
it
er
ia
 
Au
th
or
s’
 c
on
cl
us
io
ns
 
ser
ies
). 
pr
im
ary
 ca
re,
 ou
tpa
tie
nt 
an
d c
om
mu
-
nit
y s
ett
ing
s. 
tes
 m
ell
itu
s in
 a p
rim
ary
 ca
re,
 ou
tpa
tie
nt,
 or
 
co
mm
un
ity
 se
tti
ng
. T
yp
es 
of 
int
erv
en
tio
ns
: 
str
ate
gie
s t
o i
mp
ro
ve
 th
e c
are
 fo
r p
ati
en
ts 
wi
th 
dia
be
tes
, in
clu
din
g o
rga
nis
ati
on
al,
 
pr
ofe
ssi
on
al,
 an
d f
ina
nc
ial
 in
ter
ve
nti
on
s. 
Ty
pe
s o
f o
utc
om
e m
ea
su
res
: o
bje
cti
ve
ly 
me
asu
red
 he
alt
h p
rof
ess
ion
al 
pe
rfo
rm
an
ce 
or 
pa
tie
nt 
ou
tco
me
s in
 a c
lin
ica
l se
tti
ng
 an
d s
elf
-
rep
ort
ed
 m
ea
su
res
 w
ith
 kn
ow
n v
ali
dit
y a
nd
 
rel
iab
ilit
y. S
tud
ies
 th
at 
on
ly 
ev
alu
ate
d p
a-
tie
nt-
ori
en
ted
 in
ter
ve
nti
on
s w
ere
 ex
clu
de
d. 
pr
om
pte
d r
eca
ll a
nd
 re
vie
w 
of 
pa
-
tie
nts
 (c
en
tra
l co
mp
ute
ris
ed
 tr
ack
ing
 
sys
tem
s o
r n
ur
ses
 w
ho
 re
gu
lar
ly 
co
nta
ct 
the
 pa
tie
nt)
 ca
n a
lso
 im
pr
ov
e 
dia
be
tes
 m
an
ag
em
en
t. T
he
 ad
dit
ion
 
of 
pa
tie
nt-
ori
en
ted
 in
ter
ve
nti
on
s c
an
 
lea
d t
o i
mp
rov
ed
 pa
tie
nt 
he
alt
h 
ou
tco
me
s. N
ur
ses
 ca
n p
lay
 an
 im
po
r-
tan
t r
ole
 in
 pa
tie
nt-
ori
en
ted
 in
ter
ve
n-
tio
ns
, th
ro
ug
h p
ati
en
t e
du
cat
ion
 or
 
fac
ilit
ati
ng
 ad
he
ren
ce 
to 
tre
atm
en
t. 
Sh
oja
nia
 et
 al
., 
20
06
 
Me
ta-
an
aly
sis
 an
d 
me
ta-
reg
res
sio
n; 
N=
66
 (5
0 R
CT
s, 3
 
qu
asi
-ra
nd
om
ise
d 
tri
als
; 1
3 c
on
tro
lle
d 
pr
e-p
os
t s
tud
ies
) 
 
11
 ca
teg
ori
es 
of 
Qu
ali
ty 
Im
pr
ov
em
en
t 
(Q
I) s
tra
teg
ies
: a
ud
it a
nd
 fe
ed
ba
ck
; ca
se 
ma
na
ge
me
nt;
 te
am
 ch
an
ge
s; e
lec
tro
nic
 
pa
tie
nt 
reg
ist
ry;
 cli
nic
al 
ed
uc
ati
on
; 
cli
nic
ian
 re
mi
nd
ers
; fa
cil
ita
ted
 re
lay
 of
 
cli
nic
al 
inf
orm
ati
on
 to
 cli
nic
ian
s; p
a-
tie
nt 
ed
uc
ati
on
; p
rom
oti
on
 of
 se
lf-
ma
na
ge
me
nt;
 pa
tie
nt 
rem
ind
er 
sys
-
tem
s; c
on
tin
uo
us
 qu
ali
ty 
im
pr
ov
em
en
t. 
Stu
die
s w
ere
 in
clu
de
d i
f th
ey
: w
ere
 RC
Ts
, 
qu
asi
-ra
nd
om
ise
d t
ria
ls, 
or 
co
ntr
oll
ed
 be
for
e-
aft
er 
stu
die
s; i
nv
olv
ed
 ad
ult
 ou
tpa
tie
nts
 w
ith
 
typ
e 2
 di
ab
ete
s; i
nv
est
iga
ted
 an
 in
ter
ve
nti
on
 
tha
t m
et 
the
 de
fin
itio
n f
or 
at 
lea
st 
1 o
f 1
1 
sp
eci
fic
 ty
pe
s o
f Q
I s
tra
teg
ies
. T
he
 an
aly
sis
 
wa
s r
est
ric
ted
 to
 st
ud
ies
 re
po
rti
ng
 m
ea
n p
re-
an
d p
os
t-i
nte
rve
nti
on
 Hb
A1
c v
alu
es 
for
 ea
ch
 
stu
dy
 gr
ou
p. 
Mo
st 
QI
 st
rat
eg
ies
 pr
od
uc
ed
 sm
all
 to
 
mo
de
st 
im
pr
ov
em
en
ts 
in 
gly
cae
mi
c 
co
ntr
ol.
 Te
am
 ch
an
ge
s a
nd
 ca
se 
ma
na
ge
me
nt 
sh
ow
ed
 m
ore
 ro
bu
st 
im
pr
ov
em
en
ts,
 es
pe
cia
lly
 fo
r in
ter
-
ve
nti
on
s in
 w
hic
h c
ase
 m
an
ag
ers
 
co
uld
 ad
jus
t m
ed
ica
tio
ns
 w
ith
ou
t 
aw
ait
ing
 ph
ysi
cia
n a
pp
rov
al.
 
Sm
ith
 et
 al
., 
20
09
 
Me
ta-
an
aly
sis
; N
=3
 
(al
l R
CT
s) 
Sh
are
d c
are
 he
alt
h s
erv
ice
 in
ter
ve
n-
tio
ns
 de
sig
ne
d t
o i
mp
rov
e t
he
 m
an
-
ag
em
en
t o
f c
hr
on
ic d
ise
ase
 ac
ros
s t
he
 
pr
im
ary
-sp
eci
alt
y c
are
 in
ter
fac
e. 
Stu
die
s w
ere
 in
clu
de
d i
f th
ey
: w
ere
 RC
Ts
, 
CC
Ts
, co
ntr
oll
ed
 be
for
e-a
nd
-af
ter
 st
ud
ies
, o
r 
int
err
up
ted
 tim
e s
eri
es 
an
aly
ses
; d
esc
rib
ed
 
an
y t
yp
e o
f s
tru
ctu
red
 in
ter
ve
nti
on
 th
at 
inv
olv
ed
 co
nti
nu
ing
 co
lla
bo
rat
ive
 cli
nic
al 
car
e b
etw
ee
n p
rim
ary
 an
d s
pe
cia
lis
t c
are
 
ph
ysi
cia
ns
 in
 th
e m
an
ag
em
en
t o
f p
ati
en
ts 
wi
th 
pr
e-s
pe
cif
ied
 ch
ron
ic d
ise
ase
; re
po
rte
d 
an
y o
bje
cti
ve
 m
ea
su
re 
of 
pa
tie
nt 
he
alt
h 
ou
tco
me
, p
ati
en
t b
eh
av
iou
r in
clu
din
g m
ea
s-
Th
ere
 is 
no
 ev
ide
nc
e t
o s
up
po
rt 
the
 
wi
de
sp
rea
d i
ntr
od
uc
tio
n o
f s
ha
red
 
car
e s
erv
ice
s a
t p
res
en
t.  
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Au
th
or
,  
ye
ar
 o
f  
pu
bl
ic
at
io
n 
An
al
ys
is
 ty
pe
, n
o.
  
of
 s
tu
di
es
 in
cl
ud
ed
 
Co
nc
ep
t/
de
fin
it
io
n 
of
 c
hr
on
ic
 c
ar
e 
pr
og
ra
m
m
es
 
In
cl
us
io
n/
ex
cl
us
io
n 
cr
it
er
ia
 
Au
th
or
s’
 c
on
cl
us
io
ns
 
ur
es 
of 
me
dic
ati
on
 ad
he
ren
ce 
an
d u
tili
sat
ion
 
of 
he
alt
h s
erv
ice
s, p
rov
ide
r b
eh
av
iou
r, e
ffi-
cie
nc
y a
nd
 co
sts
, an
d a
cce
pta
bil
ity
 of
 th
e 
ser
vic
e t
o p
ati
en
ts 
an
d p
rov
ide
rs,
 if 
thi
s w
as 
rep
ort
ed
 us
ing
 va
lid
ate
d m
ea
su
res
 in
 a s
tud
y 
tha
t a
lso
 re
po
rte
d p
ati
en
t o
utc
om
es 
or 
pr
o-
vid
er 
be
ha
vio
ur
. T
he
 fo
llo
wi
ng
 in
ter
ve
nti
on
s 
we
re 
ex
clu
de
d: 
str
uc
tur
ed
 di
sea
se 
ma
na
ge
-
me
nt 
in 
eit
he
r p
rim
ary
 or
 sp
eci
alt
y c
are
 th
at 
did
 no
t r
ou
tin
ely
 in
vo
lve
 pr
e-s
pe
cif
ied
 ca
re 
fro
m 
the
 ot
he
r p
ro
vid
er 
for
 th
e m
ajo
rit
y o
f 
pa
rti
cip
ati
ng
 pa
tie
nts
; sp
eci
ali
st 
ou
tre
ach
 
cli
nic
s o
r s
pe
cia
lis
t li
ais
on
 se
rvi
ces
 in
 pr
i-
ma
ry 
car
e s
ett
ing
s t
ha
t w
ere
 de
fin
ed
 as
 
pla
nn
ed
 an
d r
eg
ula
r v
isi
ts 
by
 sp
eci
ali
st 
ph
y-
sic
ian
s f
rom
 a u
su
al 
pr
act
ice
 lo
cat
ion
, w
ith
 no
 
on
go
ing
 st
ru
ctu
red
 jo
int
 m
an
ag
em
en
t p
ro-
gra
mm
es 
for
 pa
rti
cip
ati
ng
 pa
tie
nts
; p
rof
es-
sio
na
l e
du
cat
ion
al 
int
erv
en
tio
ns
 or
 re
sea
rch
 
ini
tia
tiv
es 
wh
ere
 th
ere
 w
as 
no
 sp
eci
fie
d, 
str
uc
tur
ed
 cli
nic
al 
car
e d
eli
ve
red
 to
 pa
tie
nts
; 
int
erv
en
tio
ns
 di
rec
ted
 at
 co
mm
un
itie
s o
f 
pe
op
le 
ba
sed
 on
 lo
cat
ion
 or
 ag
e o
f p
art
ici
-
pa
nts
 in
 w
hic
h t
he
re 
wa
s n
o s
pe
cif
ied
, 
ch
ron
ic d
ise
ase
 m
an
ag
em
en
t c
om
po
ne
nt.
 
Ve
rh
oe
ve
n e
t a
l., 
20
07
 
Me
ta-
an
aly
sis
; N
=6
 
(al
l R
CT
s) 
 
Tw
o f
orm
s o
f IC
T-b
ase
d c
are
 fo
r d
iab
e-
tes
: te
lec
on
su
lta
tio
n (
a k
ind
 of
 te
lem
o-
nit
ori
ng
 in
clu
din
g p
ati
en
t-c
are
giv
er 
co
mm
un
ica
tio
n v
ia 
em
ail
, p
ho
ne
, au
to-
ma
ted
 m
ess
ag
ing
 sy
ste
ms
, o
the
r 
Inc
lud
ed
 w
ere
 em
pir
ica
l st
ud
ies
 ev
alu
ati
ng
 
tel
eco
ns
ult
ati
on
 an
d/
or 
vid
eo
co
nfe
ren
cin
g 
de
ve
lop
ed
 fo
r t
yp
e 1
, ty
pe
 2,
 an
d/
or
 ge
sta
-
tio
na
l d
iab
ete
s. N
o r
est
ric
tio
ns
 w
ere
 im
po
sed
 
on
 th
e q
ua
lity
 of
 st
ud
y d
esi
gn
. In
clu
de
d w
ere
 T
he
 se
lec
ted
 st
ud
ies
 su
gg
est
 th
at 
bo
th 
tel
eco
ns
ult
ati
on
 an
d v
ide
oc
on
fer
en
c-
ing
 ar
e p
rac
tic
al,
 co
st-
eff
ect
ive
, an
d 
rel
iab
le 
wa
ys 
of 
de
liv
eri
ng
 a w
ort
h-
wh
ile
 he
alt
h c
are
 se
rvi
ce 
to 
dia
be
tic
s. 
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Au
th
or
,  
ye
ar
 o
f  
pu
bl
ic
at
io
n 
An
al
ys
is
 ty
pe
, n
o.
  
of
 s
tu
di
es
 in
cl
ud
ed
 
Co
nc
ep
t/
de
fin
it
io
n 
of
 c
hr
on
ic
 c
ar
e 
pr
og
ra
m
m
es
 
In
cl
us
io
n/
ex
cl
us
io
n 
cr
it
er
ia
 
Au
th
or
s’
 c
on
cl
us
io
ns
 
eq
uip
me
nt 
wi
tho
ut 
fac
e-t
o-f
ace
 co
nta
ct,
 
or 
the
 In
ter
ne
t) a
nd
 vi
de
oc
on
fer
en
cin
g 
(re
al-
tim
e f
ace
-to
-fa
ce 
co
nta
ct,
 im
ag
e 
an
d v
oic
e, v
ia 
vid
eo
co
nfe
ren
cin
g 
eq
uip
me
nt 
to 
co
nn
ect
 ca
reg
ive
rs 
an
d 
on
e o
r m
ore
 pa
tie
nts
 sim
ult
an
eo
us
ly,
 
us
ua
lly
 fo
r in
str
uc
tio
n).
 
stu
die
s t
ha
t c
ov
ere
d c
lin
ica
l o
utc
om
es 
plu
s 
on
e o
r m
ore
 ot
he
r o
utc
om
es 
(be
ha
vio
ur
al,
 
car
e c
oo
rd
ina
tio
n, 
etc
.). 
Ex
clu
de
d w
ere
 st
ud
-
ies
 de
ali
ng
 w
ith
 br
oa
de
r t
arg
et 
gro
up
s t
ha
n 
dia
be
tic
s, s
tud
ies
 no
t a
im
ed
 at
 pa
tie
nt-
car
eg
ive
r in
ter
act
ion
 bu
t s
ole
ly 
rep
ort
ing
 
tec
hn
ica
l a
sp
ect
s o
f th
e e
qu
ipm
en
t u
sed
, an
d 
tho
se 
tha
t s
tri
ve
d f
or 
cli
nic
al 
im
pr
ov
em
en
ts 
on
ly.
 
Ho
we
ve
r, t
he
 di
ve
rsi
ty 
in 
stu
dy
 de
-
sig
n a
nd
 re
po
rte
d f
ind
ing
s m
ak
es 
a 
str
on
g c
on
clu
sio
n p
rem
atu
re.
 Im
-
pr
ov
em
en
ts 
we
re 
mo
stl
y n
ot 
sta
tis
ti-
cal
ly 
sig
nif
ica
nt.
  
Wh
itt
em
ore
 et
 
al.
, 2
00
7 
De
scr
ipt
ive
 re
vie
w;
 
N=
11
 (7
 RC
Ts
, 4
 pr
e-
po
st 
stu
die
s) 
 
 
Cu
ltu
ral
ly 
co
mp
ete
nt 
int
erv
en
tio
ns
 
de
ve
lop
ed
 fo
r H
isp
an
ic a
du
lts
 w
ith
 ty
pe
 
2 d
iab
ete
s. T
he
 m
ajo
rit
y o
f in
ter
ve
n-
tio
ns
 w
ere
 sp
eci
ali
sed
 di
ab
ete
s e
du
ca-
tio
n p
rog
ram
me
s, p
rov
ide
d o
ve
r a
 
pe
rio
d o
f ti
me
 in
 th
e c
om
mu
nit
y s
et-
tin
g. W
ith
 th
e e
xce
pti
on
 of
 tw
o i
nte
r-
ve
nti
on
s t
ha
t p
ro
vid
ed
 a s
pe
cia
lis
ed
 
dia
be
tes
 ed
uc
ati
on
 pr
og
ram
me
 by
 
tra
ine
d c
om
mu
nit
y h
ea
lth
 w
ork
ers
, al
l 
int
erv
en
tio
ns
 in
clu
de
d a
 nu
rse
 an
d/
or 
cer
tifi
ed
 di
ab
ete
s e
du
cat
or.
 M
os
t o
f th
e 
int
erv
en
tio
ns
 w
ere
 in
ter
dis
cip
lin
ary
.  
Stu
die
s w
ere
 in
clu
de
d i
f th
ey
: w
ere
 em
pir
ica
l 
rep
ort
s o
f a
 cu
ltu
ral
ly 
co
mp
ete
nt 
int
erv
en
-
tio
n t
o p
rom
ote
 se
lf-m
an
ag
em
en
t in
 Hi
sp
an
ic 
ad
ult
s w
ith
 ty
pe
 2 
dia
be
tes
; w
ere
 sa
mp
led
 
pr
im
ari
ly 
or
 co
mp
let
ely
 of
 Hi
sp
an
ic c
ult
ur
e; 
me
asu
red
 ou
tco
me
 va
ria
ble
s o
f c
lin
ica
l v
ari
-
ab
les
, b
eh
av
iou
ral
 va
ria
ble
s, o
r k
no
wl
ed
ge
. 
Ex
clu
de
d w
ere
 st
ud
ies
 co
nd
uc
ted
 in
 fo
rei
gn
 
co
un
tri
es 
in 
wh
ich
 th
e p
red
om
ina
nt 
lan
gu
ag
e 
is n
ot 
En
gli
sh
. 
 
Cu
ltu
ral
ly 
co
mp
ete
nt 
int
erv
en
tio
ns
 to
 
su
pp
ort
 se
lf-m
an
ag
em
en
t h
av
e t
he
 
po
ten
tia
l to
 im
pr
ov
e o
utc
om
es 
in 
Hi
sp
an
ic a
du
lts
 w
ith
 ty
pe
 2 
dia
be
tes
. 
Ho
we
ve
r, i
mp
rov
em
en
ts 
we
re 
mo
d-
est
 an
d a
ttr
itio
n w
as 
mo
de
rat
e t
o 
hig
h i
n m
an
y s
tud
ies
. A
dd
res
sin
g 
lin
gu
ist
ic a
nd
 cu
ltu
ral
 ba
rri
ers
 to
 ca
re 
are
 im
po
rta
nt 
be
gin
nin
gs 
to 
im
pr
ov
-
ing
 he
alt
h o
utc
om
es 
for
 Hi
sp
an
ic 
ad
ult
s w
ith
 ty
pe
 2 
dia
be
tes
. 
Wu
bb
en
 et
 al
., 
20
08
 
De
scr
ipt
ive
 re
vie
w;
 
N=
21
 (9
 RC
Ts
, 1
 CC
T, 
an
d 1
1 e
ith
er 
pr
o-
sp
ect
ive
 or
 re
tro
-
sp
ect
ive
 co
ho
rt 
de
sig
ns
). 
Dia
be
tes
 qu
ali
ty 
im
pr
ov
em
en
t s
tra
te-
gie
s d
eli
ve
red
 by
 ph
arm
aci
sts
 in
 ou
tpa
-
tie
nt 
set
tin
gs.
 
Stu
die
s w
ere
 in
clu
de
d i
f th
ey
: w
ere
 RC
Ts
, 
CC
Ts
 or
 co
ho
rt 
stu
die
s w
ith
 a c
on
tro
l g
rou
p; 
me
asu
red
 ou
tco
me
s b
efo
re 
an
d a
fte
r in
ter
-
ve
nti
on
 im
ple
me
nta
tio
n; 
pr
ov
ide
d c
om
ple
te 
da
ta;
 in
ve
sti
ga
ted
 qu
ali
ty 
im
pr
ov
em
en
t 
str
ate
gie
s im
ple
me
nte
d b
y p
ha
rm
aci
sts
 in
 
ou
tpa
tie
nt 
set
tin
gs;
 an
d m
ea
su
red
 ei
the
r 
lon
g-t
erm
 co
mp
lic
ati
on
s o
f d
iab
ete
s o
r s
ho
rt-
Ph
arm
aci
st 
int
erv
en
tio
ns
 fo
r d
iab
ete
s 
res
ult
 in
 an
 ov
era
ll i
mp
rov
em
en
t in
 
Hb
A1
c a
cro
ss 
a d
ive
rse
 gr
ou
p o
f 
set
tin
gs 
an
d s
tud
y d
esi
gn
s.  
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 70 
Au
th
or
,  
ye
ar
 o
f  
pu
bl
ic
at
io
n 
An
al
ys
is
 ty
pe
, n
o.
  
of
 s
tu
di
es
 in
cl
ud
ed
 
Co
nc
ep
t/
de
fin
it
io
n 
of
 c
hr
on
ic
 c
ar
e 
pr
og
ra
m
m
es
 
In
cl
us
io
n/
ex
cl
us
io
n 
cr
it
er
ia
 
Au
th
or
s’
 c
on
cl
us
io
ns
 
ter
m 
su
rro
ga
te 
ou
tco
me
s. E
xcl
ud
ed
 w
ere
 
int
erv
en
tio
ns
 di
rec
ted
 at
 th
e p
ati
en
t a
lon
e, 
su
ch
 as
 pa
tie
nt 
ed
uc
ati
on
, p
rom
oti
on
 of
 se
lf-
ma
na
ge
me
nt 
tec
hn
iqu
es,
 or
 pa
tie
nt 
rem
ind
-
ers
 as
 w
ell
 as
 in
ter
ve
nti
on
s t
ha
t te
ste
d t
ech
-
no
log
ica
l in
ter
ve
nti
on
s a
lon
e s
uc
h a
s e
lec
-
tro
nic
 re
gis
tri
es 
or
 dr
ug
 re
cal
l sy
ste
ms
. 
NO
TE
: R
CT
 in
dic
ate
s r
an
do
mi
sed
 co
ntr
oll
ed
 tr
ial
; C
CT
, cl
ini
cal
 co
ntr
oll
ed
 tr
ial
; H
bA
1c
, g
lyc
ate
d h
ae
mo
glo
bin
; C
HW
, co
mm
un
ity
 he
alt
h w
ork
er;
 QI
, q
ua
lity
 im
pr
ov
e-
me
nt;
 IC
T, 
inf
orm
ati
on
 an
d c
om
mu
nic
ati
on
 te
ch
no
log
ies
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Ap
pe
nd
ix
 2
: O
ve
rvi
ew
 of
 em
pir
ica
l st
ud
ies
 
St
ud
y 
Po
pu
la
ti
on
  
(m
ea
n 
ag
e,
 %
 m
al
e,
 s
ev
er
it
y,
 s
et
ti
ng
) 
In
te
rv
en
ti
on
 
Co
m
po
ne
nt
s 
 
(S
M
S,
 D
SD
, C
IS
, D
S)
 
Fo
llo
w
-u
p 
 
(m
on
th
s)
 
St
ud
y 
qu
al
it
y 
Au
be
rt 
et 
al.
, 
19
98
 
N=
13
8 (
IG=
71
, C
G=
67
); a
ge
 (m
ed
ian
): I
G=
53
 
(IQ
R 4
7-6
1),
 CG
= 5
4 (
IQ
R 4
6-6
0);
 %
 m
ale
: 
IG=
37
%,
 CG
=4
3%
; se
tti
ng
: p
rim
ary
 ca
re 
cli
nic
s in
 a g
ro
up
 m
od
el 
HM
O; 
co
un
try
: U
S. 
Th
e n
ur
se 
cas
e m
an
ag
er 
fol
low
ed
 w
rit
ten
 
alg
ori
thm
s u
nd
er 
dir
ect
ion
 of
 a f
am
ily
 ph
ysi
-
cia
n a
nd
 an
 en
do
cri
no
log
ist
. C
ha
ng
es 
in 
the
r-
ap
y w
ere
 co
mm
un
ica
ted
 to
 pr
im
ary
 ca
re 
ph
ysi
cia
ns
. A
ll p
ati
en
ts 
rec
eiv
ed
 on
go
ing
 ca
re 
thr
ou
gh
 th
eir
 pr
im
ary
 ca
re 
ph
ysi
cia
ns
. 
SM
S, D
SD
, D
S 
12
 m
on
ths
 
75
 
Be
lla
zzi
 et
 al
., 
20
03
 
N=
12
9 (
IG=
67
 [5
4 a
du
lts
+1
3 c
hil
dr
en
]; 
CG
=6
2 [
50
 ad
ult
s+
12
 ch
ild
ren
]);
 ag
e: 
IG(
ad
ult
)=3
8.9
(±1
3.3
6);
 IG
(ch
ild
)= 
14
.6(
±3
.73
); C
G(
ad
ult
)=4
9.7
(±9
.65
); 
CG
(ch
ild
)=1
4.1
(±3
.29
); %
 m
ale
: IG
=6
4.2
%,
 
CG
=n
ot 
rep
ort
ed
; se
tti
ng
: se
co
nd
ary
 
car
e/
co
mm
un
ity
 ca
re;
 co
un
try
: G
erm
an
y, 
Ita
ly 
an
d S
pa
in.
 
M2
DM
: a
 m
ult
i-a
cce
ss 
tel
em
ed
ici
ne
 sy
ste
m 
ba
sed
 on
 th
e i
nte
gra
tio
n o
f W
eb
 ac
ces
s, t
ele
-
ph
on
e a
cce
ss 
thr
ou
gh
 in
ter
act
ive
 vo
ice
 re
-
sp
on
se 
sys
tem
s, a
nd
 th
e u
se 
of 
pa
lm
top
s a
nd
 
sm
art
 m
od
em
s f
or 
da
ta 
do
wn
loa
din
g. 
SM
S, C
IS,
 DS
 
6 m
on
ths
 (m
id-
ter
m 
ass
ess
me
nt)
 
50
 
Ch
oe
 et
 al
., 
20
05
 
N=
80
 (IG
=4
1; 
CG
=3
9);
 ag
e: 
IG=
52
.2(
±1
1.2
), 
CG
=5
1.0
(±9
.0)
; %
 m
ale
: IG
=4
8.8
%,
 
CG
=4
6.1
%;
 se
tti
ng
: se
co
nd
ary
 ca
re 
(un
ive
r-
sit
y-a
ffil
iat
ed
 am
bu
lat
ory
 ca
re 
cli
nic
); c
ou
n-
try
: U
S. 
Ph
arm
aci
st-
ba
sed
 ca
se 
ma
na
ge
me
nt 
int
erv
en
-
tio
n i
n a
 ge
ne
ral
 in
ter
na
l m
ed
ici
ne
 cli
nic
 se
t-
tin
g. 
SM
S, D
SD
, C
IS,
 DS
 
Fir
st 
Hb
A1
c le
ve
l m
ea
s-
ur
ed
 af
ter
 12
-m
on
th 
int
erv
en
tio
n w
as 
us
ed
 
as 
pr
im
ary
 ou
tco
me
 
me
asu
re.
 Pa
tie
nts
 w
ere
 
all
ow
ed
 to
 ob
tai
n t
his
 
me
asu
rem
en
t u
p t
o  
24
 m
on
ths
 af
ter
 en
-
rol
lm
en
t 
85
 
Ch
um
ble
r e
t 
al.
, 2
00
5 
N=
80
0 (
IG=
40
0, 
CG
=4
00
); a
ge
: IG
=6
8.2
, 
CG
=6
1.5
; %
 m
ale
: n
ot 
rep
ort
ed
; se
tti
ng
: 
Ve
ter
an
s A
ffa
irs
; co
un
try
: U
S. 
Pa
tie
nt-
cen
ter
ed
 ca
re 
co
ord
ina
tio
n/
ho
me
-
tel
eh
ea
lth
 (C
C/
HT
) p
rog
ram
me
, as
 an
 ad
jun
ct 
to 
tre
atm
en
t fo
r v
ete
ran
s w
ith
 di
ab
ete
s. 
SM
S, D
SD
, C
IS,
 DS
 
12
 m
on
ths
 be
for
e a
nd
 
aft
er 
en
rol
lm
en
t in
 th
e 
CC
/H
T p
rog
ram
me
 
60
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St
ud
y 
Po
pu
la
ti
on
  
(m
ea
n 
ag
e,
 %
 m
al
e,
 s
ev
er
it
y,
 s
et
ti
ng
) 
In
te
rv
en
ti
on
 
Co
m
po
ne
nt
s 
 
(S
M
S,
 D
SD
, C
IS
, D
S)
 
Fo
llo
w
-u
p 
 
(m
on
th
s)
 
St
ud
y 
qu
al
it
y 
Cli
ffo
rd
 et
 al
., 
20
02
 
N=
73
 (IG
=4
8, 
CG
=2
5);
 ag
e: 
IG=
60
(±1
2),
 
CG
=6
1(±
12
); %
 m
ale
: IG
=5
8%
, C
G=
48
%;
 
set
tin
g: 
sec
on
da
ry 
car
e (
ho
sp
ita
l d
iab
ete
s 
car
e o
utp
ati
en
t c
lin
ic)
; co
un
try
: A
us
tra
lia
. 
Ph
arm
ace
uti
cal
 ca
re 
pr
og
ram
me
, ca
rri
ed
 ou
t 
by
 an
 ex
pe
rie
nc
ed
 cli
nic
al 
ph
arm
aci
st 
in 
co
op
-
era
tio
n w
ith
 di
ab
ete
s p
hy
sic
ian
s a
nd
 ot
he
r 
me
mb
ers
 of
 th
e d
iab
ete
s h
ea
lth
 ca
re 
tea
m.
 
DS
D, 
DS
 
6 m
on
ths
 
65
 
Co
ok
 et
 al
., 
19
99
 
N=
69
8 (
pa
tie
nts
 se
rve
d a
s t
he
ir o
wn
 co
n-
tro
l); 
ag
e: 
me
an
(SE
M)
=5
7.3
(0.
4);
 %
 m
ale
: 
34
%;
 se
ve
rit
y: 
no
t r
ep
ort
ed
; se
tti
ng
: G
rad
y 
Dia
be
tes
 Un
it, 
wh
ich
 pr
ov
ide
s c
are
 pr
im
ari
ly 
to 
ur
ba
n A
fri
can
-A
me
ric
an
 pa
tie
nts
 w
ith
 
typ
e 2
 di
ab
ete
s; c
ou
ntr
y: 
US
. 
Str
uc
tur
ed
 di
ab
ete
s m
an
ag
em
en
t p
rog
ram
me
. 
SM
S, D
SD
, C
IS,
 DS
 
12
 m
on
ths
 
55
 
Da
le 
et 
al.
, 
20
09
 
N=
14
1 (
IG=
44
, C
G=
97
); a
ge
: n
ot 
rep
ort
ed
; %
 
ma
le:
 IG
=5
2.4
%,
 CG
=6
4.0
%;
 se
tti
ng
: p
rim
ary
 
car
e; 
co
un
try
: U
K. 
Te
lec
are
 su
pp
ort
 pr
ov
ide
d b
y d
iab
ete
s s
pe
cia
l-
ist
 nu
rse
s. 
SM
S, C
IS 
6 m
on
ths
 
70
 
Da
vid
so
n, 
20
03
 
N=
71
3 (
IG(
A)
=2
52
, C
G(
B)
=2
52
, C
G(
C)=
20
9);
 
ag
e: 
IG(
A)
=5
2.0
(26
-79
), C
G(
B)
=5
2.6
(27
-79
), 
CG
(C)
=5
3.8
(19
-84
); %
 m
ale
: IG
(A
)=2
4%
, 
CG
(B
)=2
8%
, C
G(
C)
=3
4%
; se
tti
ng
: p
rim
ary
 
car
e; 
co
un
try
: U
S. 
Dia
be
tes
 M
an
ag
ed
 Ca
re 
Pr
og
ram
me
 (D
MC
P)
: 
dia
be
tes
 ca
re 
dir
ect
ed
 by
 nu
rse
s f
oll
ow
ing
 
de
tai
led
 pr
oto
co
ls a
nd
 al
go
rit
hm
s a
nd
 su
pe
r-
vis
ed
 by
 a d
iab
eto
log
ist
. 
DS
D, 
DS
 
7-1
2 m
on
ths
 
60
 
De
 So
nn
av
ille
 
et 
al.
, 1
99
7 
N=
41
8 (
IG=
35
0, 
CG
=6
8);
 ag
e: 
IG=
65
.3(
±1
1.9
), C
G=
64
.6(
±1
0.3
); %
 m
ale
: 
IG=
41
.1%
, C
G=
58
.8%
; se
tti
ng
: p
rim
ary
 ca
re;
 
co
un
try
: T
he
 Ne
the
rla
nd
s. 
Str
uc
tur
ed
 NI
DD
M 
car
e i
n g
en
era
l p
rac
tic
e 
wi
th 
a d
iab
ete
s s
erv
ice
 (in
 w
hic
h t
he
 GP
 is 
su
pp
ort
ed
 by
 a l
ab
ora
tor
y w
ith
 fa
cil
itie
s t
o 
vis
it p
ati
en
ts 
at 
ho
me
, a 
co
mp
ute
ris
ed
 pa
tie
nt 
reg
ist
er 
an
d r
eca
ll s
yst
em
, a 
wi
de
-an
gle
 re
tin
al 
cam
era
, an
d t
he
 po
ssi
bil
ity
 to
 co
ns
ult
 w
ith
 a 
die
tic
ian
, a 
dia
be
tes
 nu
rse
 ed
uc
ato
r, a
nd
 a 
po
dia
tri
st.
 A 
dia
be
tol
og
ist
, w
ho
 su
pe
rvi
ses
 th
e 
dia
be
tes
 se
rvi
ce,
 ca
n b
e c
on
tac
ted
 by
 te
le-
ph
on
e 2
4h
 a d
ay
). 
SM
S, D
SD
, C
IS,
 DS
 
24
 m
on
ths
 fo
r I
G, 
18
 
mo
nth
s f
or 
CG
 
65
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St
ud
y 
Po
pu
la
ti
on
  
(m
ea
n 
ag
e,
 %
 m
al
e,
 s
ev
er
it
y,
 s
et
ti
ng
) 
In
te
rv
en
ti
on
 
Co
m
po
ne
nt
s 
 
(S
M
S,
 D
SD
, C
IS
, D
S)
 
Fo
llo
w
-u
p 
 
(m
on
th
s)
 
St
ud
y 
qu
al
it
y 
Dij
ks
tra
 et
 al
., 
20
05
 
N=
76
9 (
IG=
35
1, 
CG
=4
18
); a
ge
: IG
=5
8(±
15
), 
CG
=5
8(±
16
); %
 m
ale
: IG
=4
5%
, C
G=
50
%;
 
set
tin
g: 
sec
on
da
ry 
car
e; 
co
un
try
: T
he
 Ne
th-
erl
an
ds
. 
Co
mp
reh
en
siv
e s
tra
teg
y i
nv
olv
ing
 bo
th 
pa
-
tie
nts
 an
d p
ro
fes
sio
na
ls, 
wi
th 
the
 in
tro
du
cti
on
 
of 
a d
iab
ete
s p
ass
po
rt 
as 
a k
ey
 co
mp
on
en
t.  
SM
S, C
IS 
12
 m
on
ths
 
75
 
Do
mu
rat
, 
19
99
 
N=
86
10
 (IG
=2
61
7, 
CG
=5
99
3);
 ag
e: 
no
t r
e-
po
rte
d; 
% 
ma
le:
 no
t r
ep
ort
ed
; se
tti
ng
: H
MO
; 
co
un
try
: U
S. 
Co
mp
ute
r-s
up
po
rte
d t
ea
m 
car
e. 
DS
D, 
CIS
 
12
 m
on
ths
 
70
 
Do
uc
ett
e e
t 
al.
, 2
00
9 
N=
78
 (IG
=3
6, 
CG
=4
2);
 ag
e: 
IG=
58
.7(
±1
3.3
), 
CG
=6
1.2
(±1
0.9
); %
 m
ale
: IG
=3
8.2
%,
 
CG
=4
6.3
%;
 se
tti
ng
: co
mm
un
ity
 ph
arm
acy
 
pr
act
ice
 sit
es;
 co
un
try
: U
S. 
Co
mm
un
ity
 ph
arm
aci
st-
pr
ov
ide
d e
xte
nd
ed
 
dia
be
tes
 ca
re 
ser
vic
e.  
SM
S, D
SD
 
12
 m
on
ths
 
65
 
Fa
rm
er 
et 
al.
, 
20
05
 
N=
93
 (IG
=4
7, 
CG
=4
6);
 ag
e: 
IG=
24
.5(
±4
.2)
, 
CG
=2
3.2
(±4
.2)
; %
 m
ale
: IG
= 5
9.6
%,
 
CG
=5
8.7
%;
 se
tti
ng
: re
sea
rch
ers
 in
vit
ed
 
pa
tie
nts
 w
ho
 w
ere
 re
gis
ter
ed
 ei
the
r w
ith
 th
e 
Pe
dia
tri
c T
ran
sit
ion
 Cl
ini
c o
r t
he
 Yo
un
g 
Ad
ult
 Di
ab
ete
s C
lin
ic i
n O
xfo
rd
 to
 pa
rti
ci-
pa
te;
 co
un
try
: U
K. 
A m
ob
ile
 ph
on
e-b
ase
d t
ele
me
dic
ine
 sy
ste
m 
us
ing
 re
al-
tim
e d
ata
 tr
an
sfe
r w
ith
 in
ten
siv
e 
fee
db
ack
 of
 re
su
lts
; a
 ph
on
e-b
ase
d d
iar
y o
f 
ins
uli
n d
os
e, p
hy
sic
al 
act
ivi
ty,
 an
d f
oo
d i
nta
ke
; 
an
d n
ur
se-
ini
tia
ted
 su
pp
ort
. 
SM
S, C
IS 
9 m
on
ths
 
75
 
Fo
rn
os
 et
 al
., 
20
06
 
N=
11
2 (
IG=
56
, C
G=
56
); a
ge
: IG
=6
2.4
(±1
0.5
), 
CG
=6
4.9
(±1
0.9
); %
 m
ale
: IG
=4
1.4
%,
 
CG
=4
2.9
%;
 se
tti
ng
: p
rim
ary
 ca
re 
(ph
arm
a-
cie
s);
 co
un
try
: S
pa
in.
  
Ph
arm
aco
the
rap
y F
oll
ow
-up
 (P
FU
) p
ro-
gra
mm
e f
or 
typ
e 2
 di
ab
eti
c p
ati
en
ts.
 PF
U i
s a
 
ph
arm
ace
uti
cal
 ca
re 
act
ivi
ty 
tha
t r
eq
uir
es 
the
 
inv
olv
em
en
t o
f th
e p
ha
rm
aci
st 
in 
the
 ou
tco
me
s 
of 
ph
arm
aco
the
rap
y, i
n c
oo
pe
rat
ion
 w
ith
 th
e 
he
alt
h c
are
 te
am
 an
d t
he
 pa
tie
nt.
 
SM
S, D
SD
, C
IS,
 DS
 
13
 m
on
ths
 
70
 
Fr
ied
ma
n e
t 
al.
, 1
99
8 
N: 
19
94
=9
54
, 1
99
5=
74
4, 
19
96
=1
45
7; 
ag
e: 
be
tw
ee
n 3
1 a
nd
 64
 ye
ars
; %
 m
ale
: n
ot 
re-
po
rte
d; 
set
tin
g: 
pr
im
ary
 ca
re;
 co
un
try
: U
S. 
Lo
ve
lac
e E
pis
od
es 
of 
Ca
re 
Pr
og
ram
me
, in
-
ten
de
d t
o a
dd
res
s t
he
 co
mp
lex
 ne
ed
s o
f p
a-
tie
nts
 w
ith
 ty
pe
 2 
dia
be
tes
 m
ell
itu
s b
y u
sin
g 
sp
eci
fic
 ph
ysi
cia
n-p
rov
ide
r a
nd
 pa
tie
nt 
int
er-
ve
nti
on
s. 
SM
S, D
SD
, C
IS,
 DS
 
24
 m
on
ths
 
40
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St
ud
y 
Po
pu
la
ti
on
  
(m
ea
n 
ag
e,
 %
 m
al
e,
 s
ev
er
it
y,
 s
et
ti
ng
) 
In
te
rv
en
ti
on
 
Co
m
po
ne
nt
s 
 
(S
M
S,
 D
SD
, C
IS
, D
S)
 
Fo
llo
w
-u
p 
 
(m
on
th
s)
 
St
ud
y 
qu
al
it
y 
Ga
bb
ay
 et
 al
., 
20
06
 
N=
33
2 (
IG=
15
0, 
CG
=1
82
); a
ge
: IG
=6
5(±
12
), 
CG
=6
4(±
20
); %
 m
ale
: IG
=5
7%
, C
G=
52
%;
 
set
tin
g: 
pr
im
ary
 ca
re;
 co
un
try
: U
S. 
Nu
rse
 ca
se 
ma
na
ge
me
nt,
 co
ns
ist
ing
 of
 co
ord
i-
na
tio
n o
f c
are
, p
ati
en
t e
du
cat
ion
 an
d c
ou
ns
el-
lin
g, a
nd
 clo
se 
mo
nit
ori
ng
 of
 he
alt
h o
utc
om
es.
 S
MS
, D
SD
, C
IS,
 DS
 
6 a
nd
 12
 m
on
ths
 
65
 
Ga
ry 
et 
al.
, 
20
03
 
N=
70
 (IG
=3
6, 
CG
=3
4);
 ag
e: 
IG=
60
(±7
), 
CG
=5
7(±
8);
 %
 m
ale
: IG
=2
2%
, C
G=
26
%;
 
set
tin
g: 
pr
im
ary
 ca
re;
 co
un
try
: U
S. 
Co
mb
ine
d n
ur
se 
cas
e m
an
ag
em
en
t (N
CM
)/ 
co
mm
un
ity
 he
alt
h w
ork
er 
(CH
W)
 in
ter
ve
nti
on
. S
MS
, D
SD
 
24
 m
on
ths
 
85
 
Go
ldf
rac
ht 
& 
Po
rat
h, 
20
00
 
N=
87
6; 
ag
e: 
67
,5%
 of
 pa
tie
nts
 w
ere
 ag
e 6
0 
ye
ars
 or
 ol
de
r; %
 m
ale
: 4
8%
; se
tti
ng
: H
MO
, 
pr
im
ary
 ca
re;
 co
un
try
: Is
rae
l. 
Ad
mi
nis
tra
tiv
e a
nd
 qu
ali
ty 
ass
ur
an
ce 
int
er-
ve
nti
on
s.  
DS
D, 
CIS
, D
S 
24
 m
on
ths
 
60
 
Go
ng
 et
 al
., 
19
99
 
N=
81
 (IG
=4
7, 
CG
=3
4);
 ag
e (
me
dia
n):
 IG
=6
8, 
CG
=6
6; 
% 
ma
le:
 no
t r
ep
ort
ed
; se
tti
ng
: o
utp
a-
tie
nt 
cli
nic
 of
 un
ive
rsi
ty-
aff
ilia
ted
 te
ach
ing
 
ho
sp
ita
l; c
ou
ntr
y: 
US
. 
Ca
re 
pr
ov
ide
d b
y a
 Di
ab
ete
s D
ise
ase
 M
an
ag
e-
me
nt 
Cli
nic
 (D
DM
C) 
for
 ty
pe
 2 
dia
be
tes
 pa
-
tie
nts
 w
ho
 w
ere
 in
itia
ted
 on
 se
lf-m
on
ito
rin
g o
f 
blo
od
 gl
uc
os
e (
SM
BG
). C
are
 in
 th
e D
DM
C i
s 
pr
ov
ide
d b
y p
ha
rm
aci
sts
 (a
mo
ng
 w
hic
h a
 
cer
tifi
ed
 di
ab
ete
s e
du
cat
or)
, p
ha
rm
acy
 pr
ac-
tic
e r
esi
de
nts
, d
oc
tor
 of
 ph
arm
acy
 st
ud
en
ts,
 
an
d a
 nu
rse
 pr
act
itio
ne
r. 
SM
S, D
SD
, C
IS,
 DS
 
24
 m
on
ths
 
65
 
Gr
an
t e
t a
l., 
20
04
 
N=
30
79
 (IG
=8
98
; C
G=
21
81
); a
ge
: 
IG=
65
.1(
±1
2.9
), C
G=
65
.4(
±1
2.8
); %
 m
ale
: 
IG=
47
.7%
, C
G=
55
.6%
; se
tti
ng
: fo
ur
 ou
tpa
-
tie
nt 
pr
im
ary
 ca
re 
me
dic
al 
cli
nic
s w
ith
in 
an
 
aca
de
mi
c m
ed
ica
l ce
ntr
e; 
co
un
try
: U
S.  
Po
pu
lat
ion
-le
ve
l st
rat
eg
ies
 to
 or
ga
nis
e a
nd
 
de
liv
er 
dia
be
tes
 ca
re.
  
DS
D, 
CIS
 
20
 m
on
ths
 
55
 
He
na
ult
 et
 al
., 
20
02
 
N=
56
 (IG
=2
1, 
CG
=3
5);
 ag
e: 
av
era
ge
 ag
e o
f a
ll 
eli
gib
le 
pa
tie
nts
 w
as 
66
 ye
ars
 (r
an
ge
 41
-87
 
ye
ars
); %
 m
ale
: IG
=1
00
%,
 CG
=1
00
%;
 se
t-
tin
g: 
Ve
ter
an
s A
ffa
irs
 M
ed
ica
l C
en
ter
; co
un
-
try
: U
S. 
A p
rog
ram
me
 of
 tr
an
sm
itt
ing
 cli
nic
al 
rec
om
-
me
nd
ati
on
s f
or 
alt
eri
ng
 di
ab
ete
s c
are
 vi
a 
em
ail
. 
CIS
, D
S 
6.3
(±2
.4)
 m
on
ths
 
45
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St
ud
y 
Po
pu
la
ti
on
  
(m
ea
n 
ag
e,
 %
 m
al
e,
 s
ev
er
it
y,
 s
et
ti
ng
) 
In
te
rv
en
ti
on
 
Co
m
po
ne
nt
s 
 
(S
M
S,
 D
SD
, C
IS
, D
S)
 
Fo
llo
w
-u
p 
 
(m
on
th
s)
 
St
ud
y 
qu
al
it
y 
He
tle
vik
 et
 al
., 
20
00
 
N=
77
6 (
IG=
36
8, 
CG
=4
08
); a
ge
: 
IG=
66
.3(
±1
4.1
), C
G=
68
.2(
13
.1)
; %
 m
ale
: 
IG=
46
%,
 CG
=4
2%
; se
tti
ng
: p
rim
ary
 ca
re;
 
co
un
try
: N
orw
ay
. 
Im
ple
me
nta
tio
n o
f c
lin
ica
l g
uid
eli
ne
s f
or 
dia
be
tes
 m
ell
itu
s in
 ge
ne
ral
 pr
act
ice
 w
ith
 a 
sp
eci
fic
 co
mp
ute
r-b
ase
d c
lin
ica
l d
eci
sio
n 
su
pp
ort
 sy
ste
m 
(C
DS
S) 
as 
pa
rt 
of 
the
 in
ter
ve
n-
tio
n. 
 
CIS
, D
S 
18
 m
on
ths
 an
d 2
1 
mo
nth
s 
60
 
Hi
rsc
h e
t a
l., 
20
02
 
N=
10
9 (
IG=
44
, C
G=
65
); a
ge
: IG
=6
0, 
CG
=5
7; 
% 
ma
le:
 IG
=3
6%
, C
G=
49
%;
 se
tti
ng
: a
cad
em
ic 
fam
ily
 pr
act
ice
 cli
nic
; co
un
try
: U
S. 
A m
ult
ifa
cet
ed
 in
ter
ve
nti
on
 in
clu
din
g p
ha
rm
a-
cis
t c
ase
 m
an
ag
em
en
t, n
ur
se 
an
d n
utr
itio
nis
t 
co
un
sel
lin
g, p
rov
ide
r d
ida
cti
cs 
an
d c
om
pu
ter
-
ise
d c
om
pli
an
ce 
fee
db
ack
 in
 su
pp
or
t o
f s
tag
ed
 
dia
be
tes
 m
an
ag
em
en
t (S
DM
). 
DS
D, 
CIS
, D
S 
14
 m
on
ths
 
65
 
Ila
g e
t a
l., 
20
03
  
N=
15
4 (
IG=
83
, C
G=
71
); a
ge
: IG
=5
9(±
14
), 
CG
=5
9(±
12
); %
 m
ale
: IG
=4
3%
, C
G=
51
%;
 
set
tin
g: 
un
ive
rsi
ty-
aff
ilia
ted
 pr
im
ary
 ca
re 
int
ern
al 
me
dic
ine
 pr
act
ice
s a
ffil
iat
ed
 w
ith
 a 
ma
na
ge
d c
are
 or
ga
nis
ati
on
 (M
CO
); c
ou
ntr
y: 
US
. 
Th
e A
nn
ua
l D
iab
ete
s A
sse
ssm
en
t P
rog
ram
me
 
(A
DA
P)
 w
as 
de
sig
ne
d a
s a
 po
pu
lat
ion
-ba
sed
 
pr
og
ram
me
 of
 ev
alu
ati
on
 an
d f
ee
db
ack
 to
 
su
pp
ort
 di
ab
ete
s c
lin
ica
l p
rac
tic
e g
uid
eli
ne
s. 
SM
S, C
IS,
 DS
 
24
 m
on
ths
 
75
 
Ke
lly
 & 
Ro
d-
ge
rs,
 20
00
 
N=
48
 (IG
=3
2, 
CG
=1
6);
 ag
e: 
IG=
47
.7(
±1
3.2
), 
CG
=5
0.2
(±8
.9)
; %
 m
ale
: IG
=4
0.6
%,
 
CG
=5
6.3
%;
 se
tti
ng
: m
an
ag
ed
 ca
re 
aff
ilia
ted
 
ph
ysi
cia
ns
 gr
ou
p; 
co
un
try
: U
S. 
A p
ha
rm
aci
st-
ma
na
ge
d d
iab
ete
s s
erv
ice
, in
 
wh
ich
 pa
tie
nts
 re
cei
ve
d d
os
ag
e a
dju
stm
en
ts,
 
dia
be
tes
 se
lf-m
an
ag
em
en
t tr
ain
ing
, an
d p
eri
-
od
ic a
sse
ssm
en
t o
f tr
ea
tm
en
t g
oa
ls b
y p
ha
r-
ma
cis
ts.
 
SM
S, D
SD
, C
IS 
7 m
on
ths
 fo
r H
bA
1c
 
va
lue
s a
nd
 bl
oo
d p
res
-
su
res
; 9
 m
on
ths
 fo
r 
lip
ids
 
70
 
Kim
 & 
Oh
, 
20
03
 
N=
36
 (IG
=2
0, 
CG
=1
6);
 ag
e: 
IG=
59
.7(
±7
.3)
, 
CG
=6
0.9
(±5
.8)
; %
 m
ale
: IG
=3
5%
, C
G=
25
%;
 
set
tin
g: 
en
do
cri
no
log
y o
utp
ati
en
t d
ep
art
-
me
nt 
of 
ter
tia
ry 
car
e h
os
pit
al 
(un
ive
rsi
ty-
aff
ilia
ted
 m
ed
ica
l ce
ntr
e);
 co
un
try
: S
ou
th 
Ko
rea
.  
Nu
rse
 te
lep
ho
ne
 in
ter
ve
nti
on
. 
SM
S, D
SD
, C
IS 
3 m
on
ths
 (1
2 w
ee
ks
) 
60
 
Kim
 et
 al
., 
20
09
 
N=
79
 (IG
=4
0, C
G=
39
); a
ge:
 IG
=5
6.2
(±8
.4)
, 
CG
=5
6.6
(±7
.6)
; %
 m
ale
: IG
=6
2.5
%,
 CG
=4
8.7
%;
 
set
tin
g: c
om
mu
nit
y c
are
; co
un
try
: U
S. 
SH
IP-
DM
: a
 st
ru
ctu
red
, cu
ltu
ral
ly-
ba
sed
 be
ha
v-
iou
ral
 in
ter
ve
nti
on
 pr
og
ram
me
 th
at 
foc
us
es 
on
 
em
po
we
rin
g p
ati
en
ts 
wi
th 
gre
ate
r k
no
wl
ed
ge
, 
SM
S, D
SD
, C
IS 
18
 an
d 3
0 w
ee
ks
 
60
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St
ud
y 
Po
pu
la
ti
on
  
(m
ea
n 
ag
e,
 %
 m
al
e,
 s
ev
er
it
y,
 s
et
ti
ng
) 
In
te
rv
en
ti
on
 
Co
m
po
ne
nt
s 
 
(S
M
S,
 D
SD
, C
IS
, D
S)
 
Fo
llo
w
-u
p 
 
(m
on
th
s)
 
St
ud
y 
qu
al
it
y 
sel
f-e
ffic
acy
, an
d s
elf
-he
lp 
sk
ills
 co
nc
ern
ing
 
dia
be
tes
. T
he
 SH
IP-
DM
 co
ns
ist
ed
 of
 3 
co
nc
ur
-
ren
t in
ter
ve
nti
on
 co
mp
on
en
ts:
 2-
ho
ur
 w
ee
kly
 
ed
uc
ati
on
 se
ssi
on
s f
or 
6 w
ee
ks
, h
om
e g
luc
os
e 
mo
nit
ori
ng
 w
ith
 te
let
ran
sm
iss
ion
, an
d 
mo
nth
ly 
tel
ep
ho
ne
 co
un
sel
lin
g b
y a
 bi
lin
gu
al 
nu
rse
 fo
r 2
4 w
ee
ks
. 
Ko
 et
 al
., 2
00
4
N=
17
8 (
IG=
90
, C
G=
88
); a
ge
: IG
=5
5.0
(±9
.0)
, 
CG
=5
6.0
(±1
0.2
); %
 m
ale
: IG
=4
8.9
%,
 
CG
=3
8.6
%;
 se
tti
ng
: p
rim
ary
 ca
re;
 co
un
try
: 
Ho
ng
 Ko
ng
. 
A s
tru
ctu
red
 he
alt
h e
du
cat
ion
 pr
og
ram
me
 by
 a 
dia
be
tic
 ed
uc
ati
on
 nu
rse
. 
SM
S, D
SD
 
12
 m
on
ths
 
55
 
Ko
 et
 al
., 2
00
7
N=
43
7 (
IG=
21
9, 
CG
=2
18
); a
ge
: 
IG=
53
.3(
±9
.3)
, C
G=
54
.1(
±7
.4)
; %
 m
ale
: 
IG=
42
%,
 CG
=4
5,9
%;
 se
tti
ng
: h
os
pit
al 
car
e; 
co
un
try
: S
ou
th 
Ko
rea
.  
SID
EP
: in
pa
tie
nt,
 st
ru
ctu
red
 in
ten
siv
e d
iab
ete
s 
ed
uc
ati
on
 pr
og
ram
me
. T
he
 pr
og
ram
me
 w
as 
de
sig
ne
d f
or
 gr
ou
p e
du
cat
ion
 (5
-10
 pa
tie
nts
). 
Th
e e
du
cat
ion
 te
am
 w
as 
co
mp
os
ed
 of
 a d
iab
e-
tol
og
ist
, ce
rti
fie
d d
iab
ete
s e
du
cat
or 
(nu
rse
 or
 
die
tic
ian
), o
ph
tha
lm
olo
gis
t, r
eh
ab
ilit
ati
on
 
the
rap
ist
, p
ha
rm
aci
st,
 ps
ych
olo
gis
t, f
am
ily
 
me
dic
ine
 do
cto
r a
nd
 re
ha
bil
ita
tio
n m
ed
ici
ne
 
do
cto
r.  
SM
S, D
SD
 
48
 m
on
ths
 
75
 
Kr
ass
 et
 al
., 
20
06
 
N=
11
8 (
IG=
39
, C
G=
79
); a
ge
: IG
=6
4.1
(±9
.1)
, 
CG
=6
4.2
(±1
0.5
); %
 m
ale
: IG
=7
2%
, C
G=
58
%;
 
set
tin
g: 
pr
im
ary
 ca
re 
(co
mm
un
ity
 ph
arm
a-
cie
s) 
an
d s
eco
nd
ary
 ca
re 
(sp
eci
ali
sed
 di
ab
e-
tes
 cli
nic
 ph
arm
aci
es)
; co
un
try
: A
us
tra
lia
. 
Co
nti
nu
ity
 of
 ca
re 
mo
de
l fo
r t
yp
e 2
 di
ab
ete
s, 
wh
ich
 co
mp
ris
es 
an
 in
itia
l co
ns
ult
ati
on
 w
ith
 a 
ph
arm
aci
st 
in 
the
 cli
nic
, w
rit
ten
 co
mm
un
ica
-
tio
n t
o t
he
 pa
tie
nt'
s c
om
mu
nit
y p
ha
rm
aci
st 
an
d G
P, 
an
d o
ng
oin
g m
on
ito
rin
g o
f th
e p
ati
en
t 
by
 th
e c
om
mu
nit
y p
ha
rm
aci
st 
on
 th
e b
asi
s o
f a
 
de
fin
ed
 pr
oto
co
l. 
SM
S, D
SD
, C
IS,
 DS
 
6 m
on
ths
 
65
 
Kr
ass
 et
 al
., 
20
07
 
N=
29
9 (
IG=
15
7, 
CG
=1
42
); a
ge
: 6
2(±
11
); %
 
ma
le:
 51
%;
 se
tti
ng
: p
rim
ary
 ca
re 
(ph
arm
a-
cie
s);
 co
un
try
: A
us
tra
lia
. 
Th
e P
ha
rm
acy
 Di
ab
ete
s C
are
 Pr
og
ram
me
: a
 
co
mm
un
ity
 ph
arm
acy
 di
ab
ete
s s
erv
ice
 m
od
el.
 S
MS
, D
SD
, C
IS,
 DS
 
6 m
on
ths
 
65
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St
ud
y 
Po
pu
la
ti
on
  
(m
ea
n 
ag
e,
 %
 m
al
e,
 s
ev
er
it
y,
 s
et
ti
ng
) 
In
te
rv
en
ti
on
 
Co
m
po
ne
nt
s 
 
(S
M
S,
 D
SD
, C
IS
, D
S)
 
Fo
llo
w
-u
p 
 
(m
on
th
s)
 
St
ud
y 
qu
al
it
y 
Kr
ein
 et
 al
., 
20
04
 
N=
20
9 (
IG=
10
6, 
CG
=1
03
); a
ge
: IG
=6
1(±
10
), 
CG
=6
1(±
11
); %
 m
ale
: IG
=9
8%
, C
G=
95
%;
 
set
tin
g: 
De
pa
rtm
en
t o
f V
ete
ran
s A
ffa
irs
 
Me
dic
al 
Ce
nte
rs;
 co
un
try
: U
S. 
A c
oll
ab
ora
tiv
e c
ase
 m
an
ag
em
en
t in
ter
ve
nti
on
 
for
 pa
tie
nts
 w
ith
 po
orl
y c
on
tro
lle
d t
yp
e 2
 
dia
be
tes
. 
SM
S, D
SD
, C
IS,
 DS
 
Me
an
 fo
llo
w-
up
 of
 
19
(±2
) m
on
ths
 
85
 
Le
go
rre
ta 
et 
al.
, 1
99
6 
N=
39
0 (
IG-
A=
11
7, 
CG
-A
=8
8; 
IG-
B=
12
3, 
CG
-
B=
62
); a
ge
: IG
-A
=6
0.8
(±1
0.5
), C
G-
A=
59
.6(
±1
0.9
), I
G-B
=5
7.5
(±1
4.0
), C
G-
B=
68
.6(
±9
.1)
; %
 m
ale
: IG
-A
=4
7%
, C
G-
A=
52
%,
 IG
-B=
52
%,
 CG
-B=
50
%;
 se
tti
ng
: si
te 
A w
as 
a t
yp
ica
l p
art
ici
pa
tin
g m
ed
ica
l g
rou
p 
(P
MG
), s
ite
 B 
wa
s a
n i
nd
ep
en
de
nt 
ph
ysi
cia
n 
org
an
isa
tio
n (
IPA
), b
oth
 pr
ov
ide
d h
ea
lth
 
car
e t
o H
MO
 m
em
be
rs;
 co
un
try
: U
S. 
A d
iab
ete
s m
an
ag
em
en
t p
rog
ram
me
 us
ing
 
nu
rse
s w
ho
 fo
llo
w 
sp
eci
all
y d
ev
elo
pe
d p
rot
o-
co
ls, 
lin
ke
d t
o a
 co
mp
ute
r s
yst
em
 de
sig
ne
d t
o 
im
pr
ov
e c
om
pli
an
ce.
 
DS
D, 
CIS
, D
S  
Th
e e
nd
po
int
 va
lue
 w
as 
the
 la
st 
rep
ort
ed
 va
lue
 
aft
er 
a p
ati
en
t h
ad
 
pa
rti
cip
ate
d i
n t
he
 
pr
og
ram
me
, o
r h
ad
 
be
en
 id
en
tifi
ed
 in
 th
e 
co
ntr
ol 
sit
e, f
or 
at 
lea
st 
12
 m
on
ths
 bu
t fo
r n
o 
lon
ge
r t
ha
n 2
8 m
on
ths
. 5
0 
Le
un
g e
t a
l., 
20
05
 
N=
16
0 (
IG=
80
, C
G=
80
); a
ge
: IG
=6
4.5
(±9
.7)
, 
CG
=6
5.8
(±7
.8)
; %
 m
ale
: IG
=6
2.5
%,
 CG
=5
5%
; 
set
tin
g: 
sec
on
da
ry 
car
e (
un
ive
rsi
ty-
ba
sed
 
pu
bli
c h
os
pit
al)
; co
un
try
: C
hin
a. 
A d
ise
ase
 m
an
ag
em
en
t p
rog
ram
me
 fo
r p
a-
tie
nts
 w
ith
 ty
pe
 2 
dia
be
tic
 ne
ph
rop
ath
y, e
xe
-
cu
ted
 by
 a t
ea
m 
of 
dia
be
tes
 sp
eci
ali
sts
 an
d a
 
ph
arm
aci
st,
 pr
esc
rib
ing
: (1
) r
eg
ula
r fo
llo
w-
up
; 
(2)
 re
gu
lar
 la
bo
rat
ory
 m
on
ito
rin
g; 
(3)
 at
tai
n-
me
nt 
of 
tre
atm
en
t ta
rge
ts;
 an
d (
4) 
tre
atm
en
t 
ad
he
ren
ce 
an
d t
he
 ro
le 
of 
the
 ph
arm
aci
st.
 
SM
S, D
SD
, C
IS,
 DS
 
24
 m
on
ths
 
80
 
Lit
ak
er 
et 
al.
, 
20
03
 
N=
15
7 (
IG=
79
, C
G=
78
); a
ge
: IG
=6
0.5
(±8
.5)
, 
CG
=6
0.6
(±9
.6)
; %
 m
ale
: IG
=4
1%
, C
G=
42
%;
 
set
tin
g: 
ter
tia
ry 
car
e t
ea
ch
ing
 ho
sp
ita
l; 
co
un
try
: U
S. 
Ch
ron
ic d
ise
ase
 m
an
ag
em
en
t p
rog
ram
me
 
inv
olv
ing
 a n
ur
se 
pr
act
itio
ne
r –
 ph
ysi
cia
n 
tea
m.
  
SM
S, D
SD
, C
IS,
 DS
 
12
 m
on
ths
 
75
 
Ma
isl
os
 & 
We
ism
an
, 
20
04
 
N=
63
 (IG
=4
1, 
CG
=2
2);
 ag
e: 
IG=
58
(±1
4),
 
CG
=6
3(±
9);
 %
 m
ale
: IG
=5
0%
, C
G=
35
%;
 
set
tin
g: 
pr
im
ary
 ca
re 
(H
MO
); c
ou
ntr
y: 
Isr
ae
l.
Th
e W
est
ern
 Ne
ge
v M
ob
ile
 Di
ab
ete
s C
are
 
Pr
og
ram
me
 ap
pli
es 
a m
ult
idi
sci
pli
na
ry 
me
tho
d t
o t
he
 tr
ea
tm
en
t o
f p
ati
en
ts 
wi
th 
dia
be
tes
. T
he
 te
am
 is 
co
mp
os
ed
 of
 a p
hy
sic
ian
 
sp
eci
ali
sed
 in
 di
ab
ete
s, a
 di
eti
cia
n, 
an
d a
 di
ab
e-
tes
 nu
rse
 ed
uc
ato
r.  
SM
S, D
SD
, C
IS,
 DS
 
6 m
on
ths
 
60
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St
ud
y 
Po
pu
la
ti
on
  
(m
ea
n 
ag
e,
 %
 m
al
e,
 s
ev
er
it
y,
 s
et
ti
ng
) 
In
te
rv
en
ti
on
 
Co
m
po
ne
nt
s 
 
(S
M
S,
 D
SD
, C
IS
, D
S)
 
Fo
llo
w
-u
p 
 
(m
on
th
s)
 
St
ud
y 
qu
al
it
y 
Ma
jum
da
r e
t 
al.
, 2
00
3 
N=
39
3 (
IG=
21
0, 
CG
=1
83
); a
ge
: 
IG=
63
.9(
±1
2.7
), C
G=
62
.0(
±1
2.4
); %
 m
ale
: 
IG=
48
.7%
, C
G=
37
.6%
; se
tti
ng
: m
ult
idi
sci
pli
-
na
ry 
dia
be
tes
 ou
tre
ach
 se
rvi
ce 
(pr
im
ary
 
car
e);
 co
un
try
: C
an
ad
a. 
Mu
ltid
isc
ipl
ina
ry 
dia
be
tes
 ou
tre
ach
 se
rvi
ce 
for
 
im
pr
ov
ing
 th
e q
ua
lity
 of
 ca
re 
for
 ru
ral
 pa
tie
nts
 
wi
th 
typ
e 2
 di
ab
ete
s, c
on
sis
tin
g o
f s
ix 
mo
nth
ly 
vis
its
 by
 a t
rav
eli
ng
 te
am
 of
 sp
eci
ali
st 
ph
ysi
-
cia
ns
, n
ur
ses
, d
iet
ici
an
s, a
nd
 a p
ha
rm
aci
st.
  
DS
D, 
DS
  
6 m
on
ths
 
65
 
Mc
Ka
y e
t a
l., 
20
02
 
N=
80
 (IG
=4
0, 
CG
=4
0);
 ag
e: 
IG=
62
.1(
±9
.5)
, 
CG
=6
0.8
(±9
.1)
; %
 m
ale
: IG
=4
5.0
%,
 
CG
=4
7.5
%;
 se
tti
ng
: h
om
e-b
ase
d c
are
; co
un
-
try
: U
S. 
Th
e D
iab
ete
s N
etw
ork
 (D
-N
et)
, an
 in
ter
ne
t-
ba
sed
 di
ab
ete
s s
elf
-m
an
ag
em
en
t a
nd
 pe
er 
su
pp
ort
 in
ter
ve
nti
on
. 
SM
S, C
IS 
 
3 m
on
ths
 
60
 
Mc
Ma
ho
n e
t 
al.
, 2
00
5 
N=
10
4 (
IG=
52
, C
G=
52
); a
ge
: IG
=6
4(±
7),
 
CG
=6
3(±
7);
 %
 m
ale
: IG
=9
9%
, C
G=
10
0%
; 
set
tin
g: 
Ve
ter
an
s A
ffa
irs
 ho
sp
ita
l-b
ase
d a
nd
 
co
mm
un
ity
-ba
sed
 cli
nic
s; c
ou
ntr
y: 
US
. 
We
b-b
ase
d c
are
 m
an
ag
em
en
t. 
SM
S, D
SD
, C
IS,
 DS
 
12
 m
on
ths
 
65
 
Me
di-
Ca
l T
yp
e 
2 D
iab
ete
s 
Stu
dy
, 2
00
4 
N=
31
7 (
IG=
17
1, 
CG
=1
46
); a
ge
: 
IG=
57
.0(
±0
.9)
, C
G=
56
.9(
±1
.0)
; %
 m
ale
: 
IG=
27
.4%
, C
G=
29
.1%
; se
tti
ng
: th
ree
 cli
nic
al 
sit
es 
(on
e c
om
mu
nit
y-b
ase
d p
rog
ram
me
 
wi
thi
n a
 co
un
ty-
wi
de
 m
an
ag
ed
 ca
re 
pla
n f
or 
Me
di-
Ca
l re
cip
ien
ts,
 tw
o u
niv
ers
ity
-ba
sed
 
cen
ter
s);
 co
un
try
: U
S. 
Int
en
siv
e d
iab
ete
s c
ase
 m
an
ag
em
en
t fo
r d
isp
a-
rat
e p
op
ula
tio
ns
. 
SM
S, D
SD
, C
IS,
 DS
 
Me
an
 du
rat
ion
 of
 fo
l-
low
-up
 w
as 
25
.3 
mo
nth
s 
75
 
Mé
na
rd
 et
 al
., 
20
05
 
N=
72
 (IG
=3
6, 
CG
=3
6);
 ag
e: 
IG=
53
.7(
±7
.5)
, 
CG
=5
5.9
(±8
.6)
; %
 m
ale
: IG
=7
5%
, C
G=
61
.1%
; 
set
tin
g: 
co
mm
un
ity
/h
os
pit
al 
car
e; 
co
un
try
: 
Ca
na
da
.  
An
 in
ten
siv
e m
ult
i-th
era
py
 pr
og
ram
me
 pr
o-
vid
ed
 by
 a m
ult
idi
sci
pli
na
ry 
tea
m.
  
SM
S, D
SD
 
12
 an
d 1
8 m
on
ths
 
80
 
O'C
on
no
r e
t 
al.
, 2
00
5 
N=
75
4 (
IG=
42
8, 
CG
=3
26
); a
ge
: IG
=5
7.6
, 
CG
=5
8.0
; %
 m
ale
: IG
=5
3.7
%,
 CG
=5
4.9
%;
 
set
tin
g: 
pr
im
ary
 ca
re;
 co
un
try
: U
S. 
Th
e I
DE
AL
 (Im
pr
ov
ing
 Ca
re 
for
 Di
ab
ete
s 
Th
rou
gh
 Em
po
we
rm
en
t, A
cti
ve
 Co
lla
bo
rat
ion
, 
an
d L
ea
de
rsh
ip)
 m
od
el:
 a q
ua
lity
 im
pr
ov
em
en
t 
(Q
I) i
nte
rve
nti
on
. 
SM
S, D
SD
, C
IS,
 DS
 
Th
e p
ro
jec
t h
ad
 th
ree
 
seq
ue
nti
al 
ph
ase
s o
ve
r 
a 4
2-m
on
th 
pe
rio
d o
f 
tim
e.  
65
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St
ud
y 
Po
pu
la
ti
on
  
(m
ea
n 
ag
e,
 %
 m
al
e,
 s
ev
er
it
y,
 s
et
ti
ng
) 
In
te
rv
en
ti
on
 
Co
m
po
ne
nt
s 
 
(S
M
S,
 D
SD
, C
IS
, D
S)
 
Fo
llo
w
-u
p 
 
(m
on
th
s)
 
St
ud
y 
qu
al
it
y 
Od
eg
ard
 et
 al
., 
20
05
 
N=
77
 (IG
=4
3, 
CG
=3
4);
 ag
e: 
IG=
51
.6(
±1
1.6
), 
CG
=5
1.9
(±1
0.4
); %
 m
ale
: IG
=5
2%
, C
G=
62
%;
 
set
tin
g: 
pr
im
ary
 ca
re 
(U
niv
ers
ity
 of
 W
ash
-
ing
ton
 M
ed
ici
ne
 Cl
ini
cs)
; co
un
try
: U
S. 
A p
ha
rm
aci
st 
int
erv
en
tio
n c
om
po
sed
 of
 de
ve
l-
op
me
nt 
of 
a d
iab
ete
s c
are
 pl
an
, re
gu
lar
 ph
ar-
ma
cis
t-p
ati
en
t c
om
mu
nic
ati
on
 on
 di
ab
ete
s 
car
e p
rog
res
s, a
nd
 ph
arm
aci
st-
pr
ov
ide
r c
om
-
mu
nic
ati
on
 on
 th
e s
ub
jec
t's
 di
ab
ete
s p
rog
res
s.
SM
S, D
SD
, C
IS 
Pa
tie
nts
 re
cei
ve
d a
 
ph
arm
aci
st 
int
erv
en
-
tio
n (
IG)
 or
 us
ua
l ca
re 
(CG
) fo
r 6
 m
on
ths
 
fol
low
ed
 by
 a 6
-m
on
th 
us
ua
l-c
are
 ob
ser
va
tio
n 
pe
rio
d f
or 
bo
th 
gro
up
s 
70
 
O'H
are
 et
 al
., 
20
04
 
N=
36
1 (
IG=
18
0, 
CG
=1
81
); a
ge
: m
ea
n a
ge
 at
 
ba
sel
ine
 58
.9(
±1
1.7
); %
 m
ale
: IG
=5
3%
, 
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ABSTRACT 
The growing recognition of care fragmentation is causing many countries to 
explore new approaches to health care delivery that can bridge the boundaries 
between professions, providers and institutions, and so better support the rising 
number of people with chronic health problems. This study examines the role of 
the regulatory, funding and organisational context for the development and 
implementation of approaches to chronic care, using examples from Austria, 
Germany, and the Netherlands. We find that the three countries have imple-
mented a range of policies and approaches to achieve better coordination within 
and across the primary and secondary care interface and so better meet the 
needs of patients with chronic conditions. This has involved changes to the 
regulatory framework to support more coordinated approaches to care (Austria, 
Germany), coupled with financial incentives (Austria, Germany), or changes in 
payment systems (the Netherlands). What is common to the three countries is 
the comparative ‘novelty’ of policies and approaches aimed at fostering coordi-
nated care; however, the evidence of their impact remains unclear. 
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INTRODUCTION 
The rising number of people with chronic conditions presents challenges for all 
health systems. In the European Union, in 2006, between 20% to over 40% of 
the population aged 15 years and over reported a long-standing health problem 
and one-fourth currently receives medical long-term treatment.[1] The complex 
nature of many chronic health problems requires a delivery system that in-
volves coordinated inputs from a wide range of health professionals over an 
extended period of time and that places patients at the centre as co-producers of 
care to optimise health outcomes.[2,3] Yet, service delivery has developed in 
ways that have tended to fragment care, both within and between sectors, 
through, for example, structural and financial barriers dividing providers at the 
primary/secondary care and at the health care and social care interface.[4] 
The growing recognition of this fragmentation is causing many countries to 
explore new approaches to health care delivery that can bridge the boundaries 
between professions, providers and institutions and so provide appropriate 
support to patients with long-standing health problems. Key elements suggested 
to address fragmentation include improved collection and sharing of informa-
tion, moving care into the community, and aligning payment schemes to incen-
tivise care coordination and enhance integration of provision of services.[5] 
However, countries vary in their attempts to do so and approaches that are be-
ing implemented reflect the characteristics of individual health systems as they 
relate to the relationships between, and responsibilities of, different stake-
holders in the regulation, funding, and delivery of health care.[6]  
This study discusses some of the key approaches to overcoming fragmenta-
tion in health care, with a particular focus on the role of the regulatory, funding 
and organisational context for the development and implementation of ap-
proaches to chronic care. We illustrate these approaches with examples from 
Austria, Germany and the Netherlands.  
Our analysis is based on a review of the published and grey literature, com-
plemented by data collected within the DISMEVAL (‘Developing and Validating 
Disease Management Evaluation Methods for European Health Care Systems’) 
project, using a common data collection template which is described in detail 
elsewhere.[7]  
In order to contextualise chronic care development in each country, we pro-
vide a concise overview of selected features of the countries’ health systems. We 
describe the key regulatory and policy measures making possible current chron-
ic care strategies, highlighting some of the main approaches to overcoming 
fragmentation in chronic care and reviewing the documented evidence of their 
impact.  
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Background on chronic care in Austria, Germany and the Netherlands 
The implementation of chronic care policies in Austria, Germany and the Neth-
erlands has to be understood in the overall context of health care governance 
and organisation. The three health care systems are principally based on the 
Bismarckian model of statutory health insurance (SHI), characterised by a uni-
versal, mandatory insurance scheme with responsibility for the health care sys-
tem shared by government (central and state governments in Austria and Ger-
many) and corporatist actors. More recently, the three systems have followed 
different paths, in particular with regard to the introduction of market elements 
into the system. In brief, in 1993, Germany introduced free choice of SHI[8], 
whereas the Netherlands moved to a mandatory, regulated private insurance 
system with competing private insurance funds in 2006.[9] In Austria, competi-
tion among health insurers, although discussed, has so far not been pur-
sued.[10] In terms of the provision of health care, the Netherlands is unique 
among SHI systems in western Europe in that general practitioners (GPs) act as 
gatekeepers to specialist care, a characteristic feature maintained after the 2006 
reform.[9] In contrast, Austria and Germany principally allow for free choice of 
office-based generalist and specialist care providers outside hospital.[8,10] Ta-
ble 1 provides an overview of selected characteristics of health care governance 
and provision in each country.  
THE EVOLUTION OF CHRONIC CARE POLICIES 
Care fragmentation, particularly at the boundary between primary and secon-
dary care, has been a main concern in all three countries, and it has prompted a 
series of various regulatory measures and activities (Table 2). However, the 
pace, breadth, and depth with which relevant initiatives and policies have been 
implemented have varied.  
Thus, in Germany, provisions to support more integrated models of care 
were introduced as early as 1993, subsequently strengthened by the 2000 SHI 
Reform Act and the 2004 SHI Modernisation Act, which removed certain legal 
and financial obstacles towards better integration.[8] In parallel, in 2002, the 
government introduced structured care programmes for those with chronic 
disease, frequently referred to as ‘disease management programmes’ (DMPs), in 
an explicit effort to provide insurers and providers with incentives to encourage 
evidence-based chronic care.[11] Defined as ‘the coordinated treatment and 
care of patients during the entire duration of a (chronic) disease across bounda-
ries between providers and on the basis of scientific and up-to-date evi-
dence’[12], DMPs became the predominant approach to chronic illness care in 
Germany. Subsequent reforms introduced additional measures to strengthen 
coordination within the ambulatory care sector, most notably the 2004 intro-
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duction of GP-centered care and of medical care centers or policlinics.[13], and 
provisions to enable the use of non-medical staff in chronic illness care from 
2008.[14]  
The Netherlands, in the 1990s, saw the introduction of the concept of shared 
care, based on the principle of cooperation and coordination between generalist 
and specialist caregivers with shared overall responsibility.[16] Although 
spreading rapidly throughout the 1990s, lack of sufficient funding challenged 
their viability and sustainability. From the 2000s, disease management ap-
proaches received growing interest[17], but uptake remained limited[18], main-
ly because of lack of a structured framework.[19] More recently, the 2006 health 
insurance reform, which granted insurers extended powers to negotiate with 
provider organisations, facilitated the development of new forms of service 
delivery and payment for more integrated care. This involved the initially diabe-
tes-focused establishment of GP-formed ‘care groups’, who contract with health 
insurers on the basis of a ‘bundled payment’ for a defined package of diabetes 
care.[20] This was strengthened by the 2008 ‘Programmatic approach to chron-
ic illness care’ and proposals to generally fund chronic care through bundled 
payment schemes, accompanied by regulatory measures to strengthen the role 
of nurses in the care of the chronically ill (Table 2).[9] 
 
Table 1: Selected features of health care systems in Austria, Germany and the Netherlands [8-10, 13, 
15] 
 Austria Germany The Netherlands  
Health expenditure (2008) 
% GDP 10.5 10.5 9.9 
Per capita expendi-
ture (US$ PPP) 
3,970 3,737 4,063 
Main sources of 
financing (2008) 
SHI: 44.1% 
Taxation: 32.8% 
OOP: 15.1% 
VHI: 4.5% 
SHI: 67.9% 
Taxation: 8.8% 
OOP: 13.0% 
VHI: 9.5% 
SHI: 70.2% 
Taxation: 5.1% 
OOP: 5.7% 
VHI: 5.6% 
Governance of the public health system  
Principle responsi-
bilities 
Shared by central govern-
ment, 9 state governments, 
and corporatist actors; 
responsibility for hospital 
sector mainly with the fed-
eral states 
Shared by central 
government, 16 state 
governments, and 
corporatist actors; 
responsibility for 
hospital sector mainly 
with the federal states
Shared by federal and 
local authorities and 
corporatist actors 
Main supervi-
sory/regulatory 
body independent of 
government (year 
established) 
Federal Health Agency 
(Bundesgesundheitsagentur) 
(2005); separate legal entity 
responsible for developing 
the framework for planning 
health service provision in 
Federal Joint Commit-
tee (Gemeinsamer 
Bundesausschuss, G-
BA) (2004); decision-
making body in SHI 
system, sets legal 
Dutch Health Care 
Authority (Nederlandse 
Zorgautoriteit, NZa) 
(2006); responsible for 
monitoring and admin-
istering the markets for 
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all sectors, management of 
the interface between sec-
tors, development of per-
formance-orientated reim-
bursement systems in all 
health care sectors 
framework for health 
care provision, issues 
binding directives, 
develops recommen-
dations for DMPs, 
develops quality as-
surance measures for 
ambulatory, hospital, 
and integrated care 
health care provision, 
health insurance, and 
the purchasing of health 
care; oversees the 
lawful implementation 
of the Health Insurance 
Act and Exceptional 
Medical Expenses Act  
Principles of health care provision outside hospital 
Provision of pri-
mary/generalist and 
specialist care out-
side hospital 
Office-based primary and 
specialist care physicians; 
outpatient clinics 
Office-based primary 
and specialist care 
physicians 
General practitioners in 
group practices  
Choice of provider in 
primary/ambulatory 
care 
Yes Yes Yes; registration with 
GP required  
GP gatekeeping No Voluntary (‘GP con-
tracts’) 
Yes; access to specialist 
care upon referral only 
Payment of physi-
cians in pri-
mary/ambulatory 
care 
Blended system of fee-for-
service with capitated ele-
ment for basic services; 
determined by payment 
schemes based on public 
services or private law and 
supplemented by bonuses 
defined by the state 
Combination of capita-
tion and fee-for service 
based on centrally 
negotiated “uniform 
value scale” (EBM) by 
the Federal Associa-
tion of SHI physicians 
and the National 
Association of SHI 
Funds  
Combination of capita-
tion and fee-for-service; 
maximum remunera-
tion fees for GPs negoti-
ated between National 
Association of GPs, 
Health Insurers Nether-
lands and Ministry of 
Health, Welfare and 
Sport 
Payment of hospitals Performance-oriented hospi-
tal financing system (LKF) 
(1997) 
German diagnosis-
related groups (G-
DRG) (phased in from 
2003) 
Diagnosis and treat-
ment combinations 
(DBCs) (2005) 
NOTE: PPP indicates purchasing power parity; SHI, statutory health insurance; OOP, out-of-pocket 
payment; VHI, voluntary health insurance; DBCs, Diagnosis and treatment combinations; DMPs, 
disease management programmes; EBM, Einheitlicher Bewertungsmassstab; GPs, general practitio-
ners; LKF, Leistungsorientierte Krankenanstalten-finanzierung; G-DRG, German diagnosis-related 
groups.  
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Table 2: Overview of the regulatory framework for chronic care policies and approaches imple-
mented during the 2000s in Austria, Germany and the Netherlands  
Country Title of reform/regulation Stated aim(s) of reform/regulation 
Austria 2005 Health Reform Act Established state health funds (Landesgesundheits-
fonds) (2006); created financial pool at state level 
(Reform pool) as a means to promote coordination 
of and cooperation between ambulatory and hospi-
tal care; established Federal Health Agency; intro-
duced e-card and made provisions for planning and 
accordance of electronic patient record (ELGA) by 
introducing the Health Data Transmission Law 
(Gesundheitstelematikgesetz) 
 2008 Agreement according to 
Federal Constitution Article 
15a on the Organisation and 
Financing of the Health Care 
System 2008-2013 
Commits to continue and develop further measures 
implemented with the 2005 reform, including 
(among others) the integrated planning of health 
services across sectors; the implementation of 
needs- and patient-centered pilot projects in ambu-
latory care, and the strengthening and further 
development of the reform pool to support chronic 
care approaches 
 2010 Act to Strenghten Ambu-
latory Care  
Introduced right for physicians to establish group 
practices (‘ambulatory care centres’) as limited 
liability company 
Germany 2000 SHI Reform Act  Introduced provisions for the development of inte-
grated care structures between the ambulatory care 
and hospital sector; required SHI funds to set aside 
a defined amount per member for primary preven-
tion or health promotion activities 
 2001 Risk Structure Compen-
sation Reform Act  
Introduced, from 2002, structured care pro-
grammes for those with chronic disease (disease 
management programmes) into the German health 
care system 
 2004 SHI Modernisation Act  Established Federal Joint Committee; strengthened 
integrated care and GP-centered care (through GP 
contracts); introduced medical care centres which 
provide care across several health care specialities 
within the ambulatory care sector 
 2007 Act to Strengthen Compe-
tition within SHI  
Made health insurance mandatory for all and intro-
duced the morbidity-adjusted risk compensation 
scheme with effect from 2009 
 2008 Long-term Care Reform 
Act 
Enabled delegation of selected medical tasks to non-
medical staff in the framework of pilot projects  
 2008 Act on the Advancement 
of Organisational Structures 
within SHI  
Further strengthened provisions for GP-centered 
care 
Netherlands 2006 Health Insurance Act Established single mandatory insurance system; 
introduced possibility of selective contracting with 
collectives to target care delivery to those with 
chronic conditions 
 2007 Social Support Act Introduced provisions to enable chronically ill 
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and/or disabled people to live independently and 
participate in society 
 2009 Act for Allowances for 
Chronically Ill and Handi-
capped Persons  
Introduced entitlement for chronically ill and dis-
abled persons to receive a fixed allowance to com-
pensate for excessive health care expenses 
 2009, Amendment of the 1993 
Individual Health Care Profes-
sions Act  
Facilitated use of nurses in the care of chronically ill 
and elderly people, enabling clinical nurse special-
ists with set qualifications to autonomously perform 
common and minor medical procedures  
NOTE: SHI indicates statutory health insurance; GP, general practitioner. 
 
In Austria, activities to strengthen more integrated provision of care have been a 
more recent phenomenon, with the 2005 health reform contributing to the de-
velopment of related approaches.[10] It established, in 2006, the State Health 
Funds in each of Austria’s nine federal states and created a financial pool at state 
level (Reform pool), which combines funds from SHI and regional governments 
to finance projects that coordinate health care delivery across sectors, in par-
ticular between ambulatory and hospital care. These ‘reform pool projects’ have 
formed the basis for the majority of current approaches to chronic care in Aus-
tria, most frequently disease management programmes. Other efforts have 
aimed, since 2007, to establish ambulatory care centres to enhance integration 
of service delivery, particularly for those with chronic illness.[21] This was part 
of a wider policy development including the conclusion of agreements between 
the medical profession and health insurance funds to establish group practices, 
and the 2008–2013 government programme that made improving patient ac-
cess to ambulatory care services a priority as part of an overall move to increase 
the effectiveness and efficiency of integrated health care services in the Austrian 
health care system.[22]  
APPROACHES TO CHRONIC CARE 
The regulatory and policy measures facilitated the implementation of chronic 
care approaches. This section describes in more detail the key features of ap-
proaches pursued in each of the countries, focusing on commonalities and dif-
ferences between countries. As indicated above, the overarching care model 
tends to be a form of disease management, whose main characteristics as they 
relate to funding mechanisms, distribution and uptake, alongside principles of 
provider and patient participation and the coordination process are summa-
rised in Tables 3 and 4. 
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A focus on single chronic conditions 
Most approaches pursued in all three countries tend to be disease-specific, with 
type 2 diabetes most typically targeted. The focus on diabetes is perhaps not 
surprising, given the disease and cost burden associated with this condition 
worldwide.[23] However, a focus on diabetes was also prompted by existing 
examples of care models that could be drawn upon. For example, in the Nether-
lands, the development of diabetes care groups was greatly informed by a care 
model developed in Maastricht, the Maastricht Transmural Diabetes Organisa-
tion, which originates from the 1990s.[19] In Austria, the diabetes DMP was 
modelled, in part, on the disease management programme for type 2 diabetes 
developed in Germany. Other diseases targeted include cardiovascular disease, 
chronic respiratory disease, and breast cancer (Germany). 
However, the focus on single diseases has been identified as a concern, given 
the often multiple health problems among people with chronic conditions. In an 
attempt to address this, regulation in Germany has mandated the development 
of additional disease management modules for obesity and chronic heart failure 
to supplement existing DMPs.[11] In the Netherlands, a framework to address 
overweight and obesity within the care group approach is being developed.[24] 
Approaches addressing a wider spectrum of needs, including those arising from 
multiple conditions, frequently centering on populations aged 65 years and 
above (here referred to as ‘generalist’ approaches) have also been introduced 
but have as yet remained geographically localised and/or restricted to pilot 
programmes. 
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Disease management as a means to strengthen coordination 
The overarching approach to strengthen care coordination is through some 
form of disease management although the content and scope of related ap-
proaches differs considerably between the three countries. Thus, the care 
groups in the Netherlands have been conceived as a multidisciplinary team ap-
proach with a physician (‘director’) overseeing the overall coordination be-
tween the various participating care providers, whereas patient management is, 
to great extent, delegated to nurses (Table 4). In contrast, in Germany and Aus-
tria, disease management has remained very much within the traditional struc-
ture of care provided by doctors within the ambulatory care sector, although 
following a strict protocol overseeing the patient management between levels of 
care, and in which non-medical staff (typically confined to practice assistants) 
play, if anything, a small role. Indeed, the use of non-medical staff such as spe-
cialised nurses or practice assistants in Austria and Germany is a fairly recent 
phenomenon. Examples include GP contracts in Germany[14] or home care for 
patients with chronic heart failure in Salzburg, Austria.[25] In Germany, services 
provided by non-medical staff may include monitoring; the assessment of men-
tal, physical, or psychological problems; and coordination with other service 
providers. However, by law, all services must be assigned and performed under 
the supervision of the GP.[26]  
Incentivising the implementation of care coordination 
Several approaches use financial incentives, usually targeted at physicians al-
though funders have also benefitted from additional (time limited) resources 
earmarked for care coordination and integration initiatives. For example, in 
Germany, to make disease management programmes an attractive option for the 
SHI funds, their introduction was linked to the risk structure compensation 
scheme (RSA). This provided SHI funds with a substantial financial incentive to 
offer DMPs as part of their portfolio of services and to motivate their members 
to take part in these programmes. This strategy had considerable success: by 
October 2009, SHI funds offered over 13,300 DMPs and a total of 5.5 million 
patients had signed up to at least one DMP.[27] However, since 2009, following 
a reform of the RSA scheme with the introduction of a morbidity-adjusted RSA, 
the financial incentive for SHI funds has been reduced markedly, and numbers 
of patients signing up for DMPs have been stagnating since.[14] Whether this 
stagnation reflects a saturation effect or is a consequence of the reduced finan-
cial incentive is as yet unclear. 
At the same time, SHI funds were also given the possibility to designate fi-
nancial resources, of a total of 1% of their income, for selective contracting with 
single providers or networks of providers.[8] The nature and scope of inte-
grated care contracts has varied, with many focusing on the interface between 
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acute hospital and rehabilitative care. By the end of 2008, approximately 6400 
integrated care contracts had been concluded, covering 6% of all SHI insured. 
However, by the end of 2008, when the financial incentive was concluded, less 
than half of these contracts had incorporated elements of intersectoral care.[28]  
In the Netherlands, the bundled payment scheme is based on the principle 
of a care group, a legal entity that brings together providers (mostly GPs) in 
primary care. As the principal contractor, the care group enters into a contract 
with a health insurer to provide a package of care for a given condition accord-
ing to a nationally developed care standard (‘bundled payment contract’). The 
price for the package of care is negotiated between the provider care group and 
the insurance fund on the basis of the performance of the care group. Conceived 
as an ‘experiment’ in 2007, with 10 diabetes care groups receiving start-up 
funding for a period of 16 months and accompanying evaluation[20], the gov-
ernment subsequently decided to roll-out this strategy nationally for the deliv-
ery of care for patients with diabetes, chronic obstructive pulmonary disease 
(COPD), or vascular risk.[29] However, although diabetes care contracts have 
achieved national coverage, the negotiation of bundled payments for COPD care 
and vascular risk management has remained a challenge.[30]  
In Austria, as noted earlier, the reform pool made it possible to explicitly 
fund projects in integrated care, including disease management programmes 
described above, as well as a wide range of other approaches, such as various 
forms of case management including managed discharge[31] or integrated care 
for stroke patients.[5] However, implementation of reform pool activities has 
been uneven across states and related projects have been slow to take off partly 
because of a lack of financial incentives for physicians to participate in such 
projects. There has been limited federal oversight of the reform pool funds and 
projects, leading to duplication of efforts and a lack of scale-efficiency in some 
regions. The highest number of projects was funded in 2007 (23), at a cost of 
€11 million, but project activity fell subsequently. Of all funds available, only 
16% had been put to use, but this varied greatly by region with over 30% used 
in Styria and only 1.5% in Tyrol.[32] 
Encouraging uptake of programmes by patients and providers 
In all three countries, participation in the coordinated care approaches is volun-
tary for physicians and patients, and they are funded within the statutory sys-
tem, thus making them principally available to all eligible patients. However, 
coverage is varied, in the case of diabetes care programmes ranging from some 
4.3% of the population with type 2 diabetes in Austria[33] up to ~60% in Ger-
many.[34,35] In the Netherlands, approximately two-thirds of an estimated 
750,000 people with diabetes are covered by a bundled payment contract.[30]  
 The comparatively low uptake in Austria partly reflects variation in avail-
ability of relevant programmes across the different states, which, in turn, re-
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flects variation in the participation rates of primary care physicians in such pro-
grammes [36], ranging from an estimated 16% in Lower Austria and Vienna to 
36% in Salzburg (authors’ estimates based on Habl and Bachner[37]). Low par-
ticipation may reflect physicians’ resistance to the (perceived or real) additional 
administrative burden imposed by DMPs.  
The administrative burden caused by documentation requirements was ini-
tially also a concern for physicians in Germany, following the introduction of 
DMPs[11]; processes have since been simplified. In Germany, ~65% of GPs par-
ticipate in the diabetes DMP, which may be explained by financial incentives 
offered to participating physicians. In the Netherlands, participation rates of GPs 
in structured care programmes are likely to be higher, with relevant incentives 
inherent in the structure of the bundled payment contract, offering considerable 
means to negotiate prices. Participation is estimated at 77% of all GPs[30] and is 
likely to increase further with government plans to move all care for diabetes 
(and other chronic conditions) to bundled payment contracts.  
What has the impact been? 
The preceding sections have demonstrated how all three countries reviewed 
here have implemented a range of policies and approaches to achieve better 
coordination within and across the primary and secondary care interface and so 
better meet the needs of patients with chronic conditions. This has involved 
changes to the regulatory framework to support more coordinated approaches 
to care (Austria, Germany), coupled with financial incentives (Austria, Germany) 
or changes in payment systems (the Netherlands). What is common to the three 
countries, as indeed in most other OECD countries[5], is the comparative ‘nov-
elty’ of policies and approaches aimed at fostering coordinated care, and the 
evidence of their impact remains unclear.  
 In Germany, evidence from the statutory evaluation of diabetes DMPs points 
to improved quality of care for participating patients.[34,35] The few existing 
controlled studies provide limited evidence of improved outcomes, such as qual-
ity of life[38] and mortality[39,40] as well as reduced costs.[40] However, the 
extent to which improved survival can indeed be attributed to the diabetes DMP 
remains uncertain[34,35,39], with other studies failing to provide evidence of 
improved medical outcomes.[41] In addition to methodological challenges, a 
major question remains as to whether disease-specific approaches, such as the 
German DMPs, are suited to meet the needs of the typical patient in primary 
care who frequently has multiple health problems with complex needs.[14] 
More general approaches, such as integrated care contracts or policlinics, might 
potentially be better equipped to respond to more complex patient needs, yet 
evidence of their effect within the German health care system remains poorly 
understood because of lack of systematic evaluation.  
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In Austria, the phasing-in of DMPs was accompanied by evaluation in almost 
all federal states. For example, the diabetes DMP Therapie Aktiv, implemented 
in Salzburg, was evaluated using a cluster-randomised controlled trial. The evi-
dence was mixed, however, with non-significant improvements in metabolic 
control, the main clinical outcome, although other measures (weight and choles-
terol) improved significantly.[42] Improved process measures were also ob-
served for the diabetes DMPs implemented in Lower Austria, for example, dem-
onstrating a reduction in hospital utilisation among those enrolled in a DMP 
pointing to the potential for cost savings although the overall evidence for DMPs 
to actually do so has remained inconclusive.[43]  
In the Netherlands, findings from the evaluation of the first year of the 10 
‘experimental’ diabetes care groups found wide variation in number and type of 
participants, the content of the packages of care covered, and price (between 
€258 and €474 per patient per year).[20] Thus, contracts differed in the extent 
to which they offer additional services beyond the core package of care, such as 
smoking cessation guidance and/or foot care. Importantly, as the precise con-
tent of care is not clearly defined, there is a risk of ‘double-billing’ of selected 
care components, although the extent to which this is happening in practice is 
unknown. Evidence of impact on outcomes has remained inconclusive thus far. 
An expectation that diabetes care groups will, through improving the quality of 
(diabetes) care, lead to cost reductions could not be verified at 12-month follow-
up; indeed, although costs might be saved due to reduced hospitalisations, they 
may at the same time increase because of ‘intensification’ of care for diabetic 
patients[20], an observation that was also made for selected DMPs in Aus-
tria.[43] 
DISCUSSION 
In this paper, we have traced the evolution of chronic care in Austria, Germany, 
and the Netherlands, all of which are principally financed from SHI. We find that 
countries have implemented a range of policies and approaches to overcome 
fragmentation in the health care system to achieve better coordination within 
and across the primary and secondary care interface and so better meet the 
needs of those with chronic conditions. A predominant model of care in the form 
of structured disease management has emerged in all three countries, although 
the evolution of these models has differed. Thus, in Germany, disease manage-
ment was introduced in a top-down process, using a regulatory framework to 
ensure nationwide implementation.[11] The Dutch model, although imple-
mented nationwide upon government initiative, evolved from an experiment 
with a limited set of providers and informed by earlier experience of a delivery 
model developed in the 1990s.[19] In Austria, disease management pro-
grammes were made possible within the framework of a new financial instru-
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ment at the level of federal states, with states introducing such approaches 
broadly modelled on German DMPs. However, programmes have been slow to 
take off because projects require additional funds, and therefore disincentivis-
ing project approval.[5]  
Recent reforms in Austria have attempted to shift supply from inpatient to 
outpatient settings and improve patient access to ambulatory care services. 
However, these reforms have been restricted to physicians and are yet to take 
off in practice. Overall, this highlights the challenges experienced in Austria to 
arriving at an overarching strategic approach in a system that involves multiple 
actors in the negotiation of ambulatory care, including 21 SHI funds, the Federa-
tion of Austrian Social Security Institutions, the Austrian Medical Association, 
and associations of other health professions.[10] One area where the central 
government has taken a clear position is in efforts to promote a more integrated 
approach to planning, which is now being pursued towards coordinated supply 
across health care sectors.  
In Germany, in contrast, while also involving multiple actors, negotiations 
relating to the ambulatory care sector are centralised at the national level[8], 
which may have facilitated the development of a national framework. However, 
it should be noted that the introduction of DMPs was strongly supported by SHI 
funds such as the general regional funds, which, because of their member pro-
file, were disadvantaged by the RSA and their national association took a leading 
role in the promotion of the programmes. The government was also very sup-
portive of swift implementation of DMPs and it took provisions to do so despite 
resistance from many stakeholders.  
At the same time, although the creation of a strict national regulatory 
framework has been viewed as beneficial in ensuring that programmes meet 
appropriate standards, there have been concerns that this may limit the way in 
which this approach is able to address local need.[11] The Dutch approach of 
‘incremental’ implementation[44], starting out with a select set of pilots ex-
perimenting with bundled payment and that are being evaluated for subsequent 
roll-out may be regarded as an approach that combines centrally defined re-
quirements and local autonomy, although it should be noted that national roll-
out was advocated by the government before evaluation findings were available.  
Ham[45] has highlighted how competing pressures on organisations, that arise 
from policies initiated by health care reformers on one hand and established 
ways of delivery on the other, are likely to result in a gap between policy intent 
and actual implementation.[45] A critical role has to be played by professionals, 
who exert a large degree of control in health care organisations such as primary 
care practices and hospitals. Failure to engage them in the reform process is 
likely to hamper sustainable change. Indeed, as work on ‘chains of care’ in Swe-
den has demonstrated, approaches that engaged professionals, or were indeed 
initiated by professionals themselves, succeeded in developing improved inter-
organisational and interprofessional coordinated structures, whereas those 
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initiated top-down by councils did not.[46] However, a supportive policy envi-
ronment was also found to be critical for success.  
Fundamentally, it is, however, important to highlight that DMPs in Germany 
and Austria did not fundamentally alter (or indeed challenge) existing struc-
tures in the health care system. Services continue to be provided within the 
existing delivery structure, comprising family physicians, specialists in private 
practice, and hospitals. The integration of non-medical health professionals into 
the care system, which has led to considerable improvements in chronic care 
elsewhere, has only recently been pursued, although remaining limited to cer-
tain settings. In Germany, although wider use of nurses was considered and 
supported by the German nurses association as a means to strengthen the role 
of nurse practitioners, other stakeholders, in particular family physicians and 
their associations, were concerned about introducing another layer of care as 
well as losing control over the provision of medical care. It is interesting to note, 
in this context, that the role of nurses in the Dutch care groups, although promi-
nent, has been reduced somewhat compared to the model that informed their 
development.[19] Here, the specialist diabetes nurse acted as liaison between 
the hospital and primary care for all patients and indeed acted as consultant to 
the GP, who was responsible for the management of diabetes patients with low 
intensity needs. In 2007, the model was transformed into the diabetes care 
group by the Regional General Practitioners Organisation in the Maastricht re-
gion. Thus, professional resistance to change remains a challenge in all systems.  
Finally, one of the greatest challenges for the systems reviewed here re-
mains the development of a system-wide model of care for patients with chronic 
disease. As noted earlier, disease-specific approaches such as disease manage-
ment programmes are ill-suited to meet the needs of the typical patient in pri-
mary care, who frequently has multiple health problems with complex 
needs.[2,3] The Dutch care groups, although disease-focused, are envisaged as 
multidisciplinary care teams and, through stratification of patients according to 
severity and required care intensity, may go some way to meeting the require-
ments of those with multiple health problems. However, more generalist ap-
proaches such as the integrated care contracts implemented in Germany are 
potentially better equipped to respond to more complex patient needs, yet the 
evidence as to their effect within the German health care system remains poorly 
understood. There is a need for more systematic evaluation of new models of 
care as a means to inform the development of efficient and effective interven-
tions to address the growing burden of chronic conditions in Europe and else-
where. 
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ABSTRACT 
Objective: To assess the differentiated effects of population-based disease man-
agement programmes (DMPs) for type 2 diabetes on intermediate clinical out-
comes in the Netherlands.  
Methods: Data covering a period from 20 to 24 months between January 2008 
and December 2010 were collected from 18 Dutch care groups (primary care 
provider networks that have bundled payment contracts for delivery of diabetes 
DMPs). Meta-analysis and meta-regression methods were used to conduct dif-
ferentiated analyses of these programmes’ effects over time on 4 clinical indica-
tors: glycated haemoglobin, low-density lipoprotein, systolic blood pressure, 
and body mass index. Heterogeneous average results were stratified according 
to various patient and process characteristics to investigate whether differences 
in these features could explain variation in outcomes.  
Results: Between 56% and 71% of patients (N=105,056) had valid first- and 
second-year measurements of the study outcomes. Although average changes in 
these measures over time were small, stratified analyses demonstrated that 
clinically relevant improvements were achieved in patients with poor first-year 
health values. Interactions with age, disease duration, comorbidity, and smoking 
status were not consistent across outcomes; nonetheless, heterogeneity in re-
sults decreased considerably when simultaneously correcting for known patient 
characteristics. Positive effects tended to diminish with longer length of follow-
up, while greater measurement frequency was associated with improved re-
sults, especially in patients with poor health.  
Conclusions: Our data suggest that tailored disease management, in which not 
only evidence-based guidelines but also patient characteristics directly deter-
mine care processes, including self-management support, has great potential to 
improve the cost-effectiveness of current chronic care delivery. 
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INTRODUCTION 
Rising costs, an aging population, and the recognition of severe deficiencies in 
traditional care have motivated the development of innovative models for 
chronic illness management. Examples include shared care, case management, 
and stepped care, but perhaps most well known internationally are disease 
management and the Chronic Care Model.[1-3] Differences aside, these concepts 
have in common their basic assumption that better treatment today will result 
in better health and less expensive care in the future. Specific quality improve-
ment efforts tend to focus on: (1) reducing fragmentation between providers 
and settings; (2) stimulating evidence-based practice; (3) promoting active and 
planned follow-up; and (4) supporting patients’ self-management.[4-7]  
Developed in the United States, disease management programmes (DMPs) 
have quickly spread to other countries such as Canada, the United Kingdom, and 
Germany, which now has some of the largest DMPs in the world.[8,9] In the 
primary care-oriented Dutch health system, chronic disease management initia-
tives developed from the 1990s onward. Initially, uptake of these initiatives 
remained limited, mainly due to lack of a structured framework and fragmen-
tary funding.[10,11] The 2006 health insurance reform granted health insurers 
extended power to negotiate with care providers and, in so doing, facilitated the 
development of a more integrated funding method, the so-called ‘bundled pay-
ment system’.[12-14] Under this system, insurers pay care groups, which are 
provider networks based in primary care, a single fee for the full range of outpa-
tient services for a specific chronic condition.[15] Bundled payments are seen as 
a way to stimulate primary care providers, predominantly general practitioners 
(GPs), to engage in multidisciplinary cooperation and deliver integrated, evi-
dence-based disease management in an ambulatory setting, therefore limiting 
the need for specialist care.[16,17] 
Although the evidence base for their impact on the quality and outcomes of 
care is limited, integrally financed DMPs for type 2 diabetes quickly achieved 
national coverage in the Netherlands. In March 2010, more than 100 groups 
representing approximately 80% of GPs had a bundled payment contract for 
diabetes care.[17,18] In the same year, the payment system was expanded to 
cover the management of chronic obstructive pulmonary disease (COPD) and 
vascular risks. Hence, the support for disease management in the Netherlands 
appears to be a matter more of faith than fact, as is the case in other countries as 
well. International studies and reviews of DMPs demonstrate highly heteroge-
neous results and so far have failed to answer the basic question of what works 
best for whom, not least because of variation in both methodology and nomen-
clature.[3,19-22] It is, however, especially the multicomponent and population-
based nature of disease management that makes it difficult to draw unambigu-
ous conclusions concerning effectiveness. Analysing complex DMPs necessitates 
a clear framework that links expected outcomes to the characteristics of both 
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the programme and its target population, and measures effects over an ade-
quate period of time.[23]  
As part of the DISMEVAL (Developing and Validating Disease Management 
Evaluation Methods for European Health Care Systems) project, this study’s 
objective was to assess the effects of the Dutch diabetes DMPs on a range of 
intermediate clinical outcomes. To investigate heterogeneity in results across 
different care processes and patients, we designed the study as a population-
based, multilevel meta-analysis and meta-regression. Given that experimental 
comparisons were not possible, because of the nationwide roll-out of the DMPs 
and the unsuitability of using historical controls[9], these methods allow for the 
most in-depth assessment of effectiveness. Such differentiated insight, which 
goes beyond the ‘grand means’ that currently inform many health system redes-
igns, can support professionals and policymakers in their efforts to better meet 
the complex care needs of the growing and inherently diverse population of 
chronically ill patients. 
METHODS 
Study design and participants  
The bundled payment system for generic diabetes disease management in the 
Netherlands obliges care groups to provide insurers with a specific number of 
performance indicators for both processes and outcomes on an annual ba-
sis.[24] We retrospectively gathered individual patient data on these indicators 
from a convenience sample of 18 groups, which were set up between 2006 and 
2009 and represent nearly all regions of the Netherlands. Nine groups were part 
of an experimental pilot concerning bundled payments evaluated by the Na-
tional Institute for Public Health and the Environment (RIVM)[15]; to include 9 
other, non-experimental groups, 14 care groups were approached (response 
rate 64.3%).  
Across the included groups, 106,623 patients had at least 1 registered visit 
during the research period, which – depending on the availability of data – was 
either 20 or 24 months between January 2008 and December 2010. We ex-
cluded type 1 diabetes patients (N=1567) because they are treated primarily by 
specialists. Since patient data were drawn from groups’ clinical information 
systems, plausibility was verified through range checks. Outliers were removed 
based on cut-off points determined by Dutch diabetes experts (Appendix 1). 
Missing values were not imputed.  
Because patient data were not available for the period before introduction 
of the bundled payment system, we assessed the effects of the diabetes DMPs by 
comparing the last measurement of each clinical outcome during the first year of 
the research period (or the first 8 months for the 2 groups with a 20-month 
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research period) with the last measurement of that outcome in the second year. 
Per outcome-specific analysis, we excluded patients who: (1) lacked registra-
tions of the first- or second-year measurement, or both; (2) missed registrations 
of 1 or more of the patient and/or process characteristics used for stratification; 
and/or (3) had an observation period between first- and second-year outcome 
measurement of fewer than 3 months. The maximum length of follow-up per 
patient was 23 months. The study flow chart is shown in Figure 1. 
 
 
Figure 1: Study flowchart 
NOTE: HbA1c indicates glycated haemoglobin; LDL, low-density lipoprotein; SBP, systolic blood 
pressure; BMI, body mass index 
Patients included in 
HbA1c-specific 
analyses: 
N=75,127 
Patients included in 
LDL-specific  
analyses:  
N=58,697 
Patients included in 
SBP-specific  
analyses:  
N=73,437 
Patients included in 
BMI-specific  
analyses:  
N=63,341 
Missing patient 
characteristic(s): 
N=32,468 
Missing patient 
characteristic(s): 
N=24,178 
Missing patient 
characteristic(s): 
N=30,918 
Missing patient 
characteristic(s): 
N=24,816 
Missing process 
characteristic(s): 
N=23,873 
Missing process 
characteristic(s): 
N=25,849 
Missing process 
characteristic(s): 
N=22,495 
Missing process 
characteristic(s): 
N=26,892 
Outcome-specific analyses
Patients under treatment 
identified in care groups’ 
information systems: 
N=106,623
Excluded:
Type I diabetes mellitus: N=1567 
Eligible patients
N=105,056 
Excluded LDL:
Length of follow-up  
<3 months: N=3451 
No first measurement: 
N=31,539 
No second measure-
ment: N=20,062 
No measurement: 
N=8693
Excluded SBP:
Length of follow-up 
<3 months: N=3842 
No first measurement: 
N=21,343 
No second measure-
ment: N=10,060 
No measurement: 
N=3626
Excluded HbA1c: 
Length of follow-up  
<3 months: N=1244 
No first measurement: 
N=22,070 
No second measure-
ment:  N=10,399 
No measurement: 
N=3784
Excluded BMI: 
Length of follow-up  
<3 months: N=4042 
No first measurement: 
N=30,670 
No second measure-
ment: N=19,520 
No measurement: 
N=12,517 
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Diabetes disease management programmes in the Netherlands 
In 2007, 10 Dutch care groups started experimenting with a bundled payment 
system that allows the different components of care for generic type 2 diabetes 
to be purchased, delivered, and billed as a single product or service. Care groups 
are legal entities in primary care, which consist of multiple care providers, are 
most commonly owned by GPs, and form the principal contracting partners for 
health insurers involved in bundled payment contracts.[17] Groups either de-
liver the various components of a diabetes DMP themselves or subcontract 
other providers, including GPs, physical therapists, dieticians, laboratories, 
and/or specialists, to do so. The price of a specific programme (i.e. care bundle) 
as well as the fees for individual subcontractors are freely negotiable between 
care groups on the one hand and health insurers or care professionals on the 
other. Patients are automatically enrolled by their GP.[15,16]  
The services to be covered in the diabetes DMPs are codified by a national 
care standard for generic diabetes care.[25] This standard is based on existing 
evidence-based guidelines for GPs and includes general modules (e.g. informa-
tion, education and self-management support, smoking cessation, physical activ-
ity, nutrition and diet) as well as disease-specific modules.[24] The latter com-
prise a defined frequency of GP visits, regular foot and eye examinations, and 
laboratory testing. To stimulate task redistribution from GPs to practice nurses, 
who traditionally play an important role in Dutch chronic care, the standard 
describes care in terms of functions rather than providers, defining what ser-
vices must be delivered rather than by whom or where.[16,25] For more infor-
mation on the contents of the Dutch diabetes DMPs, the diabetes care standard 
can be accessed online: http://www.diabetesfederatie.nl/zorg/zorg-
standaard.html.  
Definition of variables and data validation 
We defined intermediate clinical outcomes as mean changes in glycated haemo-
globin (HbA1c), low-density lipoprotein (LDL), systolic blood pressure (SBP), 
and body mass index (BMI) between the first- and second-year measurements. 
In addition, we assessed and compared the proportions of patients within 3 
target range groups for glycaemic control (HbA1c≤53 mmol/mol; HbA1c=54-74 
mmol/mol; HbA1c≥75 mmol/mol) at these 2 measurement points.[25]  
Care processes were described in terms of measurement frequency and 
range, and duration of care. We codified measurement frequency as the number 
of registrations of each clinical outcome during follow-up; to describe meas-
urement range, we assessed the number of different outcomes registered, which 
across care groups could be a maximum of 8 (i.e. HbA1c, total cholesterol, LDL 
and high-density lipoprotein, triglycerides, SBP and diastolic blood pressure, 
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BMI). Duration of care was defined as the number of months between the first- 
and second-year measurements of each clinical outcome. 
To describe patients, we used age in years, disease duration in years, health 
status, comorbidity, and smoking status. Health status was determined by the 
first-year values of each clinical outcome. Comorbidity was defined as the pres-
ence of 1 or more of the 4 most frequently registered co-occurring conditions 
across the included care groups (i.e. angina pectoris, myocardial infarction, 
stroke, transient ischemic attack). We dichotomised smoking status as previous 
smoker or non-smoker versus current smoker.  
Data analysis 
We used a 2-step approach to population-based, multilevel meta-analysis, in 
which we clustered the individual patient data by care group.[26,27] During the 
first step, we conducted paired-sampled t-tests (2-sided; α=0.05) using SPSS 
version 18 (IBM Corporation, Armonk, New York) to calculate the group-specific 
mean differences in clinical values and associated standard deviations. In the 
second step, these were synthesised with Review Manager (RevMan version 
5.1.1; The Cochrane Collaboration) into pooled mean differences and 95% con-
fidence intervals, for which – owing to significant heterogeneity in results – we 
used the random-effects meta-analysis model of DerSimonian and Laird.[28] 
Using this model, we weighted the aggregate effects by the inverse of their vari-
ances while assuming random treatment effects across care groups.[29] To 
quantify heterogeneity, we calculated the I2 statistic – which can range from 0% 
to 100% – on the basis of the χ2 test.[30] For outcomes showing moderate 
(I2>50%) to high (I2>75%) heterogeneity, subgroup analyses were conducted to 
examine the consistency of results across diabetes care processes and pa-
tients.[26] For this purpose, most continuous variables were categorised into 2 
or 3 groups on the basis of either scientific literature (age[31,32], disease dura-
tion[33]) or median values (measurement frequency, length of follow-up). We 
dichotomised measurement range as 8 outcomes (the maximum number of 
clinical indicators that could be registered) versus fewer than 8 outcomes; first-
year health status was categorised according to the target range values for clini-
cal outcomes included in the diabetes care standard.[25] 
We used multilevel meta-regression analysis of individual patient data, 
stratified by care group, to further assess the influence of potential effect modi-
fiers as well as to investigate potential interactions between care processes and 
patient characteristics.[34,35] To conduct the meta-regressions, we used the 
PROC MIXED command in the SAS 9.2 software (SAS Institute Inc, Cary, North 
Carolina), which uses a random-effects iterative method to provide a maximum 
likelihood estimate of the regression parameters. The meta-regression models 
were multivariable, though process and patient characteristics were included 
separately; continuous covariates were included as such. For each clinical out-
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come, we calculated the intraclass correlation coefficient to assess the percent-
age of total heterogeneity in effects occurring between care groups. The larger 
the intraclass correlation coefficient, the greater the proportion of variance that 
can be attributed to differences between rather than within groups.[36] We 
examined collinearity with the variance inflation factor: a variance inflation 
factor value of greater than 10 is generally taken as an indication of serious 
multicollinearity.[37] Explained heterogeneity was expressed as the percentage 
change in between-group variance (τ2) and within-group variance (σ2). 
RESULTS 
Diabetes care processes and patients 
With regard to care processes, patients’ SBP was assessed most frequently (me-
dian=4) during the period between the first- and second-year measurements, 
followed by BMI (median=3) and HbA1c (median=2). LDL was measured least 
often (median=1). Across care groups, the average share of patients with the 
maximum outcome measurement range varied from 44.4% to 86.7%, with a 
mean of 62.3%. Median length of follow-up varied from 10 to 12 months be-
tween groups. 
Table 1 shows the patients’ main characteristics and first-year clinical val-
ues. Age ranged from 15 to 105 years with a mean of 65.7 (±11.9) years. Diabe-
tes duration varied from 0 to 76 years with a mean of 4.8 (±5.6) years. Approxi-
mately 16% of patients had a known comorbidity; 18.4% were registered as 
current smokers. Depending on the clinical outcome of interest, roughly 56% to 
71% of patients (N=105,056) had both a first- and second-year measurement. 
For most outcomes, the mean first-year values for patients were within normal 
range. Mean first-year BMI (29.7±5.2 kg/m2), however, signified severe over-
weight to borderline obesity. 
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Table 1: Characteristics of the research population 
Characteristic Patients for whom characteristic 
was known, % (n) 
(N =105,056)  
Estimate,  
Mean ± SD 
First-year age  99.9 (105,013) 65.7 ± 11.9 
First-year diabetes duration  71.9 (75,498)  4.8 ± 5.6 
First-year health status   
 HbA1c (mmol/mol; target <53) 71.5 (75,127) 50.2 ± 9.8 
 LDL cholesterol (mmol/l; target <2.5) 55.9 (58,697)  2.6 ± 0.9 
 SBP (mmHg; target <140) 69.9 (73,437) 140.4 ± 18.0 
 BMI (kg/m2; target <25) 60.3 (63,341)  29.7 ± 5.2 
Comorbidity† 94.5 (99,278)   
 None 84.2 (75,357)  
 One or more 15.8 (14,165)  
Smoking status 74.6 (78,384)  
 No or Ex-smoker 81.6 (63,943)  
 Current smoker 18.4 (14,441)  
NOTE: †Included were four major comorbidity associated with diabetes mellitus: angina pectoris, 
myocardial infarction, stroke, and transient ischemic attack; HbA1c indicates glycated haemoglobin; 
LDL, low-density lipoprotein; SBP, systolic blood pressure; BMI, body mass index 
Clinical outcomes 
Table 2 shows the overall results of the random-effects meta-analysis across 18 
care groups, presented per clinical outcome. Mean HbA1c increased by 0.17 
mmol/mol (95% confidence interval [CI]: -0.60 to 0.93) between the first- and 
second-year measurements. LDL was reduced significantly by a mean of 0.09 
mmol/l (95% CI: -0.13 to -0.05); SBP decreased significantly by an average of 
0.95 mmHg (95% CI -1.25, -0.64). There was a small average decrease in BMI of 
0.04 kg/m2 (95% CI: -0.10 to 0.02). Except for BMI, the effects of the diabetes 
DMPs on all intermediate outcomes were moderately to highly heterogeneous, 
with I2 values ranging from 57% for SBP to 98% for HbA1c.  
 
Table 2: Results of the overall random-effects meta-analysis per clinical outcome 
Intermediate outcome Care groups, 
n 
Patients,  
n 
Mean difference 
[95%CI] 
Heterogeneity,  
I2 
HbA1c (mmol/mol) 18 75,127 0.17 [-0.60, 0.93] 98%* 
LDL (mmol/l) 18 58,697 -0.09 [-0.13, -0.05]* 93%* 
SBP (mmHg) 18 73,437 -0.95 [-1.25, -0.64]* 57%* 
BMI (kg/m2) 18 63,341 -0.04 [-0.10, 0.02]  0% 
NOTE: HbA1c indicates glycated haemoglobin; LDL, low-density lipoprotein; SBP, systolic blood 
pressure; BMI, body mass index; *Statistically significant (p<0.05); I2 quantifies the total level of 
heterogeneity in effects 
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Figure 2 shows the proportions of patients within 3 target range groups for 
glycaemic control at the first- and second-year measurements. Glycaemic con-
trol improved in the vast majority of patients, especially in the group with highly 
uncontrolled diabetes (HbA1c≥75 mmol/mol). Diabetes was brought under 
control in roughly 68% of these patients; in 19%, the values improved to 53 
mmol/mol or lower. Of the patients with first-year HbA1c concentrations be-
tween 53 and 75 mmol/mol, approximately 36% improved their glycaemic con-
trol, 60% remained within the same range, and 4% deteriorated. Of those within 
target range at the first measurement (HbA1c≤53 mmol/mol), 83% maintained 
their HbA1c control, whereas HbA1c control deteriorated up to levels of <75 
mmol/mol in 16.5%. Roughly 0.5% saw their HbA1c increase to ≥75 mmol/mol. 
In terms of mean age and disease duration, the patients within target range at 
the first-year measurement were most comparable to the overall patient popu-
lation. Those in the subgroups with initial HbA1c values above 53 mmol/mol 
and 75 mmol/mol were significantly younger but had a longer-than-average 
disease duration.  
 
Pa
ti
en
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, %
 
Baseline (mmol/mol) 
Follow-up 
 
Figure 2: Glycaemic control from first- to second-year measurement according to target values [25] 
NOTE: HbA1c indicates glycated haemoglobin 
Investigating heterogeneity 
With regard to heterogeneity, the intraclass correlation coefficients identified in 
the meta-regression – ranging from 0.1% to 4.3% across outcomes – suggest 
that the vast majority of variance in effects on HbA1c, LDL, and SBP occurs 
within rather than between care groups. Subgroup meta-analysis and meta-
regression were conducted to investigate to what extent this heterogeneity can 
be explained by variation in care processes and patient characteristics. Evidence 
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for multicollinearity (variance inflation factor >10) among the different covari-
ates on these levels was not identified (Tables 3-6).  
Variation in care processes 
Table 3 shows that subgroup meta-analyses identified 1 significant difference in 
effects based on a process characteristic: patients with a length of follow-up of 1 
year or less achieved greater reductions in SBP than patients followed for more 
than 1 year. The meta-regressions demonstrated relationships between length 
of follow-up and all clinical outcomes, indicating that as the duration of care 
increases, the positive effects of the DMPs are difficult to maintain. A higher 
measurement frequency was associated with progressively greater reductions 
in all included outcomes, although statistical significance was not achieved for 
HbA1c. The results for measurement range (<8 outcomes vs. 8 outcomes) were 
inconsistent. Despite the identified interactions, simultaneously correcting for 
the 3 known process features resulted in no more than minor changes in the 
existing heterogeneity in effects within groups. 
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Table 3: Effect of process characteristics on changes in HbA1c, LDL, and SBP levels between first- 
and second-year measurements 
 Groups,  
n 
Patients, 
n 
Mean difference 
 [95% CI; I²] 
RC Change 
in τ2, %
Change  
in σ2, % 
VIF 
HbA1c, mmol/mol 18 75,127 0.17 [-0.60, 0.93; 98*]  26 -0.1  
Measurement frequency 14   -   1.04 
 ≤Median  27,322 0.09 [-0.85, 1.03]     
 >Median  20,913 -0.06 [-1.47, 1.36]     
Measurement range 18  -*   1.05 
 <8 outcomes  15,641 0.13 [-1.08, 1.34]     
 8 outcomes  51,820 0.05 [-0.66, 0.75]     
Length of follow-up 18  +*   1.05 
 ≤1 year  57,069 0.02 [-0.77, 0.81]     
 >1 year  18,058 0.53 [-0.22, 1.27]     
LDL, mmol/l 18 58,697 -0.09* [-0.13, -0.05; 93*]  -36.9 0.7  
Measurement frequency 14  -*   1.02 
 ≤Median  25,420 -0.08* [-0.12, -0.05]     
 >Median  10,782 -0.20* [-0.26, -0.15]     
Measurement range 18  -   1.00 
 <8 outcomes   6500 -0.10* [-0.15, -0.05]     
 8 outcomes  45,301 -0.10* [-0.14, -0.06]     
Length of follow-up 18  +*   1.02 
 ≤1 year  43,901 -0.09* [-0.13, -0.05]     
 >1 year  14,796 -0.11* [-0.15, -0.06]     
SBP, mmHg 18 73,437 -0.95* [-1.25, -0.64; 57*]  15.6 5.2  
Measurement frequency 14  -*   1.08 
 ≤Median  21,764 -0.99* [-1.57, -0.41]     
 >Median  25,824 -1.01* [-1.38, -0.64]     
Measurement range 18  +*   1.06 
 <8 outcomes  14,397 -1.60* [-2.02, -1.17]     
 8 outcomes  50,392 -0.79* [-1.15, -0.43]     
Length of follow-up 18  +*   1.07 
 ≤1 year  55,686 -1.27* [-1.60, -0.95]     
 >1 year  17,751 -0.04 [-0.52, 0.44]    
NOTE: HbA1c indicates glycated haemoglobin; LDL, low-density lipoprotein; SBP, systolic blood 
pressure; CI, confidence interval; RC, regression coefficient; VIF, variance inflation factor; 
*Statistically significant (p<0.05); +=positive; -=negative 
Variation in patient characteristics 
The findings from the analyses stratified by patient characteristics are displayed 
in Tables 4 to 6. Both the subgroup meta-analyses and the meta-regressions 
demonstrated an association between progressively greater health improve-
ments and initially poorer clinical values. Across the 18 care groups, patients 
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with a first-year HbA1c of ≥75 mmol/mol achieved a mean reduction in this 
clinical measure of 16.8 mmol/mol, whereas those starting within the target 
range (≤53 mmol/mol) experienced a slight deterioration (1.79 mmol/mol). For 
LDL and SBP, similar interactions were found. The results of the remaining 
analyses (i.e. for age, disease duration, comorbidity, and smoking status) were 
less conclusive and inconsistent across clinical outcomes. Nevertheless, simul-
taneously including all patient characteristics into a meta-regression model 
allowed for substantial reductions in within-group variance in results. 
 
Table 4: Effect of patient characteristics on changes in HbA1c levels between first- and second-year 
measurements 
 Groups,  
n 
Patients, 
n 
Mean difference 
[95% CI; I²] 
RC Change
in τ2, %
Change 
in σ2, % 
VIF 
HbA1c (mmol/mol) 18 75,127 0.17 [-0.60, 0.93; 98*]  -12.5 -23.5  
Age 18  -*   1.12 
 ≤59 years  20,538 0.21 [-0.56, 0.98]     
 60-69 years  24,204 0.23 [-0.55, 1.02]     
 ≥70 years  30,382 0.03 [-0.78, 0.83]     
Disease duration 14  +*   1.09 
 ≤2 years  21,261 -0.12 [-1.12, 0.88]     
 3-5 years  13,342 0.11 [-0.76, 0.98]     
 ≥5 years  20,474 -0.07 [-1.08, 0.95]     
First-year HbA1c 18  -*   1.05 
 ≤53  51,545 1.79* [1.17, 2.41]     
 54-74  21,637 -2.62* [-3.46, -1.78]     
 ≥75  1945 -16.82* [-18.67, -14.96]     
Comorbidity 16  +*   1.03 
 No  53,065 0.04 [-0.63, 0.71]     
 Yes  10,183 -0.06 [-0.76, 0.65]     
Smoking 17  +*   1.04 
 No/previously  46,277 0.23 [-0.28, 0.73]     
 Yes  10,375 0.20 [-0.85, 1.25]     
NOTE: HbA1c indicates glycated haemoglobin; CI, confidence interval; RC, regression coefficient; 
VIF, variance inflation factor; *Statistically significant (p<0.05); +=positive; -=negative 
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Table 5: Effect of patient characteristics on changes in LDL levels between first- and second-year 
measurements 
 Groups,  
n 
Patients, 
n 
Mean difference 
[95% CI; I²] 
RC Change
in τ2, %
Change 
in σ2, % 
VIF 
LDL (mmol/l) 18 58,697 -0.09* [-0.13, -0.05; 93*]  -33.9 -21.7  
Age 18  +*   1.11 
 ≤59 years  15,857 -0.12* [-0.16, -0.07]     
 60-69 years  19,364 -0.09* [-0.13, -0.05]     
 ≥70 years  23,474 -0.08* [-0.12, -0.03]     
Disease duration 14  -   1.05 
 ≤2 years  16,756 -0.14* [-0.19, -0.08]     
 3-5 years  10,607 -0.08* [-0.12, -0.03]     
 ≥5 years  15,857 -0.06* [-0.10, -0.01]     
First-year LDL  18  -*   1.02 
 <2.5  29,311 0.15* [0.12, 0.18]     
 2.5-3.5  19,984 -0.17* [-0.20, -0.14]     
 >3.5  9402 -0.72* [-0.77, -0.67]     
Comorbidity 16  -*   1.04 
 No  39,721 -0.10* [-0.14, -0.06]     
 Yes  7994 -0.08* [-0.15, -0.01]     
Smoking 17  -   1.03 
 No/previously  38,294 -0.09* [-0.13, -0.04]     
 Yes  7762 -0.11* [-0.15, -0.06]     
NOTE: LDL indicates low-density lipoprotein; CI, confidence interval; RC, regression coefficient; VIF, 
variance inflation factor; *Statistically significant (p<0.05); +=positive; -=negative 
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Table 6: Effect of patient characteristics on changes in SBP between first- and second-year meas-
urements 
 Groups,  
n 
Patients, 
n 
Mean difference 
[95% CI; I²] 
RC Change
in τ2, %
Change 
in σ2, % 
VIF 
SBP (mmHg) 18 73,437 -0.95* [-1.25, -0.64; 57*] 74.8 -29.9  
Age 18  +*   1.15 
 ≤59 years  20,139 -0.57* [-0.92, -0.23]     
 60-69 years  23,689 -1.00* [-1.38, -0.62]     
 ≥70 years  29,605 -1.34* [-1.72, -0.96]     
Disease duration 14  +   1.04 
 ≤2 years  21,673 -1.04* [-1.47, -0.62]     
 3-5 years  13,117 -0.55* [-0.97, -0.13]     
 ≥5 years  19,645 -1.22* [-1.61, -0.84]     
First-year SBP 18  -*   1.04 
 ≤140  42,784 4.59* [4.21, 4.97]     
 >140  30,653 -8.91* [-9.67, -8.16]     
Comorbidity 16  -*   1.04 
 No  50,780 -0.93* [-1.29, -0.58]     
 Yes  9788 -1.25* [-1.75, -0.75]     
Smoking 17  -   1.04 
 No/previously  46,908 -0.90* [-1.24, -0.56]     
 Yes  10,504 -1.07* [-1.54, -0.59]     
NOTE: SBP indicates systolic blood pressure; CI, confidence interval; RC, regression coefficient; VIF, 
variance inflation factor; *Statistically significant (p<0.05); +=positive; -=negative 
Combining variation in processes and patients 
Meta-regression identified 1 significant interaction between care processes and 
patients that was consistent across all included outcomes (Table 7). This inter-
action indicates that the poorer a patient’s initial values were, the more benefi-
cial frequent measurement of that particular clinical outcome was in terms of 
achieving improvements. 
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Table 7: Interactions between measurement frequency and first-year clinical values, and effects of 
the diabetes DMPs on HbA1c, LDL and SBP 
 Groups,  
n 
Patients,  
n 
Coefficient Change in 
τ2, % 
Change in 
σ2, % 
HbA1c, mmol/mol 14 48,235  -11.2 -19.2 
Intercept   13.2497*   
Measurement frequency   1.5295*   
First-year HbA1c    -0.2743*   
Measurement frequency X  
First-year HbA1c 
  -0.02614*   
LDL, mmol/l 14 36,202  -62.2 -21.2 
Intercept   0.6997*   
Measurement frequency   0.1095*   
First-year LDL   -0.3024*   
Measurement frequency X 
First-year LDL  
  -0.05091*   
SBP, mmHg 14 47,588  69.8 -23.0 
Intercept   63.5490*   
Measurement frequency   1.8236*   
First-year SBP   -0.4683*   
Measurement frequency X  
First-year SBP 
  -0.01115*   
NOTE: HbA1c indicates glycated haemoglobin; LDL, low-density lipoprotein; SBP, systolic blood 
pressure; *Statistically significant (p<0.05) 
DISCUSSION 
As far as we are aware, this study is one of the largest to date (N=105,056) that 
analysed the effects of population-based disease management on the intermedi-
ate outcomes of diabetes care. In terms of the Chronic Care Model[1,4], the 
DMPs for diabetes in the Netherlands can be considered a ‘light’ form of practice 
redesign, focusing primarily on improvements in 2 areas: decision support and 
the delivery system design. During the 12-month evaluation of the bundled 
payment system, Dutch providers indeed reported improved evidence-based 
practice and coordination of care based on the guiding principles of the diabetes 
care standard.[15-17] Thus far, self-management support is not part of most 
contracts and, as such, is less of a target point for improvement efforts. While 
contracts do include record-keeping obligations and the diabetes care standard 
emphasises the importance of adequate data exchange, clinical information 
systems also remain underdeveloped.[15] 
Based solely on the undifferentiated mean changes in clinical values shown 
by our meta-analysis – which differ from a simple paired t-test to the extent that 
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they are pooled and weighted per care group – one would conclude that the 
Dutch DMPs have little impact on the health of patients suffering from type 2 
diabetes. However, one of the strengths of multilevel meta-analysis and meta-
regression of individual patient data is that these methods allow for the investi-
gation of subgroups of patients for whom certain care processes might be more 
or less effective. Most notably, the stratified results suggest that the DMPs are 
considerably more beneficial for patients with poorly controlled diabetes than 
for those within the target range of important clinical indicators. A recent meta-
analysis of the international literature conducted by Pimouguet et al.[21] sup-
ports this finding, which – given that the vast majority of patients included in 
our research had good first-year values for HbA1c, LDL, and SBP – provides a 
plausible explanation for the small average effects of the diabetes DMPs. Con-
trary to what is often assumed, the patients benefiting most from disease man-
agement in our study were not those recently diagnosed with diabetes, but 
rather patients with a longer-than-average disease duration. Stratified analyses 
for HbA1c showed that in patients with controlled diabetes (HbA1c≤53 
mmol/mol), whose clinical values leave limited room for further improvement, 
the DMPs implemented in the Netherlands successfully maintained HbA1c levels 
within target range, thereby preventing the severe complications associated 
with deteriorating glycaemic control.[32,38] Although the interactions between 
the effects of the DMPs and patient characteristics other than first-year health 
status were far less conclusive, the existing heterogeneity in results was re-
duced considerably after simultaneously correcting for patient features. Charac-
teristics not included in our study (e.g. level of education, socioeconomic status) 
may be equally important and informative, given their influence on people’s 
health care behaviours.[39] 
The rising prevalence of long-term conditions strains the human and finan-
cial capital of current health care systems in many countries and urges cost-
effective solutions.[40,41] Our study was based on the assumption that evalua-
tions of DMPs should take into account the heterogeneous nature of care proc-
esses and patients (something that randomised controlled trials have thus far 
failed to do[9,19,21]) because this information can help health care profession-
als and policymakers to achieve such solutions. In its current form, the Dutch 
bundled payment system appears to motivate care providers to deliver highly 
standardised diabetes care based on performance indicators monitored by 
health insurers.[15] Among other things, these indicators prescribe a defined 
intensity of service delivery and target values for clinical measures. Our findings 
support a move toward a more tailored approach to disease management, in 
which the characteristics of patients directly determine care processes. Fre-
quent monitoring was shown to be especially useful for improving clinical val-
ues in patients with poorly controlled diabetes. For those in relatively good 
health, perhaps as a result of having previously been monitored intensively, a 
less physician-guided form of care that emphasises self-management might be 
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equally effective – and probably less costly – for maintaining glycaemic control. 
Multiple studies have shown that self-management support programmes can 
improve patients’ health behaviours and clinical and social outcomes, and re-
duce medical costs.[42,43] Further research is necessary to assess whether 
intensive, physician-guided disease management might indeed be redundant for 
relatively healthy subgroups of diabetes patients and could be replaced by ade-
quate self-management support.  
Tailoring care provision for diabetes requires improvements in the clinical 
information systems used to register data in the daily practice of health care, as 
valid and reliable information concerning the patient under treatment must 
guide decisions on care content and dose. Despite record-keeping obligations, 
missing values were ubiquitous in the data sets gathered from our care groups. 
Tailored disease management further necessitates broad implementation of 
effective strategies for self-management support (which should reach beyond 
the boundaries of the health care system) to provide patients with the knowl-
edge, skills, resources, and confidence to care for their illness(es).[1,44,45] Most 
importantly, however, the financial incentives embedded in funding systems 
should motivate providers to deliver high-quality care rather than to achieve 
overly standardised levels of service delivery, as appears to be the case with the 
Dutch bundled payment system. Health care professionals cannot be expected to 
work in a patient-centered – or for that matter, efficient – manner if they are 
reimbursed on the basis of performance indicators stipulating, for instance, that 
patients should be seen at least 4 times per year, regardless of their care needs 
or self-management skills.  
Future evaluations of disease management should utilise longitudinal data 
in order to improve insights into the long-term impact on patients’ health. In 
line with previous research[21,46], our findings suggest that studies conducted 
over shorter periods of time might overestimate effects, as length of follow-up is 
negatively related to health outcomes. Coming to strong conclusions regarding 
how we can best treat patients who have 1 or more chronic diseases requires 
more population-based research. Randomised controlled trials, generally per-
ceived as the gold standard for evaluating health care interventions, not only are 
difficult to apply to analyses of complex DMPs but also produce results that are 
difficult to generalise to the larger and inherently more heterogeneous popula-
tions of chronically ill patients.[47] Future studies should take into account the 
variation in both patients and interventions, and focus on gaining differentiated 
insights into the modes of care provision that are most effective for treating 
specific subgroups of chronically ill patients such as those suffering from severe 
multimorbidity.  
Most of the limitations of this study relate to the choice to collect data in a 
retrospective fashion. Of the 18 included care groups, no more than 2 were able 
to provide data on all of the requested process and patient characteristics, and 
intermediate outcomes. As a result, few analyses of the interactions between 
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these variables could be conducted on the basis of data from all groups. Within 
care groups, we had to exclude considerable numbers of patients lacking valid 
registrations of included characteristics or outcomes. Nonetheless, our popula-
tion did not differ from other diabetes populations studied in the Netherlands in 
terms of average age or disease duration, or from the overall Dutch population 
with respect to percentage of smokers.[15,48,49] The prevalence of co-
occurring conditions was considerably lower in our research group than in the 
total cohort of Dutch diabetes patients[50], which likely signifies registration 
problems. Gathering data retrospectively also limited our choice of effect meas-
ures to the included set of intermediate clinical outcomes; more patient-
centered indicators (e.g. health-related quality of life, self-efficacy, patient satis-
faction) were not available. Furthermore, we were not able to stratify patients 
based on information about their GP (practice) or their use of services offered 
by other professionals, even though variation on the provider level likely causes 
heterogeneity in effects. Finally, the recent implementation of the diabetes 
DMPs in the Netherlands did not allow for analyses of time series, nor were we 
able to assess changes in the processes of diabetes care as a consequence of the 
implementation of these programmes.  
Strengths of our study include the large sample size, the setting in daily 
health care practice, an adequate length of follow-up, and the analytic methods 
used for evaluation, which allowed us to determine the differential effects of 
disease management for diabetes across different care processes and patients.  
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Appendix 1: Cut-off points for data cleaning 
Indicator Lower Upper Excluded, n Excluded, % 
Glycated haemoglobin (HbA1c, mmol/mol) 18 108 913 0.5 
Low-density lipoprotein (LDL, mmol/l) 1 7.3 2110 1.3 
Systolic blood pressure (SBP, mmHg) 70 250 25 0.01 
Body Mass Index (BMI, kg/m2) 16 70 123 0.08 
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ABSTRACT 
Background: Self-management support is a key component of effective chronic 
care management, yet in practice appears to be the least implemented and most 
challenging. This study explores whether and how self-management support is 
integrated into chronic care approaches in 13 European countries. In addition, it 
investigates the level of and barriers to implementation of support strategies in 
health care practice. 
Methods: We conducted a review among the 13 participating countries, based 
on a common data template informed by the Chronic Care Model. Key infor-
mants presented a sample of representative chronic care approaches and re-
lated self-management support strategies. The cross-country review was com-
plemented by a Dutch case study of health professionals’ views on the imple-
mentation of self-management support in practice.  
Results: Self-management support for chronically ill patients remains relatively 
underdeveloped in Europe. Similarities between countries exist mostly in in-
volved providers (nurses) and settings (primary care). Differences prevail in 
mode and format of support, and materials used. Support activities focus pri-
marily on patients’ medical and behavioural management, and less on emotional 
management. According to Dutch providers, self-management support is not 
(yet) an integral part of daily practice; implementation is hampered by barriers 
related to, among others, funding, information technology, and medical culture.  
Conclusions: Although collaborative care for chronic conditions is becoming 
more important in European health systems, adequate self-management sup-
port for patients with chronic disease is far from accomplished in most coun-
tries. There is a need for better understanding of how we can encourage both 
patients and health care providers to engage in productive interactions in daily 
chronic care practice, which can improve health and social outcomes. 
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INTRODUCTION 
The rising incidence and prevalence of chronic conditions – especially cardio-
vascular disease, cancer, chronic respiratory illness, and diabetes – pose a threat 
to the long-term sustainability of health care delivery systems worldwide.[1,2] 
In many countries, the direct medical costs of managing chronic disease, and in 
particular multimorbidity, already take up a disproportionate share of the na-
tional health care budget.[3-5] Conversely, the quality of services provided to 
patients has remained largely suboptimal, with consequences for disease con-
trol and patient experience.[6,7]  
In response, a wide range of innovative care concepts has been developed 
and implemented in many OECD countries.[8,9] One influential framework to 
conceptualise chronic care has been the Chronic Care Model (CCM).[10,11] Con-
ceived as an ‘evidence-based guide to comprehensive health care system redes-
ign’[12], it proposes six components to be core to providing high-quality, pa-
tient-centered chronic care: community resources and policies; the health care 
system; self-management support; delivery system design; clinical information 
systems; and decision support.[10] 
While the CCM recognises the importance of interrelated change in multiple 
areas of care to better meet the needs of the chronically ill, self-management 
support has been identified as a key component of the framework.[13] Chronic 
illness confronts patients with a spectrum of needs that requires them to alter 
their behaviour and engage in activities that promote physical and psychological 
well-being, which often have a more direct impact on disease control than the 
actions of health professionals.[14,15] Evidence across multiple conditions sug-
gests that effective self-management support can improve persons’ self-efficacy, 
i.e. their belief in their own ability to accomplish specific goals[16], and health-
related behaviours, which, in turn, may impact their health and/or functional 
status.[17-21] Yet, in practice, approaches to self-management support appear 
to be the least implemented and most challenging area of chronic care manage-
ment.[22] This is in part because self-management support will have to be tar-
geted to meet individual needs, with consequent demands on providers’ time 
and resources in practice. Moreover, to help patients improve their self-efficacy 
requires communication skills and psychological counselling techniques which 
have not traditionally been part of most medical professionals’ training.[23,24]  
In this study, we review whether and how self-management support is inte-
grated with existing approaches to chronic care management in 13 European 
countries, and the extent to which these approaches provide patients with the 
knowledge, skills, and confidence to effectively manage their condition. Nested 
within this review, we examine one country, the Netherlands, in more detail, 
assessing the level of and barriers to implementation of self-management sup-
port in current health care practice from the perspective of care professionals.  
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Defining self-management support 
Self-care and self-management are two distinct concepts that are often used 
interchangeably.[25] While self-care has been defined by the World Health Or-
ganisation (WHO) as ‘the activities that individuals, families, and communities 
undertake with the intention of enhancing health, preventing disease, limiting 
illness, and restoring health’[26], self-management tends to refer to the active 
participation of patients in their treatment.[27] According to Corbin and 
Strauss[28], self-management concentrates on three distinct sets of activities: 
(1) medical management, which refers to tasks such as taking medication and 
adhering to dietary advice; (2) behavioural management, that is, learning new 
meaningful roles in the context of a specific condition; and (3) emotional man-
agement, which refers to dealing with the feelings of frustration, fright, and de-
spair that are often experienced by chronically ill individuals. Self-management 
support is generally understood to target all three sets of tasks set out by the 
Corbin and Strauss framework. The CCM proposes that ‘by using a collaborative 
approach, providers and patients work together to identify problems, set priori-
ties, establish goals, create treatment plans and solve issues along the way’.[29] 
To facilitate patients to play such an active role in their care, patient education is 
usually a key part of self-management support.[30] Standardised interventions 
to support patients’ self-management furthermore may combine services avail-
able within health care (e.g. dietary advice, collaborative care planning) with 
services in the broader community (e.g. exercise programmes, peer sup-
port).[10,31] 
METHODS 
Data template 
This paper builds on work carried out within the DISMEVAL (Developing and 
Validating Disease Management Evaluation Methods for European Health Care 
Systems) project, a European collaborative project that aimed to identify ‘best 
practices’ in the area of disease management evaluation.[32] As part of DISME-
VAL, a common template was developed for the collection of qualitative data on 
approaches to chronic care management in Europe. Template development was 
based on a structured questionnaire used in a previous study and informed, to 
great extent, by the CCM.[8] Thus, the template sought to gather information on: 
(1) the health system and policy context; and (2) the type and format of ap-
proaches to managing chronic disease, examining the nature and scope of the 
components identified by the CCM as crucial to effective chronic care manage-
ment. The template was paper-based, written in English, and used simple 
checkboxes as well as open-ended questions. Where appropriate and relevant, 
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sections included a glossary of definitions of terms and guidance for completion 
by means of examples and checklists. A shortened copy of the data collection 
template can be found elsewhere.[32] This paper reports the findings across 
countries pertaining to the CCM-component self-management support. 
Key informants 
Data collection using the finalised template was undertaken by key informants 
in 13 countries, which were selected to capture the range of approaches to fund-
ing and governing health care, different levels of economic development, and 
geographical spread across Europe. We thus included: Austria, Denmark, Eng-
land, Estonia, France, Germany, Hungary, Italy, Latvia, Lithuania, the Nether-
lands, Spain and Switzerland. Of these 13 countries, seven were represented by 
DISMEVAL project partners (Austria, Denmark, England, France, Germany, the 
Netherlands, and Spain) who were invited to complete the template. DISMEVAL 
project partners included two to four expert health service researchers per 
country. For countries not represented in DISMEVAL, key informants were iden-
tified from an established network of country experts in eight European coun-
tries (the International Healthcare Comparisons Network).[33] Informants thus 
identified had to demonstrate expertise in the area of chronic disease and/or an 
understanding of the health policy and system context of the country in question 
as shown by relevant publications in the academic literature and/or roles in 
relevant government advisory bodies. One to four researchers and/or policy-
makers per country, who fulfilled these criteria, were selected as key informants 
for Estonia, Hungary, Italy, Latvia, Lithuania, and Switzerland (see Acknowl-
edgments).  
Data collection 
In completing the template, informants were asked to adopt an evidence-based, 
comprehensive approach, by making use of the best data available and cooper-
ating with organisations involved in the management of chronic disease. Where 
appropriate and necessary, additional information was gathered through inter-
views with key stakeholders and reviews of work in progress, such as pilot pro-
jects and committee reports. As it was beyond the scope of DISMEVAL to pro-
vide a complete inventory of all chronic care management approaches being 
implemented in the included countries, key informants were asked to present a 
sample of approaches considered representative of a given health system in 
terms of the type and setting of delivery model, providers involved, key strate-
gies employed, and population covered. For each approach, respondents de-
scribed whether and how self-management support activities were imple-
mented according to the CCM-related Assessment of Chronic Illness Care (ACIC) 
survey[34]; that is, patient education, collaborative care planning, provision of 
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self-management tools, and structured follow-up. Principal data collection was 
carried out from June 2009 to December 2009, with sequential follow-up review 
untill July 2011 to complete missing data and clarify information.  
Case study 
Template completion in the 13 countries was complemented by a case study of 
the Dutch DISMEVAL partner, which aimed to assess health professionals’ per-
spectives of the level of and barriers to implementation of self-management 
support activities in daily practice. Interviews were undertaken with a purpose-
ful sample of 27 providers involved in disease management for type 2 diabetes 
in the Netherlands, using an ACIC-informed semi-structured interview 
guide.[32] Respondents represented an equal number of professionals from 
three different health care disciplines (i.e. managers, general practitioners 
(GPs), and nurses) and were selected from diverse care settings in terms of geo-
graphical location and practice size. The interviews were conducted mostly face-
to-face, with five undertaken by telephone, by one member of the Dutch re-
search team (AE) between February and June 2011. All interviews were audio 
recorded and transcribed. 
Data analysis 
We used a general inductive approach to data analysis, in which emerging 
themes related to self-management support were identified through examina-
tion of the completed data template containing evidence from 13 countries. The 
data were analysed in detail by the lead author (AE) to identify key themes, 
which were discussed with and agreed by all coauthors. In total, three catego-
ries of themes were distinguished: (1) support mode and content (‘what’); (2) 
support format and materials (‘how’); and (3) support providers and locations 
(‘who and where’). Data were then organised into a purposely built matrix com-
prising the three emerged categories of themes, which facilitated systematic 
cross-country comparison of self-management support approaches in the 13 
countries. For consistency, the same matrix was used to process and analyse the 
transcripts of the Dutch interviews concerning the implementation of self-
management support in practice.  
RESULTS 
An overview of self-management support in 13 countries 
Table 1 provides an overview of approaches to chronic disease management or 
their equivalent in the 13 countries reviewed here. Keeping in mind that the 
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overview is based on a sample of approaches considered representative of a 
given country context, the findings suggest that many countries have imple-
mented a range of frequently small-scale chronic care management programmes 
at the local or regional level. In some cases, these have been conceptualised as 
pilot studies for subsequent roll-out to larger areas, while there are also exam-
ples of approaches that aim to target the entire population, in particular where 
these have been embedded within the existing primary care system. The major-
ity of chronic care approaches in Europe as reviewed here involves some form 
of patient self-management support (see Table 1), although there are consider-
able differences in terms of: (1) mode and content (‘what’); (2) format and ma-
terials (‘how’); and (3) providers and locations (‘who and where’).  
Support mode and content 
Most chronic care approaches reviewed here involve education for self-
management, frequently in the form of group-based exercises and/or one-to-
one activities. For example, within the Austrian disease management pro-
gramme ‘Therapie Aktiv’, nine hours of patient education including self-
management training are offered in four modules with a group size of three to 
12 patients. The German disease management programmes, which were intro-
duced between 2003 and 2006 for six conditions (breast cancer, type 1 and 2 
diabetes, coronary heart disease, asthma and chronic obstructive pulmonary 
disease), offer self-management support activities for each disease. Here too, 
self-management training is usually undertaken in groups, although individual 
support is an option.  
With regard to content, the education offered within the reviewed support 
approaches tends to focus on three broad topics: (1) information about the dis-
ease; (2) information about healthy behaviour (e.g. physical training sessions, 
nutritional consultation sessions, and smoking cessation programmes); and (3) 
practical instructions concerning, for instance, blood glucose monitoring, foot 
examination, or insulin injection.  
Respondents from 10 countries – except Latvia, Lithuania and Spain – re-
ported that patients are involved in setting care goals and developing individual 
treatment plans (i.e. collaborative care planning). Patients’ needs, activities, 
problems and accomplishments are regularly assessed by means of structured 
follow-up in all countries except for Latvia, where self-management support 
appears relatively most underdeveloped. Within the German disease manage-
ment programmes, individual treatment goals (concerning, for example, blood 
pressure, weight and exercise) are discussed between patients and their doctors 
during regular three to six-monthly follow-up consultations. French patients 
enrolled in provider networks have a ‘personal care plan’, which is set up jointly 
with their physician and contains treatment goals as well as concrete care 
measures. 
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nte
d i
n 
Øs
ter
br
o h
ea
lth
 ca
re 
cen
tre
 
an
d B
isp
eb
jer
g h
os
pit
al 
in 
Co
pe
nh
ag
en
 fo
r p
eri
od
 of
 
thr
ee
 ye
ars
, su
bs
eq
ue
nt 
tra
ns
fer
 in
to 
us
ua
l ca
re;
 
ele
me
nts
 of
 th
e p
rog
ram
me
 
tak
en
 up
 by
 Co
pe
nh
ag
en
 
Cit
y a
nd
 ho
sp
ita
ls 
Ed
uc
ati
on
 an
d r
eg
ula
r 
do
cu
me
nta
tio
n o
f s
elf
-
ma
na
ge
me
nt 
ne
ed
s a
nd
 
act
ivi
tie
s; i
nv
olv
em
en
t in
 
de
ve
lop
ing
 in
div
idu
ali
sed
 
tre
atm
en
t p
lan
s a
nd
 go
al 
set
tin
g; 
acc
ess
 to
 ph
ysi
cal
 
ex
erc
ise
 in
ter
ve
nti
on
; in
-
for
ma
tio
n 
Re
gio
na
l d
ise
ase
 
ma
na
ge
me
nt 
pr
o-
gra
mm
es 
On
go
ing
 
An
 in
ter
dis
cip
lin
ary
, 
int
ers
ect
ora
l a
nd
 co
ord
i-
na
ted
 ef
for
t u
sin
g e
vi-
de
nc
e-b
ase
d r
eco
mm
en
-
da
tio
ns
 an
d c
oo
rd
ina
tio
n 
of 
an
d c
om
mu
nic
ati
on
 
be
tw
ee
n a
ll p
art
ies
  
Ty
pe
 2 
dia
be
-
tes
, C
OP
D (
in 
pr
ep
ara
tio
n: 
CV
D, 
de
me
n-
tia
, m
us
cu
lo-
sk
ele
tal
 
dis
ord
er)
 
DM
P G
en
era
l p
rac
tit
ion
er 
Ea
rly
 st
ag
e; 
DM
Ps
 fo
r C
OP
D 
an
d t
yp
e 2
 di
ab
ete
s im
ple
-
me
nte
d i
n C
ap
ita
l R
eg
ion
 
(en
d 2
01
0);
 DM
Ps
 fo
r o
the
r 
co
nd
itio
ns
 an
d/
or
 in
 ot
he
r 
reg
ion
s a
re 
pla
nn
ed
 or
 
be
ing
 de
ve
lop
ed
 
Str
uc
tur
ed
 (d
ise
ase
-sp
eci
fic
 
an
d g
en
era
l) e
du
cat
ion
; 
inf
orm
ati
on
; in
vo
lve
me
nt 
in 
de
ve
lop
ing
 ca
re 
tre
atm
en
t 
pla
n a
nd
 go
al 
set
tin
g i
nc
lud
-
ing
 ag
ree
ing
 tim
eli
ne
 an
d 
me
tho
ds
 fo
r e
va
lua
tio
n o
f 
go
als
; re
gu
lar
 as
ses
sm
en
t 
an
d f
oll
ow
-up
 of
 pr
ob
lem
s 
an
d n
ee
ds
 
Int
eg
rat
ed
 cli
nic
al 
pa
thw
ay
s 
20
08
 (c
an
cer
) 
20
10
 (h
ea
rt 
dis
ea
se)
 
To
 en
su
re 
fas
t a
nd
 op
ti-
ma
l tr
ea
tm
en
t a
nd
 m
an
-
ag
em
en
t o
f p
ati
en
ts 
wi
th 
he
art
 di
sea
se/
can
cer
 
He
art
 di
s-
ea
se,
 ca
nc
er 
Ca
re 
('p
ath
wa
y')
 co
ord
ina
-
tor
 (s
pe
cia
lis
t n
ur
se)
 
As
 a n
ati
on
al 
pr
og
ram
me
, 
int
eg
rat
ed
 cli
nic
al 
pa
thw
ay
s 
wi
ll b
e i
mp
lem
en
ted
 ac
ros
s 
De
nm
ark
 
No
t s
pe
cif
ied
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Ta
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gr
ou
p 
Pr
in
ci
pa
l  
co
or
di
na
to
r 
D
is
tr
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ut
io
n 
Se
lf-
m
an
ag
em
en
t  
su
pp
or
t 
En
gl
an
d 
 
 
 
 
 
 
Ex
pe
rt 
Pa
tie
nts
 
pr
og
ram
me
 (E
EP
) 
20
01
 
(pi
lot
) 
To
 de
ve
lop
 th
e c
on
fid
en
ce 
an
d m
oti
va
tio
n o
f p
a-
tie
nts
 to
 us
e t
he
ir o
wn
 
sk
ills
 an
d k
no
wl
ed
ge
 to
 
tak
e e
ffe
cti
ve
 co
ntr
ol 
ov
er 
life
 w
ith
 a c
hr
on
ic i
lln
ess
 
Ge
ne
ral
ist
 
an
d d
ise
ase
-
sp
eci
fic
  
Pa
tie
nt/
ser
vic
e u
ser
 
20
06
 go
ve
rn
me
nt 
po
lic
y s
et 
to 
inc
rea
se 
EE
P p
lac
es 
to 
>1
00
,00
0 b
y 2
01
2; 
EE
P a
lso
 
av
ail
ab
le 
as 
on
lin
e c
las
ses
 
so
 in
 th
eo
ry 
acc
ess
ibl
e t
o 
ev
ery
on
e w
ith
 in
ter
ne
t 
acc
ess
 
Ed
uc
ati
on
 of
 pa
tie
nts
 by
 la
y 
ins
tru
cto
rs 
aim
ed
 at
 
str
en
gth
en
ing
 co
mp
ete
nc
ies
 
an
d s
kil
ls t
o c
op
e w
ith
 
ch
ron
ic i
lln
ess
 in
clu
din
g 
de
ve
lop
me
nt 
of 
car
e p
lan
s 
Ca
se 
ma
na
ge
me
nt/
 
co
mm
un
ity
 m
atr
on
 2
00
4 
To
 en
ab
le 
int
en
siv
e, 
ho
me
-ba
sed
 ca
se 
ma
n-
ag
em
en
t fo
r o
lde
r p
eo
ple
 
at 
ris
k o
f h
os
pit
ali
sat
ion
 
an
d o
the
r h
igh
-in
ten
sit
y 
ser
vic
e u
ser
s 
Old
er 
pe
op
le 
at 
ris
k o
f 
ho
sp
i-
tal
isa
tio
n 
Sp
eci
ali
st 
nu
rse
 
20
04
 po
lic
y f
ore
saw
 im
ple
-
me
nta
tio
n o
f c
ase
 m
an
ag
e-
me
nt 
an
d a
pp
oin
tm
en
t o
f 
3,0
00
 co
mm
un
ity
 m
atr
on
s 
by
 al
l P
CT
s in
 20
07
; th
ere
 
are
 no
w 
be
tw
ee
n 6
20
 an
d 
1,3
50
 co
mm
un
ity
 m
atr
on
s 
Ed
uc
ati
on
 pr
ov
ide
d b
y 
sp
eci
ali
st 
nu
rse
; in
vo
lve
-
me
nt 
in 
de
ve
lop
me
nt 
of 
car
e 
pla
n a
nd
 go
als
; re
gu
lar
 
ass
ess
me
nt 
an
d d
oc
um
en
ta-
tio
n o
f n
ee
ds
 an
d a
cti
vit
ies
 
Pa
rtn
ers
hip
s f
or 
old
er 
pe
op
le 
pr
oje
ct 
(P
OP
P)
 
20
05
–2
01
0 
To
 pr
ov
ide
 pe
rso
n-
cen
tre
d a
nd
 in
teg
rat
ed
 
ser
vic
es 
for
 ol
de
r p
eo
ple
, 
en
co
ur
ag
e i
nv
est
me
nt 
in 
car
e a
pp
roa
ch
es 
tha
t 
pr
om
ote
 he
alt
h, 
we
llb
ein
g 
an
d i
nd
ep
en
de
nc
e, t
o 
pr
ev
en
t/d
ela
y n
ee
d f
or 
hig
he
r in
ten
sit
y o
r in
sti
-
tut
ion
al 
car
e 
Old
er 
pe
op
le 
(>6
5 y
ea
rs)
 
Va
rie
d: 
mu
ltid
isc
ipl
ina
ry 
tea
m 
(he
alt
h a
nd
 so
cia
l 
car
e);
 so
cia
l o
r 'h
yb
rid
' 
wo
rke
r; v
olu
nte
er 
org
an
i-
sat
ion
 
PO
PP
 ra
n a
 to
tal
 of
 14
6 
pr
oje
cts
 in
vo
lvi
ng
 52
2 
org
an
isa
tio
ns
 in
clu
din
g t
he
 
po
lic
e a
nd
 ho
us
ing
 as
so
cia
-
tio
ns
; 8
5%
 of
 pr
oje
cts
 se
-
cu
red
 fu
nd
ing
 be
yo
nd
 th
e 
pil
ot 
ph
ase
 in
to 
us
ua
l ca
re 
Va
rie
d: 
inv
olv
em
en
t o
f o
lde
r 
pe
op
le 
in 
pr
oje
ct 
de
ve
lop
-
me
nt,
 op
era
tio
n a
nd
 ev
alu
a-
tio
n; 
pe
er 
su
pp
or
t, i
nc
lud
ing
 
EE
P; 
sta
ff a
nd
 vo
lun
tee
rs 
act
ing
 as
 ‘n
av
iga
tor
s’ t
o 
he
lpi
ng
 ol
de
r p
eo
ple
 
thr
ou
gh
 th
e s
yst
em
; fo
llo
w-
up
; e
xp
ert
 ca
rer
 pr
og
ram
me
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Ta
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et
  
gr
ou
p 
Pr
in
ci
pa
l  
co
or
di
na
to
r 
D
is
tr
ib
ut
io
n 
Se
lf-
m
an
ag
em
en
t  
su
pp
or
t 
Int
eg
rat
ed
 ca
re 
pil
ot 
pr
og
ram
me
 
20
09
–2
01
1 
To
 im
pr
ov
e t
he
 qu
ali
ty 
of 
car
e a
nd
 ou
tco
me
s f
or 
pa
tie
nts
, to
 en
ha
nc
e 
pa
rtn
ers
hip
s o
n c
are
 
pr
ov
isi
on
 an
d t
o m
ak
e 
mo
re 
eff
ici
en
t u
se 
of 
sca
rce
 re
so
ur
ces
 
Ge
ne
ral
ist
 
an
d d
ise
ase
-
sp
eci
fic
 (e
.g. 
dia
be
tes
, 
CO
PD
, d
e-
me
nti
a) 
Va
rie
d: 
GP
-le
d c
are
, m
ul-
tid
isc
ipl
ina
ry 
tea
m 
wo
rk-
ing
, n
ur
se-
led
 ca
se 
ma
n-
ag
em
en
t, s
kil
led
 ke
y 
wo
rke
r-l
ed
 ca
re 
co
ord
ina
-
tio
n 
Th
e p
ilo
t p
rog
ram
me
 in
-
vo
lve
s 1
6 p
rim
ary
 ca
re 
tru
sts
 
Va
rie
d: 
pa
tie
nt 
ed
uc
ati
on
 
an
d p
rov
isi
on
 of
 se
lf-
ma
na
ge
me
nt 
too
ls b
y s
en
ior
 
nu
rse
s; t
rai
nin
g i
n s
elf
-
ma
na
ge
me
nt 
of 
me
dic
ine
s 
Es
to
ni
a 
 
 
 
 
 
 
Qu
ali
ty 
ma
na
ge
me
nt 
in 
pr
im
ary
 he
alt
h 
car
e 
20
03
 (c
om
-
ple
tio
n o
f G
P 
sys
tem
) 
Ch
ron
ic d
ise
ase
 m
an
ag
e-
me
nt 
as 
a c
on
cep
t n
ot 
est
ab
lis
he
d b
ut 
ind
ire
ctl
y 
em
be
dd
ed
 in
 th
e o
ve
ral
l 
str
uc
tur
e a
nd
 or
ga
nis
a-
tio
n o
f th
e h
ea
lth
 ca
re 
sys
tem
 
Ty
pe
 2 
dia
be
-
tes
, ca
rd
io-
va
scu
lar
 
dis
ea
se 
(ch
ron
ic 
he
art
 fa
ilu
re,
 
IH
D)
 
Ge
ne
ral
 pr
act
itio
ne
r 
Qu
ali
ty 
ma
na
ge
me
nt 
fra
me
-
wo
rk 
for
 di
ab
ete
s a
nd
 
ch
ron
ic C
VD
 im
ple
me
nte
d 
acr
os
s E
sto
nia
 an
d c
ov
eri
ng
 
all
 GP
 pr
act
ice
s 
Ed
uc
ati
on
 pr
ov
ide
d b
y 
GP
/fa
mi
ly 
nu
rse
; in
vo
lve
-
me
nt 
in 
de
ve
lop
me
nt 
of 
car
e 
pla
n; 
reg
ula
r a
sse
ssm
en
t 
an
d f
oll
ow
-up
; a
dd
itio
na
l 
su
pp
ort
 by
 ho
me
 ca
re 
nu
rse
 
or 
so
cia
l w
ork
er 
wh
ere
 
ne
ces
sar
y 
Ch
ron
ic d
ise
ase
 
ma
na
ge
me
nt 
at 
the
 
pr
im
ary
/se
co
nd
ary
 
car
e i
nte
rfa
ce 
Va
rio
us
 
Ch
ron
ic d
ise
ase
 m
an
ag
e-
me
nt 
as 
a c
on
cep
t n
ot 
est
ab
lis
he
d b
ut 
ind
ire
ctl
y 
em
be
dd
ed
 in
 th
e o
ve
ral
l 
str
uc
tur
e a
nd
 or
ga
nis
a-
tio
n o
f th
e h
ea
lth
 ca
re 
sys
tem
 
Mu
ltip
le 
scl
ero
sis
, 
Pa
rki
ns
on
's 
dis
ea
se,
 
sch
izo
ph
re-
nia
, C
OP
D 
Sp
eci
ali
st 
(ce
ntr
e);
 co
-
mo
rb
idi
tie
s m
an
ag
ed
 by
 
GP
 in
 co
ord
ina
tio
n w
ith
 
sp
eci
ali
st 
Im
ple
me
nte
d a
cro
ss 
Es
ton
ia 
as 
pa
rt 
of 
us
ua
l ca
re 
Ed
uc
ati
on
 (s
pe
cia
lis
t);
 
inv
olv
em
en
t in
 de
ve
lop
me
nt 
of 
car
e p
lan
; re
gu
lar
 as
ses
s-
me
nt 
an
d f
oll
ow
-up
; m
en
-
tor
ing
/p
ee
r-s
up
po
rt 
thr
ou
gh
 pa
tie
nt 
ass
oc
iat
ion
s 
(e.
g. M
ult
ipl
e s
cle
ros
is, 
Pa
rki
ns
on
's d
ise
ase
); s
up
-
po
rt 
at 
ho
me
 by
 nu
rse
 or
 
so
cia
l w
ork
er 
wh
ere
 ne
ces
-
sar
y 
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D
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ce
 
 
 
 
 
 
 
He
alt
h a
cti
on
 by
 
tea
ms
 of
 se
lf-
em
plo
ye
d h
ea
lth
 
pr
ofe
ssi
on
als
 
(A
SA
LE
E)
 
20
04
–2
00
7 
To
 im
pr
ov
e h
ea
lth
 ca
re 
qu
ali
ty 
by
 de
leg
ati
ng
 
sel
ect
ed
 ta
sk
s t
o n
ur
ses
  
Dia
be
tes
, C
VD
 T
rai
ne
d n
ur
se 
AS
AL
EE
 is 
a n
on
-pr
ofi
t 
org
an
isa
tio
n w
hic
h, 
as 
of 
20
07
, b
rou
gh
t to
ge
the
r 4
1 
GP
s a
nd
 8 
nu
rse
s in
 18
 GP
 
pr
act
ice
s 
Ed
uc
ati
on
 on
 di
sea
se 
pr
o-
vid
ed
 by
 tr
ain
ed
 nu
rse
 
So
ph
ia 
dia
be
tes
 ca
re 
pr
og
ram
me
 
20
08
 
To
 im
pr
ov
e t
he
 co
ord
ina
-
tio
n, 
eff
ici
en
cy 
an
d q
ua
lity
 
of 
dia
be
tic
 ca
re 
Ty
pe
 1 
an
d 2
 
dia
be
tes
 
Ge
ne
ral
 pr
act
itio
ne
r, i
n 
co
lla
bo
rat
ion
 w
ith
 nu
rse
 
Ex
pe
rim
en
tal
 ph
ase
 ta
r-
ge
ted
 pa
tie
nts
 of
 6,
00
0 G
Ps
 
(6.
4%
 of
 al
l G
Ps
) in
 10
 
de
pa
rtm
en
ts;
 ex
pa
nd
ed
 in
 
20
10
 to
 re
ach
 17
,50
0 G
Ps
 in
 
19
 de
pa
rtm
en
ts;
 ai
m 
to 
rol
l-
ou
t a
cro
ss 
Fra
nc
e b
y 2
01
3 
Ad
vic
e a
nd
 in
for
ma
tio
n o
n 
sel
f-m
an
ag
em
en
t o
f d
ise
ase
 
an
d h
ea
lth
 be
ha
vio
ur
; fa
cil
i-
tat
ing
 co
mm
un
ica
tio
n w
ith
 
he
alt
h p
rof
ess
ion
als
; a
cce
ss 
to 
de
dic
ate
d p
rog
ram
me
 
we
bs
ite
 
H
ea
lth
 n
et
w
or
ks
  
 
 
 
 
 
Dia
be
tes
 ne
tw
ork
s: 
RE
VE
SD
IAB
 
20
01
  
To
 im
pr
ov
e t
he
 qu
ali
ty 
of 
car
e f
or 
pe
op
le 
wi
th 
dia
be
tes
 ty
pe
 2 
Ty
pe
 2 
dia
be
-
tes
 
Pa
thw
ay
 co
ord
ina
tor
: 
ge
ne
ral
 pr
act
itio
ne
r o
r 
nu
rse
 
RE
VE
SD
IAB
 is 
ba
sed
 in
 3 
de
pa
rtm
en
ts 
in 
the
 Pa
ris
 
reg
ion
, in
vo
lvi
ng
, in
 20
07
-
20
08
 ar
ou
nd
 50
0 h
ea
lth
 
pr
ofe
ssi
on
als
 in
 Es
so
nn
e 
de
pa
rtm
en
t; o
ve
ral
l, i
n 
20
07
, th
ere
 w
ere
 72
 di
ab
e-
tes
 ne
tw
ork
s, i
nv
olv
ing
 
14
,00
0 h
ea
lth
 pr
ofe
ssi
on
als
Inf
orm
ati
on
 an
d e
du
cat
ion
 
(e.
g. d
iet
); c
oa
ch
ing
 by
 
nu
rse
s; i
nv
olv
em
en
t in
 
de
ve
lop
ing
 tr
ea
tm
en
t p
lan
 
tow
ard
s a
 ‘fo
rm
al’
 ag
ree
-
me
nt 
be
tw
ee
n p
ati
en
t a
nd
 
ne
tw
ork
; re
gu
lar
 as
ses
s-
me
nt 
an
d f
oll
ow
-up
 in
clu
d-
ing
 pa
tie
nt 
‘lo
g-b
oo
k’ 
co
m-
ple
ted
 w
ith
 do
cto
r c
on
su
lte
d 
Co
ord
ina
tio
n o
f 
pr
ofe
ssi
on
al 
car
e f
or 
the
 El
de
rly
 (C
OP
A)
 
20
06
 
To
 be
tte
r in
teg
rat
e s
erv
ice
 
pro
vis
ion
 be
tw
ee
n h
ea
lth
 
an
d s
oci
al c
are
; to
 re
du
ce 
ina
pp
rop
ria
te 
he
alt
h c
are
 
us
e, i
nc
lud
ing
 ER
 an
d 
ho
sp
ita
l u
tili
sat
ion
; to
 
Fra
il e
lde
rly
 
(>6
5 y
ea
rs)
 
Sp
eci
ali
st 
nu
rse
 as
 ca
se 
ma
na
ge
r 
Th
e n
etw
ork
 is 
est
ab
lis
he
d 
in 
on
e d
ist
ric
t o
f P
ari
s o
nly
 
an
d i
n 2
00
7 i
nv
olv
ed
 79
 ou
t 
of 
20
0 p
rim
ary
 ca
re 
ph
ysi
-
cia
ns
 pr
act
isi
ng
 in
 th
e a
rea
 
Inv
olv
em
en
t in
 de
ve
lop
ing
 
tre
atm
en
t p
lan
 an
d g
oa
l 
set
tin
g 
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gr
ou
p 
Pr
in
ci
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co
or
di
na
to
r 
D
is
tr
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ut
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Se
lf-
m
an
ag
em
en
t  
su
pp
or
t 
pre
ve
nt 
lon
g-t
erm
 nu
rsi
ng
 
ho
me
 in
sti
tut
ion
ali
sat
ion
 
M
ea
su
re
s i
n 
th
e 
20
03
–2
00
7 
Ca
nc
er
 P
la
n 
 
 
 
 
Pr
oto
co
l fo
r d
ise
ase
 
co
mm
un
ica
tio
n a
nd
 
pr
om
oti
on
 of
 sh
are
d 
de
cis
ion
-m
ak
ing
 
(D
isp
os
itif
 
d’a
nn
on
ce)
 
20
04
 
To
 im
pr
ov
e t
he
 or
ga
nis
a-
tio
n o
f p
roc
ess
es 
an
d 
co
mp
ete
nc
ies
 in
 di
scu
ss-
ing
 a c
an
cer
 di
ag
no
sis
, 
an
d p
rom
oti
ng
 sh
are
d 
de
cis
ion
-m
ak
ing
 be
tw
ee
n 
pr
ofe
ssi
on
als
, p
ati
en
ts 
an
d t
he
ir c
are
rs 
Ca
nc
er 
Sp
eci
ali
st 
As
 pa
rt 
of 
the
 na
tio
na
l 
can
cer
 pl
an
 pr
inc
ipa
lly
 
rol
led
 ou
t a
cro
ss 
the
 co
un
-
try
 w
ith
in 
the
 tim
efr
am
e o
f 
the
 20
03
-20
07
 Ca
nc
er 
Pla
n; 
by
 20
06
, o
nly
 ha
lf o
f th
e 
fun
ds
 se
t a
sid
e b
y r
eg
ion
s 
ha
d b
ee
n u
sed
 fo
r t
his
 
pu
rp
os
e a
nd
 ac
ces
sib
le 
to 
all
 ne
wl
y d
iag
no
sed
 ca
nc
er 
pa
tie
nts
 
Ac
ces
s t
o d
ed
ica
ted
 tim
e 
inf
orm
ing
 ab
ou
t th
e i
lln
ess
 
an
d s
up
po
rt;
 in
vo
lve
me
nt 
in 
de
cis
ion
-m
ak
ing
; a
cce
ss 
to 
ps
ych
olo
gic
al 
an
d s
oc
ial
 
su
pp
ort
; re
gu
lar
 as
ses
sm
en
t 
of 
pa
tie
nt 
ne
ed
s; f
oll
ow
-up
 
Mu
lti-
dis
cip
lin
ary
 
tea
m 
me
eti
ng
 (R
CP
)2
00
4 
To
 pr
om
ote
 th
e s
yst
em
-
ati
c u
se 
of 
mu
ltid
isc
ipl
i-
na
ry 
tea
ms
 in
 th
e d
ev
el-
op
me
nt 
of 
can
cer
 ca
re 
pla
ns
 so
 as
 to
 im
pr
ov
e t
he
 
qu
ali
ty 
of 
can
cer
 di
ag
no
-
sis
, tr
ea
tm
en
t a
nd
 su
p-
po
rt 
Ca
nc
er 
'M
éd
eci
n r
éfé
ren
t' (
fre
-
qu
en
tly
 su
rge
on
) 
As
 pa
rt 
of 
the
 na
tio
na
l 
can
cer
 pl
an
 pr
inc
ipa
lly
 
rol
led
 ou
t a
cro
ss 
the
 co
un
-
try
 w
ith
in 
tim
efr
am
e o
f 
20
03
-20
07
 Ca
nc
er 
Pla
n a
nd
 
acc
ess
ibl
e t
o a
ll n
ew
ly 
dia
gn
os
ed
 ca
nc
er 
pa
tie
nts
 
As
 im
ple
me
nte
d w
ith
in 
Dis
po
sit
if d
’an
no
nc
e 
Re
gio
na
l ca
nc
er 
ne
tw
ork
s 
20
04
 
To
 co
ord
ina
te 
all
 re
lev
an
t 
act
ors
 an
d l
ev
els
 of
 ca
re 
in 
the
 m
an
ag
em
en
t o
f 
can
cer
, an
d t
o g
ua
ran
tee
 
the
 qu
ali
ty 
an
d e
qu
ity
 of
 
car
e a
cro
ss 
all
 re
gio
ns
 
Ca
nc
er 
As
 in
 RC
P 
As
 pa
rt 
of 
the
 na
tio
na
l 
can
cer
 pl
an
 ro
lle
d o
ut 
acr
os
s t
he
 co
un
try
 w
ith
in 
the
 tim
efr
am
e o
f th
e 2
00
3-
20
07
 Ca
nc
er 
Pla
n a
nd
 
acc
ess
ibl
e t
o a
ll c
an
cer
 
pa
tie
nts
 
As
 im
ple
me
nte
d w
ith
in 
Dis
po
sit
if d
’an
no
nc
e 
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D
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tr
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ut
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n 
Se
lf-
m
an
ag
em
en
t  
su
pp
or
t 
Lo
cal
 ca
nc
er 
or 
loc
al 
mu
lti-
pa
tho
log
y 
ne
tw
ork
s 
20
04
 
To
 fa
cil
ita
te 
the
 lo
cal
 
ma
na
ge
me
nt 
an
d m
on
i-
tor
ing
 of
 ca
nc
er 
pa
tie
nts
 
thr
ou
gh
 be
tte
r in
teg
ra-
tio
n o
f G
Ps
 in
to 
ne
tw
ork
s 
of 
can
cer
 ca
re 
Ca
nc
er 
Ge
ne
ral
 pr
act
itio
ne
r 
As
 pa
rt 
of 
the
 na
tio
na
l 
can
cer
 pl
an
 pr
inc
ipa
lly
 
rol
led
 ou
t a
cro
ss 
the
 co
un
-
try
 w
ith
in 
the
 tim
efr
am
e o
f 
the
 20
03
-20
07
 Ca
nc
er 
Pla
n 
an
d a
cce
ssi
ble
 to
 al
l ca
nc
er 
pa
tie
nts
 
As
 im
ple
me
nte
d w
ith
in 
Dis
po
sit
if d
’an
no
nc
e 
Ge
rm
an
y 
 
 
 
 
 
 
Dis
ea
se 
ma
na
ge
-
me
nt 
pr
og
ram
me
s 
20
03
 
Or
ga
nis
ati
on
al 
ap
pr
oa
ch
 
to 
me
dic
al 
car
e t
ha
t 
inv
olv
es 
the
 co
ord
ina
ted
 
tre
atm
en
t a
nd
 ca
re 
of 
pa
tie
nts
 w
ith
 ch
ro
nic
 
dis
ea
se 
acr
os
s p
ro
vid
ers
 
on
 th
e b
asi
s o
f s
cie
nti
fic
 
an
d u
p-t
o-d
ate
 ev
ide
nc
e 
Ty
pe
 1 
an
d 2
 
dia
be
tes
; IH
D 
(+h
ea
rt 
fai
lur
e),
 
br
ea
st 
can
cer
, 
ast
hm
a/
 
CO
PD
  
DM
P p
hy
sic
ian
 
DM
Ps
 ar
e o
ffe
red
 by
 SH
I 
fun
ds
 ac
ros
s G
erm
an
y; 
in 
20
10
 th
ere
 w
ere
 ~2
,00
0 
DM
Ps
 fo
r e
ach
 co
nd
itio
n; 
nu
mb
er 
of 
pa
rti
cip
ati
ng
 
ph
ysi
cia
ns
 va
rie
s, ~
65
% 
GP
s a
ct 
as 
DM
P p
hy
sic
ian
 
for
 ty
pe
 2 
dia
be
tes
 (5
7%
 on
 
IH
D)
 
Ed
uc
ati
on
 pr
og
ram
me
 in
 
gro
up
 se
ssi
on
s; i
nv
olv
em
en
t 
in 
ag
ree
ing
 tr
ea
tm
en
t g
oa
ls;
 
reg
ula
r fo
llo
w-
up
, w
ith
 
pa
tie
nt 
rem
ind
ers
 fo
r m
iss
ed
 
ses
sio
ns
; so
me
 SH
I fu
nd
s 
als
o o
ffe
r t
ele
ph
on
e s
erv
ice
s 
to 
fur
the
r s
up
po
rt 
the
ir 
me
mb
ers
 pa
rti
cip
ati
ng
 in
 
DM
Ps
 
GP
 co
ntr
act
s 
20
04
 
To
 im
pr
ov
e t
he
 co
ord
ina
-
tio
n o
f c
are
 an
d 
str
en
gth
en
 th
e r
ole
 of
 
pr
im
ary
 ca
re 
in 
the
 Ge
r-
ma
n h
ea
lth
 sy
ste
m 
Ge
ne
ral
ist
 
(so
me
 co
n-
tra
cts
 ta
rge
t 
ov
er 
65
s) 
Ge
ne
ral
 pr
act
itio
ne
r/ 
fam
ily
 ph
ysi
cia
n 
By
 th
e e
nd
 of
 20
07
, 5
5 G
P 
co
ntr
act
s h
ad
 be
en
 co
n-
clu
de
d w
ith
 GP
 pa
rti
cip
a-
tio
n v
ary
ing
 am
on
g r
eg
ion
s
An
nu
al 
ch
eck
up
s; a
dv
ice
 on
 
pr
ev
en
tiv
e m
ea
su
res
 an
d 
inf
orm
ati
on
; a
sse
ssm
en
t o
f 
car
dio
va
scu
lar
 ris
k f
act
ors
 
(‘a
rr
ib
a’
) s
up
po
rts
 sh
are
d 
de
cis
ion
-m
ak
ing
 on
 tr
ea
t-
me
nt 
op
tio
ns
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Pr
in
ci
pa
l  
co
or
di
na
to
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D
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ib
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n 
Se
lf-
m
an
ag
em
en
t  
su
pp
or
t 
Me
dic
al 
car
e c
en
tre
s 
(M
VZ
): P
oli
ku
m 
Be
rli
n 
20
04
 
To
 pr
ov
ide
 co
mp
reh
en
-
siv
e, c
oo
rd
ina
ted
 an
d 
int
erd
isc
ipl
ina
ry 
car
e 
Ge
ne
ral
ist
 
Mu
ltid
isc
ipl
ina
ry 
tea
m 
Th
ere
 ar
e ~
1,5
00
 M
VZ
 
(20
10
), w
ith
 a t
ota
l o
f 7
,50
0 
ph
ysi
cia
ns
 (>
80
% 
as 
sal
a-
rie
d e
mp
loy
ee
s [
65
,00
0 
ph
ysi
cia
ns
 w
ork
 in
 so
lo 
pr
act
ice
; 1
9,5
00
 in
 gr
ou
p 
pr
act
ice
s])
; P
oli
ku
m 
em
-
plo
ys 
45
-50
 ph
ysi
cia
ns
 
Ed
uc
ati
on
 pr
og
ram
me
s (
e.g
. 
we
igh
t r
ed
uc
tio
n, 
str
ess
 
ma
na
ge
me
nt,
 sm
ok
ing
 
ces
sat
ion
) a
nd
 pr
act
ica
l 
ins
tru
cti
on
 (e
.g. 
sel
f-
mo
nit
ori
ng
 of
 in
su
lin
 th
er-
ap
y) 
Int
eg
rat
ed
 ca
re:
 
He
alt
hy
 Ki
nz
igt
al 
20
05
 
To
 es
tab
lis
h m
ore
 ef
fi-
cie
nt 
an
d o
rga
nis
ed
 
he
alt
h c
are
 fo
r t
he
 re
si-
de
nts
 of
 th
e K
inz
igt
al 
are
a
Ge
ne
ral
ist
  
Ca
re 
co
ord
ina
tor
 (p
hy
si-
cia
n /
 ps
ych
oth
era
pis
t) 
By
 th
e e
nd
 of
 20
08
, ~
6,4
00
 
int
eg
rat
ed
 ca
re 
co
ntr
act
s 
ha
d b
ee
n c
on
clu
de
d. 
Ho
w-
ev
er,
 co
nte
nt 
an
d s
co
pe
 
va
rie
s w
ide
ly;
 He
alt
hy
 
Kin
zig
tal
 in
vo
lve
s 7
0 p
ro-
vid
ers
 (2
01
0) 
Re
gu
lar
 ch
eck
up
s a
nd
 ris
k 
ass
ess
me
nts
; in
vo
lve
me
nt 
in 
de
ve
lop
me
nt 
of 
ind
ivi
du
al 
tre
atm
en
t/ 
pr
ev
en
tio
n p
lan
s 
an
d g
oa
l se
tti
ng
; re
pr
ese
nta
-
tio
n t
hr
ou
gh
 pa
tie
nt 
ad
vi-
so
ry 
bo
ard
 an
d a
 pa
tie
nt 
om
bu
ds
ma
n  
Co
mm
un
ity
 nu
rse
s: 
Ca
re 
ass
ist
an
t in
 
fam
ily
 pr
act
ice
 
(V
erA
H)
 
20
05
 
To
 su
pp
ort
 GP
 se
rvi
ces
 in
 
un
de
r-s
erv
ed
 ar
ea
s 
Ge
ne
ral
ist
 
(ty
pic
all
y 
tar
ge
tin
g 
ov
er 
65
s) 
Pr
act
ice
 as
sis
tan
t 
Inc
orp
ora
ted
 in
 se
lec
ted
 GP
 
mo
de
ls, 
see
 ab
ov
e 
Ac
ces
s t
o t
rai
ne
d c
ase
 m
an
-
ag
ers
 
H
un
ga
ry
 
 
 
 
 
 
 
Ca
re 
co
ord
ina
tio
n 
pil
ot 
(CC
P)
 
19
98
/9
9–
20
08
To
 in
cen
tiv
ise
 pr
ov
ide
rs 
to 
tak
e r
esp
on
sib
ilit
y f
or
 
the
 sp
ect
ru
m 
of 
ser
vic
es 
(pr
im
ary
 to
 te
rti
ary
 ca
re)
 
for
 an
 en
rol
led
 po
pu
lat
ion
 
in 
a d
efi
ne
d a
rea
 
Ge
ne
ral
ist
 
Ca
re 
org
an
isa
tio
n (
CC
O)
: 
(gr
ou
ps
 of
) g
en
era
l p
rac
ti-
tio
ne
rs,
 po
lic
lin
ic o
r h
os
pi-
tal
  
Th
e C
CP
 gr
ad
ua
lly
 ex
-
pa
nd
ed
 fro
m 
9 c
are
 co
ord
i-
na
tor
s in
 19
99
 to
 16
 ca
re 
co
ord
ina
tor
s in
 20
05
 w
he
n 
1,5
00
 GP
 pr
act
ice
s p
art
ici
-
pa
ted
; e
sta
bli
sh
ed
 in
 th
e 
reg
ion
 of
 Ve
res
eg
yh
áz,
 th
e 
CC
P w
as 
ter
mi
na
ted
 in
 20
08
Ed
uc
ati
on
 by
 sp
eci
ali
sed
 
nu
rse
s; i
nv
olv
em
en
t in
 
de
ve
lop
ing
 tr
ea
tm
en
t p
lan
 
an
d g
oa
l se
tti
ng
; a
cce
ss 
to 
sel
f-m
an
ag
em
en
t to
ols
; 
reg
ula
r a
sse
ssm
en
t o
f p
rob
-
lem
s a
nd
 ac
co
mp
lis
hm
en
ts 
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N
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e 
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im
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d
Ai
m
/g
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D
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ip
ti
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Ta
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et
  
gr
ou
p 
Pr
in
ci
pa
l  
co
or
di
na
to
r 
D
is
tr
ib
ut
io
n 
Se
lf-
m
an
ag
em
en
t  
su
pp
or
t 
As
thm
a d
ise
ase
 
ma
na
ge
me
nt 
pr
o-
gra
mm
e 
20
04
 
To
 en
ha
nc
e t
he
 qu
ali
ty 
of 
ast
hm
a c
are
  
As
thm
a 
Sp
eci
ali
st 
(as
thm
a) 
nu
rse
 
Th
e p
rog
ram
me
 ha
s e
vo
lve
d 
int
o a
 fo
rm
al 
na
tio
na
l n
et-
wo
rk 
of 
ast
hm
a n
ur
ses
, w
ith
 
aro
un
d 8
50
 tr
ain
ed
 as
thm
a 
nu
rse
s a
cro
ss 
Hu
ng
ary
 
(20
10
); t
he
 nu
mb
er 
of 
pu
lm
on
ary
 di
sp
en
sar
ies
 is 
aro
un
d 1
60
 (2
00
7) 
Pa
tie
nt 
ed
uc
ati
on
 on
 
ast
hm
a; 
acc
ess
 to
 se
lf-
mo
nit
ori
ng
 to
ols
; in
vo
lve
-
me
nt 
in 
tre
atm
en
t p
lan
, go
al-
set
tin
g, d
eci
sio
nm
ak
ing
; 
reg
ula
r a
sse
ssm
en
t o
f p
rob
-
lem
s a
nd
 ac
co
mp
lis
hm
en
ts 
 
Tr
ea
tm
en
t (a
nd
 
fin
an
cin
g) 
pr
oto
co
ls
20
05
 (c
an
cer
)
To
 co
ntr
ol 
co
sts
 of
 tr
ea
t-
me
nt 
su
ch
 as
 th
os
e f
or 
ex
pe
ns
ive
 dr
ug
s in
 th
e 
cas
e o
f c
an
cer
 ca
re 
As
thm
a/
 
CO
PD
, C
VD
 
(he
art
 fa
ilu
re,
 
IH
D, 
str
ok
e),
 
can
cer
 
Va
rie
s b
y d
ise
ase
 (e
.g. 
ge
ne
ral
 pr
act
itio
ne
r fo
r 
hy
pe
rte
ns
ion
; sp
eci
ali
st 
for
 
can
cer
) 
As
 pa
rt 
of 
the
 m
ain
 sy
ste
m,
 
co
ve
rag
e, i
n p
rin
cip
le,
 is 
10
0%
. In
 pr
act
ice
, th
e 
ad
he
ren
ce 
to 
tre
atm
en
t 
pr
oto
co
ls i
s r
are
ly 
au
dit
ed
 
Inf
orm
ati
on
 m
ate
ria
l o
n 
can
cer
, h
yp
ert
en
sio
n a
nd
 
oth
er 
CV
D; 
sel
f-m
an
ag
em
en
t 
su
pp
ort
 by
 pa
tie
nt 
ass
oc
ia-
tio
ns
 an
d b
y h
ea
lth
 ca
re 
sta
ff 
pr
e-d
isc
ha
rge
 fo
r h
os
pit
al-
ise
d p
ati
en
ts 
 
Glu
co
.ne
t 
20
09
 
To
 pr
ov
ide
 a d
eci
sio
n-
su
pp
ort
 to
ol 
to 
gu
ide
 
pa
tie
nts
 in
 th
e m
on
ito
rin
g 
an
d a
na
lys
is o
f th
eir
 
blo
od
 su
ga
r le
ve
ls  
Ty
pe
 1 
an
d 2
 
dia
be
tes
  
Int
ern
et-
ba
sed
 se
lf-
ma
na
ge
me
nt 
su
pp
ort
 to
ol 
In 
pr
inc
ipl
e, a
va
ila
ble
 to
 
ev
ery
 pa
tie
nt 
wi
th 
dia
be
tes
 
thr
ou
gh
 th
e i
nte
rn
et 
Ac
ces
s t
o w
eb
-ba
sed
 so
ft-
wa
re 
tha
t p
erm
its
 au
tom
ati
c 
up
loa
d o
f s
elf
-m
on
ito
rin
g 
da
ta 
an
d f
ee
db
ack
 
Mu
ltif
un
cti
on
al 
co
mm
un
ity
 ce
ntr
es 
On
go
ing
 
To
 im
pr
ov
e e
ffic
ien
cy 
in 
the
 he
alt
h c
are
 sy
ste
m 
thr
ou
gh
 be
tte
r q
ua
lity
 of
 
car
e a
t lo
we
r c
os
ts 
Ge
ne
ral
ist
 
Co
mm
un
ity
 ce
ntr
e 
Pr
og
ram
me
 im
ple
me
nta
tio
n 
is o
ng
oin
g; 
it i
s a
nti
cip
ate
d 
tha
t 5
0–
60
 ce
ntr
es/
 pr
o-
jec
ts 
wi
ll b
e e
sta
bli
sh
ed
 
Pa
tie
nt 
ed
uc
ati
on
 m
ay
 be
 
pr
ov
ide
d 
Dia
be
tes
 ca
re 
ma
n-
ag
em
en
t p
rog
ram
me
Va
rio
us
  
To
 im
pr
ov
e t
he
 ca
re 
of 
pa
tie
nts
 w
ith
 ty
pe
 2 
dia
be
tes
 th
rou
gh
 a r
an
ge
 
of 
me
asu
res
, w
ith
 nu
rse
-
led
 ca
re 
at 
its
 co
re 
Ty
pe
 2 
dia
be
-
tes
  
Dia
be
tes
 sp
eci
ali
st 
(ph
ysi
-
cia
n, 
nu
rse
) 
Ex
ten
t to
 w
hic
h p
rog
ram
me
 
ha
s b
ee
n i
mp
lem
en
ted
 by
 
sp
eci
ali
st 
dia
be
tes
 ou
tpa
-
tie
nt 
un
its
 is 
no
t w
ell
 un
-
de
rst
oo
d; 
in 
20
08
, th
ere
 
we
re 
17
6 s
pe
cia
lis
t d
iab
ete
s E
du
cat
ion
 pr
ov
ide
d b
y a
 
dia
be
tes
 nu
rse
; a
cce
ss 
to 
sel
f-m
on
ito
rin
g d
ev
ice
s 
(gl
uc
om
ete
r);
 re
gu
lar
 fo
l-
low
-up
 to
 ro
uti
ne
ly 
ass
ess
 
pr
ob
lem
s a
nd
 ac
co
mp
lis
h-
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gr
ou
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Pr
in
ci
pa
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co
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to
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D
is
tr
ib
ut
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n 
Se
lf-
m
an
ag
em
en
t  
su
pp
or
t 
un
its
, in
clu
din
g 4
1 i
n B
ud
a-
pe
st 
me
nts
, b
oth
 in
 pe
rso
n a
nd
 by
 
tel
ep
ho
ne
 
It
al
y 
 
 
 
 
 
 
Le
on
ard
o P
ilo
t 
Pr
oje
ct,
 Pu
gli
a 
20
04
–2
00
7 
To
 im
pr
ov
e t
he
 qu
ali
ty 
an
d e
ffe
cti
ve
ne
ss 
of 
he
alt
h c
are
 fo
r t
ho
se 
wi
th 
ch
ron
ic c
on
dit
ion
s a
nd
 to
 
fac
ilit
ate
 sy
ste
ma
tic
 
int
eg
rat
ion
 in
to 
the
 ex
ist
-
ing
 or
ga
nis
ati
on
al 
fra
me
-
wo
rk 
set
 by
 lo
cal
 he
alt
h 
ag
en
cie
s 
Ty
pe
 1 
an
d 2
 
dia
be
tes
, 
ch
ron
ic h
ea
rt 
fai
lur
e, h
igh
 
car
dio
va
scu
-
lar
 ris
k 
Sp
eci
ali
st 
nu
rse
 
To
tal
 of
 85
 GP
s in
 Pu
gli
a 
reg
ion
 (~
2.5
% 
of 
GP
s p
rac
-
tis
ing
 in
 th
e r
eg
ion
), w
ork
-
ing
 w
ith
 so
me
 30
 ca
re 
ma
na
ge
rs 
 
Ed
uc
ati
on
 ba
sed
 on
 th
e 
‘ei
gh
t p
rio
rit
ies
’ ap
pr
oa
ch
 
de
fin
ed
 by
 Lo
rig
; sy
ste
ma
tic
 
ass
ess
me
nt 
of 
pa
tie
nt 
ne
ed
s 
(in
 pe
rso
n/
 by
 te
lep
ho
ne
) 
an
d f
oll
ow
-up
 
Int
eg
rat
ion
, M
an
-
ag
em
en
t a
nd
 As
sis
-
tan
ce 
for
 di
ab
ete
s 
(IG
EA
) 
20
06
 
Na
tio
na
l st
rat
eg
y t
o 
su
pp
ort
 th
e i
mp
lem
en
ta-
tio
n o
f d
ise
ase
 m
an
ag
e-
me
nt 
for
 ty
pe
 2 
dia
be
tes
 
at 
reg
ion
al 
lev
el 
Ty
pe
 2 
dia
be
-
tes
  
Mu
ltid
isc
ipl
ina
ry 
tea
m/
nu
rse
  
(ca
se 
ma
na
ge
me
nt)
 
Im
ple
me
nta
tio
n a
t r
eg
ion
al 
lev
el 
ha
s b
ee
n a
 gr
ad
ua
l 
pr
oc
ess
; 3
5%
 of
 GP
 pr
ac-
tic
es 
in 
Pie
dm
on
t p
art
ici
-
pa
te 
(20
09
); a
s a
 go
ve
rn
-
me
nt 
sp
on
so
red
 pr
o-
gra
mm
e i
nv
olv
em
en
t o
f a
ll 
GP
s a
nti
cip
ate
d 
Str
uc
tur
ed
 di
ab
ete
s e
du
ca-
tio
n b
y t
rai
ne
d s
taf
f (s
pe
cia
l-
ist
s, n
ur
ses
, G
Ps
); i
nv
olv
e-
me
nt 
in 
de
ve
lop
ing
 ca
re 
pla
n; 
acc
ess
 to
 se
lf-
ma
na
ge
me
nt 
too
ls;
 ro
uti
ne
 
ass
ess
me
nts
 of
 pr
ob
lem
s 
an
d a
cco
mp
lis
hm
en
ts 
Pr
oje
ct 
Ra
ffa
ell
o, 
Ma
rch
e a
nd
 Ab
ru
zzi
20
07
 
To
 as
ses
s t
he
 ef
fec
tiv
e-
ne
ss 
of 
an
 in
no
va
tiv
e 
mo
de
l o
f p
ati
en
t c
are
 fo
r 
the
 pr
ev
en
tio
n o
f c
ard
io-
va
scu
lar
 di
sea
se 
on
 th
e 
ba
sis
 of
 di
sea
se 
an
d c
are
 
ma
na
ge
me
nt 
in 
ge
ne
ral
 
pr
act
ice
 
Ty
pe
s 1
 an
d 2
 
dia
be
tes
, 
car
dio
va
scu
-
lar
 ris
k 
Sp
eci
ali
st 
nu
rse
 
Th
e r
ese
arc
h p
roj
ect
 in
-
vo
lve
s 1
6 c
lus
ter
s o
f G
Ps
 
pa
rti
cip
ati
ng
 in
 th
e e
xp
eri
-
me
nta
l a
rm
 of
 th
e s
tud
y  
Pa
rti
cip
ati
on
 in
 de
vis
ing
 
car
e p
lan
 an
d d
eci
sio
n-
ma
kin
g; 
acc
ess
 to
 co
ach
ing
 
an
d f
oll
ow
-up
 ac
tiv
itie
s b
y 
tel
ep
ho
ne
, d
oc
tor
’s o
ffic
e o
r 
pa
tie
nt’
s h
om
e; 
acc
ess
 to
 
inf
orm
ati
on
 m
ate
ria
l o
n 
dis
ea
se,
 se
rvi
ces
 av
ail
ab
ilit
y 
an
d l
ife
sty
le 
C H A P T E R  6  
 148 
 
 
 
N
am
e 
Ye
ar
  
im
pl
em
en
te
d
Ai
m
/g
en
er
al
  
D
es
cr
ip
ti
on
 
Ta
rg
et
  
gr
ou
p 
Pr
in
ci
pa
l  
co
or
di
na
to
r 
D
is
tr
ib
ut
io
n 
Se
lf-
m
an
ag
em
en
t  
su
pp
or
t 
Fro
m 
On
-D
em
an
d t
o 
Pr
oa
cti
ve
 Pr
im
ary
 
Ca
re,
 Tu
sca
ny
 
20
09
 
A t
hr
ee
-ye
ar 
str
ate
gy
 
tow
ard
s t
he
 de
ve
lop
me
nt 
of 
a n
ew
 or
ga
nis
ati
on
al 
ap
pr
oa
ch
 to
 he
alt
h c
are
 
tha
t e
mp
ha
sis
es 
pr
oa
cti
ve
 
pa
tie
nt 
car
e 
Hy
pe
rte
n-
sio
n, 
dia
be
-
tes
, ch
ron
ic 
he
art
 fa
ilu
re,
 
CO
PD
, st
rok
e 
Mu
ltip
rof
ess
ion
al 
tea
ms
 
('m
od
ule
') (
ge
ne
ral
 pr
act
i-
tio
ne
r le
ad
, co
mm
un
ity
 
he
alt
h d
oc
tor
, sp
eci
ali
st 
nu
rse
) 
Tw
o s
tag
e-i
mp
lem
en
tat
ion
: 
ini
tia
l p
ha
se 
in 
20
10
 in
-
vo
lve
s e
sta
bli
sh
me
nt 
of 
 
~5
0 m
od
ule
s w
ith
 ad
dit
ion
 
of 
mo
du
les
 on
go
ing
; p
roj
ect
 
ex
pe
cte
d t
o g
o i
nto
 fu
lly
 
op
era
tio
na
l st
ag
e i
n 2
01
1 
Ed
uc
ati
on
 an
d c
ou
ns
ell
ing
; 
ins
tru
cti
on
 in
 se
lf-
mo
nit
ori
ng
 ac
tiv
itie
s; i
n-
vo
lve
me
nt 
in 
de
ve
lop
ing
 an
d 
co
ns
en
t to
 ca
re 
pla
n; 
reg
ula
r 
ass
ess
me
nts
 of
 pr
ob
lem
s 
an
d n
ee
ds
; su
pp
or
t b
y s
oc
ial
 
wo
rke
rs 
wh
ere
 ne
ed
ed
 
La
tv
ia
 
 
 
 
 
 
 
Ge
ne
ral
 pr
im
ary
 
he
alt
h c
are
 sy
ste
m 
19
96
/9
8  
(P
HC
 re
for
m)
 
No
t a
pp
lic
ab
le 
Ge
ne
ral
ist
  
Ge
ne
ral
 pr
act
itio
ne
r 
Ch
ron
ic d
ise
ase
 m
an
ag
e-
me
nt 
em
be
dd
ed
 w
ith
in 
pr
im
ary
 ca
re 
inv
olv
ing
 al
l 
GP
s 
No
t s
pe
cif
ied
 
Li
th
ua
ni
a 
 
 
 
 
 
 
Cli
nic
al 
gu
ide
lin
es 
Fro
m 
20
02
 
To
 co
ntr
ol 
me
dic
ati
on
 
co
sts
; to
 im
pr
ov
e c
oll
ab
o-
rat
ion
 be
tw
ee
n p
rim
ary
 
an
d s
eco
nd
ary
 ca
re 
Dia
be
tes
, 
CV
D, 
br
ea
st 
can
cer
, 
ch
ron
ic r
en
al 
fai
lur
e, m
ul-
tip
le 
scl
ero
-
sis
, d
ep
res
-
sio
n; 
hig
h-
int
en
sit
y 
us
ers
 
Ge
ne
ral
 pr
act
itio
ne
r o
r 
sp
eci
ali
st 
(de
pe
nd
ing
 on
 
co
nd
itio
n) 
Cli
nic
al 
gu
ide
lin
es 
sh
ou
ld 
in 
pr
inc
ipl
e b
e i
mp
lem
en
ted
 
acr
os
s h
ea
lth
 se
rvi
ces
 in
 
Lit
hu
an
ia;
 pr
eci
se 
da
ta 
are
 
no
t a
va
ila
ble
 
Ro
uti
ne
 as
ses
sm
en
t o
f 
cli
nic
al 
ind
ica
tor
s  
Im
pr
ov
ing
 in
ter
sec
-
tor
al 
co
lla
bo
rat
ion
 
Fro
m 
20
04
 
To
 im
pr
ov
e c
oll
ab
ora
tio
n 
be
tw
ee
n h
ea
lth
 an
d s
oc
ial
 
car
e 
Ge
ne
ral
ist
 
an
d d
ise
ase
-
sp
eci
fic
 
(di
ab
ete
s, 
CV
D, 
can
cer
, 
ch
ron
ic r
en
al 
 Nu
rse
 
Pr
inc
ipa
lly
 im
ple
me
nte
d i
n 
all
 60
 m
un
ici
pa
liti
es 
of 
Lit
hu
an
ia 
Ro
uti
ne
 as
ses
sm
en
t o
f 
pr
ob
lem
s a
nd
 ac
co
mp
lis
h-
me
nts
; a
cce
ss 
to 
ps
ych
os
o-
cia
l re
ha
bil
ita
tio
n s
erv
ice
s in
 
so
me
 ca
ses
 (m
en
tal
 he
alt
h) 
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gr
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Pr
in
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pa
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co
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di
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D
is
tr
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ut
io
n 
Se
lf-
m
an
ag
em
en
t  
su
pp
or
t 
fai
lur
e, m
ul-
tip
le 
scl
ero
-
sis
, d
ep
res
-
sio
n, 
HI
V/
AID
S) 
N
et
he
rl
an
ds
 
 
 
 
 
 
 
Str
ok
e S
erv
ice
 De
lft 
19
97
 (p
ilo
t) 
Ev
olv
ed
 fro
m 
pil
ot 
pr
oje
ct 
for
 im
pr
ov
ing
 st
ro
ke
 ca
re 
ini
tia
ted
 in
 19
97
 an
d 
fun
de
d b
y t
he
 Ne
the
r-
lan
ds
 In
sti
tut
e f
or
 He
alt
h 
Re
sea
rch
 an
d D
ev
elo
p-
me
nt 
(Zo
nM
w)
 
Str
ok
e 
Sh
are
d c
are
 nu
rse
 
Fo
llo
wi
ng
 th
e e
xp
eri
en
ces
 
of 
pil
ots
 th
e g
ov
ern
me
nt 
act
ive
ly 
pr
om
ote
d f
ur
the
r 
im
ple
me
nta
tio
n t
hr
ou
gh
 
‘br
ea
kth
ro
ug
h p
ro
jec
ts’
 an
d 
be
nc
hm
ark
ing
 of
 st
rok
e 
ser
vic
es;
 as
 a r
esu
lt, 
by
 
20
03
, ea
ch
 re
gio
n h
ad
 
de
ve
lop
ed
 at
 le
ast
 on
e 
str
ok
e s
erv
ice
 (a
 to
tal
 of
 69
 
in 
20
03
) 
Ed
uc
ati
on
 ad
ap
ted
 to
 th
e 
wi
sh
es 
an
d n
ee
ds
 of
 th
e 
ind
ivi
du
al 
pa
tie
nt 
an
d 
his
/h
er 
car
ers
 (v
erb
al 
or 
wr
itt
en
; co
mm
un
ica
ted
 in
 
gro
up
 m
ee
tin
gs 
alt
ern
ati
ng
 
wi
th 
ind
ivi
du
al 
ses
sio
ns
 or
 
thr
ou
gh
 m
ed
ia 
su
ch
 as
 
int
ern
et 
or 
DV
D)
 
Ma
tad
or 
dis
ea
se 
ma
na
ge
me
nt 
pr
o-
gra
mm
e M
aa
str
ich
t-
He
uv
ell
an
d 
20
00
-20
06
 
Bu
ild
s o
n a
 pi
lot
 sc
he
me
 
est
ab
lis
he
d i
n 1
99
6, 
wh
ich
 us
ed
 sp
eci
ali
sed
 
dia
be
tes
 nu
rse
s t
o r
ed
uc
e 
the
 nu
mb
er 
of 
pa
tie
nts
 
see
n b
y m
ed
ica
l sp
eci
al-
ist
s in
 ou
tpa
tie
nt 
car
e 
Ty
pe
 2 
dia
be
-
tes
 
Co
re 
tea
m 
of 
ge
ne
ral
 
pr
act
itio
ne
rs,
 sp
eci
ali
st 
dia
be
tes
 nu
rse
 an
d e
nd
o-
cri
no
log
ist
 
In 
20
06
, a 
tot
al 
of 
63
 of
 90
 
GP
s (
70
%)
 in
 th
e M
aa
str
ich
t 
reg
ion
 pa
rti
cip
ate
d i
n t
he
 
Ma
tad
or 
pr
og
ram
me
 
Ac
ces
s t
o ‘
Dia
be
tes
 In
ter
ac-
tiv
e E
du
cat
ion
 Pr
og
ram
me
’ 
(D
IEP
), c
om
pr
isi
ng
 lif
est
yle
 
int
erv
en
tio
n t
rai
nin
g c
om
-
po
ne
nt 
for
 pr
ov
ide
rs 
to 
en
ga
ge
 pa
tie
nts
 in
 th
e d
ev
el-
op
me
nt 
of 
tre
atm
en
t p
lan
 
an
d g
oa
ls;
 DI
EP
 w
eb
sit
e; 
sys
tem
ati
c p
ati
en
t fo
llo
w-
up
 
Pr
im
ary
 ca
re 
bu
nd
le 
for
 ty
pe
 2 
dia
be
tes
 
Ma
ast
ric
ht-
He
uv
ell
an
d 
20
07
 
Th
e p
rim
ary
 ca
re 
bu
nd
le 
for
 di
ab
ete
s t
yp
e 2
 de
-
scr
ibe
s t
he
 w
ho
le 
co
nti
n-
uu
m 
of 
car
e f
or 
dia
be
tes
 
Ty
pe
 2 
dia
be
-
tes
  
Ge
ne
ral
 pr
act
itio
ne
r 
All
 re
gio
na
l G
Ps
 ar
e m
em
-
be
rs 
of 
car
e g
rou
p M
aa
s-
tri
ch
t-H
eu
ve
lla
nd
 an
d a
s 
su
ch
 pa
rti
cip
ate
 in
 th
e 
Re
gu
lar
 ch
eck
up
s t
ha
t in
-
clu
de
 ed
uc
ati
on
 on
 se
lf-
ma
na
ge
me
nt 
by
 pr
act
ice
 
nu
rse
s/s
pe
cia
lis
ed
 di
ab
ete
s 
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gr
ou
p 
Pr
in
ci
pa
l  
co
or
di
na
to
r 
D
is
tr
ib
ut
io
n 
Se
lf-
m
an
ag
em
en
t  
su
pp
or
t 
pa
tie
nts
 an
d i
s f
ina
nc
ed
 
on
 th
e b
asi
s o
f th
e b
un
-
dle
d p
ay
me
nt 
sys
tem
 
dia
be
tes
 ca
re 
pr
og
ram
me
 
(ju
st 
un
de
r 9
0 G
Ps
 by
 th
e 
en
d o
f 2
00
9);
 th
ere
 w
ere
 97
 
car
e g
rou
ps
 in
 M
arc
h 2
01
0 
wi
th 
bu
nd
led
 pa
ym
en
t 
co
ntr
act
 w
ith
 a h
ea
lth
 
ins
ur
er,
 m
os
tly
 fo
r d
iab
ete
s 
car
e 
nu
rse
s, d
ep
en
din
g o
n t
he
 
lev
el 
of 
ne
ed
 
Na
tio
na
l ca
re 
sta
n-
da
rd
 fo
r v
asc
ula
r 
ris
k m
an
ag
em
en
t 
20
10
 
De
scr
ibe
s t
he
 m
ini
mu
m 
req
uir
em
en
ts 
for
 ap
pr
o-
pr
iat
e, p
ati
en
t-c
en
ter
ed
 
car
e a
lon
g t
he
 ca
re 
co
n-
tin
uu
m 
fro
m 
pr
ev
en
tio
n 
an
d e
arl
y d
ete
cti
on
 to
 
tre
atm
en
t a
nd
 re
ha
bil
ita
-
tio
n 
Va
scu
lar
 ris
k 
Ce
ntr
al 
car
e g
ive
r (
de
ter
-
mi
ne
d b
y p
rog
ram
me
) 
Th
ere
 ar
e r
ela
tiv
ely
 fe
w 
car
e g
rou
ps
 fo
r t
he
 pr
ov
i-
sio
n o
f v
asc
ula
r r
isk
 m
an
-
ag
em
en
t; o
f 5
5 c
are
 gr
ou
ps
 
su
rve
ye
d i
n e
arl
y 2
01
0, 
tw
o 
ha
d a
 bu
nd
led
 pa
ym
en
t 
co
ntr
act
 in
 pl
ace
 fo
r v
asc
u-
lar
 ris
k m
an
ag
em
en
t, 1
7 
pr
ep
are
d t
o c
on
tra
ct 
Inv
olv
em
en
t in
 sh
are
d 
de
cis
ion
-m
ak
ing
, d
ev
elo
p-
me
nt 
of 
car
e p
lan
 an
d g
oa
l 
set
tin
g; 
acq
uir
e s
elf
-
ma
na
ge
me
nt 
co
mp
ete
nc
ies
 
thr
ou
gh
 ‘ta
sk
-or
ien
ted
 
co
mm
un
ica
tio
n’;
 m
oti
va
-
tio
na
l in
ter
vie
wi
ng
; a
nd
/o
r 
‘em
oti
on
al-
ori
en
ted
 co
m-
mu
nic
ati
on
’ 
Sp
ai
n 
 
 
 
 
 
 
Ca
se 
ma
na
ge
me
nt,
 
An
da
luc
ía 
20
02
 
To
 im
pr
ov
e t
he
 qu
ali
ty 
of 
life
 of
 pe
rso
ns
 w
ith
 
ch
ron
ic c
on
dit
ion
s, r
e-
du
ce 
the
 bu
rd
en
 pl
ace
d 
on
 ca
rer
s, p
rov
ide
 im
-
pr
ov
ed
 ac
ces
s t
o s
oc
ial
 
car
e a
nd
 re
ha
bil
ita
tio
n 
ser
vic
es 
an
d r
ed
uc
e 
em
erg
en
cy 
ad
mi
ssi
on
s 
Me
nta
l h
ea
lth
 
dis
ord
ers
, 
ch
ron
ic 
dis
ea
se,
 th
e 
ov
er 
65
s 
 
Nu
rse
 ca
se 
ma
na
ge
r 
Ov
er 
a p
eri
od
 of
 fo
ur
 to
 fiv
e 
ye
ars
, m
ore
 th
an
 30
0 c
ase
 
ma
na
ge
rs,
 lin
ke
d t
o p
rim
ary
 
car
e t
ea
ms
, w
ere
 de
plo
ye
d 
to 
car
e f
or 
sev
en
 m
illi
on
 
res
ide
nts
 in
 An
da
luc
ía 
Ind
ivi
du
ali
sed
 an
d i
nte
gra
l 
ass
ess
me
nt;
 ca
se 
ma
na
ge
rs 
off
er 
su
pp
ort
 w
or
ks
ho
ps
 fo
r 
the
 m
ain
 ca
rer
s o
f p
eo
ple
 
inc
lud
ed
 in
 th
e p
ro
gra
mm
e 
to 
pr
ov
ide
 in
for
ma
tio
n o
n 
pa
tie
nt 
car
e a
nd
 se
lf-c
are
 in
 
the
 ho
me
; a
ll c
ase
 m
an
ag
ers
 
ha
ve
 m
ob
ile
 ph
on
es 
to 
be
 
rea
ch
ab
le 
to 
the
ir p
ati
en
ts 
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gr
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Pr
in
ci
pa
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co
or
di
na
to
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D
is
tr
ib
ut
io
n 
Se
lf-
m
an
ag
em
en
t  
su
pp
or
t 
Ex
pe
rt 
Pa
tie
nts
 
Pr
og
ram
me
, C
ata
lo-
nia
 
20
06
 
To
 pr
om
ote
 pa
tie
nt 
sel
f-
ma
na
ge
me
nt;
 im
pr
ov
e 
qu
ali
ty 
of 
life
, k
no
wl
ed
ge
, 
be
ha
vio
ur
 an
d l
ife
sty
le;
 
inv
olv
e p
ati
en
ts 
in 
the
ir 
car
e a
nd
 in
cre
ase
 sa
tis
fac
-
tio
n 
He
art
 fa
ilu
re,
 
an
ti-
co
ag
ula
nt 
the
rap
y, a
nd
 
CO
PD
 
Pa
tie
nt/
ser
vic
e u
ser
 an
d 
pr
im
ary
 ca
re 
tea
m 
By
 20
10
, 3
1 g
rou
ps
 of
 EP
P 
ha
d b
ee
n d
ev
elo
pe
d b
y 1
8 
pr
im
ary
 ca
re 
tea
ms
 of
 th
e 
Ca
tal
an
 He
alt
h I
ns
tit
ute
 
wi
th 
tot
al 
of 
28
7 p
art
ici
-
pa
nts
 (2
4 a
s e
xp
ert
 pa
-
tie
nts
) 
Ed
uc
ati
on
 of
 pa
tie
nts
 by
 la
y 
ins
tru
cto
rs 
aim
ed
 at
 
str
en
gth
en
ing
 co
mp
ete
nc
ies
 
an
d s
kil
ls t
o c
op
e w
ith
 
ch
ron
ic i
lln
ess
 in
clu
din
g 
de
ve
lop
me
nt 
of 
car
e p
lan
s 
Sw
it
ze
rl
an
d 
 
 
 
 
 
 
Ph
ysi
cia
n n
etw
or
k 
De
lta
, G
en
ev
a 
19
92
 
Ph
ysi
cia
n n
etw
ork
s f
orm
 
pa
rt 
of 
the
 se
rvi
ce 
str
uc
-
tur
e i
n a
mb
ula
tor
y c
are
; 
De
lta
 w
as 
co
nc
eiv
ed
 as
 an
 
HM
O a
nd
 in
 20
04
 tr
an
s-
for
me
d i
nto
 a p
hy
sic
ian
 
ne
tw
ork
 
Ge
ne
ral
ist
; 
DM
Ps
 fo
r 
dia
be
tes
, 
he
art
 fa
ilu
re 
an
d a
sth
ma
 
un
de
r d
e-
ve
lop
-m
en
t 
Pr
im
ary
 ca
re 
ph
ysi
cia
ns
/ 
Ge
ne
ral
 pr
act
itio
ne
rs 
In 
20
10
, th
e D
elt
a n
etw
ork
 
co
mp
ris
ed
 16
0 p
rim
ary
 
car
e p
hy
sic
ian
s (
10
-20
% 
ge
ne
ral
ist
s, i
nte
rn
ist
s, G
Ps
); 
in 
Va
ud
 ca
nto
n, 
the
 ne
tw
ork
 
inc
lud
es 
20
 ph
ysi
cia
ns
  
Re
gu
lar
 in
for
ma
tio
n (
tw
o 
inf
orm
ati
on
 le
tte
rs 
pe
r 
ye
ar)
, d
eta
ilin
g p
ro
vis
ion
s 
for
 ac
ces
s t
o h
ea
lth
 pr
om
o-
tio
n a
nd
 di
sea
se 
pr
ev
en
tio
n 
co
ns
ult
ati
on
s a
nd
 ac
tiv
itie
s; 
we
bs
ite
  
Dia
ba
ide
 di
ab
ete
s 
car
e n
etw
ork
 
20
04
 
De
ve
lop
ed
 ba
sed
 on
 an
 
inv
en
tor
y o
f th
e n
ee
ds
 of
 
dia
be
tic
 pa
tie
nts
 in
 th
e 
reg
ion
 of
 Ny
on
-M
org
es,
 
Ca
nto
n d
e V
au
d a
nd
 th
e 
cre
ati
on
 of
 a w
or
kin
g 
gro
up
 of
 he
alt
h c
are
 
sta
ke
ho
lde
rs 
inv
olv
ed
 in
 
dia
be
tes
 ca
re 
Ty
pe
 1 
an
d 2
 
dia
be
tes
  
En
do
cri
no
log
ist
-
dia
be
tol
og
ist
 
Joi
ntl
y r
un
 by
 th
e A
sso
cia
-
tio
n R
ése
au
 de
 So
ins
 de
 la
 
Cô
te 
(on
e o
f th
e f
ive
 ca
re 
ne
tw
ork
s o
pe
rat
ing
 in
 th
e 
can
ton
 of
 Va
ud
) a
nd
 tw
o 
reg
ion
al 
ho
sp
ita
ls  
Inf
orm
ati
on
 m
ate
ria
l; c
us
-
tom
ise
d f
ace
-to
-fa
ce 
sel
f-
ma
na
ge
me
nt 
ed
uc
ati
on
 an
d 
fol
low
-up
; re
gu
lar
 as
ses
s-
me
nt 
of 
pr
ob
lem
s a
nd
 ne
ed
s; 
inv
olv
em
en
t in
 go
al 
set
tin
g 
an
d d
ev
elo
pin
g a
 tr
ea
tm
en
t 
pla
n 
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D
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Se
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an
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em
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pp
or
t 
Br
ea
st 
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Support format and materials 
Respondents from all but two countries (Latvia and Lithuania) reported the use 
of support materials to help patients manage their chronic disease. In some 
programmes, the format of support is limited to written information, such as 
brochures detailing provisions for access to health promotion and disease pre-
vention services. An example is the Delta Physician Network programme in 
Geneva, Switzerland. German statutory health insurance (SHI) funds provide 
disease management patients with information leaflets about their condition in 
situations where they develop complications, do not comply with treatment and 
referral guidelines, fail to reach their treatment goals (e.g. target blood pres-
sure), or miss appointments for follow-up and patient training. In most of the 
reviewed chronic care programmes, such as the Danish SIKS project and the 
Italian Raffaello project, written information materials complement oral patient 
education, which offers patients an opportunity to ask questions and discuss 
problems with health professionals. In Austria, education is also provided 
through awareness campaigns and targeted lectures for stroke patients within 
‘Integrated-stroke-care-Upper-Austria’ and similar projects in other states.  
Respondents from four countries reported that local projects offer patients 
access to interactive websites, such as ‘Gluco.net’ in Hungary, ‘DIEP.info’ in the 
Netherlands, and comparable initiatives in France and Switzerland. In Anda-
lucía, Spain, a school for patients was developed in 2008 to instruct individuals 
on the management of their chronic illness. In addition, the region has a 24-hour 
health service telephone line which patients can contact in case of doubts or 
questions. Telephone-based support is also provided in projects in Germany, 
Hungary, and Italy, as well as in the French disease management programme for 
diabetes (the Sophia project) to provide patients with personalised information 
on how to manage their disease.  
Respondents from three countries reported the use of peer support in spe-
cific chronic care programmes. In Switzerland, peer support is part of a regional 
breast cancer clinical pathway introduced between 2008 and 2009, which is 
hospital-based and targets adults with breast cancer. In Estonia, peer support is 
offered through patient associations. Some of the Partnerships for Older People 
Projects (POPP) in England also offer peer support, for example in the form of 
broader health and well-being advice from other older people.  
Support providers and locations 
In all reviewed countries, self-management support is offered by health profes-
sionals including physicians and/or, more often, trained nurses. The latter is the 
case in Austria, Denmark, England, Estonia, France, Germany, Hungary, Italy, the 
Netherlands, and Switzerland. In England, the 2004 NHS Improvement Plan 
introduced the concept of the ‘community matron’, a specialised senior nursing 
role undertaking intensive home-based case management for elderly people at 
risk of hospitalisation and other high-intensity care users.  
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In Denmark, self-management training is provided either in outpatient clinics 
associated with the hospital, i.e. for patients with severe chronic disease, or in 
the municipalities for non-complex patients. In Estonia, support can be provided 
at home by a nurse or social worker. For some conditions, community services, 
such as the Estonian Parkinson’s Association, may be involved in supporting 
patients by providing information materials, organising lectures, and offering 
practical training and mentoring. Within the Italian Leonardo project, a care 
manager, usually a specialist nurse, guides patients in raising their level of self-
awareness. Although few of the reviewed approaches to self-management sup-
port in the 13 countries use lay expertise, one well-known example is the Eng-
lish Expert Patient Programme, a six-week lay-led educational course for 
chronically ill patients.  
Case study: Dutch health professionals’ perspective on the implementation 
of self-management support in daily practice 
Textbox 1 summarises the Dutch approach to structured disease management 
for chronic conditions and, in particular, the self-management support activities 
included in that approach.  
 
Textbox 1: Chronic care management and self-management support in the Netherlands 
In January 2010, after several years of experiments, a bundled payment sys-
tem for integrated chronic care provision on the basis of evidence-based care 
standards for type 2 diabetes care[35], COPD care[36], and vascular risk 
management[37] was implemented in the Netherlands. Under this system, 
health insurers pay a single fee to one or more of the approximately 100 re-
gional care groups that are currently in place. Care groups are legal entities in 
primary care, mostly owned by GPs, which deliver care and/or subcontract 
(other) providers to deliver services. The insurers’ bundled payment con-
tracts cover a complete package of outpatient chronic care services for a spe-
cific condition, which is informed by national care standards.[38-40]  
Supporting self-management is a key element of the Dutch care standards for 
integrated chronic care delivery. This is illustrated by the description of the 
role of patients in managing their disease in the standard for type 2 diabetes 
care[35]:  
“Following diagnosis of type 2 diabetes by the GP, medical history, lifestyle and 
physical fitness are mapped. Subsequently, an individual risk profile, treatment 
goals, and a treatment plan are drafted based on guidelines. The treatment 
plan is discussed with the patient and general target values are translated into 
individual goals, with the patient’s contribution playing a central role. In order 
to allow the patient to contribute to treatment, an educational course is com-
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pleted. The individual treatment plan contains targets for weight, glucose regu-
lation, blood pressure, lipids and kidney function. Moreover, agreements are 
made regarding lifestyle changes, cardiovascular risk profile, feet, eyes, and 
kidney function. Check-ups occur at least three-monthly, paying specific atten-
tion to complaints, problems, lifestyle changes, weight, glucose regulation, 
blood pressure and other conditions (un)related to diabetes.” 
Support mode and content 
Our interviews indicate that the Dutch approach to self-management support 
for chronically ill patients is individual- rather than group-based, and focuses on 
educating patients about their condition as well as about healthy behaviours 
and self-monitoring skills. According to respondents, patient education is still 
very much traditional in the Netherlands, with health professionals deciding 
what information and skills to teach, rather than allowing patients to identify 
their problems and providing them with techniques to make decisions and take 
appropriate actions:  
“We ask patients about their lifestyle. We give them advice about their life-
style. And if that is not enough, we can refer them to a dietician or physical thera-
pist” (Nurse).  
Although collaborative care planning is emphasised in the Dutch care stan-
dard for type 2 diabetes, none of the interviewed professionals report actually 
working with individual treatment plans. Insufficient information technology 
(IT) and counteracting financial arrangements are mentioned as barriers to-
wards more individual care management:  
“We’re still very much in the development phase, searching for ways to support 
patients’ self-management. It’s not an integral part of the care process yet, nor has 
it been implemented in protocols or IT” (GP).  
“The current financing system focuses on measurable results and, in so doing, 
hampers self-management. GPs tell patients: ‘you have to visit four times a year, 
whether you need it or not’. That completely opposes any form of self-
management” (Manager). 
The latter comment illustrates the reports of the vast majority of profes-
sionals that there is structured follow-up of patients, which is motivated by 
reimbursement of care professionals on the basis of performance indicators 
stipulating, among others, that patients should be seen in general practice at 
least four times per year. Some respondents believe such ‘far-reaching’ stan-
dardisation of care provision opposes self-management, while others indicate 
that regular monitoring of diabetes patients is key to achieving good health 
outcomes.  
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Support format and materials 
Most respondents note that while supporting self-management is an important 
goal of their care programmes, the operationalisation of this care component 
remains underdeveloped. Nationwide approaches do not (yet) exist and re-
gional interventions are often not standardised in care groups’ diabetes care 
protocols, meaning that efforts can differ between practices and providers. The 
lack of proactive policymaking on self-management support is mentioned by 
some respondents as a barrier to broad dissemination of local ‘best practices’:  
“As far as self-management support goes, we’re still very much searching for 
ways to operationalise; we realise that it is important, but we still have a long way 
to go” (Manager).  
Some groups report using motivational interviewing or web-based educa-
tion programmes, such as DIEP.info, to help patients in their efforts towards 
self-management. In most groups, however, support efforts appeared to be lim-
ited:  
“There is attention for patients’ self-care during consultations, but self-
management support has not yet been institutionalised” (Manager).  
In the broader community, cognitive-behavioural interventions are widely 
available for smoking cessation and physical exercise, amongst others, yet such 
programmes are rarely part of regional diabetes care packages, which are cov-
ered entirely by the basic social health insurance (SHI) package that is manda-
tory for Dutch citizens. Hence, additional payments might be necessary in order 
to gain access to such services.  
Support providers and locations 
The interviews with Dutch health professionals suggest that in practice, nurses 
are most involved in supporting patients’ efforts to self-manage their disease 
“simply because they have more time to do so” (GP). General practice nurses usu-
ally see patients at least three times per year; during these quarterly check-ups 
– as well as during the annual, more elaborate visit with the GP – patients’ self-
management needs and activities are assessed and education concerning diabe-
tes self-monitoring is provided. When deemed necessary, patients may be re-
ferred to dieticians, physical therapists, other primary care-based health pro-
viders, and/or community services that can support them in improving their 
health-related behaviours.  
DISCUSSION 
In this paper, we reviewed self-management support approaches for patients 
with chronic conditions in 13 European countries. We find that, in general, self-
management support remains relatively underdeveloped in Europe, although 
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some countries appear further than others in implementing the key support 
components distinguished by the CCM, i.e. patient education, collaborative care 
planning, provision of self-management tools, and structured follow-up. This 
difference might be explained, in part, by facilitative factors in countries’ health 
system context, such as the financing context which might incentivise self-
management support efforts, and/or in what can broadly be viewed as medical 
culture, including length of consultation[41], nature of doctor-patient communi-
cation[42], or interdisciplinary teamwork [43]. At the same time, although there 
are differences in the ‘what, how, who and where’ of support activities across 
countries, there are considerable similarities as well. Important commonalities 
were: (1) the role of nurses as main support givers, which research has shown 
to lead to better outcomes for the chronically ill[44-46]; and (2) the setting of 
support activities in primary care, which is widely regarded as most suitable to 
serve as ‘medical home’ for chronically ill patients.[47] Moreover, respondents 
from most countries reported on the presence of collaborative care planning 
and structured follow-up of patients’ self-management over time, as suggested 
by the CCM, although it is often unclear how (well) these activities are imple-
mented in practice. Findings from recent international surveys of patients’ ex-
periences with chronic care suggest that there are still substantial shortfalls in 
the actual level of patient engagement in terms of patient-provider communica-
tion, shared decision-making, and follow-up and support between visits.[7,48]  
The self-management support approaches reviewed here differ primarily in 
terms of mode, format, and materials. Across and within countries, patients are 
offered a wide variety of educational resources and services, ranging from writ-
ten materials only to different combinations of individual and/or group-based 
education sessions, interactive websites, telephone services, and/or peer sup-
port. According to a systematic review by Barlow et al.[49], diversity in self-
management interventions is advisable because ‘no approach will meet the 
needs of all participants at all points in time’. With regard to content, support 
efforts in the 13 countries tend to focus primarily on the first two sets of activi-
ties distinguished in the Corbin and Strauss framework[28], namely medical and 
behavioural management, but less so on helping patients deal with the emo-
tional consequences of chronic illness. Active involvement of patient associa-
tions in chronic care provision, which is the case in some countries, might be an 
important step towards better support for patients’ emotional management. The 
six-month evaluation of the Expert Patient Programme in England showed that 
lay-led education efforts can result in improvements in patients’ partnerships 
with doctors, their self-efficacy, self-reported energy levels, health-related qual-
ity of life, and psychological wellbeing.[50] In Austria, the added benefit of peer 
support in the Therapy Aktiv programme is currently being evaluated.[51]  
Our interviews with health professionals in the Netherlands suggest that, 
despite the emphasis on the role of patients in recent chronic care policymaking, 
the actual degree of self-management support in practice remains limited, an 
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observation also reported for other countries.[7,8,48] Care providers seem to 
recognise that engaging patients as partners in their care is key to achieving 
better health outcomes, yet experience difficulties in operationalising this phe-
nomenon in their daily working routines. Based on the barriers to patient par-
ticipation perceived by our respondents, improvements seem necessary in exist-
ing IT arrangements and financial incentives to support the use of individual 
treatment plans. Moreover, it will be important to create a tighter connection 
between the field of health promotion and the health care system, for instance 
by including smoking cessation interventions as part of disease management 
programmes.[31] Broad implementation of self-management support, and of a 
collaborative approach to chronic care more generally, will require a paradigm 
shift among health professionals, who have traditionally been trained to take 
control of and responsibility for patients’ acute health problems.[52] Studies in 
the area of shared decision-making suggest that adoption of the so-called ‘em-
powerment paradigm’ – which acknowledges that chronically ill patients pro-
vide most of their care themselves – will require time and effort, and a suppor-
tive health system context in terms of medical education, care processes, quality 
measurement, and provider reimbursement.[53] There is a need for further 
research into barriers and facilitators to implementation to strengthen the dis-
semination and, with that, the impact of effective self-management support 
approaches for chronically ill patients within the financial and time-related con-
straints of daily health care practice.  
An important strength of this study is the relatively large number of coun-
tries reviewed, which allowed us to provide a broad overview of approaches to 
self-management support in Europe. Adding an in-depth analysis of support 
activities in the Netherlands offered more insight into the actual level of and 
barriers to implementation of self-management support in daily health care 
practice. A limitation of our study is that, despite the use of a data template and 
the operationalisation of self-management support, country-specific descrip-
tions of support approaches differed in their level of detail and thus some ap-
proaches might be relatively underrepresented in this paper. The most impor-
tant weakness of the research, however, is that we were unable to include the 
patient perspective, as it was not possible to survey a sufficiently large sample 
of patients in each country within the time frame of our study. It is likely that 
patients’ perceptions of the (degree of) self-management support they receive 
will differ from those of researchers, policymakers/advisors, and health profes-
sionals. Existing work has highlighted how, from a patient’s perspective, support 
for self-management for those with chronic disease in Europe and elsewhere 
remains underdeveloped, with a 2011 survey of people with chronic conditions 
in 11 countries finding 20 to 60 percent to report that health professionals do 
not help them make treatment plans they can carry out in daily life.[54] More-
over, 25 to 50 percent felt that their doctor did not spend sufficient time with 
them or explained things in a way that patients would find easy to under-
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stand.[54] Combined with our own findings, these findings further stress the 
importance of future research in the area of self-management support.  
CONCLUSION 
The findings from our 13-country study of self-management support ap-
proaches suggest that while Europe might increasingly be talking the talk of 
patient participation in chronic care, it appears to be far from walking the walk. 
Support activities are relatively underdeveloped and remain quite traditional, 
that is, focused on medical and behavioural skills, with limited attention for the 
emotional consequences of illness. Reported barriers to implementation of self-
management support include insufficient IT and counteractive financial incen-
tives, but also a lack of (proactive policy to stimulate) adoption of the ‘empow-
erment paradigm’ in health care practice. There is a need for better understand-
ing of how we can encourage both patients and health professionals to engage in 
productive interactions in daily chronic care practice, which can improve health 
and social outcomes. Involving patients as ‘experts’ and ‘peer supporters’ might 
be an important step towards improving emotional support in chronic care. 
Future research should investigate to what extent barriers related to health 
system context and/or medical culture are hampering the implementation of 
effective self-management support theories in practice.  
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ABSTRACT 
Objective: To illustrate how routine health care data can be used to conduct 
rigorous evaluations of disease management impact.  
Design: The study builds on the European DISMEVAL project, which tested and 
validated advanced evaluation methods, such as difference-in-differences analy-
sis and regression discontinuity analysis, on data from existing disease man-
agement approaches in six countries.  
Setting: Austria, Denmark, France, Germany, the Netherlands, and Spain. 
Participants: Health care providers and/or statutory insurance funds providing 
routine data from their disease management interventions, mostly retrospec-
tively.  
Interventions: This study did not make an intervention but evaluated the im-
pact of existing disease management interventions implemented in European 
care settings.  
Main outcome measures: Outcome measures were largely dependent on avail-
able routine data, but could concern health care structures, processes, and out-
comes.  
Results: Data covering 10 to 36 months were gathered concerning more than 
154,000 patients with three conditions. Data on intermediate health outcomes 
were most commonly available, followed by process measures. The analyses 
demonstrated significant positive effects of disease management on process 
quality (Austria, Germany), yet no more than clinically moderate improvements 
in intermediate health outcomes (Austria, France, Netherlands, Spain) or pace of 
disease progression (Denmark) in intervention patients, where possible com-
pared to a matched control group.  
Conclusions: Routine health care data provide a useful resource for rigorous, 
‘real-world’ disease management evaluation. Besides offering large numbers 
and enabling long-term follow-up, they allow for retrospective creation of con-
trol groups and provide baseline data. A disadvantage is that routine measures 
can be too narrow to adequately reflect quality of care.  
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INTRODUCTION 
Over the past two decades, many countries have implemented disease manage-
ment approaches to improve the quality of care for persons with chronic condi-
tions, enhance health outcomes, and, ultimately, mitigate costs.[1-3] Notwith-
standing variation in the nature and scope of approaches, disease management 
can broadly be defined as ‘a system of coordinated health care interventions and 
communications for populations with conditions in which patient self-care ef-
forts are significant’.[4] In this context, interventions and communications typi-
cally involve actions to enhance patient monitoring and education, increase the 
coordination of care, and/or stimulate service standardisation.[5,6]  
While intuitively appealing, the available evidence on the ability of disease 
management to achieve its intended goals remains uncertain.[7] Much of what 
we know about the impact of approaches on the quality and outcomes of care 
comes from small-scale pilot studies that are frequently conducted in academic 
settings, the results of which are difficult to generalise.[8] Once programmes are 
rolled out, there is typically little incentive for researchers to continue tracking 
their impact with less rigorous observational study designs, which are opera-
tionally feasible for use in routine practice.[9] Conversely, approaches used to 
benchmark disease management performance in routine care settings tend to be 
limited methodologically, so reducing the scientific credibility and relative use-
fulness of findings of intervention effect.[10] 
Given that disease management is essentially a population-based care strat-
egy, developing study methods that are both scientifically robust and feasible 
for evaluation in daily practice will be pivotal to improve available evidence on 
effectiveness and enable continuous quality improvement. The European col-
laborative DISMEVAL (‘Developing and Validating Disease Management Evalua-
tion Methods for European Health Care Systems’) project sought to support this 
process by testing and validating potentially valuable evaluation methods on 
data from existing approaches to disease management in six countries: Austria, 
Denmark, France, Germany, the Netherlands, and Spain.[11] Building on that 
work, the aim of this study is to illustrate how routine data available in health 
care practice can be used to conduct rigorous evaluations of the impact of dis-
ease management approaches on the quality and outcomes of care for chroni-
cally ill patients.  
METHODS 
The testing and validation of disease management evaluation methods carried 
out within DISMEVAL comprised studies conducted in six countries. A key re-
quirement for country cases to be included in the project was the availability of 
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routine data from existing, population-based approaches to chronic disease 
management. In order to capture a wide range of approaches, we applied a 
broad definition of ‘disease management’, considering those that included at 
least one of the following elements: (a) a collaborative model of care among 
providers such as physicians, hospitals, laboratories, and pharmacies; (b) pa-
tient education; and (c) monitoring/collection of patient outcomes data for the 
early detection of potential complications.[12] Approaches studied were: dis-
ease management programmes for type 2 diabetes in Austria and Germany, type 
2 diabetes care groups in the Netherlands, provider networks for diabetes and 
for cancer in France, an interdisciplinary and -sectoral rehabilitation pro-
gramme for people with chronic obstructive pulmonary disease (COPD) in 
Denmark, and a nurse-led intervention targeting a working-age population at 
risk of cardiovascular disease in Spain. All interventions were implemented in a 
non-experimental setting; the only exception was the diabetes disease manage-
ment programme in Salzburg, Austria, which was implemented as a pragmatic 
cluster-randomised controlled trial. An overview of the principle disease man-
agement approaches analysed is presented in Table 1.  
We defined routine data as ‘existing, observational health care performance 
data originally collected for purposes other than scientific research’.[13] Table 2 
illustrates that such data were gathered retrospectively from different sources 
depending on the evaluation methods being tested. These included providers 
(Austria, Denmark, France, the Netherlands) and statutory (health) insurance 
funds (Austria, France, Germany, Spain). Two country studies combined avail-
able, routine performance data with newly collected research data as part of the 
intervention design (Austria, Denmark). Based on Donabedian’s framework for 
quality assessment in health care, relevant performance measures could con-
cern health care structures, processes, and outcomes.[14] Within the ‘outcome’ 
domain, we distinguished: (1) intermediate clinical outcomes related to disease 
control, e.g. glycated haemoglobin (HbA1c) in diabetes patients; (2) definite 
clinical outcomes, e.g. mortality and functional status; (3) patient experience, 
e.g. patient satisfaction and quality of life; (4) health care utilisation, e.g. hospital 
admission rates; and (5) financial outcomes, e.g. direct health care costs of the 
intervention.[8]  
As interventions and the settings in which they were implemented varied, 
so did the approaches to testing and validating evaluation methods, which were 
informed, in part, by a review of evaluation methods conducted within DISME-
VAL.[15] In Table 1, the methodological aims of the six country-specific disease 
management evaluations are summarised.  
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Table 2: Data source(s) per country study 
Country study Routine data Newly collected data 
Austria Health insurance funds Providers (General practitioners) 
Denmark Danish national registers Hospital 
France Providers (diabetes provider networks) 
Statutory health insurance (control) 
 
Germany Statutory health insurance fund   
Netherlands Providers (Care groups)  
Spain Mutual Fund for Workers’ Injuries and 
Occupational Diseases 
 
RESULTS 
Table 3 shows the main characteristics of the evaluations conducted in the six 
country studies. Evaluations analysed data from between 118 to 105,056 pa-
tients, with length of follow-up ranging from 10 to 36 months. Analytical tools 
for creating comparison groups included different approaches to matching, such 
as propensity score matching (Denmark, Germany, Spain), difference-in-
differences analysis (Denmark), regression discontinuity analysis (Spain), and 
calibration (France). The Dutch case study employed meta-analysis and meta-
regression techniques to assess the impacts of (components of) the intervention 
on different patient groups. 
We present the results of our study by first illustrating the performance 
measures that were possible to collect from routine data in each country. We 
then describe the effects of the disease management approaches that were pos-
sible to measure given the routine data.  
 
Table 3: DISMEVAL evaluations in six countries 
 Research population 
(IG/CG) 
Length of  
follow-up 
Principal approach Analytic tools 
Austria 649/840 Mean: 401±47 
days 
Cluster-randomised 
controlled trial 
Randomised controlled 
comparison using inten-
tion-to-treat analysis 
Denmark Functioning and  
quality: 118/0 
2 years Before-after, no 
comparison  
Mixed-model linear 
regression  
 Utilisation: 118/118 2 years Before-after, with 
comparison  
Propensity score match-
ing 
Difference-in-
differences analysis 
France 241/2,415 1 year Before-after, with 
comparison 
 
 
Calibration  
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 Research population 
(IG/CG) 
Length of  
follow-up 
Principal approach Analytic tools 
Germany 6,663/37,342 3 years Before-after, with 
comparison  
Comparison of propen-
sity score matching, 
propensity score 
weighting, and direct 
covariate matching 
Netherlands 105,056/0 Mean: 11-12 
months 
Before-after, no 
comparison 
Meta-analysis  
Meta-regression 
Spain 1,128/627 10-14 months Before-after, with 
comparison 
Propensity score match-
ing 
Regression discontinu-
ity analysis 
NOTE: IG/CG indicates intervention group/control group 
Available performance measures in routine data 
An overview of the performance measures assessed in the six DISMEVAL coun-
try studies is presented in Table 4. Data concerning measures of structure were 
not routinely reported for any of the approaches evaluated here. We found that 
process measures were more commonly available and could be analysed in 
three country studies, including measures of adherence to guidelines concerning 
regular foot-, eye- and HbA1c-measurement (Austria and Germany), prescrip-
tion rates (Germany), the frequency and range of clinical measurements, and 
length of follow-up (Netherlands), and participation in patient education (Aus-
tria). 
All country studies assessed intermediate clinical outcome measures; the 
only exception was the evaluation of the German diabetes disease management 
programme. Intermediate measures most commonly included body mass index 
(BMI), blood pressure, cholesterol, and HbA1c levels. Definite clinical outcome 
measures included the prevalence of micro- and macrovascular complications 
and mortality (Germany), and physical functioning (Denmark). Measures of 
patient experience were only available to the Danish country study, which 
evaluated general and disease-specific quality of life. Data on health care utilisa-
tion or costs were not routinely available in most country studies except for 
Denmark (COPD-specific utilisation) and Germany (non-specific utilisation and 
cost).  
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Table 4: Performance measures used in six country-specific disease management evaluations  
Domain Performance measures  
Process      
Austria Regular HbA1c 
measurement 
Annual eye exami-
nation  
Annual foot exami-
nation 
Patient education   
Germany Regular HbA1c 
measurement  
Annual eye exami-
nation  
Guideline-adherent 
medication  
  
Netherlands Frequency of 
clinical measure-
ments 
Range of clinical 
measurements  
Length of follow-up   
Outcome Intermediate 
clinical  
Definite  
clinical 
Patient  
experience 
Utilisation Costs 
Austria HbA1c 
Cholesterol 
Creatinine 
Blood pressure 
BMI 
    
Denmark1 Blood pressure  
Weight  
Waist circumfer-
ence 
BMI 
Physical function-
ing 
 
Quality of life, 
disease specific and 
general 
GP visits  
Specialist visits  
Hospital contacts 
Bed days 
Outpatient visits 
ER visits 
Medication 
 
France HbA1c 
BMI 
Renal function 
    
Germany2  Microvascular 
complications 
Macrovascular 
complications  
Mortality 
 Ambulatory care 
Hospital days 
Inpatient 
Prescription  
Netherlands HbA1c 
Cholesterol 
Blood pressure 
BMI 
    
Spain Cholesterol 
Blood pressure 
BMI 
Cardiovascular 
risk 
 
 
 
   
NOTE: 1Danish utilisation measures are COPD-specific; 2German utilisation and cost measures are 
all-cause; HbA1c indicates glycated haemoglobin; BMI, body mass index 
Disease management impact 
Table 5 shows the impact of the disease management approaches evaluated in 
the six country studies on included performance measures.  
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Effects on process measures 
The Austrian study demonstrated significantly greater improvements in all 
measures of process quality in the intervention group compared to the control 
group after one year. Similarly, the German country study found evidence for 
participation in the disease management programme for diabetes to improve 
process measures. The evaluation of the Dutch diabetes care groups, using a 
before-after design, found that more frequent measurement of clinical values 
appeared to be accompanied by greater health improvements, especially in pa-
tients with poor glycaemic control, while a longer length of follow-up was asso-
ciated with less positive effects. Table 5 illustrates these findings specifically 
with regard to effects on HbA1c levels; similar results were found on all other 
included outcome measures.  
Effects on outcome measures 
Intermediate clinical outcomes 
The Austrian country study found statistically significant, modest reductions in 
intervention patients’ HbA1c levels (-0.13%; p=0.026) and BMI (-0.27 kg/m2; 
p=0.004) compared to control patients. The evaluation of the Danish rehabilita-
tion programme for COPD found significant reductions in the intervention 
group’s diastolic blood pressure (-2.3 mmHg; p<0.05) and BMI (-0.2 kg/m2; 
p<0.05). However, these findings were observed for an uncontrolled design only 
as available data did not allow for a controlled analysis of intermediate clinical 
outcome measures. The evaluation of the French diabetes provider networks 
identified significant improvements in the intervention groups’ HbA1c concen-
trations (-0.23%; p=0.002) and BMI (-0.29 kg/m2; p=0.019) after one year of 
disease management compared to a national reference, while renal function 
deteriorated significantly (-4.87 ml/min; p<0.001). The uncontrolled Dutch 
country study found modest average improvements in intervention patients’ 
cholesterol values, blood pressure, and BMI, while HbA1c levels somewhat in-
creased after a median one year follow-up. Subgroup analyses suggested for the 
Dutch intervention to be considerably more beneficial for patients with poorly 
controlled diabetes, as illustrated by the significantly greater than average im-
provements in these patients’ HbA1c levels displayed in Table 5. This finding 
was consistent across all outcome measures. The evaluation of a nurse-led in-
tervention for the prevention of cardiovascular risk in a working age population 
in Spain found greater improvements in all intermediate outcomes except for 
HDL cholesterol, among those with a moderate to high cardiovascular risk who 
received the intervention compared to those with an equally moderate to high 
cardiovascular risk but who were not available to receive the intervention.  
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Definite clinical outcomes 
The German country study was unable to demonstrate a statistically significant 
difference in the risk for micro- and macrovascular complications between in-
tervention and control groups after three years. The analyses did find a signifi-
cant reduction in mortality in the intervention group, especially during the first 
year after enrolment in the programme. Using an uncontrolled design, the Dan-
ish evaluation found statistically significant improvements in intervention pa-
tients’ physical functioning.  
Patient experience, care utilisation and costs 
In terms of effects on patient experience, the Danish country study identified 
significant improvements in the quality of life of patients participating in the 
rehabilitation intervention for COPD. With regard to utilisation, it found the 
intervention to decrease the pace of COPD progression, as measured by a non-
significant increase in COPD-specific hospital contacts, bed days, outpatient 
visits, and emergency room visits in the intervention group, while these indica-
tors significantly increased in the entire sample. The German evaluation found 
evidence that intensified care – as indicated by improvements in process meas-
ures – was accompanied by higher utilisation and costs. Thus, participants in the 
disease management programme showed an increase in the number of outpa-
tient visits and prescription costs, although hospital days and inpatient costs did 
not differ from the control group.  
DISCUSSION 
Experimental study designs, particularly randomised controlled trials, are gen-
erally considered to provide the most scientific rigour for determining the ef-
fects of an intervention.[10,15] In such designs, individuals are randomly as-
signed to either the intervention group or a control group, giving each person an 
equal chance to be chosen for the intervention so that any observed difference 
in outcome is not affected by systematic differences in factors, known and un-
known, between those who receive a given intervention and those who do 
not.[16,17] However, use of an experimental design may not be possible and/or 
desirable for population-based disease management interventions, which are 
implemented in operational settings, target large and inherently heterogeneous 
patient populations, and do not usually have a control group available.[18,19] In 
such cases, observational study designs are more suitable and can be sufficiently 
robust if certain data problems are taken into account.[10,20] 
This paper demonstrates how routine health care performance data can 
provide a useful resource in the design of rigorous non-experimental studies. 
Such data, which are typically inexpensive to collect from the perspective of 
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researchers, provide a potentially rich source of longitudinal information on a 
large number of patients with different health problems across diverse health 
care settings.[21,22] Thus, within DISMEVAL, we were able to include mostly 
routine data describing a period of 10 to 36 months from more than 154,000 
patients receiving disease management or usual care for three different condi-
tions in six European countries. Perhaps even more important, routine data can 
be used to retrospectively create matched control groups and provide baseline 
data, which is essential for any evaluation that aims to assess whether or not the 
intervention under study did indeed have an effect on the intervention group 
that would not have occurred otherwise.[15]  
However, despite the practical and methodological advantages of using a 
routine dataset in situations where randomisation is not possible, it may be 
inadequate for the purpose of evaluation as it is typically used for administra-
tive purposes only and may not record measures of interest.[21,22] Our analy-
ses show that this was the case for the majority of routine data used in DISME-
VAL. Within the datasets made available by health care providers and insurance 
funds, there was an emphasis on intermediate clinical outcomes, such as blood 
pressure and cholesterol, while data on process measures, definite clinical out-
comes, patient experience, health care utilisation, or costs were accessible in 
two or three cases only. This reflects to certain degree the context within which 
related programmes and approaches were being implemented, with intermedi-
ate measures used to monitor progress towards treatment goals.[23] There is, 
however, also a general tendency to focus on intermediate health outcomes in 
disease management evaluations, in part because of their ease of measurement 
with standard tests and procedures in place, even though the relevance for long-
term health outcomes sometimes remains unclear.[15,24]  
Despite the use of rigorous analytic methods, ranging from propensity score 
matching and calibration to regression discontinuity analysis and meta-
regression, the results of our six country case studies must be interpreted with 
caution, keeping the methodological limitations of observational research in 
mind.[9,10,15] Further research into the ‘real-world’ impact of disease man-
agement on a broad range of process and outcome measures is crucial to sup-
port health care professionals in working towards more patient-centered, effec-
tive and efficient chronic care delivery, which were stipulated as important 
health system objectives in the Institute of Medicine’s seminal Crossing the Qual-
ity Chasm report.[25] Our study suggests that this may necessitate additional 
data collection efforts in practice, with consequent resource implications.[13] 
Also, there is a need to allow for sufficient length of observation in disease man-
agement evaluations, consistent with what is known about the time course of a 
disease, to enable valid conclusions to be drawn about health effects. Intermedi-
ate clinical outcome measures are heavily influenced by an individual’s health 
behaviour, improvements in which are often difficult to maintain over time. 
Adequate length of follow-up is also necessary for measurement of ‘hard’ clinical 
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outcomes, such as morbidity and mortality. This is illustrated by the German 
country study as well as by an unrelated Danish trial[26], both of which could 
not demonstrate effects on the prevalence of various types of diabetes-related 
complications within a time frame of three and six years respectively. The Ger-
man evaluation did observe a significantly higher risk of death among control 
patients compared to intervention patients. However, this mortality difference 
between groups fell considerably after the first year of enrolment in the disease 
management programme; hence, it was more likely a result of selection bias 
than an effect attributable to the intervention.[11,20]  
Limitations 
This study has several limitations. Most notably, data collection was influenced 
by the availability and validity of data for research purposes as well as by meth-
odological choices. Thus, the performance measures assessed in DISMEVAL do 
not fully describe the spectrum of metrics that may be potentially useful for 
disease management evaluation in the individual countries. Rather, each set of 
measures included in a specific country study represents what could be meas-
ured in a scientifically sound fashion on the basis of routine performance data. 
Furthermore, the diversity of disease management approaches studied in DIS-
MEVAL limits the potential for cross-country comparisons of effectiveness. Fi-
nally, while concerted efforts were made to obtain detailed and valid datasets to 
allow, where possible, for the retrospective creation of suitable treatment-
control matches adjusted for confounding variables, unobserved confounders 
may still have resulted in misleading intervention effects.  
CONCLUSIONS 
Routine health care performance data provide a valuable resource for ‘real-
world’ disease management evaluations using advanced observational study 
designs. They contain the large numbers and opportunities for long-term follow-
up required to investigate health effects; moreover, they allow for retrospective 
creation of control groups and provide baseline data, both of which are neces-
sary to detect a true treatment effect. A disadvantage of using routine data is 
that the measures systematically assessed in health care can be too narrow to 
adequately reflect the quality of care provided. These data tend to emphasise 
intermediate clinical outcomes and, to a somewhat lesser extent, process meas-
ures. Additional data collection and evaluation efforts over sufficient observa-
tion periods may be necessary to gain insight into the impact of disease man-
agement strategies on definite clinical outcomes, measures of patient experi-
ence, health care utilisation, and costs.  
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ABSTRACT 
Background: Evaluating large-scale disease management interventions imple-
mented in actual health care settings is a complex undertaking for which univer-
sally accepted methods do not exist. Fundamental issues, such as a lack of con-
trol patients and limited generalisability, hamper the use of the ‘gold-standard’ 
randomised controlled trial, while methodological shortcomings restrict the 
value of observational designs. Advancing methods for disease management 
evaluation in practice is pivotal to learn more about the impact of population-
wide approaches. Methods must account for the presence of heterogeneity in 
effects, which necessitates a more granular assessment of outcomes.  
Methods: This paper introduces multilevel regression methods as valuable 
techniques to evaluate ‘real-world’ disease management approaches in a man-
ner that produces meaningful findings for everyday practice. In a worked exam-
ple, these methods are applied to retrospectively gathered routine health care 
data covering a cohort of 105,056 diabetes patients who receive disease man-
agement for type 2 diabetes mellitus in the Netherlands. Multivariable, multi-
level regression models are fitted to identify trends in clinical outcomes and 
correct for differences in characteristics of patients (age, disease duration, base-
line health, comorbidity, smoking status) and the intervention (measurement 
frequency and range, length of follow-up).  
Results: After a median one year follow-up, the Dutch disease management 
approach was associated with small average improvements in systolic blood 
pressure, low-density lipoprotein, and body mass index, while a slight deteriora-
tion occurred in glycated haemoglobin. Differential findings suggest that pa-
tients with poorly controlled diabetes tend to benefit most from disease man-
agement in terms of improved clinical measures. Additionally, a greater meas-
urement frequency was associated with better outcomes, while longer length of 
follow-up was accompanied by less positive results.  
Conclusions: Despite concerted efforts to adjust for potential sources of con-
founding and bias, there ultimately are limits to the validity and reliability of 
findings from uncontrolled research based on routine intervention data. While 
our findings are supported by previous randomised research in other settings, 
the trends in outcome measures presented here may have alternative explana-
tions. Further practice-based research, perhaps using historical data to retro-
spectively construct a control group, is necessary to confirm results and learn 
more about the impact of population-wide disease management.  
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INTRODUCTION 
Disease management is commonly defined as a ‘system of coordinated health 
care interventions and communications for populations with conditions in 
which patient self-care efforts are significant’.[1] Originally developed in the US, 
disease management interventions have been introduced in many countries to 
address widespread deficiencies in the care for chronically ill patients, including 
fragmentation, insufficient evidence-based practice, and limited self-
management support.[2] However, especially outside of the US, available evi-
dence about the impact of disease management remains uncertain and tends to 
be based on mostly small studies, which frequently target high-risk patients and 
are performed in academic settings.[3] Although some large-scale, realistic 
evaluations have already been conducted[4], there remains a need for better 
insight into the effects of comprehensive, population-based approaches, such as 
have been implemented in, for example, Germany and the Netherlands.[5] 
An important reason for this limited evidence base is the lack of universally 
accepted methods for ‘real-world’ disease management evaluation that are both 
scientifically sound and operationally feasible.[6,7] According to Linden et al.[8], 
three fundamental limitations preclude use of the ‘gold-standard’ randomised 
controlled trial (RCT). First, from a practical perspective, population-wide im-
plementation of approaches can make it difficult to find a suitable number of 
control subjects. Second, withholding treatment that is assumed to be effective 
from control patients poses an ethical dilemma. Third and most important, 
however, the strict in- and exclusion criteria limit generalisability of findings 
across patients and contexts. Observational research designs are more suitable 
for practice-based disease management evaluation, yet commonly have meth-
odological flaws that limit the validity and reliability of findings.[9]  
Advancing existing methods for disease management evaluation in routine 
situations where randomisation is not possible will be pivotal in drawing valid 
conclusions about the impact of this care concept on the quality and outcomes of 
chronic care provision. Evaluation methods must account for the presence of 
heterogeneity in effects of disease management, produced by differences in 
interventions and targeted patients.[10-13] This variation necessitates calcula-
tion of more detailed effect estimates than the commonly assessed ‘grand 
means’ across large populations of patients, if they are to be informative for day-
to-day clinical practice.  
The aim of this paper is to introduce multilevel regression methods as useful 
techniques for the analysis of patient data in practice-based disease manage-
ment evaluation. These methods enable researchers to identify differences in 
outcomes as a function of features of the intervention and/or patient popula-
tion, and, in so doing, support efforts to create effective and efficient disease 
management strategies. The article starts with a brief, non-technical description 
of the proposed analytic approach. Subsequently, a worked example is given of 
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its application in the evaluation of a population-wide disease management in-
tervention for type 2 diabetes mellitus implemented in the Netherlands. This 
evaluation, which was part of the European collaborative DISMEVAL (‘Develop-
ing and Validating Disease Management Evaluation Methods for European 
Health Care Systems’) project[5,14], was designed as an uncontrolled cohort 
study using routine patient data gathered retrospectively from clinical practice.  
MULTILEVEL REGRESSION METHODS: WHAT AND WHY? 
In health services research, especially studies conducted in practice settings, 
data commonly have a hierarchical nature, with variable measures – such as 
cholesterol measurements – clustered within different levels of the hierar-
chy.[15] For example, in a practice-based study examining factors that influence 
the use of shared decision-making in general practice, patients would be clus-
tered within physicians, who in turn might be nested within group practices. 
Traditional statistical methods, such as linear regression analysis, tend to ignore 
the multilevel structure of routine health care data and do not account for the 
possibility of similarities among individuals clustered within higher-level 
units.[16] Yet in reality, subjects within clusters are often more alike than ran-
domly chosen individuals with regard to important characteristics, such as so-
ciodemographic features. Hence, assuming that observations within clusters are 
uncorrelated is unrealistic and can result in false conclusions about associations 
between particular variables.[16,17]  
Multilevel regression methods enable researchers to explicitly include the 
hierarchical nature of practice data into their analyses.[15] Similar in essence to 
simple regressions, multilevel regression entails predicting an outcome variable 
according to the values of one or more explanatory variables, which may be 
measured at different levels in the hierarchy.[18] The latter are usually called 
covariates, i.e. characteristics that might influence the size of a particular inter-
vention’s effects. Person-level covariates can enter the model in two different 
ways. First, they may appear as ordinary covariates at level one of the hierarchy. 
Second, they may appear in interaction terms with intervention characteristiccs. 
These interaction terms capture the idea of ‘effect modification’ by allowing the 
person-level variables to modify the intervention effect.  
Applying multilevel regression methods is of particular relevance when pa-
tient outcomes are regarded as heterogeneous, as is typically the case with dis-
ease management. In a simple two-level model, total heterogeneity in effects can 
be divided into two variance components: within-groups and between-
groups.[16] Multilevel regression techniques make it possible to capitalise on 
this variation in three ways, the outcomes of which can support further im-
provements in the quality and outcomes of disease management.[19] First, it 
enables identification of subgroups of patients for whom treatment is associated 
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with the most positive effects. Second, it permits investigation of characteristics 
of an intervention, either active (treatment features) or passive (setting fea-
tures), that are associated with favourable outcomes.[18,20] Third, it allows for 
multiple factors measured at different levels in the hierarchy to be examined 
together, the results of which may facilitate stratified medicine. In the remain-
der of this paper, we will show how multilevel regression methods were applied 
in our evaluation of the Dutch approach to disease management for type 2 dia-
betes.  
WORKED EXAMPLE: DUTCH DISEASE MANAGEMENT EVALUATION 
In 2007, the Netherlands Organisation for Health Research and Development 
(ZonMw) started a governmentally subsidised pilot called the ‘Integrated Diabe-
tes Care research programme’ to overcome existing barriers to coordination of 
care for type 2 diabetes patients. As part of the pilot, ten so-called ‘care groups’ – 
i.e. provider networks in primary care, gathering mostly general practitioners 
(GPs) and affiliated personnel – were offered financial incentives to start ex-
perimenting with a bundled payment system that allows the different compo-
nents of outpatient care for type 2 diabetes to be purchased, delivered, and 
billed as a single product (i.e. a disease management intervention).[21,22] Care 
groups are responsible for all patients covered by their diabetes care pro-
gramme; they deliver services themselves and/or subcontract services from 
other providers, such as physical therapists, dieticians, laboratories, and, to a 
limited extent, specialists.[23] A national evidence-based care standard for type 
2 diabetes care guides negotiations between care groups and health insurers on 
the content and price of diabetes care programmes.[24] 
One of the main goals of implementing the bundled payment system was to 
stimulate the transfer of non-complex chronic care from the hospital setting to 
general practice, which traditionally is a strong sector in the Netherlands and is 
widely regarded as most suitable to serve as ´medical home´ for chronically ill 
patients.[25] Nearly all Dutch citizens are registered with a GP, who constitutes 
the first point of contact for care-seeking individuals and acts as gatekeeper for 
secondary care.[23] Although some regional bundled payment contracts include 
a limited amount of specialist care, these services are generally reserved for 
patients with complex and unstable long-standing health problems, such as type 
1 diabetes patients and/or multimorbid patients.  
Despite uncertainty about the effectiveness of the new financing and deliv-
ery system, care groups with bundled payment contracts for type 2 diabetes 
disease management interventions rapidly achieved national coverage in the 
Netherlands.[26] For evaluators, this broad dispersion, combined with the un-
suitability of using historical controls – evidence suggests that the quality of 
diabetes care improves over time as a secular trend[27] – limits the use of ex-
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perimental comparisons. Thus, to analyse the impact of the Dutch approach to 
disease management for type 2 diabetes, we conducted an uncontrolled, prac-
tice-based cohort study using multilevel regression methods. Although these 
methods preclude the establishment of cause-effect relationships, they enabled 
us to identify trends in outcome measures that might suggest that components 
of the intervention under consideration have an effect for (subgroups of) type 2 
diabetes patients.[28] Our study was conducted in five steps: (1) participant 
selection; (2) data collection and validation; (3) variable definition; (4) data 
analysis; (5) outcome interpretation.  
Participant selection 
We selected a convenience sample of 18 care groups, which were set up be-
tween the years 2006 and 2009. Nine groups were part of the pilot of the bun-
dled payment system, for which they were selected ensuring diversity in geo-
graphical location and size.[21] We used the same criteria to include nine addi-
tional, non-experimental groups, i.e. regional initiatives that have a bundled 
payment contract for diabetes disease management interventions with a health 
insurer but do not receive (financial) support from the pilot. The 18 care groups 
represent all but one region of the Netherlands, employ between 7 and 230 GPs 
per group, and cover patient populations ranging from 348 to 18,531 persons. 
From each group, we selected all type 2 diabetes patients with at least one regis-
tered visit to general practice during the research period (N=106,623), which – 
depending on the availability of data – was either 20 or 24 months between 
January, 2008 and December, 2010. We excluded type 1 diabetes patients 
(N=1567), because they are treated primarily by specialists.  
Data collection and validation 
The bundled payment system for chronic care in the Netherlands requires care 
groups to register a specific number of performance indicators for care proc-
esses and clinical outcomes on an annual basis. We retrospectively gathered 
patient data on a selection of those indicators from the clinical information sys-
tems of our 18 care groups. Data plausibility was verified through range checks; 
we removed outliers in clinical values based on cut-off points determined by 
Dutch diabetes experts (see Table 1). Missing values were not imputed.  
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Table 1: Cut-off points for data cleaning 
Indicator Lower Upper Excluded, n Excluded, % 
Glycated haemoglobin (HbA1c, mmol/mol) 18 108 913 0.5 
Low-density lipoprotein (LDL, mmol/l) 1 7.3 2110 1.3 
Systolic blood pressure (SBP, mmHg) 70 250 25 0.01 
Body Mass Index (BMI, kg/m2) 16 70 123 0.08 
 
Because patient data were not available for the period before introduction of the 
bundled payment system, we used the last measurement of each clinical out-
come registered per patient during the first year of the research period (or first 
eight months, for the two groups with a 20-month research period) as baseline. 
Thus, the baseline data used in this study represent data at the introduction of 
the disease management intervention (i.e. bundled payment system). Given that 
patients were enrolled at different time points during the first year, using the 
last measurement registered in that period as baseline was preferred over the 
first measurement to minimise heterogeneity in follow-up duration between 
patients. This is a conservative decision because for some cases a portion of the 
programme effects will be incorporated in the baseline measurements.  
 To identify trends in outcome measures, we calculated changes in clinical 
parameters from baseline to follow-up, which was operationalised as the last 
measurement of each clinical outcome per patient registered during the second 
year of the research period. Large correlations between observations within 
person make the choice of modeling change scores rather than separate cross-
sections compelling for maximising statistical power. Modeling change scores 
also controls for unmeasured but fixed person-level covariates. Before conduct-
ing each outcome-specific analysis, we excluded patients who: (1) lacked valid 
registrations of baseline or follow-up measurement, or both; (2) missed regis-
trations of one or more of the characteristics used as covariates in the multilevel 
regression analyses; and/or (3) had an observation period between baseline 
and follow-up of less than three months. The maximum length of follow-up per 
patient was 23 months. The study flowchart is shown in Figure 1. 
 
C H A P T E R  8  
 190 
 
Figure 1: Study flowchart 
NOTE: HbA1c indicates glycated haemoglobin; LDL, low-density lipoprotein; SBP, systolic blood 
pressure; BMI, body mass index 
Variable definition 
To enable investigation of heterogeneity in effects on clinical outcomes, we de-
fined relevant variables relating to patient characteristics and active features of 
the intervention. Figure 2 shows a graphical conceptualisation of the included 
variables and the number of care groups able to provide data on those variables.  
 
Patients included in 
HbA1c-specific 
analyses: 
N=75,127 
Patients included in 
LDL-specific  
analyses:  
N=58,697 
Patients included in 
SBP-specific  
analyses:  
N=73,437 
Patients included in 
BMI-specific  
analyses:  
N=63,341 
Missing patient 
characteristic(s): 
N=32,468 
Missing patient 
characteristic(s): 
N=24,178 
Missing patient 
characteristic(s): 
N=30,918 
Missing patient 
characteristic(s): 
N=24,816 
Missing process 
characteristic(s): 
N=23,873 
Missing process 
characteristic(s): 
N=25,849 
Missing process 
characteristic(s): 
N=22,495 
Missing process 
characteristic(s): 
N=26,892 
Outcome-specific analyses
Patients under treatment 
identified in care groups’ 
information systems: 
N=106,623
Excluded:
Type I diabetes mellitus: N=1567 
Eligible patients
N=105,056 
Excluded LDL:
Length of follow-up  
<3 months: N=3451 
No first measurement: 
N=31,539 
No second measure-
ment: N=20,062 
No measurement: 
N=8693
Excluded SBP:
Length of follow-up 
<3 months: N=3842 
No first measurement: 
N=21,343 
No second measure-
ment: N=10,060 
No measurement: 
N=3626
Excluded HbA1c: 
Length of follow-up  
<3 months: N=1244 
No first measurement: 
N=22,070 
No second measure-
ment:  N=10,399 
No measurement: 
N=3784
Excluded BMI: 
Length of follow-up  
<3 months: N=4042 
No first measurement: 
N=30,670 
No second measure-
ment: N=19,520 
No measurement: 
N=12,517 
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Figure 2: Conceptual overview of variables (and number of registering care groups) 
NOTE: A1C indicates glycated haemoglobin; LDL, low-density lipoprotein; SBP, systolic blood pres-
sure; BMI, body mass index 
 
With regard to intervention features, we coded measurement frequency as the 
number of registrations of each clinical outcome during follow-up. To describe 
measurement range, we assessed the amount of different outcomes registered 
per patient over baseline, which could be a maximum of eight (i.e. glycated hae-
moglobin, total cholesterol, low- and high-density lipoprotein, triglycerides, 
systolic and diastolic blood pressure, and body mass index). Duration of care 
was defined as an individual patient’s length of follow-up in months.  
To describe patients, we used these characteristics: age (in years), disease 
duration (in years), health status, comorbidity, and smoking status. Health sta-
tus was determined by the baseline values of each clinical outcome. Comorbidity 
was defined as the presence, registered since diagnosis of type 2 diabetes (that 
is, either before or during the research period), of one or more of the four most 
frequently registered co-occuring conditions across the included care groups, 
i.e. angina pectoris, myocardial infarction, stroke, and/or transient ischemic 
attack. We dichotomised smoking status as previous or non-smoker versus cur-
rent smoker. Finally, we defined clinical outcomes as changes over baseline in 
glycated haemoglobin (HbA1c), low-density lipoprotein (LDL), systolic blood 
pressure (SBP), and body mass index (BMI).  
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Data analysis 
We conducted univariate analyses to describe intervention and patient charac-
teristics, which were reported either as means and associated standard devia-
tions (age, disease duration, health status), median values (measurement fre-
quency, length of follow-up), or percentages (comorbidity, smoking, measure-
ment range). Using paired sample t-tests (two-sided, α=0.05), we calculated the 
care group-specific and overall mean differences in clinical outcomes between 
baseline and follow-up, and 95% confidence intervals. To quantify the hetero-
geneity in clinical results among our 18 care groups, we calculated the I2 statis-
tic on the basis of the chi-square (χ2) test. I2 describes the percentage of total 
variation in effects across groups that is due to heterogeneity rather than 
chance. The principal advantage of I2 – which lies between 0 and 100% with 
larger values showing increasing heterogeneity – is that it can be calculated and 
compared across groups irrespective of differences in size and type of outcome 
data.[29]  
For outcomes showing moderate (I2>50%) to high (I2>75%) heterogeneity, 
multivariable, two-level hierarchical regression models – with patients at level 
one and care groups at level two – were used to analyse the influence of selected 
covariates on changes in clinical outcomes between baseline and follow-up. Two 
separate models were fit to test all covariates related to patient and intervention 
characteristics, respectively. In a third series of models, we investigated every 
possible interaction between patient characteristics and intervention features. 
The models used were similar to the kind that might be fit in a multicenter 
study, i.e. mixed models incorporating a random care group effect (PROC MIXED 
command in the SAS 9.2 Software, SAS Institute Inc, Cary, North Carolina), which 
was considered most suitable given the possibility of ‘residual heterogene-
ity’.[30] Where possible, covariates were analysed both as continuous and as 
categorical variables, with categories based on scientific literature (age[31], 
disease duration[32]), on median values (measurement frequency, length of 
follow-up), or, in the case of baseline health status, on the target values for clini-
cal parameters incorporated in the Dutch care standard for type 2 diabetes.[24] 
Measurement range was categorised as eight registered outcomes versus less 
than eight registered outcomes.  
For each outcome, we calculated the intraclass correlation coefficient (ICC) 
which describes the proportion of total heterogeneity in effects attributable to 
between-group variance rather than within-group variance.[33] We examined 
collinearity with the variance inflation factor (VIF): a VIF value greater than 10 
is generally taken as an indication of serious multicollinearity.[34] The regres-
sion coefficients obtained from our multilevel analyses describe how a specific 
effect estimate changes following a unit increase in a covariate; whether there is 
actually a relationship between both is expressed in the statistical significance. 
We expressed ‘explained heterogeneity’ as the percentage change in between-
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group variance (τ2) and within-group variance (σ2) after correcting for selected 
covariates.  
Interpretation of results 
Univariate analyses 
Included in our analyses were 105,056 patients, about half of whom (50.6%) 
were female. The average age of the research population was 65.7 (±11.9) years 
and average disease duration 4.8 (±5.6) years. Further details are shown in Ta-
ble 2. With regard to care processes, patients’ SBP was assessed most frequently 
during follow-up (median=4), followed by BMI (median=3), and HbA1c (me-
dian=2). LDL was measured least often (median=1). Across groups, the average 
share of patients with the maximum measurement range varied from 44.4 to 
86.7%, with a mean of 62.3%. Median length of follow-up was 12 months. 
 
Table 2: Baseline characteristics of the research population 
Characteristic Patients for whom characteristic 
was known, % (n) 
(N =105,056)  
Estimate,  
Mean ± SD 
Age  99.9 (105,013) 65.7 ± 11.9 
Diabetes duration  71.9 (75,498) 4.8 ± 5.6 
Health status   
 HbA1c (mmol/mol; target <53) 71.5 (75,127) 50.2 ± 9.8 
 LDL (mmol/l; target <2.5) 55.9 (58,697) 2.6 ± 0.9 
 SBP (mmHg; target <140) 69.9 (73,437) 140.4 ± 18.0 
 BMI (kg/m2; target <25) 60.3 (63,341) 29.7 ± 5.2 
Comorbidity† 94.5 (99,278)   
 None 84.2 (75,357)  
 One or more 15.8 (14,165)  
Smoking status 74.6 (78,384)  
 No or Ex-smoker 81.6 (63,943)  
 Current smoker 18.4 (14,441)  
NOTE: †Included were four major comorbidity associated with diabetes mellitus: angina pectoris, 
myocardial infarction, stroke, and transient ischemic attack; HbA1c indicates glycated haemoglobin; 
LDL, low-density lipoprotein; SBP, systolic blood pressure; BMI, body mass index 
 
Table 3 presents the mean changes over baseline in clinical outcomes across the 
total of 18 care groups. Overall, we found a small, non-significant increase in 
HbA1c levels between baseline and follow-up, while small but significant reduc-
tions in mean levels were observed for LDL and SBP. Except for BMI, all out-
comes showed moderate to high statistical heterogeneity, from 57% for SBP to 
98% for HbA1c, suggesting that the effects of the diabetes disease management 
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interventions on these outcomes varied across care groups. To elucidate this 
heterogeneity and identify trends in the measured results, multilevel regression 
analyses were conducted.  
 
Table 3: Mean changes over baseline per clinical outcome 
Intermediate outcome Care groups, 
n 
Patients,  
n 
Mean change 
[95%CI] 
Heterogeneity,  
I2 
HbA1c (mmol/mol) 18 75,127 0.17 [-0.60, 0.93] 98%* 
LDL (mmol/l) 18 58,697 -0.09 [-0.13, -0.05]* 93%* 
SBP (mmHg) 18 73,437 -0.95 [-1.25, -0.64]* 57%* 
BMI (kg/m2) 18 63,341 -0.04 [-0.10, 0.02] 0% 
NOTE: HbA1c indicates glycated haemoglobin; LDL, low-density lipoprotein; SBP, systolic blood 
pressure; BMI, body mass index; *Statistically significant (p<0.05); I2 quantifies the total level of 
heterogeneity in effects 
Multilevel regression analyses 
The results of the multilevel regression analyses are summarised in Table 4, 
which shows the changes in between- and within-group heterogeneity in effects 
on HbA1c, LDL and SBP after correcting for included covariates, with the direc-
tion of covariate influence indicated (positive or negative). We observed that the 
vast majority of variance in the effects of disease management on clinical out-
comes occurred within care groups rather than between groups, with ICCs rang-
ing from 0.1 to 4.3% across outcomes. Simultaneously correcting for known 
patient characteristics resulted in the most considerable reductions in within-
group variance in effects. We found no evidence of multicollinearity in any of the 
regression models.  
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Table 4: Directions of regression coefficients and associated changes in between-group (τ2) and 
within-group (σ2) variance in effects 
Intermediate outcome HbA1c LDL SBP BMI 
Intervention characteristics     
Measurement frequency (N=14) - -* -* - 
Measurement range (N=18) -* - +* + 
Length of follow-up (N=18) +* +* +* + 
 Change in τ 2 26.0% -37.0% 15.6% 15.6% 
 Change in σ2 -0.1% 0.7% 5.2% 1.8% 
Patient characteristics     
Age (N=18) -* +* +* -* 
Disease duration (N=14) +* - + +* 
Health status (N=18) -* -* -* -* 
Comorbidity (N=16) +* -* -* + 
Smoking status (N=17) +* - - -* 
 Change in τ2 -12.5% -33.9% 74.8% 22.3% 
 Change in σ2 -23.5% -21.7% -29.9% 3.4% 
NOTE: +=positive regression coefficient; -=negative regression coefficient; *statistically significant 
(p<0.05); HbA1c indicates glycated haemoglobin; LDL, low-density lipoprotein; SBP, systolic blood 
pressure; BMI, body mass index 
 
The multilevel regression model incorporating intervention characteristics 
showed that two covariates significantly influenced the effects of disease man-
agement in a consistent manner across clinical outcomes. Whereas a greater 
measurement frequency of clinical outcomes was associated with better results 
on those outcomes, longer length of follow-up was accompanied by diminishing 
positive effects on HbA1c, LDL and SBP. The results for measurement range 
were inconsistent across clinical outcomes.  
The model for patient characteristics found significant and consistent asso-
ciations between health status (i.e. baseline clinical values) and intervention 
effects, suggesting that the impact of disease management becomes progres-
sively better as patients’ initial health values are poorer. Figure 3 demonstrates 
how across the 18 care groups, diabetes patients with a baseline HbA1c of ≥75 
mmol/mol achieved a mean reduction in this clinical outcome of 16.8 mmol/mol 
(95% CI: -18.7, -15.0), whereas those starting within the target range for HbA1c 
(≤53 mmol/mol) experienced a slight deterioration in glycaemic control (1.79 
mmol/mol [95% CI: 1.2, 2.4]). The HbA1c levels of those with baseline values 
between 54 and 74 mmol/mol reduced by an average of 2.6 mmol/mol (95% CI: 
-3.5, -1.8). For LDL and SBP, similar trends were found. Those with poor base-
line values tended to show the greatest improvements. The findings for age, 
disease duration, comorbidity and smoking status were less conclusive and 
inconsistent across clinical outcomes.  
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Figure 3: Glycaemic control (mmol/mol) from baseline to follow-up according to the target values 
of the Dutch care standard for type 2 diabetes mellitus 
NOTE: HbA1c indicates glycated haemoglobin  
 
The multilevel regression models incorporating covariates related to both pa-
tients and the intervention found one significant interaction that was consistent 
across all included outcomes. Thus, for patients with poorer initial values of a 
particular clinical outcome, more frequent assessment of that outcome was 
associated with progressively greater health improvements than was the case 
for patients with healthier baseline levels.  
DISCUSSION 
Evaluating the effects of population-wide disease management interventions 
implemented in actual health care settings is a complex undertaking.[35] The 
Dutch example described in this paper illustrates how practical issues, such as a 
lack of suitable control patients, can limit the use of experimental comparisons 
to establish whether a given intervention yields a ‘true’ effect. Indeed, attribut-
ing observed changes in outcome measures to the disease management ap-
proach under consideration is one of the key challenges in practice-based 
evaluation.[5,14] In cases like ours, where rigorous performance assessment is 
complicated because data collection is tied to the intervention and real baseline 
data is lacking, a frequently used solution is to report data from a first observa-
tion period as baseline and to use changes from this baseline as estimates of 
effects.[6] Such an observational approach is susceptible to various sources of 
confounding and bias, which threaten the internal validity of study results and 
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cannot always be observed and/or measured so as to enable statistical adjust-
ment. In evaluating complex health service innovations such as disease man-
agement, however, even randomisation is unlikely to successfully control for the 
large number of factors and interactions on different levels that might influence 
outcomes.[36]  
Although results must be interpreted with caution, given the methodological 
limitations of uncontrolled research, the value of our proposed methods lies in 
the opportunity to analyse routine data from clinical practice in a manner that 
produces meaningful results for further development of disease management 
strategies. Rather than providing a single effect estimate across many patients, 
which offers little guidance on what works and for whom, multilevel regression 
models allow researchers to capitalise on existing heterogeneity in effects by 
conducting a more granular assessment of the impact of an intervention’s fea-
tures on the health outcomes of different patient groups. Our univariate analysis 
results demonstrate that a simple, unclustered comparison of Dutch disease 
management patients’ baseline and follow-up clinical measures would have led 
to the conclusion that the effects of the intervention are small at best. Yet our 
multilevel regression findings reveal that for patients with poor baseline clinical 
values, disease management was associated with significant and clinically rele-
vant health improvements after a median follow-up of 12 months. Although this 
might suggest regression to the mean, which is a common phenomenon in dis-
ease management research, this is to some extent refuted by the small percent-
age of patients (17% for HbA1c) in the healthiest disease categories whose clini-
cal values moved towards to the mean, despite the degenerative nature of diabe-
tes. A 2008 large-scale, practice-based disease management evaluation con-
ducted in Germany[4] as well as a recent meta-analysis of 41 RCTs[10] also 
found that disease management is most beneficial for poorly controlled diabetes 
patients, which – given that the vast majority of our patients had healthy base-
line values of most clinical parameters – provides a plausible explanation for the 
small average effects of the Dutch disease management strategy for type 2 dia-
betes on health outcomes. 
With regard to the effectiveness of different intervention features, the find-
ings from our covariate analyses suggest that particularly for patients with poor 
disease control, intensive monitoring of clinical values might be an important 
intervention feature that is associated with better health outcomes. Other stud-
ies of disease management for diabetes have shown a similar association be-
tween more intensive interventions and better glycaemic control.[10,37] The 
well-known population management model used by Kaiser Permanente divides 
patients with chronic conditions into three distinct groups based on their de-
gree of health care need: (1) supported self-management, for patients with a 
relatively low level of need for health care (65-80%); (2) disease management, 
for patients at increased risk because their condition is unstable (15-30%); and 
(3) case management, for highly complex patients requiring active management 
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by specialists (5%), such as type 1 diabetes patients in the Netherlands.[38,39] 
Further research is necessary to assess whether intensive disease management 
might indeed be redundant for the relatively healthy subgroup of diabetes pa-
tients and could be substituted by adequate self-management support pro-
grammes that integrate primary care and community services.[40] Future stud-
ies might also investigate the impact of passive intervention characteristics (i.e. 
setting features) on changes in patients’ health outcomes. While a separate, 
unreported analysis of four passive intervention characteristics in this research 
– that is, experimental status of the care groups (pilot vs. non-pilot), care group 
size, diabetes care bundle price, and level of collaboration with specialists – 
demonstrated no significance for the effects of disease management on any of 
the studied outcomes, other factors could be of more relevance.[5]  
Also in line with previous research, we found that longer length of follow-up 
was accompanied by less positive effects on clinical outcomes.[10,11] Although 
this seems counterintuitive, given that increased measurement frequency was 
accompanied by better results, there is no strict dose-response relationship in 
the Dutch disease management approach, which means that patients with a 
longer observation period were not necessarily seen more often than patients 
followed over a shorter time frame. A plausible explanation for the identified 
association between length of follow-up and clinical outcomes could be that the 
positive effects of education on patients’ self-management behaviour – and, 
consequently, their glycaemic control – are difficult to maintain over time, which 
means that effects measured after a short duration of care might be overesti-
mated.[41,42] 
Limitations 
Although our findings are confirmed by previous randomised research, there 
ultimately are limits in the level of confidence we can have in our results given 
the lack of an untreated comparison group and true baseline data. The trends in 
outcome measures presented here may have alternative explanations that can-
not be explored within the available data. A cautious approach would therefore 
be to treat these results as exploratory and look for further opportunities to 
confirm them in other settings, perhaps using historical benchmarking data 
derived from a comparable population (matched within strata) and corrected 
for secular trends. In particular the counter-intuitive association between length 
of follow-up and clinical outcomes might be explained by some unmeasured 
confounders, such as patients’ socioeconomic status or educational level, both of 
which are known to greatly influence individuals’ health behaviour.[43] Alterna-
tively, the lack of pre-intervention data may have introduced post-treatment 
bias, which leads to underestimation of intervention effects and could also to 
some extent explain results not lasting over time. Future research would benefit 
from analysing multiple repeated measurements over time, the opportunity for 
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which was limited in this study due to the relatively recent implementation of 
the studied disease management strategy in the Netherlands.  
Bias might also have been introduced by missing values, which were nu-
merous in the routine data provided by our 18 care groups and necessitated 
exclusion of 28 to 44% of patients across the four outcome-specific analyses. 
Nonetheless, our findings cover a relatively large population (approximately 
14% of known diabetes patients in the Netherlands in 2011[44]), which did not 
differ from other diabetes populations studied in the Netherlands in terms of 
average age and disease duration, nor was the percentage of smokers different 
from that in the overall Dutch population.[21,45,46] The prevalence of co-
occurring conditions, however, was considerably lower in our research group as 
compared to the total population of Dutch diabetes patients.[47] This observa-
tion might signify registration problems but could also indicate that patients 
with comorbidity are more likely to be treated by specialists than by primary 
care providers in the Netherlands.  
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Chapter 9 
General discussion 
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INTRODUCTION 
The aim of the research presented in this dissertation was to advance the sci-
ence underlying disease management evaluation and, in so doing, to strengthen 
existing evidence on the impact of complex, population-wide disease manage-
ment approaches implemented in actual health care settings in the Netherlands 
and abroad. This final chapter summarises the main findings from the individual 
studies, explores several methodological considerations for conducting ‘real-
world’ disease management evaluation, and discusses the strengths and limita-
tions of the applied study methods. Subsequently, the policy context in which 
findings should be viewed is explored. The chapter ends with recommendations 
for disease management policy, practice, and research.  
GENERAL CONCLUSIONS 
To ensure that the evaluations conducted in this research were based on ade-
quate knowledge of the intervention under study, the first part of the disserta-
tion (Chapters 2 through 4) provided an exploration of the concept disease 
management and reviewed existing evidence concerning its impact on the qual-
ity and outcomes of chronic care. In the second part (Chapters 5 through 8), we 
conducted realistic evaluations – using a mixture of quantitative and qualitative 
research methods – of the level of implementation and effects of (specific com-
ponents) of disease management approaches in actual health care settings in 
Europe, with a particular focus on the Netherlands.  
Exploring the concept and impact of disease management 
Disease management constitutes an important and widespread innovation in 
the care for chronically ill patients, which has been conceptualised in vastly 
different ways over the past twenty years.[1] Early definitions range from ‘dis-
crete programmes directed at reducing costs and improving outcomes for pa-
tients with particular conditions’[2] to ‘an approach to patient care that coordi-
nates medical resources for patients across the entire delivery system’.[3] More 
recently, the Care Continuum Alliance (CCA), formerly known as the Disease 
Management Association of America (DMAA), defined disease management as ‘a 
system of coordinated health care interventions and communications for popu-
lations with conditions in which patient self-care efforts are significant’.[4] This 
new conceptualisation explicitly adopts a broader view on chronic care, thus 
illustrating international efforts to move towards a more population-based ap-
proach to managing long-standing health problems, often based on the Chronic 
Care Model (CCM).[5] Where traditional disease management interventions 
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focus on improving the provision of care for specific conditions in distinct popu-
lations[6], the CCM targets comprehensive, interrelated changes in the behav-
iour of patients and providers (micro-level), the organisation of the care process 
(meso-level), and the design of the health system in which these elements come 
together (macro-level), which is viewed as part of a broader community.[5,7]  
In line with the new, more comprehensive definition of disease manage-
ment, the systematic review of the international literature presented in this 
dissertation focused explicitly on interventions comprising at least two of the 
four meso-level components of the CCM, which are self-management support, 
delivery system design, clinical information systems, and decision support.[5] 
The findings illustrated that disease management has been investigated exten-
sively over the past years: we were able to include 15 systematic reviews and 61 
empirical studies published between 1995 and 2011 concerning multicompo-
nent interventions for adult patients with type 2 diabetes. Interventions con-
cerned mostly small-scale pilot programmes, which differed considerably in 
terms of both the combination and operationalisation of care components, al-
though strategies integrating all CCM elements were generally found to be the 
least common. This suggests that the CCM, which is inherently a disruptive 
health system innovation, is being implemented into health care practice in an 
incremental manner, which limits its potential for success in improving the 
quality and outcomes of chronic care. 
Variation in the scope and content of chronic care programmes was also vis-
ible when comparing nationwide approaches implemented in Austria, Germany, 
and the Netherlands, which thus far tend to be fully disease-specific, although 
some pilot programmes are being conducted locally that address a wider spec-
trum of both disease-specific and generic health needs. While the main goal of 
introducing disease management in these three countries was to strengthen the 
coordination of care services, the strategies used to achieve this varied signifi-
cantly, reflecting differences in the regulation, funding, and organisation of na-
tional health systems. For example, while in the Netherlands the introduction of 
disease management triggered considerable organisational reform in primary 
care, traditional structures were maintained in Austria and Germany. Differ-
ences between countries were also found with regard to the involvement of 
non-medical staff in disease management, approaches to incentivise implemen-
tation, and the level of participation by patients and providers.  
By analysing the Dutch approach to disease management from the patient’s 
perspective, we found that while this care strategy targets the ‘right’ areas for 
improvement – that is, those areas were Dutch persons with long-standing 
health problems report experiencing gaps in quality – further effort is needed to 
support the implementation of essential reform elements in practice. Notwith-
standing differences between regions, thus far improving the coordination and 
evidence-based standardisation of care for non-complex cases of chronic dis-
ease appears to have been the main priority in the Netherlands; more work is 
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needed to develop adequate clinical information systems, increase patient par-
ticipation, and reduce fragmentation in the care continuum for complex and 
multimorbid chronically ill patients. The latter two objectives are arguably more 
difficult to realise than what has been accomplished so far, as they require a 
fundamental culture shift in health care from a supply- to a demand-driven en-
vironment.[8]  
With regard to disease management impact, prior evaluations of the ap-
proaches implemented in Austria, Germany, and the Netherlands show mixed 
(preliminary) results. Findings point towards improved quality of care, mainly 
in terms of coordination and evidence-based practice, yet fail to provide conclu-
sive evidence of improved health outcomes and/or reduced costs.[9-11] Our 
systematic review demonstrated generally positive results of international dis-
ease management strategies for type 2 diabetes mellitus on care processes and 
clinical outcomes, yet identified considerable heterogeneity in effects across 
empirical trials, which was partially explained by differences in the number of 
care components that constitute a given disease management intervention. Con-
form the presumption of the CCM that changes are needed in multiple areas in 
order to considerably improve the quality of chronic care[12], comprehensive 
interventions – which were found to be least common internationally – attained 
the strongest effect estimates. Variation in length of follow-up also to some ex-
tent explained heterogeneity in effects on care processes and intermediate 
health outcomes: compared to studies of longer duration, trials with limited 
follow-up (<1 year) reported more promising, though perhaps overestimated, 
results. This pleads for evaluations focusing on a broader range of performance 
measures, including both short-term outcomes (e.g. patient-reported health 
measures, quality of life) and long-term outcomes (e.g. prevalence of micro- and 
macrovascular complications, mortality), which should be measured across 
sufficiently long observation periods in order to distinguish the sustained effects 
of disease management from mere temporal influences.[13]  
Advancing disease management science and evidence 
This research illustrated how routine health care data can be used to conduct 
rigorous and meaningful evaluations of the ‘real-world’ impact of disease man-
agement approaches implemented in actual health care settings in Europe. 
Across six country studies, which were conducted in Austria, Denmark, France, 
Germany, the Netherlands and Spain, a wide range of sophisticated quasi-
experimental and observational analytic methods were tested and validated on 
available data from existing disease management approaches. By explicitly tak-
ing into account relevant data problems and potential sources of bias and con-
founding in disease management research, these methods produced sufficiently 
valid findings to support further quality efforts in chronic care practice, al-
though results must be interpreted with caution in light of these limitations.  
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Specific evaluation methods were selected based on the nature and content of 
the disease management interventions under study. Thus, to assess the impact 
of the Dutch approach to disease management for type 2 diabetes mellitus – 
which can be characterised as a heterogeneous, multicomponent, population-
wide intervention – we used multilevel regression methods to identify trends in 
health outcomes as a function of features of the approach and/or patient popu-
lation. Most notably, findings suggested that: (1) patients with poorly controlled 
type 2 diabetes mellitus benefit most from disease management in terms of 
improved clinical outcomes; (2) a greater measurement frequency of clinical 
outcomes is associated with better results, particularly for patients with poor 
disease control; and (3) longer length of follow-up is accompanied by less posi-
tive effects. Although there are limits to the level of confidence that we can have 
in these findings, given the lack of an untreated comparison group and true 
baseline data, the identified trends in health outcomes were supported by 
(meta-analyses of) previous randomised research.[14-16] Moreover, a growing 
consensus that certain subpopulations of chronically ill patients offer greater 
opportunities for improving care quality and outcomes, including costs, can be 
recognised in the increased interest in prospective patient identification meth-
ods for chronic care management programmes.[17]  
Based on a qualitative review of approaches in 13 countries, we found that 
self-management support – which is arguably the central but also most difficult 
to implement component of high-quality chronic care management – remains 
relatively underdeveloped in Europe, which supports our review-based obser-
vation that the implementation of the CCM in practice is incremental and far 
from complete. Self-management support activities were found to focus mainly 
on proper medication use and health-related behaviours, with limited attention 
to patients’ emotional management. Across Europe, support services are offered 
mainly in primary care by nurses; differences prevail in the mode and format of 
support, and materials used. Our interviews with Dutch care providers sug-
gested that barriers related to, amongst others, funding, information technology 
and medical culture hamper the integration of self-management support in daily 
chronic care practice.  
METHODOLOGICAL CONSIDERATIONS 
This section will address the most important methodological considerations for 
practice-based disease management evaluation, based on experience of work 
undertaken in this dissertation. Additionally, the strengths and weaknesses of 
the methods used are discussed, and potential sources of bias in the research 
findings are explored. 
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Selecting a study design for disease management evaluation 
Given the need to improve quality of care and the limited resources available for 
health care provision, rigorous evaluations and sound evidence are crucial pre-
requisites for adequate decision-making on how to best care for the growing 
group of chronically ill patients.[18] Here, from a methodological viewpoint, it is 
important to distinguish between efficacy and effectiveness: whereas the former 
concept refers to the impact of an intervention under ideal circumstances, the 
latter denotes results under normal conditions in practice settings.[19] In the 
case of complex, population-wide health service interventions, such as disease 
management, which comprise multiple, interrelated care components, demon-
strating effectiveness is inherently difficult. Design choice is influenced by inevi-
table trade-offs between scientific rigour and practical feasibility, and these 
determine the extent to which causal inferences can be derived about the impact 
of a given intervention on relevant performance measures.[20]  
Our research has demonstrated how in practice situations where randomi-
sation is not possible and/or desirable, due to the complex nature and wide-
spread implementation of a given disease management strategy, quasi-
experimental and observational study designs can be used to produce robust 
findings about intervention impact in daily health care practice. The most suit-
able approach in such a situation is to utilise a pre-post design with a control 
group matched for known differences.[21] The DISMEVAL country studies in, 
for example, Denmark, Germany and France showed that matched control 
groups can be constructed retrospectively on the basis of routine health care 
data using advanced analytic techniques, such as propensity score matching or 
calibration.  
In cases such as the Netherlands, where sufficient numbers of control pa-
tients are no longer available and data collection is tied to the intervention, an 
uncontrolled pre-post design is the most robust research design possible for 
realistic evaluation.[20] While using such a design did not allow us to draw 
causal inferences, it provided opportunities to identify trends in the health out-
comes of patients who receive disease management in the natural environment 
of health care. Notwithstanding the obvious methodological limitations of un-
controlled research, we argue that practice-based studies must constitute a 
crucial part of disease management evaluation; randomised controlled research 
is rightly regarded as the ‘gold standard’ in clinical decision-making but is never 
sufficient in itself when the aim is to assess the effectiveness of interventions 
with long, complex causal pathways that in reality can be affected by numerous 
characteristics of care processes, patients, and settings.[22] In such cases, ran-
domised controlled trials (RCTs) can only determine efficacy and should be 
combined with realistic evaluations to produce meaningful findings concerning 
the effectiveness of disease management in actual health care settings.  
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Multilevel regression methods 
Using both quantitative and qualitative study methods, we found that disease 
management is associated with vast amounts of heterogeneity, a conclusion that 
has also been drawn in previous studies and that has hampered synthesis of 
effect estimates in meta-analyses.[23] Interventions differ in terms of the com-
bination and nature of care components offered, patients vary in demographics, 
disease severity, and socioeconomic status, amongst others, and care is pro-
vided in unlike contexts influenced by diverse regulations, funding mechanisms, 
and organisational cultures. Given this heterogeneity, evaluations focused on 
assessing ‘grand mean’ effects of disease management across large populations 
of patients produce unacceptably artificial results, which offer little guidance for 
day-to-day clinical practice where individual patients are treated.  
To allow for a more granular assessment of the impact of the Dutch ap-
proach to disease management, we used multilevel regression methods, which 
enabled us to investigate trends in patients’ health outcomes as a function of 
features of the intervention and/or target population. Using multivariable, two-
level hierarchical regression models – with patients at level one and care groups 
at level two – we analysed the associations between health outcomes and a con-
siderable number of covariates. Contrary to our a priori assumptions, variance 
in the effects of disease management on the care group level was virtually non-
existent, while our interviews with health professionals suggested that some 
groups are considerably further than others in facilitating high-quality care 
provision through implementation of, for example, clinical information systems 
and adequate decision support. That no more than minor variation was identi-
fied in results between care groups might be due to the relatively limited sample 
size on this aggregate level (N=18). An alternative explanation could be that the 
effects of health system change on care processes and, ultimately, on outcomes 
require time to come about and our study was, in this sense, preliminary. It has 
been suggested that three to five years are needed for a given intervention to be 
fully implemented and for any individual level effect to become evident.[24,25] 
On the patient level, vast amounts of heterogeneity were identified in the ef-
fects of the Dutch approach to type 2 diabetes management on health outcomes. 
Variation in intervention features, such as the frequency of clinical outcome 
measurements, could elucidate some of the existing variance in effects, yet the 
most explanatory covariates were those related to patients. Previous studies 
have confirmed this finding, which we believe stresses the need to tailor disease 
management provision to the needs and characteristics of relevant subgroups of 
patients.[14,23] Besides the level of diabetes control, which we found to be sig-
nificantly associated with clinical outcomes, other relevant patient features 
might be socioeconomic status and education level, given their influence on 
people’s self-management behaviour, which in turn is a powerful determinant of 
their health.[26]  
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Routine data and performance measures 
The choice to retrospectively gather routine health care data for a ‘real-world’ 
evaluation of the Dutch disease management approach has several methodo-
logical consequences. Besides the obvious advantages – which include the op-
portunity to collect large numbers, assess relatively long-term effects within a 
narrow time frame, capture information on daily practice of health care provi-
sion and registration, and minimise the financial costs of data collection[27,28] 
– an important limitation is that the performance measures available to us in-
herently constituted an ‘opportunity sample’, the composition of which was 
determined mainly by the data sources used. The 18 Dutch care groups included 
in this research were able to provide data concerning intermediate clinical out-
comes and, to a lesser extent, care processes. Patient-centered performance 
measures, such as quality of life, patient satisfaction, and patient-reported 
health outcomes, were not systematically assessed in most care groups nor did 
current data collection efforts – which are guided predominantly by regulations 
set by external agents, such as health care insurers and governmental agencies – 
support efforts towards population management based on patients’ degree of 
health care need.[29] In general, what appeared to be lacking in routine chronic 
care practice in the Netherlands is a systems approach to service delivery and 
assessment, based firmly on continuous efforts to learn about and improve the 
influence of health care structures on the provision of recommended care proc-
esses, which subsequently affect the health, functional and social status of dif-
ferent patient groups, and, ultimately, the costs of care provision.  
Besides offering a narrow view on quality of care, retrospectively collected 
routine data from clinical practice are innately less valid and reliable than data 
gathered prospectively and explicitly for research.[27] This is particularly true 
in the context of Dutch chronic care, where clinical information systems are 
used for multiple purposes, amongst which internal and external performance 
monitoring and provider reimbursement by health insurers. We subjected 
available data to systematic scrutiny to assess the magnitude and implications of 
missing and invalid values for the analysis and interpretation of findings. A lack 
of completeness was the major issue in the Dutch datasets; invalid outlier values 
were comparatively less prevalent. Across our 18 care groups, no more than two 
were able to provide data concerning the full spectrum of evaluated indicators. 
Within the data that could be provided, a considerable number of patients 
lacked (valid) registrations of one or more of the included variables. Alongside 
shortcomings in the quality of supporting information technology, an important 
reason for the observed lack of completeness of data available for our evaluation 
might be the relative inexperience of care groups in operating shared clinical 
information systems.  
The fact that only a small set of analyses could be conducted on the basis of 
data from all groups and all patients likely introduced bias. While it is difficult to 
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assess the size of this bias, the research population did not differ systematically 
from other diabetes populations studied in the Netherlands on important vari-
ables, such as average age and disease duration, nor was the percentage of 
smokers different from that in the overall Dutch population.[11,30,31] However, 
the prevalence of four important co-occurring conditions associated with diabe-
tes – that is, angina pectoris, stroke, myocardial infarction, and transient 
ischemic attack – was lower in our patient sample than would have been ex-
pected based on the characteristics of the total population of Dutch diabetes 
patients.[32] This might be attributable to registration problems but could also 
reflect the generic nature of the Dutch primary care-based disease management 
approach, in which complicated cases are managed primarily by medical spe-
cialists. 
Length of observation 
Another important consideration in evaluating disease management approaches 
relates to the timeframe for observation, which should be aligned with the goals 
of performance assessment.[21] Our systematic review illustrated that there is a 
tendency for studies of individual disease management strategies to be con-
ducted over a period of 12 months or less. If the goal of evaluation is to deter-
mine the level of implementation of recommended care processes, then such a 
relatively short time frame might be sufficient.[1] However, if an evaluation 
aims to assess the impact of a specific approach on, for example, patients’ health 
outcomes, then there is a strong need to allow for longer length of follow-up 
(>12 months). This is important for at least two reasons. First, when measuring 
the impact of disease management on intermediate health outcomes – which is 
the primary goal of most evaluations – then a sufficient length of follow-up is 
needed to distinguish temporal influences from sustainable effects.[24,33] Our 
research demonstrated that short term evaluations (<12 months) might overes-
timate effects on measures related to disease control, perhaps because the im-
provements in individuals’ health behaviour that are necessary for adequate 
control are difficult to maintain over time.[34,35]  
Second, sufficient length of follow-up is necessary to assess whether im-
provements in intermediate health outcomes, such as glycated haemoglobin 
(HbA1c) and systolic blood pressure (SBP), actually result in achievement of the 
long-term oriented goals of disease management, which include improving func-
tional status, preventing complications, and, ultimately, reducing direct health 
care costs. Such ‘hard’ outcomes require time to come about, as illustrated by 
the German country study in DISMEVAL as well as by an unrelated Danish 
trial[36], both of which could not demonstrate effects on the prevalence of vari-
ous types of diabetes-related complications within a time frame of three and six 
years respectively. The ten-year post-trial data from the landmark United King-
dom Prospective Diabetes Study (UKPDS) did establish that intensive glucose 
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therapy results in persistent risk reductions for microvascular disease, myocar-
dial infarction, and all-cause mortality.[37] As chronic disease progression can 
involve the development of such serious long-term complications, it is critical to 
demonstrate whether disease management initiatives have lasting effects, which 
can only be evidenced by a longer period of evaluation.[38] A study duration of 
more than 12 months will also be important for assessing economic impact, 
since disease management may actually increase costs in the short term for 
some chronic diseases as a result of the investment required to implement such 
an intervention in the first place.[25] This will be especially true for evaluations 
in the area of diabetes, which has been a priority illness throughout the world 
when it comes to quality improvement efforts in health care.[39]  
Mixed methods 
Given that the implementation of disease management approaches is essentially 
a process of social change, which appears far from complete in most countries, 
simply measuring changes over time in relevant outcome measures cannot gen-
erate sufficient understanding to support decision-making in this area. Pawson 
and Tilley[40], the developers of realistic evaluation, and more recently Ber-
wick[41], have argued that the outcomes of complex interventions are depend-
ent not only on the introduction of appropriate mechanisms but also on whether 
existing contextual factors are fitting. A similar premise can be recognised in 
Donabedian’s work on quality assurance in health care, who proposes that out-
comes are produced by processes, which in turn are determined by struc-
tures.[42] Hence, there is a need for evaluations to move beyond the question of 
whether a specific disease management strategy ‘works’ towards establishing 
the conditions under which specific care processes are effective for particular 
populations of patients in different health care contexts.  
Realistic evaluation requires the use of a mixed-methods approach – that is, 
a mixture of quantitative and qualitative study techniques – to allow numerical 
data concerning the processes and outcomes of disease management to be com-
bined with qualitative information on contexts.[43] This dissertation combined 
quantitative data analyses with the use of diverse qualitative methods, specifi-
cally a document study (Chapter 2), an expert data template (Chapters 4 and 6), 
and semi-structured interviews (Chapter 6), to be able to assess not only the 
effects of different care processes on the clinical outcomes of (subgroups of) 
chronically ill patients but combine this with knowledge concerning the context 
and level of implementation of the Dutch approach to disease management for 
type 2 diabetes. Based on the additional insights gained from using a mixed-
methods research design, we will be able to, at the end of this chapter, formulate 
detailed recommendations for policy and practice concerning which further 
efforts are needed to create the health care structure and process requirements 
necessary to adequately manage chronically conditions.  
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To limit the potential for bias in the qualitative research findings, purposive 
samples of respondents were selected both for the expert data template con-
cerning chronic care management approaches in Europe and for the interviews 
with health care professionals in the Netherlands. Furthermore, the data tem-
plate was completed according to an evidence-based comprehensive approach, 
with inputs based on available scientific and grey literature including govern-
ment reports, policy statements, theses and dissertations, and research reports. 
The questionnaire for and analysis of the interviews with Dutch health care 
professionals involved in disease management for type 2 diabetes was also 
structured according to a validated instrument – that is, the CCM-related Assess-
ing Chronic Illness Care (ACIC) survey[44] – so as to minimise the potential for 
subjective findings.  
Validity and reliability of findings 
According to Linden and Adams[45], selection bias and regression to the mean 
are the major sources of bias that can cloud the interpretation of disease man-
agement outcomes when using uncontrolled, pre-post evaluation techniques. 
Selection bias ensues when a sample does not accurately reflect the population 
from which it was drawn, which can lead to distorted research findings.[45] In 
the evaluation of the Dutch approach to disease management, selection bias 
occurred on the care group level, given that one of the main, pragmatic inclusion 
criteria for participation in the research was the availability of a digitalised da-
taset describing the processes and outcomes of diabetes care over a period of at 
least 20 months between January 2008 and December 2010. Hence, the care 
groups evaluated here represent what may be viewed as a convenience sample 
of ‘early adopters’ of disease management in the Netherlands.[46] A potential 
consequence could be that our qualitative findings concerning the level of im-
plementation of disease management in the Dutch context, which suggest that 
patient-centered care is far from achieved, might to some extent even be exag-
gerative of the actual situation in the Netherlands. Although selection bias on 
the care group level may also have affected the quantitative findings concerning 
disease management effects, it is important to note that the patient sample 
drawn from the 18 groups, which represents approximately 10 percent of the 
total number of known type 2 diabetes patients in the Netherlands in 2012, did 
not differ significantly from other/larger populations on the majority of patient 
characteristics measured.[11,30,31] Moreover, the multilevel regression analy-
sis identified nearly nil variation in patient outcomes existing on the care group 
level, despite there being differences between included groups in terms of the 
level of implementation of recommended care elements.  
Regression to the mean is comparatively more likely to have influenced our 
quantitative research findings, especially given the lack of ‘true’ baseline data 
concerning the period prior to disease management implementation. Regression 
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to the mean is a statistical phenomenon that can lead researchers to mistakenly 
interpret change in specific measures over time as an effect of disease manage-
ment, while it is actually natural variation.[45] Linden and Adams[13] have 
demonstrated that, without the effect of a disease management intervention, 
patients with high health care utilisation in the baseline year tend to use fewer 
services in the following year, and vice versa. Regression to the mean is a ubiq-
uitous phenomenon in uncontrolled pre-post data and, as such, should always 
be considered as a possible cause of observed changes in outcome meas-
ures.[47] Our finding that poorly controlled diabetes patients achieved the 
strongest improvements in clinical outcomes after a median 12 months of (in-
tensive) disease management might to some extent be a result of regression to 
the mean, although this is at least partially refuted by the small percentage of 
patients (17 percent for HbA1c) in the healthiest disease categories whose clini-
cal values moved towards the mean, even despite the degenerative nature of 
type 2 diabetes.  
Despite concerted efforts to create detailed and valid datasets, the use of 
advanced research methods, and adjustment for a relatively wide range of po-
tential confounders, there ultimately are limits to the level of reliability one can 
attach to the findings from uncontrolled pre-post research. Hence, it is impor-
tant to stress that our results are supported by those of previously conducted 
(randomised) controlled trials. A recently conducted meta-analysis of 41 RCTs 
of disease management interventions for type 2 diabetes confirms our identified 
trend in health outcomes suggesting that intensive management is most benefi-
cial for patients with poor diabetes control.[14] The counterintuitive association 
found between length of follow-up and clinical outcomes has also be demon-
strated in previous systematic reviews of the disease management literature, 
including the review presented in Chapter 3 of this dissertation.[14,16]  
EXAMINING THE CONTEXT FOR RESEARCH IMPLICATIONS 
With health care expenditures rising to unprecedented levels, achieving more 
effective and efficient care provision for the growing population of chronically ill 
is high on the policy agenda in the Netherlands. Over the past five years, an im-
pressive body of grey literature has been published on developments in chronic 
care management by Dutch research institutes, governmental agencies, health 
insurers, professional groups, expert committees, and patient associations.[48] 
Without any pretence of being exhaustive, we believe it is important to summa-
rise some of the key points in the ongoing debate on how best to redesign the 
care for chronic conditions in the Netherlands, as these constitute the back-
ground against which the implications of this dissertation for future directions 
in Dutch chronic care policy and practice should be viewed.  
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Scans of the current health care landscape in the Netherlands, which were con-
ducted by the National Institute for Public Health and the Environment (RIVM) 
in 2010 and 2011, show that the implementation of bundled payments for ge-
neric disease management has triggered important improvements in the organi-
sation of Dutch chronic care.[49,50] Within a relatively short time frame, a na-
tionwide network of ambulatory care groups has been realised which have bun-
dled payment contracts with health insurers for the provision of integrated care 
for type 2 diabetes and, to a lesser extent, COPD and vascular risks. Notwith-
standing the importance of this development, there are inherent limitations and 
drawbacks to the current chronic care strategy in the Netherlands. Services are 
still provided in a predominantly disease-specific and supply-driven manner 
rather than on the basis of patient needs, as illustrated by the Health Care In-
spectorate’s (IGZ) observation that current type 2 diabetes management does 
not (yet) meet the level of patient-centeredness described in the care stan-
dard.[51] Moreover, regional differences aside, integration is generally limited 
to the non-complex services offered in primary care, which does not only com-
plicate the coordination of care across sectors for the growing group of complex, 
multimorbid elderly patients but also fails to recognise the opportunities that 
cooperation with the broader community offers for health promotion and pre-
vention, and self-management support.[52,53]  
While conform international evidence[29], the primary care sector is right-
fully considered the lead actor in Dutch chronic care, the general trend that can 
be recognised in contemporary policy recommendations is that service integra-
tion must reach beyond its boundaries to account for health needs that are bet-
ter met in either the community or the secondary care sector. Thus, the Council 
for Public Health and Care (RVZ; [54]) and, more recently the NYFER Forum for 
Economic Research[52], proposed that the reigning health care paradigm in the 
Netherlands must shift from ‘illness and treatment’ towards ‘health and behav-
iour’, which requires: (1) a central role for patients in their social environment 
rather than for diseases; (2) a focus on health and quality of life, and the im-
provement thereof; (3) adequate coordination between care consumers, pro-
viders, and organisations; and (4) integration of prevention and health care 
provision. Similarly, the Committee on the Evaluation of Bundled Payment, 
which was assigned by the Dutch Ministry of Health, Welfare and Sports to 
monitor the implementation and effects of the bundled payment system, con-
cluded that the current, disease-oriented payment method should be considered 
a ‘work in progress’ that needs to be developed further into a system that facili-
tates population health management based on individuals’ degree of need.[53] 
This supposition was shared by the Advisory Group Integrated Care of the Dutch 
Society for General Practitioners (LHV). An exploration by the Dutch Health Care 
Authority (NZa; [55]) of the possible effects of different funding mechanisms for 
integrated care demonstrated the feasibility of population-based chronic care 
funding, which will be piloted in several regions in the Netherlands in 2013. 
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RECOMMENDATIONS 
This final paragraph explores the implications of the dissertation for future di-
rections in chronic care policy making, practice, and research. In so doing, the 
Expanded Chronic Care Model (ECCM; [56]) is used as a framework to structure 
recommendations. This model, which is depicted in Figure 1, expands the scope 
and depth of the community resources and policy-linkage components of the 
original CCM so as to incorporate aspects related to health promotion and pre-
vention.[56]  
Recommendations for policy and practice 
Most notably, our research findings concerning the ´real-world’ impact of the 
Dutch approach to structured disease management for type 2 diabetes suggest 
that improving the quality and outcomes of chronic care for the entire popula-
tion of patients in the Netherlands will require a move from disease-oriented, 
standardised service delivery to more patient-centered, tailored care provision, 
including self-management support. By demonstrating that the current pro-
grammatic care strategy is beneficial mainly for a subgroup of non-complicated 
diabetes patients with poor disease control, the research provides quantitative 
data supporting recent policy recommendations to implement a more compre-
hensive population health management model, that takes into account the het-
erogeneous nature of the chronically ill and their, often multicomplex, health 
care demands.  
 
 
Figure 1: The Expanded Chronic Care Model [56] 
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Internationally as well, the importance of more tailored chronic care provision 
has been emphasised by systematic literature research and has spurred efforts 
to distinguish patient groups based on their degree of health care need. The 
well-known Kaiser Permanente population health management model, which is 
based on the CCM, divides chronically ill into: (1) patients with a relatively low 
level of need for health care (65-80%); (2) patients at increased risk because 
their condition is unstable (15-30%); and (3) highly complex patients 
(5%).[57,58] In line with the recommendations for targeted care strategies that 
follow from the Kaiser Permanente risk stratification pyramid, the latter cate-
gory of patients, that is, those with complex forms of chronic disease[57], are 
actively managed by specialists in the Dutch health system. However, no distinc-
tion is made in the Netherlands between the first two categories of patients, 
who – based on the national care standard for type 2 diabetes management – 
currently receive an equal and highly standardised intensity of service provision 
in the primary care sector, regardless of their actual level of need. Based on this 
dissertation, we recommend that the existing, standard-driven Dutch disease 
management approach should be refocused from targeting the entire population 
of non-complex cases of type 2 diabetes towards actively pursuing only those 
patients at risk for deterioration. That is, those belonging in the second category 
of health needs defined by Kaiser Permanente, for whom the effectiveness of 
structured disease management was demonstrated in this practice-based 
evaluation as well as by previous randomised research.[14]  
For patients with a relatively low level of health care need, our findings sug-
gest that intensive disease management might be redundant. The benefit that 
these patients have from receiving programmatic, provider-driven care is lim-
ited to maintaining disease control, which studies have demonstrated could be 
achieved in an equally effective and probably considerably more efficient man-
ner by adequate self-management support programmes that integrate primary 
care and community services.[59,60] If our research population is indeed an 
adequate reflection of the total Dutch (diabetes) population – which it appears 
to be in terms of average age, disease duration, clinical values, and smoking 
status – then restructuring health service provision according to patients’ de-
gree of need has the potential to significantly relieve the increasing pressure 
that chronic conditions place on the human and economic resources available to 
Dutch health care, since the vast majority of type 2 diabetes patients in the 
Netherlands will fall into the self-management support category.  
However, considerable improvements will be necessary in the level of self-
management support currently offered to chronically ill patients in the Nether-
lands – and across Europe more in general – in order to provide them with the 
information, (technological) tools, and confidence needed to adequately manage 
their health. Notwithstanding promising local initiatives to support chronically 
ill patients’ self-management, for example by means of web-based education 
programmes[61] and motivational interviewing techniques[62], chronic care 
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provision generally remains largely supply-driven and based on paternalistic 
viewpoints concerning what is best for patients, rather than on productive in-
teractions with actively involved patients aimed at creating solutions that fit 
their personal needs and circumstances. Explicit policymaking in the area of 
self-management support seems to be necessary to ensure not only that succes-
ful bottom-up innovations in this area are disseminated nationwide, but also to 
stimulate a more basic culture shift in health care from the supply-driven ‘ill-
ness and treatment’-paradigm, as formulated by the Dutch Council for Public 
Health and Care (RVZ; [54]), towards a patient-centered ‘health and behaviour’-
model. While this research focused on self-management support offered follow-
ing the diagnosis of chronic disease, the aim of which is to avoid or at least post-
pone further deterioration, it is important to emphasise that more attention to 
population-wide prevention, which is a vital element of the Kaiser Permanente 
pyramid[57], will be crucial to curb the growing epidemic of lifestyle-related, 
long-standing health problems in the Netherlands. Recent developments in this 
area – such as the introduction of the so-called ‘prevention consultation’, which 
aims to detect patients at risk for developing cardiometabolic disorders early 
and discuss their lifestyle behaviours[63] – should be viewed as promising, in 
the sense that they illustrate an increasing appreciation of the social determi-
nants of health. However, the true challenge for the Dutch health system lies in 
acknowledging the modest role it plays in determining the health status of the 
population and recognising the potential for reducing chronic disease preva-
lence that can be achieved by active cooperation with community-based health 
services.[56]  
Developing a chronic care management approach in which patients truly 
play a central role, with service delivery based on their degree of health care 
need, will require a supportive health system environment, for which we can 
formulate several recommendations based on this dissertation. First, the exist-
ing bundled payment system, which integrates almost exclusively the services 
for specific chronic conditions that can be delivered in primary care, will need to 
be reconfigured so as to stimulate cooperation and coordination across the en-
tire spectrum of care and support available to the chronically ill. This will be 
especially important to increase the quality and safety of care for the growing 
group of multimorbid elderly patients, who are at risk for adverse events due to 
existing fragmentation of care across different conditions as well as between 
primary and secondary care settings.[64] However, by, for example, incentivis-
ing collaboration between ambulatory care groups and community-based health 
services, such as tobacco use prevention and smoking cessation programmes, 
population-based chronic care funding could also be a vital means to achieving 
more adequate self-management support for those with a low level of health 
care need.[56] Second, current performance indicators, which are stipulated 
mainly by health insurers and prescribe, amongst others, the number of check-
ups that should be conducted per patient per year, are at odds with a system of 
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health care delivery that centralises patients in their social environment. Not-
withstanding the significance of standardising care according to evidence-based 
guidelines, there must be room for deviations from protocol there where either 
characteristics of patients or their social context necessitate tailored, effective 
solutions.  
Third, the ubiquitous nature of missing values in the datasets provided by 
care groups participating in this research implies that improvements are neces-
sary in data registration. While lacking and invalid data can be attributed in part 
to deficiencies in existing clinical information systems, which need to be devel-
oped further in order to meet the information needs of health care profession-
als, there also appears to be a general inexperience in and perhaps even adver-
sity towards comprehensive data registration in health care, which is often con-
sidered an administrative burden rather than a vital aspect of high-quality 
chronic care provision. A combination of stronger reinforcement policies and 
bottom-up efforts by health professionals to develop a meaningful set of quality 
and outcome indicators for chronic care evaluation is needed to stimulate more 
adequate data registration, which facilitates not only population health man-
agement based on accurate patient information, but is also a vital prerequisite 
for multidisciplinary cooperation across the considerable number of different 
health care disciplines and settings involved in patient-centered chronic care 
management.[27] Here, an important starting point might be to increase the 
level of attention payed to health care quality assurance and improvement mod-
els, including the value of data management, in the education of medical profes-
sionals.  
In conclusion, the findings from this dissertation imply that creating a bal-
ance between standardisation and individualisation in chronic care provision, 
including self-management support, is a complicated yet crucial next step in the 
process of improving the quality and outcomes of care for people with long-
standing health problems. What is needed is a systems approach to comprehen-
sive chronic care redesign, which, based on available evidence concerning ‘what 
works best for whom and under which circumstances’, actively seeks to create 
the structures that facilitate high-quality, patient-centered health management 
for the entire population of chronically ill. This must be combined with in-
creased attention for health promotion and prevention of chronic conditions, so 
as to enable not only improvements in population health and functional status, 
but also reduce or at least control the rising level of health care expenditures 
associated with chronic disease.  
Recommendations for future research 
Based on this dissertation, several recommendations can also be formulated for 
future research in the area of chronic care management. While we acknowledge 
that the RCT is the most robust approach to clinical evaluation, gaining insight 
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into the effects of complex, multicomponent care strategies, such as disease 
management, in their natural environment will require moving beyond the cur-
rent undue reliance on randomisation.[19,66] What is needed is a comprehen-
sive approach to realistic, practice-based evaluation that aims to bridge the gap 
between the scientific rigour of experimental designs and the operational feasi-
bility of observational research, and that is based on adequate knowledge of the 
(interrelated) components that constitute a given intervention, the contextual 
factors influencing success, and the characteristics of the population targeted. 
Such an approach necessitates the use of mixed-methods research, in which 
quantitative data concerning patients, treatments, and outcomes are combined 
with qualitative information on contexts.[40,41]  
Where possible, practice-based evaluations of disease management effec-
tiveness should be conducted in a controlled fashion, using advanced matching 
techniques such as propensity score matching or calibration[1], so as to mini-
mise the influence of potential confounding factors on studied outcomes. While 
such an approach cannot control for the possible impact of unobserved external 
factors on measured effects, it has been proposed that even randomisation is 
unlikely to successfully control for the large number of factors and interactions 
on different levels that might influence the outcomes of complex health service 
innovations, such as disease management.[22] Hence, it will be important for 
any evaluation, regardless of study design, to understand and explore in detail 
the nature and sources of potential bias in disease management effects, as well 
as to conduct sensitivity analysis as a means to assess the level of ‘hidden bias’ 
caused by unobserved differences in the populations under study.[1] When 
evaluation data are retrieved retrospectively from routine practice, systematic 
cleaning and validation of performance measures constitutes a crucial first step 
towards producing robust findings concerning the impact of disease manage-
ment in the actual context of health care.  
This research introduced multilevel regression methods as useful tech-
niques for meaningful analysis of patient data in practice-based disease man-
agement evaluation. Most studies of chronic care strategies, whether RCTs or 
observational studies, focus on measuring a single treatment effect across many 
patients, which offers little guidance for the day-to-day practice of chronic care 
provision, where heterogeneity is highly prevalent and an important determi-
nant of treatment success. Multilevel regression techniques allow researchers to 
capitalise on existing variation in chronic care: by enabling differences in out-
comes to be identified as a function of features of the intervention and/or pa-
tient population, these methods can provide detailed support to those involved 
in creating effective and efficient disease management strategies. In future prac-
tice-based research, the characteristics to be investigated as potentially relevant 
for the impact of disease management should go beyond those included in our 
study. Particularly, we recommend that more research is conducted into the 
influence of sociodemographic patient features, such as level of education and 
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socioeconomic status, on the potential for success of different approaches to 
disease management, so as to inform efforts to tailor the intensity of care deliv-
ery to patients’ self-management capabilities.  
The spectrum of outcomes used in disease management evaluation should 
be broadened as well, from focusing primarily on intermediate health outcomes 
related to disease control towards a comprehensive sample of performance 
measures that match the system-level goals of this care strategy. This implies 
that variables should be analysed related to care structures and quality (e.g. the 
degree of recommended care), patient-centeredness (e.g. quality of life, patient 
satisfaction), health and functional status (e.g. disease control, morbidity, mor-
tality), and health care utilisation and costs. In assessing the effects of disease 
management on such an inclusive array of performance measures, this research 
demonstrated that adequate length of observation is crucial. Achieving better 
quality and outcomes of chronic care, including costs, is a complex process that 
implies interrelated changes on multiple levels of the health system and broader 
community, in the culture of health service delivery, and the level of participa-
tion and self-care behaviour of patients. Evaluations must acknowledge this 
complexity by allowing sufficient time for intended effects to come about. While 
it is not known what period is ‘optimal’ to ensure measurement of sustainable 
effects[18], our findings suggest that studies with a length of follow-up of less 
than 12 months likely yield overestimated findings.  
To conclude, there is as much need for diversification in the evaluation of 
disease management as there is in the application of the care concept itself, in 
order to produce a robust and meaningful body of evidence supporting effective 
improvements in the structures, processes, and outcomes of care for the chroni-
cally ill. Rigorous randomised controlled studies are useful to determine the 
efficacy of specific approaches, but must be complemented by robust practice-
based evaluations demonstrating effectiveness in actual health care settings. 
Although the usefulness of specific methods will depend largely on the context 
of evaluation, ultimately what is needed is a clear framework underlying each 
disease management evaluation that draws on an understanding of the mecha-
nisms producing intervention effects, allows for sufficient time for sustainable 
effects to become apparent, and – perhaps most importantly – acknowledges 
that producing ‘grand means’ across large populations of patients is incompati-
ble with the goals of patient-centered chronic care management. In this sense, 
stimulating differentiated performance measurement in chronic care research 
might very well be the first step towards implementation of effective population 
management in daily health care practice.  
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SUMMARY 
The purpose of this dissertation was to advance current methods for evaluation 
of the ‘real-world’ effects of complex disease management approaches imple-
mented in actual health care settings on the quality and outcomes of care for 
people with chronic conditions. In so doing, the research aimed to improve the 
evidence underlying disease management and support policymakers and pro-
fessionals in their efforts to successfully redesign the care for long-standing 
health problems. Because robust evaluation requires adequate knowledge of the 
nature, scope, and context of the intervention under study, Chapters 2 through 4 
provided a detailed exploration of disease management approaches for chronic 
conditions implemented in the Netherlands and internationally. In the remain-
ing chapters, that is, Chapters 5 through 8, diverse realistic evaluation methods 
were applied to a combination of qualitative and quantitative data gathered 
from existing disease management approaches in various European health care 
systems.  
 
Chapter 2 analysed the current Dutch approach to disease management, which 
started with experiments in the area of type 2 diabetes care in 2007 and is 
based on a bundled payment system covering the full range of care standard-
driven services for non-complex cases of specific chronic diseases. By compar-
ing the goals of Dutch chronic care reform with the gaps in quality perceived by 
chronically ill patients – as indicated by the scores attained by the Netherlands 
on the 2008 Commonwealth Fund International Health Policy survey of sicker 
adults – we assessed the level of patient-centeredness of the disease manage-
ment approach implemented in the Netherlands. Findings demonstrated that 
while important improvements have been attained in Dutch chronic care, espe-
cially with regard to the level of evidence-based care provision and coordination 
in primary care, further steps are necessary to meet the complex care needs of 
patients with long-standing health problems. Specifically, more effort is needed 
to develop adequate clinical information systems, increase patient participation, 
and reduce fragmentation in the care continuum for complex and multimorbid 
chronically ill patients.  
 
Chapter 3 reviewed the international literature on disease management inter-
ventions for type 2 diabetes published between 1995 and 2011. In line with the 
Care Continuum Alliance’s new, broader definition of disease management, the 
review included interventions comprising at least two of the four meso-level 
components of the Chronic Care Model, which are self-management support, 
delivery system design, clinical information systems, and decision support. Con-
siderable variation was identified in terms of the combination and operatio-
nalisation of these four care components in the reviewed disease management 
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interventions, although programmes targeting improvements in all four ele-
ments were found to be least common internationally. The measured effects of 
interventions on the processes and outcomes of type 2 diabetes care were gen-
erally positive, yet considerable heterogeneity in effects existed between trials. 
This variance in outcomes was partially explained by differences in the number 
of care components that constitute a given disease management intervention, 
with comprehensive programmes attaining the strongest effect estimates. Varia-
tion in length of follow-up also to some extent explained heterogeneity in ef-
fects: trials with limited follow-up (<1 year) reported more promising, though 
possibly overestimated, effects on care processes and clinical outcomes than 
studies of longer duration. 
 
Chapter 4 traced the evolution of chronic care management in Austria, Ger-
many and the Netherlands, all of which are health systems principally financed 
from statutory health insurance. Although in response to the problem of frag-
mentation in chronic care delivery, a predominant model of care in the form of 
structured disease management has emerged in all three countries, specific 
reform efforts vary, reflecting differences in the regulation, funding, and organi-
sation of national health systems. Amongst others, differences exist in the extent 
of organisational reform introduced in primary care, the level of involvement of 
non-medical staff in disease management, the approaches used to incentivise 
implementation, and the extent of participation by patients and providers. Exist-
ing evidence on the impact of the approaches to disease management imple-
mented in Austria, Germany and the Netherlands remains uncertain: (prelimi-
nary) evaluation results have pointed towards improved quality of care, mainly 
in terms of coordination and standardisation, yet fail to provide conclusive 
proof of improved health outcomes and/or reduced costs.  
 
Chapter 5 aimed to assess the differentiated effects of the population-wide 
disease management approach for type 2 diabetes implemented in the Nether-
lands on four intermediate clinical outcomes, that is, glycated haemoglobin, low-
density lipoprotein, systolic blood pressure, and body mass index. For this pur-
pose, patient data (N=105,056) covering a period from 20 to 24 months be-
tween January, 2008 and December, 2010 were collected from 18 Dutch care 
groups, which are provider networks based in primary care with a bundled 
payment contract for the delivery of type 2 diabetes management. Using multi-
level regression methods – that is, meta-analysis and meta-regression – we 
found that while average changes over time in the included outcomes were 
small, clinically relevant improvements were achieved in patients with poor 
initial health values. Greater measurement frequency of clinical outcomes was 
also associated with more promising improvements in these outcomes, espe-
cially in patients with poor diabetes control. A longer length of follow-up was 
accompanied by diminishing positive effects. Based on these findings, we con-
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cluded that tailored disease management, in which not only evidence-based 
guidelines but also patient characteristics and health care needs determine care 
processes, including self-management support, has great potential to improve 
the cost-effectiveness of current chronic care delivery in the Netherlands.  
 
In Chapter 6, we explored whether and how self-management support – which 
is arguably the central component of effective chronic care – is integrated into 
existing chronic care management approaches in 13 European countries. More-
over, this chapter investigated the level of and barriers to implementation of 
support strategies in actual health care practice. Based on the findings from a 
structured expert review among the participating countries, we concluded that 
self-management support for chronically ill patients remains relatively under-
developed in Europe. Similarities between countries exist mostly in involved 
providers (nurses) and settings (primary care). Differences prevail in the mode 
and format of support, and materials used. Support activities focus primarily on 
patients’ medical and behavioural management, and less on emotional man-
agement. According to the results of a series of 27 interviews with Dutch health 
care providers involved in disease management for type 2 diabetes, it was con-
cluded that self-management support is not (yet) an integral part of daily prac-
tice in the Netherlands and that implementation is hampered by barriers related 
to, amongst others, funding, information technology, and medical culture. Im-
proving the health and social outcomes of the chronically ill will require a better 
understanding of how we can encourage both patients and health care provid-
ers to engage in productive interactions in everyday chronic care practice.  
 
Building on country studies in Austria, Denmark, France, Germany, the Nether-
lands, and Spain, Chapter 7 illustrated how routine health care data can be used 
to conduct rigorous and meaningful evaluations of disease management impact 
in the actual context of health systems. As part of the European collaborative 
DISMEVAL (‘Developing and Validating Disease Management Evaluation Meth-
ods for European Health Care Systems’) project, research teams in each of these 
countries tested and validated advanced evaluation methods, such as difference-
in-differences analysis, regression discontinuity analysis, and multilevel model-
ing, on data from existing disease management strategies, which were retrieved 
mostly retrospectively from health care providers and/or statutory insurance 
funds. Using routine data offered large numbers (~154,000 patients with three 
conditions), enabled long-term follow-up (10 to 36 months), allowed for retro-
spective creation of control groups, and provided baseline data. A disadvantage 
was that routine measures can be too narrow to adequately reflect quality of 
care, as they tend to focus mainly on intermediate health outcomes, and, to a 
lesser extent, care processes. By explicitly taking into account relevant data 
problems and potential sources of bias and confounding in practice-based dis-
ease management research, the applied methods produced sufficiently valid 
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findings to support further quality efforts in chronic care, although results must 
be interpreted with caution in light of these limitations. Most notably, findings 
pointed towards significant positive effects of disease management on process 
quality (Austria, Germany), yet no more than clinically moderate improvements 
in intermediate health outcomes (Austria, France, Netherlands, Spain) or pace of 
disease progression (Denmark) in intervention patients, where possible com-
pared to a matched control group.  
 
Chapter 8 introduced multilevel regression methods as valuable techniques to 
evaluate ‘real-world’ disease management approaches in a manner that pro-
duces robust and meaningful findings for everyday practice. In a worked exam-
ple, these methods were applied to retrospectively gathered routine health care 
data covering 105,056 diabetes patients who received disease management for 
type 2 diabetes mellitus in the Netherlands. Multivariable, multilevel regression 
models were fit to identify trends in the clinical outcomes of patients as a func-
tion of components of the intervention offered (measurement frequency and 
range, length of follow-up) and/or characteristics of the target population (age, 
disease duration, baseline health, comorbidity, smoking status). Use of multi-
level regression techniques enabled concerted efforts to adjust for potential 
sources of confounding and bias in practice-based research and produced quan-
titative evidence supporting current efforts to tailor chronic care provision to 
patients’ characteristics and degree of health care need. Although the identified 
trends in disease management outcomes were confirmed by previous random-
ised research, there ultimately are limits to the validity and reliability of findings 
from uncontrolled research based on routine intervention data. Further prac-
tice-based research is necessary to confirm results and learn more about the 
impact of population-wide disease management strategies on the quality and 
outcomes of chronic care.  
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SAMENVATTING 
Dit proefschrift had tot doel het verbeteren van de huidige methoden voor eva-
luatie van de effecten van complexe disease management strategieën, geïmple-
menteerd in de dagelijkse zorgpraktijk, op de kwaliteit en uitkomsten van zorg 
voor mensen met chronische aandoeningen. Daarmee tracht het onderzoek het 
bestaande bewijs voor disease management uit te bouwen alsook beleidsmakers 
en zorgverleners te ondersteunen bij hun inspanningen om de zorg voor lang-
durige gezondheidsproblemen succesvol te hervormen. Omdat adequaat inzicht 
in de aard, omvang en context van een interventie een noodzakelijke voorwaar-
de is voor robuuste evaluatie, exploreerden Hoofdstukken 2 tot en met 4 op 
gedetailleerde wijze een selectie van disease management strategieën voor 
chronische aandoeningen, die worden toegepast in Nederland alsook in het 
buitenland. In de resterende hoofdstukken, te weten Hoofdstukken 5 tot en met 
8, werden diverse realistische evaluatiemethoden toegepast op een combinatie 
van kwalitatieve en kwantitatieve data met betrekking tot bestaande disease 
management aanpakken in verschillende Europese zorgsystemen.  
 
Hoofdstuk 2 analyseerde de huidige Nederlandse disease management aanpak 
voor chronische aandoeningen. De eerste experimenten met deze zorgbenade-
ring startten in 2007 en richtten zich specifiek op verbetering van de kwaliteit 
van zorg voor diabetespatiënten in de eerste lijn, door middel van invoering van 
integrale financiering van gestandaardiseerde, non-complexe diabeteszorg op 
basis van keten-DBCs. Om de mate van patiëntgerichtheid van de Nederlandse 
disease management aanpak te bepalen, werden de doelen van deze zorgher-
vorming vergeleken met de tekortkomingen in kwaliteit van zorg zoals waarge-
nomen door chronisch zieke patiënten in Nederland. Daartoe werden de scores 
gebruikt van Nederlandse patiënten op de Commonwealth Fund International 
Health Policy survey uit 2008. De bevindingen toonden aan dat hoewel belang-
rijke verbeteringen zijn bereikt in de Nederlandse chronische zorg, met name in 
de standaardisatie en coördinatie van diensten binnen de eerste lijn, verdere 
stappen noodzakelijk zijn om tegemoet te kunnen komen aan de complexe 
zorgbehoeften van patiënten met langdurige gezondheidsproblemen. Verdere 
inspanningen zijn vooral nodig om ontwikkeling van adequate klinische infor-
matiesystemen te stimuleren, om participatie van patiënten in hun zorg te be-
vorderen en om fragmentatie te reduceren binnen het continuüm van zorg voor 
patiënten met gecompliceerde en meervoudige aandoeningen.  
 
In Hoofdstuk 3 werden de resultaten gepresenteerd van een review van de 
internationale literatuur betreffende disease management interventies voor 
type 2 diabetes, gepubliceerd tussen 1995 en 2011. Conform de nieuwe, uitge-
breidere definitie van disease management door de Care Continuum Alliance, 
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includeerde de review interventies bestaande uit minimaal twee van de vier 
componenten van het Chronic Care Model op mesoniveau, te weten zelfmana-
gement ondersteuning, zorgorganisatie, klinische informatiesystemen en beslis-
kundige ondersteuning. Hoewel de combinatie en operationalisering van deze 
componenten binnen de gereviewde disease management interventies aanzien-
lijk verschilden, waren programma’s die verbetering nastreefden in alle vier de 
zorgelementen het minst vaak voorkomend. De gemeten effecten van de inter-
venties op de processen en uitkomsten van type 2 diabeteszorg waren over het 
algemeen positief, maar verschilden sterk qua richting en omvang tussen stu-
dies. Variatie in het aantal zorgcomponenten per studie kon deze heterogeniteit 
in resultaten deels verklaren, waarbij bredere programma’s, bestaande uit drie 
of vier componenten, de meest positieve effecten behaalden op klinische uit-
komsten. Verschillen in observatieduur waren ook deels verklarend voor de 
heterogeniteit in disease management effecten: in kortere studies (<1 jaar) 
werden positievere, doch wellicht overschatte, resultaten gemeten dan in lange-
re studies. 
 
Hoofdstuk 4 beschreef de ontwikkeling van chronische zorg in Oostenrijk, 
Duitsland en Nederland, drie zorgsystemen die hoofdzakelijk worden gefinan-
cierd vanuit ziektekostenverzekeringen. Bestaande fragmentatie in de zorg voor 
chronische aandoeningen heeft in alle drie deze landen geleid tot de introductie 
van gestructureerde disease management modellen. Desalniettemin zijn er ver-
schillen te herkennen in de specifieke hervormingsstrategieën per land, welke 
kunnen worden teruggeleid naar verschillen in de regulering, financiering en 
organisatie van nationale zorgsystemen. Diversiteit bestaat onder meer in de 
mate van hervorming van de organisatie van zorg, de betrokkenheid van niet-
medische staf bij chronische zorgverlening, de prikkels om implementatie van 
disease management te bevorderen en de participatie van patiënten en zorgver-
leners. Het bewijs omtrent de impact van de disease management benaderingen 
in Oostenrijk, Duitsland en Nederland blijft onzeker: (voorlopige) evaluatiere-
sultaten wijzen op verbeterde kwaliteit van zorg, met name inzake coördinatie 
en standaardisatie, maar zijn er tot op heden niet in geslaagd overtuigend blijk 
te geven van verbeterde gezondheidsuitkomsten en/of verminderde kosten.  
 
Hoofdstuk 5 presenteerde de resultaten van een gedifferentieerde analyse van 
de effecten van de populatiebrede disease management aanpak voor type 2 
diabetes in Nederland op vier klinische uitkomstmaten, te weten geglyceerde 
hemoglobine, LDL cholesterol, systolische bloeddruk en body mass index. Hier-
toe werden patiëntdata (N=105,056) verzameld over een periode van 20 tot 24 
maanden tussen januari 2008 en december 2010 van 18 Nederlandse zorggroe-
pen met een keten-DBC voor type 2 diabetes management. Analyses van deze 
data met behulp van multilevel regressie methoden – waaronder diverse meta-
analyses en meta-regressies – toonden aan dat, hoewel de gemiddelde verande-
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ringen over tijd in de geïncludeerde uitkomsten bescheiden waren, er klinisch 
relevante verbeteringen werden bereikt in patiënten met ongezonde begin-
waarden. Frequentere meting van klinische uitkomstparameters werd boven-
dien geassocieerd met sterkere effecten op die parameters, vooral voor patiën-
ten met onvoldoende diabetescontrole. De analyses toonden verder aan dat 
wanneer het aantal maanden in zorg toenam, de effecten op klinische uitkom-
sten minder positief werden. De conclusie op basis van deze bevindingen was 
dat zorg op maat, waarbij niet alleen zorgstandaarden en richtlijnen maar ook 
de kenmerken en zorgbehoeften van patiënten bepalend zijn voor de processen 
van zorg, een veelbelovende strategie is om de kosteneffectiviteit van de huidige 
chronische zorgaanpak in Nederland te verbeteren.  
 
Hoofdstuk 6 trachtte in kaart te brengen in hoeverre en op welke wijze zelfma-
nagement ondersteuning, de wellicht meest belangrijke component van effec-
tieve chronische zorg, is geïntegreerd in bestaande chronische zorgstrategieën 
in 13 Europese landen. Daarnaast onderzocht dit hoofdstuk de mate van en 
barrières voor implementatie van ondersteuningsstrategieën in de dagelijkse 
zorgpraktijk. Op basis van de resultaten van een gestructureerde expert review 
in de participerende landen concludeerden we dat zelfmanagement onder-
steuning voor chronisch zieke patiënten in Europa relatief onderontwikkeld 
blijft. Gelijkenissen tussen landen hebben met name betrekking op de bij zelf-
management ondersteuning betrokken hulpverleners (verpleegkundigen) en 
sectoren (eerste lijn). Verschillen zijn veelvoorkomend in toegepaste methoden 
en systemen, alsook in gebruikte materialen. Ondersteuningsactiviteiten zijn 
primair gericht op het medische en gedragsgerelateerde zelfmanagement van 
patiënten; er is minder aandacht voor emotioneel management. De resultaten 
van een serie van 27 interviews met Nederlandse zorgverleners, die zijn betrok-
ken bij disease management voor type 2 diabetes, lieten zien dat zelfmanage-
ment ondersteuning (nog) geen integraal onderdeel is van de dagelijkse chroni-
sche zorgpraktijk, alsook dat implementatie wordt belemmerd door barrières in 
onder andere de financiering van zorg, informatie technologie en medische cul-
tuur. Om de gezondheid en sociale status van chronisch zieken te verbeteren is 
het noodzakelijk beter inzicht te krijgen in de wijze waarop we zowel patiënten 
als zorgverleners kunnen stimuleren om op productieve wijze met elkaar te 
interacteren in de dagelijkse chronische zorgpraktijk.  
 
Op basis van landenstudies in Oostenrijk, Denemarken, Frankrijk, Duitsland, 
Nederland en Spanje illustreerde Hoofdstuk 7 hoe routinematige data – die 
standaard worden verzameld in de zorgsector – gebruikt kunnen worden om de 
impact van disease management op rigoureuze en betekenisvolle wijze te evalu-
eren binnen de context van zorgsystemen. Als onderdeel van het Europese DIS-
MEVAL (‘Developing and Validating Disease Management Evaluation Methods 
for European Health Care Systems’) project hebben onderzoeksteams in elk van 
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deze landen geavanceerde evaluatiemethoden – waaronder ‘difference-in-
differences analysis’, ‘regression discontinuity analysis’ en ‘multilevel modeling’ 
– getest en gevalideerd op basis van data van bestaande disease management 
strategieën. Data werden voornamelijk retrospectief verzameld van zorgverle-
ners en zorgverzekeraars. Het gebruik van routinematige data leverde grote 
aantallen (~154,000 patiënten met drie aandoeningen), maakte lange termijn 
follow-up mogelijk (10 tot 36 maanden), bood de optie om retrospectief contro-
legroepen te creëren, en leverde baseline gegevens. Een nadeel was dat de pa-
rameters, die standaard in de zorgsector worden gemeten, te beperkt kunnen 
zijn om op adequate wijze kwaliteit weer te geven, aangezien de focus vooral ligt 
op middellange gezondheidsuitkomsten en, in mindere mate, op zorgprocessen. 
Door relevante dataproblemen en potentiële bronnen van bias en confounding 
in praktijkonderzoek expliciet in overweging te nemen, produceerden de toege-
paste methoden voldoende valide resultaten om verdere inspanningen op het 
gebied van kwaliteitsverbetering in de chronische zorg te ondersteunen. Desal-
niettemin moeten resultaten met voorzichtigheid geïnterpreteerd worden in het 
licht van de beperkingen van ongerandomiseerd onderzoek. De belangrijkste 
resultaten toonden significante positieve effecten van disease management op 
de kwaliteit van zorgprocessen (Oostenrijk, Duitsland), maar niet meer dan 
klinisch bescheiden verbeteringen in middellange gezondheidsuitkomsten (Oos-
tenrijk, Frankrijk, Nederland, Spanje) of ziekteprogressie (Denemarken) in in-
terventiepatiënten, waar mogelijk vergeleken met een gematchte controlegroep.  
 
Hoofdstuk 8 introduceerde multilevel regressie methoden als waardevolle 
technieken voor de evaluatie van disease management binnen de natuurlijke 
context van het zorgsysteem, op een manier die resulteert in robuuste en bete-
kenisvolle bevindingen voor de dagelijkse praktijk. In een uitgewerkt voorbeeld 
werden deze methoden toegepast op retrospectief verzamelde routinematige 
data van 105,056 diabetes patiënten, die disease management voor type 2 dia-
betes mellitus ontvangen in Nederland. Multivariabele, multilevel regressie 
modellen werden toegepast om trends in de klinische uitkomsten van patiënten 
te identificeren als een gevolg van verschillen in aspecten van de interventie 
(meetfrequentie, meetvariatie, observatieduur) en/of kenmerken van de be-
handelde populatie (leeftijd, ziekteduur, baseline gezondheid, comorbiditeit, 
rookstatus). Het gebruik van multilevel regressie technieken maakte het moge-
lijk om resultaten te corrigeren voor potentiële bronnen van confounding en 
bias in praktijkonderzoek; bovendien produceerden deze methoden kwantita-
tief bewijs ter ondersteuning van huidige inspanningen om maatwerk te leveren 
binnen de chronische zorg op basis van de zorgbehoeften van patienten. Hoewel 
de geïdentificeerde trends in disease management uitkomsten bevestigd wor-
den door eerder gerandomiseerd onderzoek, zijn er grenzen aan de validiteit en 
betrouwbaarheid van de bevindingen van ongecontroleerd onderzoek op basis 
van routinematige interventiedata. Meer praktijkgericht onderzoek is nodig om 
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de resultaten te bevestigen en meer te leren over de impact van populatiebrede 
disease management strategieën op de kwaliteit en uitkomsten van chronische 
zorg.  
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LIST OF ACRONYMS AND ABBREVIATIONS 
ACIC Assesing Chronic Illness Care 
BMI Body mass index 
CCA Care Continuum Alliance 
CCM Chronic Care Model 
CCT Controlled clinical trial 
CI Confidence interval 
CIS Clinical information systems 
COPD Chronic obstructive pulmonary disease 
CWF Commonwealth Fund 
DISMEVAL Developing and Validating Disease Management Evaluation Methods 
for European Health Care Systems 
DMAA Disease Management Association of America 
DMP Disease management programme 
DS Decision support 
DSD Delivery system design 
ECCM Expanded Chronic Care Model 
EU European Union 
FP7 Seventh Framework Programme for research 
GP General practitioner 
HbA1c Glycated haemoglobin 
HDL High-density lipoprotein 
IGZ Inspectie voor de Gezondheidszorg 
ICC Intraclass correlation 
IT Information technology 
LHV Landelijke Huisartsen Vereniging 
LDL Low-density lipoprotein 
MUMC+ Maastricht Universitair Medisch Centrum 
NZa Nederlandse Zorgautoriteit 
POPP Partnerships for Older People Projects 
RCT Randomised controlled trial 
RIVM Rijksinstituut voor Volksgezondheid en Milieu 
RR Relative ratio 
RSA Risk structure compensation scheme 
RVZ Raad voor de Volksgezondheid en Zorg 
SBP Systolic blood pressure 
SHI Social health insurance 
SMS Self-management support 
UKPDS United Kingdom Prospective Diabetes Study 
US United States 
VIF Variance inflation factor 
WHO World Health Organisation 
ZonMw Nederlandse organisatie voor gezondheidsonderzoek en zorginnovatie 
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maanden. Het is altijd fijn om bij jullie binnen te lopen!  
 
Ik heb in de afgelopen jaren verschillende kamergenoten gehad, waarvan ik er 
een aantal speciaal wil bedanken. Ties, tijdens mijn eerste jaren als promovenda 
heb ik veel van je geleerd en genoten van ons eindeloze gebabbel. Ik hoop dat 
het je goed gaat in de VS. Sharon, wat was het een gezellig jaar met jou op een 
kamer. Ik vond het jammer dat je vertrok, maar ben blij dat je in Eindhoven je 
plekje hebt gevonden. Lieve Janneke, Reina en Cindy, wat is het een geweldig 
feest om sinds februari vorig jaar met jullie een kamer te delen! Ik heb me vanaf 
de eerste dag welkom gevoeld en inmiddels lijkt het alsof ik al jaren op kamer 
0.044 vertoef. Bedankt voor alle gezelligheid en hilariteit onder werktijd (dit 
proefschrift lijkt me het ultieme bewijs dat in luidruchtige omgevingen een 
enorme arbeidsproductiviteit kan worden bereikt), voor de geweldige etentjes 
in Budel, Bilzen en Herderen (zo kom je nog eens ergens…) en voor jullie hulp 
bij al het ‘geregel’ dat komt kijken bij een promotie. Wat voel ik me rijk met Rei-
na als paranimf aan mijn zijde en Janneke en Cindy als ‘co-paranimfen’ op de 
eerste rij tijdens de grote dag; jullie zijn geweldig! 
 
Dankzij mijn lieve vriendengroep heb ik in de afgelopen jaren ook de nodige 
afleiding gehad van mijn onderzoek. Kim, Rian, Stefanie, Naomi, Chantal, Roel, 
Erik, Bart, Xavier, Dominique en Maarten, wat een gezellige boel is het toch altijd 
met jullie! Bedankt voor alle leuke feestjes (inclusief onnozele dansjes), de 
weekendjes weg, de chaotische etentjes, de lange avonden kletsen en alle andere 
dingen die we samen doen. Lieve Kim, al sinds onze kleutertijd delen wij alle 
leuke en minder leuke dingen in het leven. Je kent me als geen ander en staat 
altijd voor me klaar. Het is onmogelijk je in een paar zinnen te bedanken, maar 
weet dat onze vriendschap me dierbaar is en dat ik blij en dankbaar ben dat je 
ook deze mijlpaal weer met me meebeleeft.  
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Lieve pap en mam, met heel veel liefde draag ik dit proefschrift aan jullie op. 
Zonder jullie onvoorwaardelijke steun en vertrouwen, en de mogelijkheden die 
jullie me hebben gegeven, was ik hier nooit gekomen. Pap, jij staat altijd voor me 
klaar met een helpende hand, een goed advies of een brede schouder om even 
tegenaan te leunen. Weten dat jij er altijd bent, geeft me vleugels. Mam, jij hebt 
me van kleins af aan geleerd om hard te werken, om niet op te geven en bovenal 
om te geloven in mezelf. Je bent mijn grote voorbeeld en mijn meest trotse sup-
porter. Wat ben ik dankbaar dat ik altijd bij jullie terecht kan en dat jullie er zijn 
om dit bijzondere moment samen met mij mee te maken. Daniëlle, een liever 
zusje dan jij kan niemand zich wensen. Ik ben dan misschien de oudste van ons 
twee, maar van jouw enthousiasme en doorzettingsvermogen leer ik elke dag 
weer. Terwijl ik onderzoek doe naar de zorg, sta jij er dagelijks met beide benen 
midden in en de manier waarop je dat doet is een inspiratie voor me. Ik twijfel 
er niet aan dat je al je dromen zult verwezenlijken. Je betekent de wereld voor 
me en ik ben ongelofelijk blij en trots dat je naast me staat als paranimf op deze 
belangrijke dag.  
 
Huub, Marga, René en Loes, wat is het fijn om een tweede thuis te hebben bij 
jullie in Herkenrade, waar het altijd gezellig is. Bedankt voor alle manieren 
waarop jullie Rick en mij helpen en voor jullie interesse in mijn af en toe veel te 
lange verhalen over dit proefschrift. Na vandaag worden ze vast en zeker steeds 
korter! 
 
Lieve Rick, de laatste zinnen van dit dankwoord heb ik bewaard voor jou. In al je 
bescheidenheid wil je nog wel eens onderschatten hoe belangrijk jouw steun 
voor me is. Misschien helpt het dat ik het nu op papier kan zetten. Je zorgzaam-
heid, je relativeringsvermogen en je grenzeloos vertrouwen in mijn kunnen zijn 
de afgelopen jaren onmisbaar voor me geweest bij het schrijven van dit proef-
schrift. En ondertussen ben je ook nog afgestudeerd, heb je een baan gevonden 
en hebben we samen ons eerste huis gekocht. Ik ben ongelofelijk dankbaar en 
trots dat ik jou in mijn leven heb en kan niet wachten om te zien wat de toe-
komst ons nog allemaal zal brengen. Je bent mijn maatje, mijn rots, mijn grote 
liefde en mijn thuis. Lieve schat, ik hou van je.  
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